NZ719369B2 - Conjugates of Cell Binding Molecules with Cytotoxic Agents - Google Patents
Conjugates of Cell Binding Molecules with Cytotoxic Agents Download PDFInfo
- Publication number
- NZ719369B2 NZ719369B2 NZ719369A NZ71936912A NZ719369B2 NZ 719369 B2 NZ719369 B2 NZ 719369B2 NZ 719369 A NZ719369 A NZ 719369A NZ 71936912 A NZ71936912 A NZ 71936912A NZ 719369 B2 NZ719369 B2 NZ 719369B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- alkyl
- mab
- independently
- aryl
- mmol
- Prior art date
Links
- 230000027455 binding Effects 0.000 title claims abstract description 111
- 239000002254 cytotoxic agent Substances 0.000 title claims abstract description 18
- 231100000599 cytotoxic agent Toxicity 0.000 title claims abstract description 15
- 201000011510 cancer Diseases 0.000 claims abstract description 43
- 201000009910 diseases by infectious agent Diseases 0.000 claims abstract description 20
- 206010003816 Autoimmune disease Diseases 0.000 claims abstract description 17
- 201000009596 autoimmune hypersensitivity disease Diseases 0.000 claims abstract description 9
- -1 Ar-alkyl Chemical group 0.000 claims description 175
- 239000000203 mixture Substances 0.000 claims description 127
- 125000000217 alkyl group Chemical group 0.000 claims description 110
- 102000004965 antibodies Human genes 0.000 claims description 102
- 108090001123 antibodies Proteins 0.000 claims description 102
- 125000003118 aryl group Chemical group 0.000 claims description 76
- 210000004027 cells Anatomy 0.000 claims description 67
- 239000003080 antimitotic agent Substances 0.000 claims description 66
- 125000005647 linker group Chemical group 0.000 claims description 58
- 125000000623 heterocyclic group Chemical group 0.000 claims description 53
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 50
- 125000003342 alkenyl group Chemical group 0.000 claims description 48
- 239000011734 sodium Substances 0.000 claims description 43
- 239000011780 sodium chloride Substances 0.000 claims description 41
- 150000001413 amino acids Chemical group 0.000 claims description 40
- 125000000304 alkynyl group Chemical group 0.000 claims description 38
- 239000000427 antigen Substances 0.000 claims description 37
- 108091007172 antigens Proteins 0.000 claims description 37
- 102000038129 antigens Human genes 0.000 claims description 37
- 229910052760 oxygen Inorganic materials 0.000 claims description 36
- 150000003839 salts Chemical class 0.000 claims description 36
- 229910052739 hydrogen Inorganic materials 0.000 claims description 34
- 229910052717 sulfur Inorganic materials 0.000 claims description 34
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 33
- 229910052799 carbon Inorganic materials 0.000 claims description 32
- 102000007399 Nuclear hormone receptors Human genes 0.000 claims description 31
- 108020005497 Nuclear hormone receptors Proteins 0.000 claims description 31
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 30
- 125000002837 carbocyclic group Chemical group 0.000 claims description 29
- 125000004432 carbon atoms Chemical group C* 0.000 claims description 26
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 26
- 239000003814 drug Substances 0.000 claims description 25
- 239000003446 ligand Substances 0.000 claims description 24
- 229940079593 drugs Drugs 0.000 claims description 23
- 102000004169 proteins and genes Human genes 0.000 claims description 23
- 108090000623 proteins and genes Proteins 0.000 claims description 23
- 150000002148 esters Chemical class 0.000 claims description 22
- 239000002253 acid Substances 0.000 claims description 21
- 125000004475 heteroaralkyl group Chemical group 0.000 claims description 21
- 241000700605 Viruses Species 0.000 claims description 20
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 claims description 20
- 108010045030 monoclonal antibodies Proteins 0.000 claims description 20
- 102000005614 monoclonal antibodies Human genes 0.000 claims description 20
- 125000004181 carboxyalkyl group Chemical group 0.000 claims description 19
- 229910052757 nitrogen Inorganic materials 0.000 claims description 18
- 102000005962 receptors Human genes 0.000 claims description 18
- 108020003175 receptors Proteins 0.000 claims description 18
- 125000001072 heteroaryl group Chemical group 0.000 claims description 15
- 229910052731 fluorine Inorganic materials 0.000 claims description 13
- 150000002338 glycosides Chemical class 0.000 claims description 13
- 230000003389 potentiating Effects 0.000 claims description 13
- 239000011230 binding agent Substances 0.000 claims description 12
- 239000012453 solvate Substances 0.000 claims description 12
- 229910052794 bromium Inorganic materials 0.000 claims description 11
- 229910052801 chlorine Inorganic materials 0.000 claims description 11
- 230000003612 virological Effects 0.000 claims description 11
- 230000002927 anti-mitotic Effects 0.000 claims description 10
- 229910052740 iodine Inorganic materials 0.000 claims description 10
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims description 9
- 125000004429 atoms Chemical group 0.000 claims description 9
- 102100006400 CSF2 Human genes 0.000 claims description 8
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims description 8
- 229910052698 phosphorus Inorganic materials 0.000 claims description 8
- 229910052727 yttrium Inorganic materials 0.000 claims description 8
- 125000005842 heteroatoms Chemical group 0.000 claims description 7
- 229920000642 polymer Polymers 0.000 claims description 7
- 150000003568 thioethers Chemical class 0.000 claims description 7
- 102100013077 CD4 Human genes 0.000 claims description 6
- 101700022938 CD4 Proteins 0.000 claims description 6
- 102100008453 FOLH1 Human genes 0.000 claims description 6
- 101700036477 FOLH1 Proteins 0.000 claims description 6
- 102100000165 MS4A1 Human genes 0.000 claims description 6
- 101710010909 MS4A1 Proteins 0.000 claims description 6
- 210000002307 Prostate Anatomy 0.000 claims description 6
- 239000003102 growth factor Substances 0.000 claims description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 6
- 239000002502 liposome Substances 0.000 claims description 6
- 102100000189 CD22 Human genes 0.000 claims description 5
- 101700020617 CD22 Proteins 0.000 claims description 5
- 101700039191 EGFR Proteins 0.000 claims description 5
- 101700025368 ERBB2 Proteins 0.000 claims description 5
- 101710040533 TNFRSF8 Proteins 0.000 claims description 5
- 102100009538 TNFRSF8 Human genes 0.000 claims description 5
- 150000003973 alkyl amines Chemical class 0.000 claims description 5
- 150000001408 amides Chemical class 0.000 claims description 5
- 125000000732 arylene group Chemical group 0.000 claims description 5
- 239000000969 carrier Substances 0.000 claims description 5
- 108091006028 chimera Proteins 0.000 claims description 5
- 231100000433 cytotoxic Toxicity 0.000 claims description 5
- 230000001472 cytotoxic Effects 0.000 claims description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 5
- 239000002105 nanoparticle Substances 0.000 claims description 5
- 102100001249 ALB Human genes 0.000 claims description 4
- 101710027066 ALB Proteins 0.000 claims description 4
- 101710040446 CD40 Proteins 0.000 claims description 4
- 102100013137 CD40 Human genes 0.000 claims description 4
- 108010071942 Colony-Stimulating Factors Proteins 0.000 claims description 4
- 102100010782 EGFR Human genes 0.000 claims description 4
- 102100016662 ERBB2 Human genes 0.000 claims description 4
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims description 4
- 102100001475 ITGB2 Human genes 0.000 claims description 4
- 101710006663 ITGB2 Proteins 0.000 claims description 4
- 102100006037 MUC1 Human genes 0.000 claims description 4
- 101700052761 MUC1 Proteins 0.000 claims description 4
- 102100006044 MUC16 Human genes 0.000 claims description 4
- 101700008449 MUC16 Proteins 0.000 claims description 4
- 229910019946 S-S Inorganic materials 0.000 claims description 4
- 229910019939 S—S Inorganic materials 0.000 claims description 4
- 210000001744 T-Lymphocytes Anatomy 0.000 claims description 4
- 229940050528 albumin Drugs 0.000 claims description 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 4
- 150000001768 cations Chemical class 0.000 claims description 4
- 239000000412 dendrimer Substances 0.000 claims description 4
- 229920000736 dendritic polymer Polymers 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 125000005843 halogen group Chemical group 0.000 claims description 4
- 102000006495 integrins Human genes 0.000 claims description 4
- 108010044426 integrins Proteins 0.000 claims description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 4
- 102000003735 mesothelin Human genes 0.000 claims description 4
- 108090000015 mesothelin Proteins 0.000 claims description 4
- 229910052751 metal Inorganic materials 0.000 claims description 4
- 239000002184 metal Substances 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 125000001424 substituent group Chemical group 0.000 claims description 4
- 102100005826 CD19 Human genes 0.000 claims description 3
- 101700087100 CD19 Proteins 0.000 claims description 3
- 102100009705 ENG Human genes 0.000 claims description 3
- 101700010580 FLO11 Proteins 0.000 claims description 3
- 229940088597 Hormone Drugs 0.000 claims description 3
- 102000004877 Insulin Human genes 0.000 claims description 3
- 108090001061 Insulin Proteins 0.000 claims description 3
- 102000015696 Interleukins Human genes 0.000 claims description 3
- 108010063738 Interleukins Proteins 0.000 claims description 3
- 102100008333 THY1 Human genes 0.000 claims description 3
- 101700026084 THY1 Proteins 0.000 claims description 3
- 102000004338 Transferrin Human genes 0.000 claims description 3
- 108090000901 Transferrin Proteins 0.000 claims description 3
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 3
- 125000003545 alkoxy group Chemical group 0.000 claims description 3
- 230000001363 autoimmune Effects 0.000 claims description 3
- 230000001086 cytosolic Effects 0.000 claims description 3
- 230000001419 dependent Effects 0.000 claims description 3
- 150000002019 disulfides Chemical class 0.000 claims description 3
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 3
- 125000001188 haloalkyl group Chemical group 0.000 claims description 3
- 239000005556 hormone Substances 0.000 claims description 3
- 150000007857 hydrazones Chemical class 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 244000045947 parasites Species 0.000 claims description 3
- 125000001151 peptidyl group Chemical group 0.000 claims description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 3
- 125000003107 substituted aryl group Chemical group 0.000 claims description 3
- 239000012581 transferrin Substances 0.000 claims description 3
- 235000013343 vitamin Nutrition 0.000 claims description 3
- 239000011782 vitamin Substances 0.000 claims description 3
- 229930003231 vitamins Natural products 0.000 claims description 3
- FWVCSXWHVOOTFJ-UHFFFAOYSA-N 1-(2-chloroethylsulfanyl)-2-[2-(2-chloroethylsulfanyl)ethoxy]ethane Chemical compound ClCCSCCOCCSCCCl FWVCSXWHVOOTFJ-UHFFFAOYSA-N 0.000 claims description 2
- 210000003719 B-Lymphocytes Anatomy 0.000 claims description 2
- 102100016493 CD33 Human genes 0.000 claims description 2
- 101700017647 CD33 Proteins 0.000 claims description 2
- 102100016530 CD37 Human genes 0.000 claims description 2
- 101700044364 CD37 Proteins 0.000 claims description 2
- 102100003279 CD38 Human genes 0.000 claims description 2
- 101700044948 CD38 Proteins 0.000 claims description 2
- 101700078950 CD44 Proteins 0.000 claims description 2
- 102100003735 CD44 Human genes 0.000 claims description 2
- 102100005830 CD70 Human genes 0.000 claims description 2
- 101700017377 CD70 Proteins 0.000 claims description 2
- 101700002874 CD72 Proteins 0.000 claims description 2
- 102100019446 CD72 Human genes 0.000 claims description 2
- 102100005552 CR1 Human genes 0.000 claims description 2
- 102100009368 CR2 Human genes 0.000 claims description 2
- 101700020447 CR2 Proteins 0.000 claims description 2
- 102100012353 DPP4 Human genes 0.000 claims description 2
- 101700039720 DPP4 Proteins 0.000 claims description 2
- 108010016626 Dipeptides Proteins 0.000 claims description 2
- 108010055196 EphA2 Receptor Proteins 0.000 claims description 2
- 102000006815 Folate receptors Human genes 0.000 claims description 2
- 108020005243 Folate receptors Proteins 0.000 claims description 2
- 102100007544 NCAM1 Human genes 0.000 claims description 2
- 101700077124 NCAM1 Proteins 0.000 claims description 2
- 102100017963 PSCA Human genes 0.000 claims description 2
- 101700038464 PSCA Proteins 0.000 claims description 2
- 101710037934 QRSL1 Proteins 0.000 claims description 2
- 102100010587 SDC1 Human genes 0.000 claims description 2
- 101700070405 SDC1 Proteins 0.000 claims description 2
- 102100012981 TNFRSF10A Human genes 0.000 claims description 2
- 101710030971 TNFRSF10A Proteins 0.000 claims description 2
- 229940088594 Vitamin Drugs 0.000 claims description 2
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 claims description 2
- 230000003278 mimic Effects 0.000 claims description 2
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims description 2
- 150000003384 small molecules Chemical class 0.000 claims description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 210000004881 tumor cells Anatomy 0.000 claims description 2
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 2
- 101710009478 STEAP2 Proteins 0.000 claims 5
- 102100006461 STEAP2 Human genes 0.000 claims 5
- 101700073629 TDGF1 Proteins 0.000 claims 4
- 102100005491 TDGF1 Human genes 0.000 claims 4
- 108010090557 Endothelin receptor B Proteins 0.000 claims 3
- 102000013128 Endothelin receptor B Human genes 0.000 claims 3
- 101710023820 SEMA5B Proteins 0.000 claims 3
- 102100004376 SEMA5B Human genes 0.000 claims 3
- 101700069986 mab-5 Proteins 0.000 claims 3
- 102000001893 Bone Morphogenetic Protein Receptors Human genes 0.000 claims 2
- 108010040422 Bone Morphogenetic Protein Receptors Proteins 0.000 claims 2
- 102000027760 ERBB2 Human genes 0.000 claims 2
- 102100005556 SLC34A2 Human genes 0.000 claims 2
- 101710009474 STEAP1 Proteins 0.000 claims 2
- 102100006460 STEAP1 Human genes 0.000 claims 2
- 150000007942 carboxylates Chemical class 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 101700064281 ATP1 Proteins 0.000 claims 1
- 102100005868 CD180 Human genes 0.000 claims 1
- 101700060549 CD180 Proteins 0.000 claims 1
- 102100007290 CD274 Human genes 0.000 claims 1
- 101710012053 CD274 Proteins 0.000 claims 1
- 101710025651 CXCR5 Proteins 0.000 claims 1
- 102100002072 CXCR5 Human genes 0.000 claims 1
- 101710004859 ENG Proteins 0.000 claims 1
- 101700041204 ERBB3 Proteins 0.000 claims 1
- 102000027776 ERBB3 Human genes 0.000 claims 1
- 102000002045 Endothelin Human genes 0.000 claims 1
- 108050009340 Endothelin Proteins 0.000 claims 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N Endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 claims 1
- 101700021818 FCRL1 Proteins 0.000 claims 1
- 102100017784 FCRL1 Human genes 0.000 claims 1
- 102100017783 FCRL2 Human genes 0.000 claims 1
- 101700040895 FCRL2 Proteins 0.000 claims 1
- 102100008382 FCRL5 Human genes 0.000 claims 1
- 101700031417 FCRL5 Proteins 0.000 claims 1
- 108010009202 Growth Factor Receptors Proteins 0.000 claims 1
- 102000009465 Growth Factor Receptors Human genes 0.000 claims 1
- 102100005785 HLA-DOB Human genes 0.000 claims 1
- 101710007991 HLA-DOB Proteins 0.000 claims 1
- 102100013822 MSLN Human genes 0.000 claims 1
- 101700047896 MSLN Proteins 0.000 claims 1
- 210000002752 Melanocytes Anatomy 0.000 claims 1
- 210000000066 Myeloid Cells Anatomy 0.000 claims 1
- 101700008337 PSMA Proteins 0.000 claims 1
- 102000016462 Phosphate Transport Proteins Human genes 0.000 claims 1
- 108010092528 Phosphate Transport Proteins Proteins 0.000 claims 1
- 101710023762 SEMA3B Proteins 0.000 claims 1
- 102000037151 SLC-Transporter Human genes 0.000 claims 1
- 108091006187 SLC-Transporter Proteins 0.000 claims 1
- 101710035379 SLC34A2 Proteins 0.000 claims 1
- 108091006491 SLC34A2 Proteins 0.000 claims 1
- 102100010114 SLC39A6 Human genes 0.000 claims 1
- 101710017109 SLC39A6 Proteins 0.000 claims 1
- 102100009743 TNFRSF13C Human genes 0.000 claims 1
- 101710030862 TNFRSF13C Proteins 0.000 claims 1
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 claims 1
- 150000001735 carboxylic acids Chemical class 0.000 claims 1
- 102000017256 epidermal growth factor-activated receptor activity proteins Human genes 0.000 claims 1
- 108040009258 epidermal growth factor-activated receptor activity proteins Proteins 0.000 claims 1
- 102000027675 major histocompatibility complex family Human genes 0.000 claims 1
- 108091007937 major histocompatibility complex family Proteins 0.000 claims 1
- 244000005700 microbiome Species 0.000 claims 1
- 101700034546 qacC Proteins 0.000 claims 1
- 102000002938 thrombospondin family Human genes 0.000 claims 1
- 108060008245 thrombospondin family Proteins 0.000 claims 1
- 102000006240 membrane receptors Human genes 0.000 abstract description 6
- 108020004084 membrane receptors Proteins 0.000 abstract description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 116
- 150000001875 compounds Chemical class 0.000 description 108
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 102
- 239000000562 conjugate Substances 0.000 description 63
- 235000019439 ethyl acetate Nutrition 0.000 description 54
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 46
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 40
- 239000000243 solution Substances 0.000 description 38
- LIVNPJMFVYWSIS-UHFFFAOYSA-N silicon monoxide Inorganic materials [Si-]#[O+] LIVNPJMFVYWSIS-UHFFFAOYSA-N 0.000 description 35
- 238000003786 synthesis reaction Methods 0.000 description 31
- 230000015572 biosynthetic process Effects 0.000 description 30
- 230000002194 synthesizing Effects 0.000 description 29
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 26
- 238000006243 chemical reaction Methods 0.000 description 24
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 22
- 235000018102 proteins Nutrition 0.000 description 22
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
- 235000001014 amino acid Nutrition 0.000 description 21
- 230000021615 conjugation Effects 0.000 description 21
- 239000008079 hexane Substances 0.000 description 21
- 241000282414 Homo sapiens Species 0.000 description 20
- 206010028980 Neoplasm Diseases 0.000 description 18
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 18
- 201000009030 carcinoma Diseases 0.000 description 17
- 238000000034 method Methods 0.000 description 17
- 229910004373 HOAc Inorganic materials 0.000 description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 16
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 16
- 102000004196 processed proteins & peptides Human genes 0.000 description 15
- 108090000765 processed proteins & peptides Proteins 0.000 description 15
- 125000003396 thiol group Chemical group [H]S* 0.000 description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
- 230000035492 administration Effects 0.000 description 14
- 230000002401 inhibitory effect Effects 0.000 description 14
- BZKBCQXYZZXSCO-UHFFFAOYSA-N sodium hydride Inorganic materials [H-].[Na+] BZKBCQXYZZXSCO-UHFFFAOYSA-N 0.000 description 14
- 239000003112 inhibitor Substances 0.000 description 13
- 239000007787 solid Substances 0.000 description 13
- 206010025650 Malignant melanoma Diseases 0.000 description 12
- 206010035226 Plasma cell myeloma Diseases 0.000 description 12
- 238000004587 chromatography analysis Methods 0.000 description 12
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 12
- 201000001441 melanoma Diseases 0.000 description 12
- 239000012044 organic layer Substances 0.000 description 12
- 102100010912 EPCAM Human genes 0.000 description 11
- 239000002609 media Substances 0.000 description 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 11
- 238000000746 purification Methods 0.000 description 11
- ODUCDPQEXGNKDN-UHFFFAOYSA-N Nitroxyl Chemical compound O=N ODUCDPQEXGNKDN-UHFFFAOYSA-N 0.000 description 10
- 206010033128 Ovarian cancer Diseases 0.000 description 10
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 10
- 238000005984 hydrogenation reaction Methods 0.000 description 10
- PEEHTFAAVSWFBL-UHFFFAOYSA-N maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 10
- 201000009251 multiple myeloma Diseases 0.000 description 10
- 229920001223 polyethylene glycol Polymers 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 9
- 102000003886 Glycoproteins Human genes 0.000 description 8
- 108090000288 Glycoproteins Proteins 0.000 description 8
- HNBDRPTVWVGKBR-UHFFFAOYSA-N Methyl pentanoate Chemical compound CCCCC(=O)OC HNBDRPTVWVGKBR-UHFFFAOYSA-N 0.000 description 8
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 8
- 239000002202 Polyethylene glycol Substances 0.000 description 8
- 238000007792 addition Methods 0.000 description 8
- 125000003277 amino group Chemical group 0.000 description 8
- 230000015861 cell surface binding Effects 0.000 description 8
- 239000000460 chlorine Substances 0.000 description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- 235000019198 oils Nutrition 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 201000010874 syndrome Diseases 0.000 description 8
- 229940019746 Antifibrinolytic amino acids Drugs 0.000 description 7
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 7
- QRXWMOHMRWLFEY-UHFFFAOYSA-N Isoniazid Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 7
- 206010024324 Leukaemias Diseases 0.000 description 7
- 206010025323 Lymphomas Diseases 0.000 description 7
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 7
- 206010025310 Other lymphomas Diseases 0.000 description 7
- 102100009534 TNF Human genes 0.000 description 7
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 7
- 239000002585 base Substances 0.000 description 7
- 239000010410 layer Substances 0.000 description 7
- 230000001717 pathogenic Effects 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 6
- 108060002563 EPCAM Proteins 0.000 description 6
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 6
- 241000700721 Hepatitis B virus Species 0.000 description 6
- 208000009874 Lice Infestations Diseases 0.000 description 6
- 206010060862 Prostate cancer Diseases 0.000 description 6
- 108010010691 Trastuzumab Proteins 0.000 description 6
- 150000001299 aldehydes Chemical class 0.000 description 6
- 125000002947 alkylene group Chemical group 0.000 description 6
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 150000001720 carbohydrates Chemical class 0.000 description 6
- 235000014633 carbohydrates Nutrition 0.000 description 6
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 6
- 125000000524 functional group Chemical group 0.000 description 6
- 230000002496 gastric Effects 0.000 description 6
- WMFOQBRAJBCJND-UHFFFAOYSA-M lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
- 230000003211 malignant Effects 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000006011 modification reaction Methods 0.000 description 6
- 229960000060 monoclonal antibodies Drugs 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 229920001184 polypeptide Polymers 0.000 description 6
- 239000000651 prodrug Substances 0.000 description 6
- 229940002612 prodrugs Drugs 0.000 description 6
- 238000010532 solid phase synthesis reaction Methods 0.000 description 6
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 6
- 229960000575 trastuzumab Drugs 0.000 description 6
- OJZNYUDKNVNEMV-UHFFFAOYSA-M trimethylstannanylium;hydroxide Chemical compound C[Sn](C)(C)O OJZNYUDKNVNEMV-UHFFFAOYSA-M 0.000 description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
- 210000000481 Breast Anatomy 0.000 description 5
- 206010006187 Breast cancer Diseases 0.000 description 5
- 241000701022 Cytomegalovirus Species 0.000 description 5
- 206010017758 Gastric cancer Diseases 0.000 description 5
- 210000004408 Hybridomas Anatomy 0.000 description 5
- RCINICONZNJXQF-MZXODVADSA-N Intaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 5
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 5
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 5
- 102100013180 KDR Human genes 0.000 description 5
- JQXXHWHPUNPDRT-ZNQWNCHJSA-N O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)Nc2c(O)c3c(O)c4C)C)OC)c4c1c3c(O)c2C=NN1CCN(C)CC1 Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)Nc2c(O)c3c(O)c4C)C)OC)c4c1c3c(O)c2C=NN1CCN(C)CC1 JQXXHWHPUNPDRT-ZNQWNCHJSA-N 0.000 description 5
- 241000725643 Respiratory syncytial virus Species 0.000 description 5
- 229940081190 Rifampin Drugs 0.000 description 5
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M Sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 5
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N Valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 239000012267 brine Substances 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 230000000813 microbial Effects 0.000 description 5
- 229910052763 palladium Inorganic materials 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- 229960001225 rifampicin Drugs 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 201000011549 stomach cancer Diseases 0.000 description 5
- 230000001225 therapeutic Effects 0.000 description 5
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 5
- ACVAAFHNDGTZLL-UHFFFAOYSA-N 5-(2,5-dioxopyrrol-1-yl)pentanoic acid Chemical compound OC(=O)CCCCN1C(=O)C=CC1=O ACVAAFHNDGTZLL-UHFFFAOYSA-N 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 208000009899 Burkitt Lymphoma Diseases 0.000 description 4
- 102100019456 CD276 Human genes 0.000 description 4
- 101700015421 CD276 Proteins 0.000 description 4
- 102100011842 CEACAM5 Human genes 0.000 description 4
- 102100005310 CTLA4 Human genes 0.000 description 4
- 101700054183 CTLA4 Proteins 0.000 description 4
- 102100002212 CXCR4 Human genes 0.000 description 4
- 101710003734 CXCR4 Proteins 0.000 description 4
- 108010022830 Cetuximab Proteins 0.000 description 4
- 229960004679 Doxorubicin Drugs 0.000 description 4
- 241000709661 Enterovirus Species 0.000 description 4
- 241000711549 Hepacivirus C Species 0.000 description 4
- 241000725303 Human immunodeficiency virus Species 0.000 description 4
- 102000004889 Interleukin-6 Human genes 0.000 description 4
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 4
- 101710030888 KDR Proteins 0.000 description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 4
- 239000000637 Melanocyte-Stimulating Hormone Substances 0.000 description 4
- 244000278455 Morus laevigata Species 0.000 description 4
- 235000013382 Morus laevigata Nutrition 0.000 description 4
- 208000005647 Mumps Diseases 0.000 description 4
- 229960001592 Paclitaxel Drugs 0.000 description 4
- 206010034277 Pemphigoid Diseases 0.000 description 4
- 206010039491 Sarcoma Diseases 0.000 description 4
- 101710040537 TNF Proteins 0.000 description 4
- 101710030970 TNFRSF10B Proteins 0.000 description 4
- 102100012980 TNFRSF10B Human genes 0.000 description 4
- NHKZSTHOYNWEEZ-AFCXAGJDSA-N Taribavirin Chemical compound N1=C(C(=N)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NHKZSTHOYNWEEZ-AFCXAGJDSA-N 0.000 description 4
- 206010043207 Temporal arteritis Diseases 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 230000002494 anti-cea Effects 0.000 description 4
- 230000003097 anti-respiratory Effects 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 4
- 229960005395 cetuximab Drugs 0.000 description 4
- 230000001684 chronic Effects 0.000 description 4
- 230000000875 corresponding Effects 0.000 description 4
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 150000003840 hydrochlorides Chemical class 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 4
- 230000002757 inflammatory Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 201000005202 lung cancer Diseases 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000002611 ovarian Effects 0.000 description 4
- 238000002823 phage display Methods 0.000 description 4
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 4
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 4
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 description 4
- 229950006081 taribavirin Drugs 0.000 description 4
- 125000006633 tert-butoxycarbonylamino group Chemical group 0.000 description 4
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 3
- IJVLVRYLIMQVDD-UHFFFAOYSA-N 1,3-thiazole-2-carboxylic acid Chemical compound OC(=O)C1=NC=CS1 IJVLVRYLIMQVDD-UHFFFAOYSA-N 0.000 description 3
- HAXFWIACAGNFHA-UHFFFAOYSA-N 2,2'-Dipyridyldisulfide Chemical compound C=1C=CC=NC=1SSC1=CC=CC=N1 HAXFWIACAGNFHA-UHFFFAOYSA-N 0.000 description 3
- GHASVSINZRGABV-UHFFFAOYSA-N 5-flurouricil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 3
- 102100016549 ANPEP Human genes 0.000 description 3
- 206010000565 Acquired immunodeficiency syndrome Diseases 0.000 description 3
- 206010002026 Amyotrophic lateral sclerosis Diseases 0.000 description 3
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 3
- 102100013858 BSG Human genes 0.000 description 3
- 108010005144 Bevacizumab Proteins 0.000 description 3
- 210000001185 Bone Marrow Anatomy 0.000 description 3
- 241000589968 Borrelia Species 0.000 description 3
- WZENSHMKBOPZTM-UHFFFAOYSA-M C(C1=CC=CC=C1)(C1=CC=CC=C1)(C1=CC=CC=C1)SC(C(=O)[O-])C Chemical compound C(C1=CC=CC=C1)(C1=CC=CC=C1)(C1=CC=CC=C1)SC(C(=O)[O-])C WZENSHMKBOPZTM-UHFFFAOYSA-M 0.000 description 3
- ACVAAFHNDGTZLL-UHFFFAOYSA-M C1(C=CC(N1CCCCC(=O)[O-])=O)=O Chemical compound C1(C=CC(N1CCCCC(=O)[O-])=O)=O ACVAAFHNDGTZLL-UHFFFAOYSA-M 0.000 description 3
- 101710043956 CEACAM5 Proteins 0.000 description 3
- 241000222122 Candida albicans Species 0.000 description 3
- 206010007134 Candida infection Diseases 0.000 description 3
- 210000000234 Capsid Anatomy 0.000 description 3
- 201000003884 Chagas disease Diseases 0.000 description 3
- JCKYGMPEJWAADB-UHFFFAOYSA-N Chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 3
- 229960004630 Chlorambucil Drugs 0.000 description 3
- 206010008761 Choriomeningitis lymphocytic Diseases 0.000 description 3
- 229940038704 Clostridium perfringens Drugs 0.000 description 3
- 241000711573 Coronaviridae Species 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 101700079540 FAS Proteins 0.000 description 3
- 230000035693 Fab Effects 0.000 description 3
- IRXSLJNXXZKURP-UHFFFAOYSA-N Fluorenylmethyloxycarbonyl chloride Chemical compound C1=CC=C2C(COC(=O)Cl)C3=CC=CC=C3C2=C1 IRXSLJNXXZKURP-UHFFFAOYSA-N 0.000 description 3
- 229960002949 Fluorouracil Drugs 0.000 description 3
- ZJAOAACCNHFJAH-UHFFFAOYSA-N Foscarnet Chemical compound OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- 210000003714 Granulocytes Anatomy 0.000 description 3
- 208000006454 Hepatitis Diseases 0.000 description 3
- 241000724675 Hepatitis E virus Species 0.000 description 3
- 241000724709 Hepatitis delta virus Species 0.000 description 3
- 241000709721 Hepatovirus A Species 0.000 description 3
- 206010020243 Hodgkin's disease Diseases 0.000 description 3
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 3
- 241000711920 Human orthopneumovirus Species 0.000 description 3
- 208000010159 IGA Glomerulonephritis Diseases 0.000 description 3
- 102100014263 IGF1R Human genes 0.000 description 3
- 101700025802 IGF1R Proteins 0.000 description 3
- 102100019332 ITGA2B Human genes 0.000 description 3
- 102100019442 ITGAL Human genes 0.000 description 3
- 101710006573 ITGAL Proteins 0.000 description 3
- 206010021263 IgA nephropathy Diseases 0.000 description 3
- 108090001095 Immunoglobulin G Proteins 0.000 description 3
- 102000018358 Immunoglobulins Human genes 0.000 description 3
- 108060003951 Immunoglobulins Proteins 0.000 description 3
- 108010053490 Infliximab Proteins 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 102000000588 Interleukin-2 Human genes 0.000 description 3
- 229940100601 Interleukin-6 Drugs 0.000 description 3
- 208000007766 Kaposi Sarcoma Diseases 0.000 description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 210000004072 Lung Anatomy 0.000 description 3
- 210000004698 Lymphocytes Anatomy 0.000 description 3
- 208000001419 Lymphocytic Choriomeningitis Diseases 0.000 description 3
- 208000002030 Merkel Cell Carcinoma Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000872931 Myoporum sandwicense Species 0.000 description 3
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 3
- 241000243985 Onchocerca volvulus Species 0.000 description 3
- 241000712464 Orthomyxoviridae Species 0.000 description 3
- 102000033170 PRNP Human genes 0.000 description 3
- 101710024107 PRNP Proteins 0.000 description 3
- 108010061219 Panitumumab Proteins 0.000 description 3
- 208000002098 Purpura, Thrombocytopenic, Idiopathic Diseases 0.000 description 3
- 208000006265 Renal Cell Carcinoma Diseases 0.000 description 3
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 3
- 229960000329 Ribavirin Drugs 0.000 description 3
- 241000606701 Rickettsia Species 0.000 description 3
- 101710023234 Segment 5 Proteins 0.000 description 3
- 210000002966 Serum Anatomy 0.000 description 3
- 229910004298 SiO 2 Inorganic materials 0.000 description 3
- 241000191940 Staphylococcus Species 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- YBBRCQOCSYXUOC-UHFFFAOYSA-N Sulfuryl chloride Chemical class ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 3
- 101710037124 TEK Proteins 0.000 description 3
- 102100009744 TNFRSF13B Human genes 0.000 description 3
- 101710030909 TNFRSF13B Proteins 0.000 description 3
- 102100013135 TNFRSF4 Human genes 0.000 description 3
- 101710040448 TNFRSF4 Proteins 0.000 description 3
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 3
- 208000002474 Tinea Diseases 0.000 description 3
- 206010044269 Toxocariasis Diseases 0.000 description 3
- 241000223238 Trichophyton Species 0.000 description 3
- 241000893966 Trichophyton verrucosum Species 0.000 description 3
- WVPSKSLAZQPAKQ-CDMJZVDBSA-N Trovafloxacin Chemical compound C([C@H]1[C@@H]([C@H]1C1)N)N1C(C(=CC=1C(=O)C(C(O)=O)=C2)F)=NC=1N2C1=CC=C(F)C=C1F WVPSKSLAZQPAKQ-CDMJZVDBSA-N 0.000 description 3
- 241000223109 Trypanosoma cruzi Species 0.000 description 3
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 description 3
- 102100019577 VCAM1 Human genes 0.000 description 3
- 229960003048 Vinblastine Drugs 0.000 description 3
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 3
- 241000607479 Yersinia pestis Species 0.000 description 3
- IQPQWNKOIGAROB-UHFFFAOYSA-N [N-]=C=O Chemical compound [N-]=C=O IQPQWNKOIGAROB-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 230000001154 acute Effects 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 150000008064 anhydrides Chemical class 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 230000000208 anti-hepatitis Effects 0.000 description 3
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 3
- YZFXXNLDAZMHAB-AREMUKBSSA-N benzyl (2R)-2-[methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]-3-(4-phenylmethoxyphenyl)propanoate Chemical compound C([C@@H](N(C)C(=O)OC(C)(C)C)C(=O)OCC=1C=CC=CC=1)C(C=C1)=CC=C1OCC1=CC=CC=C1 YZFXXNLDAZMHAB-AREMUKBSSA-N 0.000 description 3
- 229960000397 bevacizumab Drugs 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 150000001805 chlorine compounds Chemical class 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 201000009230 common cold Diseases 0.000 description 3
- 229940030275 epigallocatechin gallate Drugs 0.000 description 3
- 229960005102 foscarnet Drugs 0.000 description 3
- 210000004602 germ cell Anatomy 0.000 description 3
- 125000005179 haloacetyl group Chemical group 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 229960000598 infliximab Drugs 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 101700075443 invA3 Proteins 0.000 description 3
- 150000002513 isocyanates Chemical class 0.000 description 3
- 150000002540 isothiocyanates Chemical class 0.000 description 3
- 201000009906 meningitis Diseases 0.000 description 3
- 229960000485 methotrexate Drugs 0.000 description 3
- 201000005962 mycosis fungoide Diseases 0.000 description 3
- 230000003000 nontoxic Effects 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 239000002777 nucleoside Substances 0.000 description 3
- 150000002923 oximes Chemical class 0.000 description 3
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 3
- 229960001972 panitumumab Drugs 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 125000000538 pentafluorophenyl group Chemical group FC1=C(F)C(F)=C(*)C(F)=C1F 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 230000002195 synergetic Effects 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 229930003347 taxol Natural products 0.000 description 3
- 150000003573 thiols Chemical class 0.000 description 3
- 229960000497 trovafloxacin Drugs 0.000 description 3
- 241000712461 unidentified influenza virus Species 0.000 description 3
- NQPDZGIKBAWPEJ-UHFFFAOYSA-M valerate Chemical compound CCCCC([O-])=O NQPDZGIKBAWPEJ-UHFFFAOYSA-M 0.000 description 3
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 3
- PENDGIOBPJLVBT-ONLVEXIXSA-N (1R,2R,4R,6R,7R,8R,10R,13R,14S)-7-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-13-ethyl-2,4,6,8,10,14-hexamethyl-6-[(E)-3-quinolin-3-ylprop-2-enoxy]-12,15-dioxa-17-azabicyclo[12.3.0]heptadecane-3,9,11,16-tetrone Chemical compound O([C@@H]1[C@@H](C)C(=O)[C@@H](C)C(=O)O[C@@H]([C@]2(OC(=O)N[C@@H]2[C@@H](C)C(=O)[C@H](C)C[C@@]1(C)OC\C=C\C=1C=C2C=CC=CC2=NC=1)C)CC)[C@@H]1O[C@H](C)C[C@H](N(C)C)[C@H]1O PENDGIOBPJLVBT-ONLVEXIXSA-N 0.000 description 2
- CIDUJQMULVCIBT-MQDUPKMGSA-N (2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4-amino-3-[[(2S,3R)-3-amino-6-(aminomethyl)-3,4-dihydro-2H-pyran-2-yl]oxy]-6-(ethylamino)-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](NC)[C@@](C)(O)CO1)O)NCC)[C@H]1OC(CN)=CC[C@H]1N CIDUJQMULVCIBT-MQDUPKMGSA-N 0.000 description 2
- XQSPYNMVSIKCOC-NTSWFWBYSA-N (2R-cis)-4-amino-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-Pyrimidinone Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1 XQSPYNMVSIKCOC-NTSWFWBYSA-N 0.000 description 2
- XNODZYPOIPVPRF-CGWDHHCXSA-N (2S)-2-methyl-4-[(2R,8R,13R)-2,8,13-trihydroxy-13-[(2R,5R)-5-[(1R)-1-hydroxytridecyl]oxolan-2-yl]tridecyl]-2H-furan-5-one Chemical compound O1[C@@H]([C@H](O)CCCCCCCCCCCC)CC[C@@H]1[C@H](O)CCCC[C@H](O)CCCCC[C@@H](O)CC1=C[C@H](C)OC1=O XNODZYPOIPVPRF-CGWDHHCXSA-N 0.000 description 2
- PMOOKBAYUNEHOF-IKHMJLPLSA-N (2S,3S,4S,5R,6R)-6-[[(4aR,6aR,6bS,8aS,14aR,14bR)-8a-carboxy-4,4,6a,6b,11,11,14b-heptamethyl-1,2,3,4a,5,6,7,8,9,10,12,13,14,14a-tetradecahydropicen-3-yl]oxy]-3,5-dihydroxy-4-[(1R,2R,3S,4R)-2,3,4-trihydroxycyclohexyl]oxyoxane-2-carboxylic acid Chemical compound O([C@H]1[C@H](O)[C@H](O[C@H]([C@@H]1O)OC1CC[C@]2(C)[C@H]3CCC=4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@]1(CCC(CC1=4)(C)C)C(O)=O)C(O)=O)[C@@H]1CC[C@@H](O)[C@H](O)[C@H]1O PMOOKBAYUNEHOF-IKHMJLPLSA-N 0.000 description 2
- JFPVXVDWJQMJEE-IZRZKJBUSA-N (6R,7R)-3-[(carbamoyloxy)methyl]-7-[(2Z)-2-(furan-2-yl)-2-(methoxyimino)acetamido]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 description 2
- WDLWHQDACQUCJR-ZAMMOSSLSA-N (6R,7R)-7-[[(2R)-2-azaniumyl-2-(4-hydroxyphenyl)acetyl]amino]-8-oxo-3-[(E)-prop-1-enyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)/C=C/C)C(O)=O)=CC=C(O)C=C1 WDLWHQDACQUCJR-ZAMMOSSLSA-N 0.000 description 2
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1,2,3-triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 description 2
- COVZYZSDYWQREU-UHFFFAOYSA-N 1,4-Butanediol, dimethanesulfonate Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 2
- WWIYQJITPCEFGT-UHFFFAOYSA-N 1,4-bis(ethenyl)benzene;(4-methylphenyl)-phenylmethanamine;styrene;hydrochloride Chemical compound Cl.C=CC1=CC=CC=C1.C=CC1=CC=C(C=C)C=C1.C1=CC(C)=CC=C1C(N)C1=CC=CC=C1 WWIYQJITPCEFGT-UHFFFAOYSA-N 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N 1-[(1S,2R,3R,4S,5R,6R)-3-carbamimidamido-6-{[(2R,3R,4R,5S)-3-{[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy}-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy}-2,4,5-trihydroxycyclohexyl]guanidine Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- VKJCJJYNVIYVQR-UHFFFAOYSA-N 2-(3-bromopropyl)isoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(CCCBr)C(=O)C2=C1 VKJCJJYNVIYVQR-UHFFFAOYSA-N 0.000 description 2
- SUVMJBTUFCVSAD-JTQLQIEISA-N 4-Methylsulfinylbutyl isothiocyanate Natural products C[S@](=O)CCCCN=C=S SUVMJBTUFCVSAD-JTQLQIEISA-N 0.000 description 2
- JTEGQNOMFQHVDC-NKWVEPMBSA-N 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-1,2-dihydropyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 2
- HGDLVVAFLRBLKJ-UHFFFAOYSA-N 5-(2,5-dioxopyrrol-1-yl)pentanehydrazide Chemical compound NNC(=O)CCCCN1C(=O)C=CC1=O HGDLVVAFLRBLKJ-UHFFFAOYSA-N 0.000 description 2
- 102100003649 ACP3 Human genes 0.000 description 2
- 102100008450 AFP Human genes 0.000 description 2
- 229940119059 Actemra Drugs 0.000 description 2
- UNFWWIHTNXNPBV-WXKVUWSESA-N Actinospectacin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 description 2
- 208000002552 Acute Disseminated Encephalomyelitis Diseases 0.000 description 2
- 108010007562 Adalimumab Proteins 0.000 description 2
- 208000000230 African Trypanosomiasis Diseases 0.000 description 2
- 208000008190 Agammaglobulinemia Diseases 0.000 description 2
- LKCWBDHBTVXHDL-RMDFUYIESA-N Amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 2
- 206010061424 Anal cancer Diseases 0.000 description 2
- 102000004145 Annexin A1 Human genes 0.000 description 2
- 108090000663 Annexin A1 Proteins 0.000 description 2
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 2
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 2
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 2
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 2
- 241001135700 Arcanobacterium haemolyticum Species 0.000 description 2
- 229960002170 Azathioprine Drugs 0.000 description 2
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 2
- 241000193738 Bacillus anthracis Species 0.000 description 2
- 229960003071 Bacitracin Drugs 0.000 description 2
- 108010001478 Bacitracin Proteins 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 208000007456 Balantidiasis Diseases 0.000 description 2
- 108010064528 Basigin Proteins 0.000 description 2
- 108010067213 Basiliximab Proteins 0.000 description 2
- 208000009299 Benign Mucous Membrane Pemphigoid Diseases 0.000 description 2
- 230000036912 Bioavailability Effects 0.000 description 2
- 206010005098 Blastomycosis Diseases 0.000 description 2
- 108010006654 Bleomycin Proteins 0.000 description 2
- 229940097269 Borrelia burgdorferi Drugs 0.000 description 2
- 241000589969 Borreliella burgdorferi Species 0.000 description 2
- 208000000594 Bullous Pemphigoid Diseases 0.000 description 2
- 102100012080 CCR5 Human genes 0.000 description 2
- 101700043583 CCR5 Proteins 0.000 description 2
- 108010049990 CD13 Antigens Proteins 0.000 description 2
- 102100019459 CD27 Human genes 0.000 description 2
- 101700056583 CD27 Proteins 0.000 description 2
- 102100019461 CD28 Human genes 0.000 description 2
- 101700033362 CD28 Proteins 0.000 description 2
- 102100019283 CD52 Human genes 0.000 description 2
- 108010065524 CD52 Antigen Proteins 0.000 description 2
- 102100008191 CD8A Human genes 0.000 description 2
- 101700054655 CD8A Proteins 0.000 description 2
- 101710043954 CEACAM3 Proteins 0.000 description 2
- 102100011836 CEACAM3 Human genes 0.000 description 2
- HXCHCVDVKSCDHU-LULTVBGHSA-N Calicheamicin Chemical class C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 description 2
- VSJKWCGYPAHWDS-FQEVSTJZSA-N Camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 2
- 241000589876 Campylobacter Species 0.000 description 2
- 229940095731 Candida albicans Drugs 0.000 description 2
- 208000005024 Castleman Disease Diseases 0.000 description 2
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N Cefalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 2
- XIURVHNZVLADCM-IUODEOHRSA-N Cefalotin Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C(O)=O)C(=O)CC1=CC=CS1 XIURVHNZVLADCM-IUODEOHRSA-N 0.000 description 2
- HVFLCNVBZFFHBT-ZKDACBOMSA-N Cefepime Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1C[N+]1(C)CCCC1 HVFLCNVBZFFHBT-ZKDACBOMSA-N 0.000 description 2
- WZOZEZRFJCJXNZ-ZBFHGGJFSA-N Cefoxitin Chemical compound N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)CC1=CC=CS1 WZOZEZRFJCJXNZ-ZBFHGGJFSA-N 0.000 description 2
- 229960002682 Cefoxitin Drugs 0.000 description 2
- 229960001668 Cefuroxime Drugs 0.000 description 2
- 210000003169 Central Nervous System Anatomy 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 229950010329 Cethromycin Drugs 0.000 description 2
- 241001647372 Chlamydia pneumoniae Species 0.000 description 2
- 241000606153 Chlamydia trachomatis Species 0.000 description 2
- 229940038705 Chlamydia trachomatis Drugs 0.000 description 2
- 206010008631 Cholera Diseases 0.000 description 2
- 241000193468 Clostridium perfringens Species 0.000 description 2
- 241000223205 Coccidioides immitis Species 0.000 description 2
- 210000001072 Colon Anatomy 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 229940047120 Colony stimulating factors Drugs 0.000 description 2
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 2
- 201000010450 Creutzfeldt-Jakob disease Diseases 0.000 description 2
- 239000004971 Cross linker Substances 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- 229960004397 Cyclophosphamide Drugs 0.000 description 2
- 108010036949 Cyclosporine Proteins 0.000 description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytosar Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N DAUNOMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
- 102100019888 DLL4 Human genes 0.000 description 2
- 101700018087 DLL4 Proteins 0.000 description 2
- 108010084740 Daclizumab Proteins 0.000 description 2
- 108010092160 Dactinomycin Proteins 0.000 description 2
- 229960000640 Dactinomycin Drugs 0.000 description 2
- 229960000975 Daunorubicin Drugs 0.000 description 2
- JWCSIUVGFCSJCK-CAVRMKNVSA-N Disodium Moxalactam Chemical compound N([C@]1(OC)C(N2C(=C(CSC=3N(N=NN=3)C)CO[C@@H]21)C(O)=O)=O)C(=O)C(C(O)=O)C1=CC=C(O)C=C1 JWCSIUVGFCSJCK-CAVRMKNVSA-N 0.000 description 2
- 108010066486 EGF Family of Proteins Proteins 0.000 description 2
- 102000018386 EGF Family of Proteins Human genes 0.000 description 2
- 208000000292 Ehrlichiosis Diseases 0.000 description 2
- 206010014599 Encephalitis Diseases 0.000 description 2
- 108010036395 Endoglin Proteins 0.000 description 2
- 206010014881 Enterobiasis Diseases 0.000 description 2
- 241000194033 Enterococcus Species 0.000 description 2
- 241000991587 Enterovirus C Species 0.000 description 2
- 229960005420 Etoposide Drugs 0.000 description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N Etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
- 102100016439 FAS Human genes 0.000 description 2
- 102100014608 FCER2 Human genes 0.000 description 2
- 101700053597 FCER2 Proteins 0.000 description 2
- 102000018233 Fibroblast growth factor family Human genes 0.000 description 2
- 108050007372 Fibroblast growth factor family Proteins 0.000 description 2
- 208000001640 Fibromyalgia Diseases 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N Folic acid Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 229960004675 Fusidic Acid Drugs 0.000 description 2
- IECPWNUMDGFDKC-MZJAQBGESA-N Fusidic acid Chemical compound O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 2
- 241000531123 GB virus C Species 0.000 description 2
- 208000007465 Giant Cell Arteritis Diseases 0.000 description 2
- RFDAIACWWDREDC-FRVQLJSFSA-N Glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 description 2
- 206010018651 Graft versus host disease Diseases 0.000 description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 description 2
- 206010018693 Granuloma inguinale Diseases 0.000 description 2
- AIJTTZAVMXIJGM-UHFFFAOYSA-N Grepafloxacin Chemical compound C1CNC(C)CN1C(C(=C1C)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1CC1 AIJTTZAVMXIJGM-UHFFFAOYSA-N 0.000 description 2
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 2
- 241000606768 Haemophilus influenzae Species 0.000 description 2
- 210000003958 Hematopoietic Stem Cells Anatomy 0.000 description 2
- 208000002672 Hepatitis B Diseases 0.000 description 2
- 206010073071 Hepatocellular carcinoma Diseases 0.000 description 2
- 208000009889 Herpes Simplex Diseases 0.000 description 2
- 208000007514 Herpes Zoster Diseases 0.000 description 2
- 241000228404 Histoplasma capsulatum Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 208000006572 Human Influenza Diseases 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 108091006822 Human Serum Albumin Proteins 0.000 description 2
- 206010020460 Human T-cell lymphotropic virus type I infection Diseases 0.000 description 2
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 2
- 241000046923 Human bocavirus Species 0.000 description 2
- 241000342334 Human metapneumovirus Species 0.000 description 2
- 241000829111 Human polyomavirus 1 Species 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- 206010020983 Hypogammaglobulinaemia Diseases 0.000 description 2
- 102100004115 ICAM1 Human genes 0.000 description 2
- 101700051176 ICAM1 Proteins 0.000 description 2
- 101710044247 ITGA2B Proteins 0.000 description 2
- 229950010245 Ibalizumab Drugs 0.000 description 2
- 102000009438 IgE Receptors Human genes 0.000 description 2
- 108010073816 IgE Receptors Proteins 0.000 description 2
- DOUYETYNHWVLEO-UHFFFAOYSA-N Imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 2
- 206010027665 Immune disorder Diseases 0.000 description 2
- 206010021425 Immune system disease Diseases 0.000 description 2
- 206010021972 Inflammatory bowel disease Diseases 0.000 description 2
- 206010022000 Influenza Diseases 0.000 description 2
- 102000006992 Interferon-alpha Human genes 0.000 description 2
- 108010047761 Interferon-alpha Proteins 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 229940047124 Interferons Drugs 0.000 description 2
- 208000006617 Islet Cell Carcinoma Diseases 0.000 description 2
- 206010023076 Isosporiasis Diseases 0.000 description 2
- 208000003456 Juvenile Arthritis Diseases 0.000 description 2
- 201000007313 Kawasaki disease Diseases 0.000 description 2
- 241000589014 Kingella kingae Species 0.000 description 2
- 241000588748 Klebsiella Species 0.000 description 2
- 206010023497 Kuru Diseases 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 2
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 2
- 229960001375 Lactose Drugs 0.000 description 2
- 229940115932 Legionella pneumophila Drugs 0.000 description 2
- 241000589242 Legionella pneumophila Species 0.000 description 2
- 208000004023 Legionellosis Diseases 0.000 description 2
- 241000589902 Leptospira Species 0.000 description 2
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N Levofloxacin Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 2
- 206010024515 Linear IgA disease Diseases 0.000 description 2
- 206010025169 Lyme disease Diseases 0.000 description 2
- 241000712899 Lymphocytic choriomeningitis mammarenavirus Species 0.000 description 2
- 102100008857 MLANA Human genes 0.000 description 2
- 101710012533 MLANA Proteins 0.000 description 2
- 101710044634 MS4A2 Proteins 0.000 description 2
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 2
- WKPWGQKGSOKKOO-RSFHAFMBSA-N Maitansine Chemical class CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N Melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N Methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N Methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 229960004857 Mitomycin Drugs 0.000 description 2
- 241000700560 Molluscum contagiosum virus Species 0.000 description 2
- HRNLUBSXIHFDHP-UHFFFAOYSA-N N-(2-aminophenyl)-4-[[(4-pyridin-3-ylpyrimidin-2-yl)amino]methyl]benzamide Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC1=NC=CC(C=2C=NC=CC=2)=N1 HRNLUBSXIHFDHP-UHFFFAOYSA-N 0.000 description 2
- 102100006167 NCL Human genes 0.000 description 2
- 229940100662 Nasal Drops Drugs 0.000 description 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 2
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 2
- 229960000808 Netilmicin Drugs 0.000 description 2
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 description 2
- 208000008795 Neuromyelitis Optica Diseases 0.000 description 2
- 206010029592 Non-Hodgkin's lymphomas Diseases 0.000 description 2
- 241001263478 Norovirus Species 0.000 description 2
- 229960000470 Omalizumab Drugs 0.000 description 2
- 108010029597 Omalizumab Proteins 0.000 description 2
- 208000002042 Onchocerciasis Diseases 0.000 description 2
- 208000010195 Onychomycosis Diseases 0.000 description 2
- 206010030861 Ophthalmia neonatorum Diseases 0.000 description 2
- 108010019613 Palivizumab Proteins 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 241001326499 Piedraia hortae Species 0.000 description 2
- 206010035228 Plasma cell neoplasms Diseases 0.000 description 2
- 241000224016 Plasmodium Species 0.000 description 2
- KQOXLKOJHVFTRN-UHFFFAOYSA-N Pleconaril Chemical compound O1N=C(C)C=C1CCCOC1=C(C)C=C(C=2N=C(ON=2)C(F)(F)F)C=C1C KQOXLKOJHVFTRN-UHFFFAOYSA-N 0.000 description 2
- 208000005384 Pneumocystis Pneumonia Diseases 0.000 description 2
- 206010073755 Pneumocystis jirovecii pneumonia Diseases 0.000 description 2
- 206010035737 Pneumonia viral Diseases 0.000 description 2
- 208000000474 Poliomyelitis Diseases 0.000 description 2
- 241000605861 Prevotella Species 0.000 description 2
- 206010036807 Progressive multifocal leukoencephalopathy Diseases 0.000 description 2
- 229940055023 Pseudomonas aeruginosa Drugs 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N Psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 2
- 102100002049 ROBO4 Human genes 0.000 description 2
- 101700023119 ROBO4 Proteins 0.000 description 2
- 101700079635 RTL1 Proteins 0.000 description 2
- 206010037742 Rabies Diseases 0.000 description 2
- 229960003876 Ranibizumab Drugs 0.000 description 2
- 108010062724 Ranibizumab Proteins 0.000 description 2
- 206010038038 Rectal cancer Diseases 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- BXNMTOQRYBFHNZ-UHFFFAOYSA-N Resiquimod Chemical compound C1=CC=CC2=C(N(C(COCC)=N3)CC(C)(C)O)C3=C(N)N=C21 BXNMTOQRYBFHNZ-UHFFFAOYSA-N 0.000 description 2
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 description 2
- 241000606723 Rickettsia akari Species 0.000 description 2
- 108010001645 Rituximab Proteins 0.000 description 2
- 241000702670 Rotavirus Species 0.000 description 2
- 241000315672 SARS coronavirus Species 0.000 description 2
- 102100008254 SELL Human genes 0.000 description 2
- 101710038663 SELL Proteins 0.000 description 2
- 206010039447 Salmonellosis Diseases 0.000 description 2
- 101710043164 Segment-4 Proteins 0.000 description 2
- 206010040550 Shigella infection Diseases 0.000 description 2
- 208000000587 Small Cell Lung Carcinoma Diseases 0.000 description 2
- 206010041067 Small cell lung cancer Diseases 0.000 description 2
- 208000001203 Smallpox Diseases 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M Sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- 208000006045 Spondylarthropathy Diseases 0.000 description 2
- 206010052775 Spondyloarthropathy Diseases 0.000 description 2
- XNKLLVCARDGLGL-JGVFFNPUSA-N Stavudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO)O1 XNKLLVCARDGLGL-JGVFFNPUSA-N 0.000 description 2
- 206010061372 Streptococcal infection Diseases 0.000 description 2
- 229940076156 Streptococcus pyogenes Drugs 0.000 description 2
- 241000193996 Streptococcus pyogenes Species 0.000 description 2
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 2
- 108091008153 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 206010042971 T-cell lymphoma Diseases 0.000 description 2
- 102100009537 TNFRSF9 Human genes 0.000 description 2
- 101710040535 TNFRSF9 Proteins 0.000 description 2
- 102100009581 TPBG Human genes 0.000 description 2
- 101700065141 TPBG Proteins 0.000 description 2
- 229960001967 Tacrolimus Drugs 0.000 description 2
- 208000004441 Taeniasis Diseases 0.000 description 2
- LPQZKKCYTLCDGQ-WEDXCCLWSA-N Tazobactam Chemical compound C([C@]1(C)S([C@H]2N(C(C2)=O)[C@H]1C(O)=O)(=O)=O)N1C=CN=N1 LPQZKKCYTLCDGQ-WEDXCCLWSA-N 0.000 description 2
- IQFYYKKMVGJFEH-CSMHCCOUSA-N Telbivudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1O[C@@H](CO)[C@H](O)C1 IQFYYKKMVGJFEH-CSMHCCOUSA-N 0.000 description 2
- LJVAJPDWBABPEJ-PNUFFHFMSA-N Telithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)[C@@H](C)C(=O)O[C@@H]([C@]2(OC(=O)N(CCCCN3C=C(N=C3)C=3C=NC=CC=3)[C@@H]2[C@@H](C)C(=O)[C@H](C)C[C@@]1(C)OC)C)CC)[C@@H]1O[C@H](C)C[C@H](N(C)C)[C@H]1O LJVAJPDWBABPEJ-PNUFFHFMSA-N 0.000 description 2
- 206010057644 Testis cancer Diseases 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- IXFPJGBNCFXKPI-FSIHEZPISA-N Thapsigargin Chemical compound CCCC(=O)O[C@H]1C[C@](C)(OC(C)=O)[C@H]2[C@H](OC(=O)CCCCCCC)[C@@H](OC(=O)C(\C)=C/C)C(C)=C2[C@@H]2OC(=O)[C@@](C)(O)[C@]21O IXFPJGBNCFXKPI-FSIHEZPISA-N 0.000 description 2
- FPZLLRFZJZRHSY-HJYUBDRYSA-N Tigecycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=C(NC(=O)CNC(C)(C)C)C(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O FPZLLRFZJZRHSY-HJYUBDRYSA-N 0.000 description 2
- 208000007712 Tinea Versicolor Diseases 0.000 description 2
- 206010056131 Tinea versicolour Diseases 0.000 description 2
- 229960000707 Tobramycin Drugs 0.000 description 2
- NLVFBUXFDBBNBW-PBSUHMDJSA-N Tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 2
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 229950007217 Tremelimumab Drugs 0.000 description 2
- 241000224526 Trichomonas Species 0.000 description 2
- 241000223229 Trichophyton rubrum Species 0.000 description 2
- 208000009920 Trichuriasis Diseases 0.000 description 2
- IEDVJHCEMCRBQM-UHFFFAOYSA-N Trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 2
- 241000223105 Trypanosoma brucei Species 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 241000202921 Ureaplasma urealyticum Species 0.000 description 2
- 101700058634 VCAM1 Proteins 0.000 description 2
- 102100015249 VEGFA Human genes 0.000 description 2
- 101700038759 VP1 Proteins 0.000 description 2
- 241000607598 Vibrio Species 0.000 description 2
- 229960004528 Vincristine Drugs 0.000 description 2
- 208000009421 Viral Pneumonia Diseases 0.000 description 2
- 208000001756 Virus Disease Diseases 0.000 description 2
- 208000001877 Whooping Cough Diseases 0.000 description 2
- 241000244005 Wuchereria bancrofti Species 0.000 description 2
- 229940118695 Yersinia pestis Drugs 0.000 description 2
- 241000607477 Yersinia pseudotuberculosis Species 0.000 description 2
- HBOMLICNUCNMMY-XLPZGREQSA-N Zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 2
- 229960002555 Zidovudine Drugs 0.000 description 2
- 206010061418 Zygomycosis Diseases 0.000 description 2
- JKEKMBGUVUKMQB-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium;tetrafluoroborate Chemical compound F[B-](F)(F)F.C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 JKEKMBGUVUKMQB-UHFFFAOYSA-N 0.000 description 2
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 2
- 201000007691 actinomycosis Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 229960002964 adalimumab Drugs 0.000 description 2
- 229930013930 alkaloids Natural products 0.000 description 2
- 125000004450 alkenylene group Chemical group 0.000 description 2
- 125000004419 alkynylene group Chemical group 0.000 description 2
- 229960004821 amikacin Drugs 0.000 description 2
- 125000004103 aminoalkyl group Chemical group 0.000 description 2
- 108010049535 anti-IgE antibodies Proteins 0.000 description 2
- 230000001512 anti-cytomegaloviral Effects 0.000 description 2
- 230000001986 anti-endotoxic Effects 0.000 description 2
- 230000003432 anti-folate Effects 0.000 description 2
- 230000002924 anti-infective Effects 0.000 description 2
- 230000002529 anti-mitochondrial Effects 0.000 description 2
- 230000001028 anti-proliferant Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 201000011165 anus cancer Diseases 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 229960003005 axitinib Drugs 0.000 description 2
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 description 2
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 2
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide Chemical compound [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 2
- 238000010462 azide-alkyne Huisgen cycloaddition reaction Methods 0.000 description 2
- 150000001540 azides Chemical class 0.000 description 2
- 201000008680 babesiosis Diseases 0.000 description 2
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 2
- 230000001580 bacterial Effects 0.000 description 2
- 229960004669 basiliximab Drugs 0.000 description 2
- 229960000626 benzylpenicillin Drugs 0.000 description 2
- 230000000975 bioactive Effects 0.000 description 2
- 230000035514 bioavailability Effects 0.000 description 2
- 230000003115 biocidal Effects 0.000 description 2
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 2
- 239000008366 buffered solution Substances 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 229960003525 cefalexin Drugs 0.000 description 2
- 229960002100 cefepime Drugs 0.000 description 2
- 229960002580 cefprozil Drugs 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 201000010002 cicatricial pemphigoid Diseases 0.000 description 2
- 229910052681 coesite Inorganic materials 0.000 description 2
- 201000011231 colorectal cancer Diseases 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 229910052906 cristobalite Inorganic materials 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 201000007336 cryptococcosis Diseases 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 229960002806 daclizumab Drugs 0.000 description 2
- WREGKURFCTUGRC-POYBYMJQSA-N ddC Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 2
- BXZVVICBKDXVGW-NKWVEPMBSA-N ddIno Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 2
- 201000004624 dermatitis Diseases 0.000 description 2
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 2
- JJTUDXZGHPGLLC-UHFFFAOYSA-N dilactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 2
- 125000005879 dioxolanyl group Chemical group 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 229930013356 epothilones Natural products 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 201000006353 filariasis Diseases 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000004052 folic acid antagonist Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 201000000628 gas gangrene Diseases 0.000 description 2
- 150000004676 glycans Polymers 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 229960000642 grepafloxacin Drugs 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 201000006215 hand, foot and mouth disease Diseases 0.000 description 2
- 101700005460 hemA Proteins 0.000 description 2
- 239000000185 hemagglutinin Substances 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
- 125000005549 heteroarylene group Chemical group 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- 229960001330 hydroxycarbamide Drugs 0.000 description 2
- VSNHCAURESNICA-UHFFFAOYSA-N hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 2
- 229940027318 hydroxyurea Drugs 0.000 description 2
- 108010004953 ibalizumab Proteins 0.000 description 2
- 150000002466 imines Chemical class 0.000 description 2
- 229960002751 imiquimod Drugs 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 201000006747 infectious mononucleosis Diseases 0.000 description 2
- 229960003130 interferon gamma Drugs 0.000 description 2
- 229940079866 intestinal antibiotics Drugs 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 239000002523 lectin Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 201000004792 malaria Diseases 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 201000005505 measles Diseases 0.000 description 2
- 201000004015 melioidosis Diseases 0.000 description 2
- 229960001924 melphalan Drugs 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- MBAHGFJTIVZLFB-UHFFFAOYSA-N methyl pent-2-enoate Chemical compound CCC=CC(=O)OC MBAHGFJTIVZLFB-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 201000007524 mucormycosis Diseases 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 239000007923 nasal drop Substances 0.000 description 2
- 201000009240 nasopharyngitis Diseases 0.000 description 2
- 239000012457 nonaqueous media Substances 0.000 description 2
- 108010044762 nucleolin Proteins 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 229960000402 palivizumab Drugs 0.000 description 2
- 201000002530 pancreatic endocrine carcinoma Diseases 0.000 description 2
- 108010092042 pemtumomab Proteins 0.000 description 2
- WSHJJCPTKWSMRR-RXMQYKEDSA-N penam Chemical compound S1CCN2C(=O)C[C@H]21 WSHJJCPTKWSMRR-RXMQYKEDSA-N 0.000 description 2
- 235000019371 penicillin G benzathine Nutrition 0.000 description 2
- 201000005702 pertussis Diseases 0.000 description 2
- 108010042024 pertuzumab Proteins 0.000 description 2
- 229960002087 pertuzumab Drugs 0.000 description 2
- 239000000546 pharmaceutic aid Substances 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229960000471 pleconaril Drugs 0.000 description 2
- 201000000317 pneumocystosis Diseases 0.000 description 2
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000004804 polysaccharides Polymers 0.000 description 2
- 230000002335 preservative Effects 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 229910052904 quartz Inorganic materials 0.000 description 2
- 229940052337 quinupristin/dalfopristin Drugs 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 201000001275 rectum cancer Diseases 0.000 description 2
- 230000002829 reduced Effects 0.000 description 2
- 229960004641 rituximab Drugs 0.000 description 2
- 201000005404 rubella Diseases 0.000 description 2
- 201000003176 severe acute respiratory syndrome Diseases 0.000 description 2
- 201000005113 shigellosis Diseases 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 201000002612 sleeping sickness Diseases 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 235000009518 sodium iodide Nutrition 0.000 description 2
- 229960003787 sorafenib Drugs 0.000 description 2
- 229960000268 spectinomycin Drugs 0.000 description 2
- 201000005671 spondyloarthropathy Diseases 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 229910052682 stishovite Inorganic materials 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 235000019527 sweetened beverage Nutrition 0.000 description 2
- 238000002626 targeted therapy Methods 0.000 description 2
- 229960003865 tazobactam Drugs 0.000 description 2
- 229960002935 telaprevir Drugs 0.000 description 2
- BBAWEDCPNXPBQM-GDEBMMAJSA-N telaprevir Chemical compound N([C@H](C(=O)N[C@H](C(=O)N1C[C@@H]2CCC[C@@H]2[C@H]1C(=O)N[C@@H](CCC)C(=O)C(=O)NC1CC1)C(C)(C)C)C1CCCCC1)C(=O)C1=CN=CC=N1 BBAWEDCPNXPBQM-GDEBMMAJSA-N 0.000 description 2
- 229960005311 telbivudine Drugs 0.000 description 2
- 229960003250 telithromycin Drugs 0.000 description 2
- 201000003120 testicular cancer Diseases 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 229960004089 tigecycline Drugs 0.000 description 2
- 201000010618 tinea cruris Diseases 0.000 description 2
- 201000004647 tinea pedis Diseases 0.000 description 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
- 108010078548 tocilizumab Proteins 0.000 description 2
- 229960003989 tocilizumab Drugs 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001131 transforming Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 108010072993 tremelimumab Proteins 0.000 description 2
- 229910052905 tridymite Inorganic materials 0.000 description 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 2
- 229940121358 tyrosine kinase inhibitors Drugs 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical class C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 2
- 201000000752 white piedra Diseases 0.000 description 2
- NIDRYBLTWYFCFV-UHFFFAOYSA-N (-)-Calanolide B Chemical compound C1=CC(C)(C)OC2=C1C(OC(C)C(C)C1O)=C1C1=C2C(CCC)=CC(=O)O1 NIDRYBLTWYFCFV-UHFFFAOYSA-N 0.000 description 1
- AYIRNRDRBQJXIF-NXEZZACHSA-N (-)-Florfenicol Chemical compound CS(=O)(=O)C1=CC=C([C@@H](O)[C@@H](CF)NC(=O)C(Cl)Cl)C=C1 AYIRNRDRBQJXIF-NXEZZACHSA-N 0.000 description 1
- ZROHGHOFXNOHSO-BNTLRKBRSA-L (1R,2R)-cyclohexane-1,2-diamine;oxalate;platinum(2+) Chemical compound [H][N]([C@@H]1CCCC[C@H]1[N]1([H])[H])([H])[Pt]11OC(=O)C(=O)O1 ZROHGHOFXNOHSO-BNTLRKBRSA-L 0.000 description 1
- JKHVDAUOODACDU-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(2,5-dioxopyrrol-1-yl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCN1C(=O)C=CC1=O JKHVDAUOODACDU-UHFFFAOYSA-N 0.000 description 1
- VQZYZXLBKBUOHE-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)butanoate Chemical compound C=1C=CC=NC=1SSC(C)CC(=O)ON1C(=O)CCC1=O VQZYZXLBKBUOHE-UHFFFAOYSA-N 0.000 description 1
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 1
- WGMMKWFUXPMTRW-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-[(2-bromoacetyl)amino]propanoate Chemical compound BrCC(=O)NCCC(=O)ON1C(=O)CCC1=O WGMMKWFUXPMTRW-UHFFFAOYSA-N 0.000 description 1
- VREDMXGEJJBZDU-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-[2-[2-[2-(3-bromo-2,5-dioxopyrrol-1-yl)ethoxy]ethoxy]ethoxy]propanoate Chemical compound O=C1C(Br)=CC(=O)N1CCOCCOCCOCCC(=O)ON1C(=O)CCC1=O VREDMXGEJJBZDU-UHFFFAOYSA-N 0.000 description 1
- PVGATNRYUYNBHO-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-(2,5-dioxopyrrol-1-yl)butanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCN1C(=O)C=CC1=O PVGATNRYUYNBHO-UHFFFAOYSA-N 0.000 description 1
- BQWBEDSJTMWJAE-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-[(2-iodoacetyl)amino]benzoate Chemical compound C1=CC(NC(=O)CI)=CC=C1C(=O)ON1C(=O)CCC1=O BQWBEDSJTMWJAE-UHFFFAOYSA-N 0.000 description 1
- GKSPIZSKQWTXQG-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-[1-(pyridin-2-yldisulfanyl)ethyl]benzoate Chemical compound C=1C=C(C(=O)ON2C(CCC2=O)=O)C=CC=1C(C)SSC1=CC=CC=N1 GKSPIZSKQWTXQG-UHFFFAOYSA-N 0.000 description 1
- PMJWDPGOWBRILU-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-[4-(2,5-dioxopyrrol-1-yl)phenyl]butanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCC(C=C1)=CC=C1N1C(=O)C=CC1=O PMJWDPGOWBRILU-UHFFFAOYSA-N 0.000 description 1
- WCMOHMXWOOBVMZ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 6-[3-(2,5-dioxopyrrol-1-yl)propanoylamino]hexanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCNC(=O)CCN1C(=O)C=CC1=O WCMOHMXWOOBVMZ-UHFFFAOYSA-N 0.000 description 1
- QYEAAMBIUQLHFQ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 6-[3-(pyridin-2-yldisulfanyl)propanoylamino]hexanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCNC(=O)CCSSC1=CC=CC=N1 QYEAAMBIUQLHFQ-UHFFFAOYSA-N 0.000 description 1
- IHVODYOQUSEYJJ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 6-[[4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexanecarbonyl]amino]hexanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCNC(=O)C(CC1)CCC1CN1C(=O)C=CC1=O IHVODYOQUSEYJJ-UHFFFAOYSA-N 0.000 description 1
- QNDVLZJODHBUFM-FCXWGWLASA-N (2R)-3-[(2S,6R,8S,11R)-2-[(E,2R)-4-[(2S,2'S,4R,4aS,6R,8aR)-4-hydroxy-2-[(1S,3S)-1-hydroxy-3-[(2S,3R,6S)-3-methyl-1,7-dioxaspiro[5.5]undecan-2-yl]butyl]-3-methylidenespiro[4a,7,8,8a-tetrahydro-4H-pyrano[3,2-b]pyran-6,5'-oxolane]-2'-yl]but-3-en-2-yl]-11-hyd Chemical compound C([C@H](O1)[C@H](C)/C=C/[C@@H]2CC[C@@]3(CC[C@H]4O[C@@H](C([C@@H](O)[C@@H]4O3)=C)[C@@H](O)C[C@H](C)[C@@H]3[C@@H](CC[C@@]4(OCCCC4)O3)C)O2)C(C)=C[C@]21O[C@H](C[C@@](C)(O)C(O)=O)CC[C@H]2O QNDVLZJODHBUFM-FCXWGWLASA-N 0.000 description 1
- XUSXOPRDIDWMFO-CTMSJIKGSA-N (2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[[(2S,3R)-3-amino-6-[(1S)-1-aminoethyl]-3,4-dihydro-2H-pyran-2-yl]oxy]-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC=C(O2)[C@H](C)N)N)[C@@H](N)C[C@H]1N XUSXOPRDIDWMFO-CTMSJIKGSA-N 0.000 description 1
- ARAIBEBZBOPLMB-UFGQHTETSA-N (2R,3R,4S)-4-[(diaminomethylidene)amino]-3-acetamido-2-[(1R,2R)-1,2,3-trihydroxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 description 1
- FFILOTSTFMXQJC-QCFYAKGBSA-N (2R,4R,5S,6S)-2-[3-[(2S,3S,4R,6S)-6-[(2S,3R,4R,5S,6R)-5-[(2S,3R,4R,5R,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-[(2R,3S,4R,5R,6R)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(E)-3-hydroxy-2-(octadecanoylamino)octadec-4-enoxy]oxan-3-yl]oxy-3-hy Chemical compound O[C@@H]1[C@@H](O)[C@H](OCC(NC(=O)CCCCCCCCCCCCCCCCC)C(O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@@H]([C@@H](N)[C@H](O)C2)C(O)C(O)CO[C@]2(O[C@@H]([C@@H](N)[C@H](O)C2)C(O)C(O)CO)C(O)=O)C(O)=O)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)O1 FFILOTSTFMXQJC-QCFYAKGBSA-N 0.000 description 1
- BXTJCSYMGFJEID-XMTADJHZSA-N (2S)-2-[[(2R,3R)-3-[(2S)-1-[(3R,4S,5S)-4-[[(2S)-2-[[(2S)-2-[6-[3-[(2R)-2-amino-2-carboxyethyl]sulfanyl-2,5-dioxopyrrolidin-1-yl]hexanoyl-methylamino]-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methoxy-5-methylheptanoyl]pyrrolidin-2-yl]-3-met Chemical compound C([C@H](NC(=O)[C@H](C)[C@@H](OC)[C@@H]1CCCN1C(=O)C[C@H]([C@H]([C@@H](C)CC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)CCCCCN1C(C(SC[C@H](N)C(O)=O)CC1=O)=O)C(C)C)OC)C(O)=O)C1=CC=CC=C1 BXTJCSYMGFJEID-XMTADJHZSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-JTQLQIEISA-N (2S)-7-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1-azatricyclo[7.3.1.0^{5,13}]trideca-5(13),6,8,11-tetraene-11-carboxylic acid Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 1
- IUQKJKPHUBJDJV-UMNBWOBWSA-N (2S,4R)-2-methyl-4-[[2-[(3R)-4-methyl-3-[methyl-[(2S,3S)-3-methyl-2-[[(2R)-1-methylpiperidine-2-carbonyl]amino]pentanoyl]amino]pentyl]-1,3-thiazole-4-carbonyl]amino]-5-phenylpentanoic acid Chemical compound N([C@@H]([C@@H](C)CC)C(=O)N(C)[C@H](CCC=1SC=C(N=1)C(=O)N[C@H](C[C@H](C)C(O)=O)CC=1C=CC=CC=1)C(C)C)C(=O)[C@H]1CCCCN1C IUQKJKPHUBJDJV-UMNBWOBWSA-N 0.000 description 1
- JETQIUPBHQNHNZ-NJBDSQKTSA-N (2S,5R,6R)-3,3-dimethyl-7-oxo-6-[[(2R)-2-phenyl-2-sulfoacetyl]amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound C1([C@H](C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)S(O)(=O)=O)=CC=CC=C1 JETQIUPBHQNHNZ-NJBDSQKTSA-N 0.000 description 1
- OQANPHBRHBJGNZ-FYJGNVAPSA-N (3E)-6-oxo-3-[[4-(pyridin-2-ylsulfamoyl)phenyl]hydrazinylidene]cyclohexa-1,4-diene-1-carboxylic acid Chemical compound C1=CC(=O)C(C(=O)O)=C\C1=N\NC1=CC=C(S(=O)(=O)NC=2N=CC=CC=2)C=C1 OQANPHBRHBJGNZ-FYJGNVAPSA-N 0.000 description 1
- RZPAKFUAFGMUPI-ZRLKJDMJSA-N (3R,5R,6S,7S,8S,9S,12S,13R,14R,15R)-6-[(2S,3R,4S,6S)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-hydroxy-8-[(2R,4S,5S,6S)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy-5,7,9,12,13,15-hexamethyl-1,11-dioxaspiro[2.13]hexadecane-10,16-dione Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@H](C)C(=O)O[C@@H](C)[C@H](C)[C@@H](O)[C@@H](C)C(=O)[C@@]2(OC2)C[C@@H](C)[C@H](O[C@H]2[C@@H]([C@H](C[C@H](C)O2)N(C)C)O)[C@@H]1C RZPAKFUAFGMUPI-ZRLKJDMJSA-N 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17 Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- OFPZNTXZCGKCMU-VXBOPZJTSA-N (3Z,5E,7R,8S,10S,11Z,13S,14R,15S,17S,20R,21S,22S)-22-[(2S,3Z)-hexa-3,5-dien-2-yl]-8,10,14,20-tetrahydroxy-7,13,15,17,21-pentamethyl-1-oxacyclodocosa-3,5,11-trien-2-one Chemical compound C=C\C=C/[C@H](C)[C@@H]1OC(=O)\C=C/C=C/[C@@H](C)[C@@H](O)C[C@H](O)\C=C/[C@H](C)[C@H](O)[C@@H](C)C[C@@H](C)CC[C@@H](O)[C@@H]1C OFPZNTXZCGKCMU-VXBOPZJTSA-N 0.000 description 1
- XIYOPDCBBDCGOE-IWVLMIASSA-N (4S,4aR,5S,5aR,12aR)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methylidene-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C=C1C2=CC=CC(O)=C2C(O)=C2[C@@H]1[C@H](O)[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O XIYOPDCBBDCGOE-IWVLMIASSA-N 0.000 description 1
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4S,4aS,5aR,12aR)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 1
- GUXHBMASAHGULD-SEYHBJAFSA-N (4S,4aS,5aS,6S,12aR)-7-chloro-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide Chemical compound C1([C@H]2O)=C(Cl)C=CC(O)=C1C(O)=C1[C@@H]2C[C@H]2[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]2(O)C1=O GUXHBMASAHGULD-SEYHBJAFSA-N 0.000 description 1
- DHPRQBPJLMKORJ-XRNKAMNCSA-N (4S,4aS,5aS,6S,12aR)-7-chloro-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O DHPRQBPJLMKORJ-XRNKAMNCSA-N 0.000 description 1
- XOZIUKBZLSUILX-GIQCAXHBSA-N (4S,7R,8S,9S,13Z,16S)-4,8-dihydroxy-5,5,7,9,13-pentamethyl-16-[(E)-1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-1-oxacyclohexadec-13-ene-2,6-dione Chemical compound O1C(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC\C(C)=C/C[C@H]1C(\C)=C\C1=CSC(C)=N1 XOZIUKBZLSUILX-GIQCAXHBSA-N 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N (5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-thiophen-2-yl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- MWTUOSWPJOUADP-XDJHFCHBSA-N (5Z)-5-(4-hydroxy-6-oxo-3-propan-2-ylcyclohexa-2,4-dien-1-ylidene)-4-(1-methylindol-5-yl)-1,2,4-triazolidin-3-one Chemical compound O=C1C=C(O)C(C(C)C)=C\C1=C\1N(C=2C=C3C=CN(C)C3=CC=2)C(=O)NN/1 MWTUOSWPJOUADP-XDJHFCHBSA-N 0.000 description 1
- BNAIICFZMLQZKW-CYAIWNQHSA-N (6E,10E,14E,18E,22E,26E,30E,34E,38E)-3,7,11,15,19,23,27,31,35,39,43-undecamethyltetratetraconta-6,10,14,18,22,26,30,34,38,42-decaen-1-ol Chemical compound OCCC(C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C BNAIICFZMLQZKW-CYAIWNQHSA-N 0.000 description 1
- XDZKBRJLTGRPSS-BGZQYGJUSA-N (6R,7R)-3-({[5-(carboxymethyl)-4-methyl-1,3-thiazol-2-yl]sulfanyl}methyl)-7-{[(2Z)-1-hydroxy-2-(2-imino-2,3-dihydro-1,3-thiazol-4-yl)-2-(methoxyimino)ethylidene]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(C)=C(CC(O)=O)S1 XDZKBRJLTGRPSS-BGZQYGJUSA-N 0.000 description 1
- RTXOFQZKPXMALH-GHXIOONMSA-N (6R,7R)-7-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(N-hydroxyimino)acetamido]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound S1C(N)=NC(C(=N\O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 RTXOFQZKPXMALH-GHXIOONMSA-N 0.000 description 1
- HJJDBAOLQAWBMH-YCRCPZNHSA-N (6R,7R)-7-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido]-3-{[(1-methyl-1H-1,2,3,4-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NN=NN1C HJJDBAOLQAWBMH-YCRCPZNHSA-N 0.000 description 1
- VAAUVRVFOQPIGI-SPQHTLEESA-N (6R,7R)-7-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido]-3-{[(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 description 1
- NNULBSISHYWZJU-LLKWHZGFSA-N (6R,7R)-7-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=CCS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 NNULBSISHYWZJU-LLKWHZGFSA-N 0.000 description 1
- DKOQGJHPHLTOJR-PUIFZAHNSA-N (6R,7R)-7-[[(2E)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-(6,7-dihydro-5H-cyclopenta[b]pyridin-1-ium-1-ylmethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound N([C@@H]1C(N2C(=C(C[N+]=3C=4CCCC=4C=CC=3)CS[C@@H]21)C([O-])=O)=O)C(=O)/C(=N/OC)C1=CSC(N)=N1 DKOQGJHPHLTOJR-PUIFZAHNSA-N 0.000 description 1
- UOCJDOLVGGIYIQ-PBFPGSCMSA-N (6R,7R)-7-[[(2R)-2-azaniumyl-2-(4-hydroxyphenyl)acetyl]amino]-8-oxo-3-(2H-triazol-4-ylsulfanylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)[C@H](N)C=2C=CC(O)=CC=2)CC=1CSC=1C=NNN=1 UOCJDOLVGGIYIQ-PBFPGSCMSA-N 0.000 description 1
- ORFOPKXBNMVMKC-DWVKKRMSSA-O (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2-carboxypropan-2-yloxyimino)acetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 ORFOPKXBNMVMKC-DWVKKRMSSA-O 0.000 description 1
- XSPUSVIQHBDITA-RKYNPMAHSA-N (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(5-methyltetrazol-2-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CN1N=NC(C)=N1 XSPUSVIQHBDITA-RKYNPMAHSA-N 0.000 description 1
- WJXAHFZIHLTPFR-JLRJEBFFSA-N (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(E)-2-[[5,6-dioxo-4-(2-oxoethyl)-1H-1,2,4-triazin-3-yl]sulfanyl]ethenyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1\C=C\SC1=NNC(=O)C(=O)N1CC=O WJXAHFZIHLTPFR-JLRJEBFFSA-N 0.000 description 1
- YWKJNRNSJKEFMK-PQFQYKRASA-N (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-8-oxo-3-(5,6,7,8-tetrahydroquinolin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound N([C@@H]1C(N2C(=C(C[N+]=3C=4CCCCC=4C=CC=3)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 YWKJNRNSJKEFMK-PQFQYKRASA-N 0.000 description 1
- LXLDMYXULSBRCX-HZEONMFJSA-N (6R,7R)-7-[[(2Z)-2-(5-amino-1,2,4-thiadiazol-3-ylidene)-2-nitrosoacetyl]amino]-8-oxo-3-[(E)-[2-oxo-1-[(3R)-pyrrolidin-3-yl]pyrrolidin-3-ylidene]methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N1SC(N)=N\C1=C(\N=O)C(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(\C=C/3C(N([C@H]4CNCC4)CC\3)=O)CS[C@@H]21 LXLDMYXULSBRCX-HZEONMFJSA-N 0.000 description 1
- UHRBTBZOWWGKMK-DOMZBBRYSA-N (6R,7R)-7-[[2-(difluoromethylsulfanyl)acetyl]amino]-3-[[1-(2-hydroxyethyl)tetrazol-5-yl]sulfanylmethyl]-7-methoxy-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound O([C@@H]1[C@@](C(N1C=1C(O)=O)=O)(NC(=O)CSC(F)F)OC)CC=1CSC1=NN=NN1CCO UHRBTBZOWWGKMK-DOMZBBRYSA-N 0.000 description 1
- GPYKKBAAPVOCIW-HSASPSRMSA-N (6R,7S)-7-[[(2R)-2-amino-2-phenylacetyl]amino]-3-chloro-8-oxo-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;hydrate Chemical compound O.C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CC[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 GPYKKBAAPVOCIW-HSASPSRMSA-N 0.000 description 1
- KMSKQZKKOZQFFG-YXRRJAAWSA-N (7S,9S)-7-[(2R,4S,5S,6S)-4-amino-6-methyl-5-[(2R)-oxan-2-yl]oxyoxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione Chemical compound O([C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@@H]1CCCCO1 KMSKQZKKOZQFFG-YXRRJAAWSA-N 0.000 description 1
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 1
- HMVYYTRDXNKRBQ-UHFFFAOYSA-N 1,3-Thiazole-4-Carboxylic Acid Chemical compound OC(=O)C1=CSC=N1 HMVYYTRDXNKRBQ-UHFFFAOYSA-N 0.000 description 1
- VYEHWIUQCXVWHH-UHFFFAOYSA-N 1-(1-methylcyclohexa-2,4-dien-1-yl)pyridin-1-ium Chemical compound C=1C=CC=C[N+]=1C1(C)CC=CC=C1 VYEHWIUQCXVWHH-UHFFFAOYSA-N 0.000 description 1
- OJQSISYVGFJJBY-UHFFFAOYSA-N 1-(4-isocyanatophenyl)pyrrole-2,5-dione Chemical compound C1=CC(N=C=O)=CC=C1N1C(=O)C=CC1=O OJQSISYVGFJJBY-UHFFFAOYSA-N 0.000 description 1
- SWQQELWGJDXCFT-PNHWDRBUSA-N 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-ethynylimidazole-4-carboxamide Chemical compound C#CC1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 SWQQELWGJDXCFT-PNHWDRBUSA-N 0.000 description 1
- JFLSOKIMYBSASW-UHFFFAOYSA-N 1-chloro-2-[chloro(diphenyl)methyl]benzene Chemical compound ClC1=CC=CC=C1C(Cl)(C=1C=CC=CC=1)C1=CC=CC=C1 JFLSOKIMYBSASW-UHFFFAOYSA-N 0.000 description 1
- LEULAXMUNMRLPW-UHFFFAOYSA-N 1-ethyl-6-fluoro-7-(4-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid;methanesulfonic acid;dihydrate Chemical compound O.O.CS(O)(=O)=O.C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCN(C)CC1 LEULAXMUNMRLPW-UHFFFAOYSA-N 0.000 description 1
- BPSLZWSRHTULGU-UHFFFAOYSA-N 1-methylpiperidin-1-ium-2-carboxylate Chemical compound CN1CCCCC1C(O)=O BPSLZWSRHTULGU-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- 125000003562 2,2-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003660 2,3-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003764 2,4-dimethylpentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- URRCWJIXJMEOET-UHFFFAOYSA-N 2-(5-methoxythiophen-2-yl)ethanethioic S-acid Chemical compound COC1=CC=C(CC(S)=O)S1 URRCWJIXJMEOET-UHFFFAOYSA-N 0.000 description 1
- SUPKOOSCJHTBAH-UHFFFAOYSA-N 2-(6-aminopurin-9-yl)ethoxymethylphosphonic acid Chemical compound NC1=NC=NC2=C1N=CN2CCOCP(O)(O)=O SUPKOOSCJHTBAH-UHFFFAOYSA-N 0.000 description 1
- AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical class CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 1
- ACTOXUHEUCPTEW-BOISPSKTSA-N 2-[(4R,5S,6S,7R,9R,10R,11E,13E,16S)-6-[(2S,3R,4R,5S,6R)-5-[(2S,4R,5R,6S)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-10-[(2R,5S,6R)-5-(dimethylamino)-6-methyloxan-2-yl]oxy-4-hydroxy-5-methoxy-9,16-dimethyl-2-o Chemical compound O([C@H]1/C=C/C=C/C[C@H](C)OC(=O)C[C@@H](O)[C@@H]([C@H]([C@@H](CC=O)C[C@H]1C)O[C@H]1[C@@H]([C@H]([C@H](O[C@@H]2O[C@@H](C)[C@@H](O)[C@](C)(O)C2)[C@@H](C)O1)N(C)C)O)OC)[C@H]1CC[C@H](N(C)C)[C@@H](C)O1 ACTOXUHEUCPTEW-BOISPSKTSA-N 0.000 description 1
- VAMSVIZLXJOLHZ-QWFSEIHXSA-N 2-[(Z)-[1-(2-amino-1,3-thiazol-4-yl)-2-[[(3S)-2,2-dimethyl-4-oxo-1-sulfooxyazetidin-3-yl]amino]-2-oxoethylidene]amino]oxyacetic acid Chemical compound O=C1N(OS(O)(=O)=O)C(C)(C)[C@@H]1NC(=O)C(=N/OCC(O)=O)\C1=CSC(N)=N1 VAMSVIZLXJOLHZ-QWFSEIHXSA-N 0.000 description 1
- BDYDMRYPUIYCOY-UHFFFAOYSA-N 2-[4-(hydroxymethyl)phenyl]-N-methylacetamide Chemical compound CNC(=O)CC1=CC=C(CO)C=C1 BDYDMRYPUIYCOY-UHFFFAOYSA-N 0.000 description 1
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-N-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-N,1-N-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- RTJUXLYUUDBAJN-KVQBGUIXSA-N 2-amino-9-[(2R,4S,5R)-4-fluoro-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@H]1C[C@H](F)[C@@H](CO)O1 RTJUXLYUUDBAJN-KVQBGUIXSA-N 0.000 description 1
- MLFIYYDKLNZLAO-UHFFFAOYSA-N 2-aminoethane-1,1-diol Chemical compound NCC(O)O MLFIYYDKLNZLAO-UHFFFAOYSA-N 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- 125000003229 2-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-oxazolidone Chemical class O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 1
- 125000004336 3,3-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- GEKJEMDSKURVLI-UHFFFAOYSA-N 3,4-dibromofuran-2,5-dione Chemical compound BrC1=C(Br)C(=O)OC1=O GEKJEMDSKURVLI-UHFFFAOYSA-N 0.000 description 1
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 description 1
- SXRAUUQQOFNBEZ-UHFFFAOYSA-N 3-[2-[2-[2-(3,4-dibromo-2,5-dioxopyrrol-1-yl)ethoxy]ethoxy]ethoxy]propanoic acid Chemical compound OC(=O)CCOCCOCCOCCN1C(=O)C(Br)=C(Br)C1=O SXRAUUQQOFNBEZ-UHFFFAOYSA-N 0.000 description 1
- ILCPJSXKCRPCRJ-UHFFFAOYSA-N 3-[2-[2-[2-(3-bromo-2,5-dioxopyrrol-1-yl)ethoxy]ethoxy]ethoxy]propanoic acid Chemical compound OC(=O)CCOCCOCCOCCN1C(=O)C=C(Br)C1=O ILCPJSXKCRPCRJ-UHFFFAOYSA-N 0.000 description 1
- YPRMWCKXOZFJGF-UHFFFAOYSA-N 3-bromofuran-2,5-dione Chemical compound BrC1=CC(=O)OC1=O YPRMWCKXOZFJGF-UHFFFAOYSA-N 0.000 description 1
- FQAWBGAIOYWONH-UHFFFAOYSA-N 3-chloroperoxybenzoic acid Chemical compound OC(=O)C1=CC=CC(OOCl)=C1 FQAWBGAIOYWONH-UHFFFAOYSA-N 0.000 description 1
- 125000003469 3-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- HXOYWJCDYVODON-UHFFFAOYSA-N 4-[4-(hydroxymethyl)-3-methoxyphenoxy]butanoic acid Chemical compound COC1=CC(OCCCC(O)=O)=CC=C1CO HXOYWJCDYVODON-UHFFFAOYSA-N 0.000 description 1
- GWNOTCOIYUNTQP-FQLXRVMXSA-N 4-[4-[[(3R)-1-butyl-3-[(R)-cyclohexyl(hydroxy)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undecan-9-yl]methyl]phenoxy]benzoic acid Chemical compound N([C@@H](C(=O)N1CCCC)[C@H](O)C2CCCCC2)C(=O)C1(CC1)CCN1CC(C=C1)=CC=C1OC1=CC=C(C(O)=O)C=C1 GWNOTCOIYUNTQP-FQLXRVMXSA-N 0.000 description 1
- ZOPBZHLJXQAQON-VWLOTQADSA-N 4-[[(3S)-3-(dimethylamino)pyrrolidin-1-yl]methyl]-N-[4-methyl-3-[(5-pyrimidin-5-ylpyrimidin-2-yl)amino]phenyl]-3-(trifluoromethyl)benzamide Chemical compound C1[C@@H](N(C)C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=CC(=CN=3)C=3C=NC=NC=3)C(C)=CC=2)C=C1C(F)(F)F ZOPBZHLJXQAQON-VWLOTQADSA-N 0.000 description 1
- CKTSBUTUHBMZGZ-CHKWXVPMSA-N 4-amino-1-[(2S,4R,5S)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)[C@H](O)C1 CKTSBUTUHBMZGZ-CHKWXVPMSA-N 0.000 description 1
- HSBKFSPNDWWPSL-CAHLUQPWSA-N 4-amino-5-fluoro-1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]pyrimidin-2-one Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1C=C[C@@H](CO)O1 HSBKFSPNDWWPSL-CAHLUQPWSA-N 0.000 description 1
- HSBKFSPNDWWPSL-VDTYLAMSSA-N 4-amino-5-fluoro-1-[(2S,5R)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]pyrimidin-2-one Chemical compound C1=C(F)C(N)=NC(=O)N1[C@@H]1C=C[C@H](CO)O1 HSBKFSPNDWWPSL-VDTYLAMSSA-N 0.000 description 1
- WZRJTRPJURQBRM-UHFFFAOYSA-N 4-amino-N-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 WZRJTRPJURQBRM-UHFFFAOYSA-N 0.000 description 1
- FAYOCELKCDKZCA-UHFFFAOYSA-N 5-hydroxy-2,4-dimethylthiophen-3-one Chemical compound CC1SC(O)=C(C)C1=O FAYOCELKCDKZCA-UHFFFAOYSA-N 0.000 description 1
- MJZJYWCQPMNPRM-UHFFFAOYSA-N 6,6-DIMETHYL-1-[3-(2,4,5-TRICHLOROPHENOXY)PROPOXY]-1,6-DIHYDRO-1,3,5-TRIAZINE-2,4-DIAMINE Chemical compound CC1(C)N=C(N)N=C(N)N1OCCCOC1=CC(Cl)=C(Cl)C=C1Cl MJZJYWCQPMNPRM-UHFFFAOYSA-N 0.000 description 1
- PLIVFNIUGLLCEK-UHFFFAOYSA-N 7-[4-(3-ethynylanilino)-7-methoxyquinazolin-6-yl]oxy-N-hydroxyheptanamide Chemical compound C=12C=C(OCCCCCCC(=O)NO)C(OC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 PLIVFNIUGLLCEK-UHFFFAOYSA-N 0.000 description 1
- WLCZTRVUXYALDD-IBGZPJMESA-N 7-[[(2S)-2,6-bis(2-methoxyethoxycarbonylamino)hexanoyl]amino]heptoxy-methylphosphinic acid Chemical compound COCCOC(=O)NCCCC[C@H](NC(=O)OCCOC)C(=O)NCCCCCCCOP(C)(O)=O WLCZTRVUXYALDD-IBGZPJMESA-N 0.000 description 1
- JNTOCHDNEULJHD-UHFFFAOYSA-N 9-(4-hydroxy-3-(hydroxymethyl)butyl)guanine Chemical compound N1C(N)=NC(=O)C2=C1N(CCC(CO)CO)C=N2 JNTOCHDNEULJHD-UHFFFAOYSA-N 0.000 description 1
- FUXVKZWTXQUGMW-FQEVSTJZSA-N 9-Aminocamptothecin Chemical compound C1=CC(N)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 FUXVKZWTXQUGMW-FQEVSTJZSA-N 0.000 description 1
- 108060000228 ADRM1 Proteins 0.000 description 1
- 101700014023 AFP Proteins 0.000 description 1
- 101700065995 AFP1 Proteins 0.000 description 1
- 102100000105 AKAP4 Human genes 0.000 description 1
- 101700022014 AKAP4 Proteins 0.000 description 1
- 102100005866 ALCAM Human genes 0.000 description 1
- 101710033748 ALCAM Proteins 0.000 description 1
- 102100011141 ALK Human genes 0.000 description 1
- 101710033641 ALK Proteins 0.000 description 1
- 229940100198 ALKYLATING AGENTS Drugs 0.000 description 1
- 102100013690 ALPG Human genes 0.000 description 1
- 101710016959 ALPG Proteins 0.000 description 1
- 102100006669 ALPP Human genes 0.000 description 1
- 229940072174 AMPHENICOLS Drugs 0.000 description 1
- 101710026735 ANKRD30A Proteins 0.000 description 1
- 102100007529 ANKRD30A Human genes 0.000 description 1
- 101710028178 ANPEP Proteins 0.000 description 1
- 101700061082 ANPX Proteins 0.000 description 1
- 101700082057 ANPY Proteins 0.000 description 1
- 101700077278 ANTF Proteins 0.000 description 1
- 229940030495 ANTIANDROGEN SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM Drugs 0.000 description 1
- 229940100197 ANTIMETABOLITES Drugs 0.000 description 1
- 102100007495 AR Human genes 0.000 description 1
- MKKYBZZTJQGVCD-XTCKQBCOSA-N ARBEKACIN Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)CC[C@H]1N MKKYBZZTJQGVCD-XTCKQBCOSA-N 0.000 description 1
- 108010007921 AVE9633 Proteins 0.000 description 1
- MCGSCOLBFJQGHM-SCZZXKLOSA-N Abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 description 1
- 229950005186 Abagovomab Drugs 0.000 description 1
- 108010061171 Abatacept Proteins 0.000 description 1
- QYQDKDWGWDOFFU-IUODEOHRSA-N Abbott-48999 Chemical compound CN(C)CCN1N=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CC=3N=C(N)SC=3)[C@H]2SC1 QYQDKDWGWDOFFU-IUODEOHRSA-N 0.000 description 1
- 108010004463 Abciximab Proteins 0.000 description 1
- MAUCONCHVWBMHK-UHFFFAOYSA-N Abexinostat Chemical compound O1C2=CC=CC=C2C(CN(C)C)=C1C(=O)NCCOC1=CC=C(C(=O)NO)C=C1 MAUCONCHVWBMHK-UHFFFAOYSA-N 0.000 description 1
- 229940028652 Abraxane Drugs 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 241000588626 Acinetobacter baumannii Species 0.000 description 1
- 206010051894 Acinetobacter infection Diseases 0.000 description 1
- 206010056508 Acquired epidermolysis bullosa Diseases 0.000 description 1
- 241000511654 Actinomyces gerencseriae Species 0.000 description 1
- 241000186041 Actinomyces israelii Species 0.000 description 1
- 206010000748 Acute febrile neutrophilic dermatosis Diseases 0.000 description 1
- 206010058994 Acute haemorrhagic leukoencephalitis Diseases 0.000 description 1
- 206010000880 Acute myeloid leukaemia Diseases 0.000 description 1
- 201000004304 Addison's disease Diseases 0.000 description 1
- 229950009084 Adecatumumab Drugs 0.000 description 1
- 208000009956 Adenocarcinoma Diseases 0.000 description 1
- 241000701242 Adenoviridae Species 0.000 description 1
- 208000010370 Adenoviridae Infections Diseases 0.000 description 1
- 206010060931 Adenovirus infection Diseases 0.000 description 1
- 208000002485 Adiposis Dolorosa Diseases 0.000 description 1
- 208000007128 Adrenocortical Carcinoma Diseases 0.000 description 1
- 229940009456 Adriamycin Drugs 0.000 description 1
- 241000607528 Aeromonas hydrophila Species 0.000 description 1
- 229950008459 Alacizumab pegol Drugs 0.000 description 1
- UUZPPAMZDFLUHD-VUJLHGSVSA-N Alatrofloxacin Chemical compound C([C@@H]1[C@H]([C@@H]1C1)NC(=O)[C@H](C)NC(=O)[C@@H](N)C)N1C(C(=CC=1C(=O)C(C(O)=O)=C2)F)=NC=1N2C1=CC=C(F)C=C1F UUZPPAMZDFLUHD-VUJLHGSVSA-N 0.000 description 1
- 108010090726 Alefacept Proteins 0.000 description 1
- 108010090838 Alemtuzumab Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 206010048594 Allergic granulomatous angiitis Diseases 0.000 description 1
- 208000004631 Alopecia Areata Diseases 0.000 description 1
- UXCAQJAQSWSNPQ-XLPZGREQSA-N Alovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](F)C1 UXCAQJAQSWSNPQ-XLPZGREQSA-N 0.000 description 1
- 229950009106 Altumomab Drugs 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N Amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 229960003805 Amantadine Drugs 0.000 description 1
- ILKJAFIWWBXGDU-MOGDOJJUSA-N Amcinonide Chemical compound O([C@@]1([C@H](O2)C[C@@H]3[C@@]1(C[C@H](O)[C@]1(F)[C@@]4(C)C=CC(=O)C=C4CC[C@H]13)C)C(=O)COC(=O)C)C12CCCC1 ILKJAFIWWBXGDU-MOGDOJJUSA-N 0.000 description 1
- 229960003099 Amcinonide Drugs 0.000 description 1
- 229950005846 Amdoxovir Drugs 0.000 description 1
- 208000004881 Amebiasis Diseases 0.000 description 1
- 206010001935 American trypanosomiasis Diseases 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N Aminocaproic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- 206010001980 Amoebiasis Diseases 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N Ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- YMARZQAQMVYCKC-OEMFJLHTSA-N Amprenavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 YMARZQAQMVYCKC-OEMFJLHTSA-N 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 241000606646 Anaplasma Species 0.000 description 1
- 241000605281 Anaplasma phagocytophilum Species 0.000 description 1
- 208000006730 Anaplasmosis Diseases 0.000 description 1
- 241001511271 Ancylostoma braziliense Species 0.000 description 1
- 241000498253 Ancylostoma duodenale Species 0.000 description 1
- 241001465677 Ancylostomatoidea Species 0.000 description 1
- 229940094957 Androgens and estrogens Drugs 0.000 description 1
- 208000009094 Anemia, Hemolytic, Autoimmune Diseases 0.000 description 1
- 206010002556 Ankylosing spondylitis Diseases 0.000 description 1
- 229950005794 Anrukinzumab Drugs 0.000 description 1
- 208000008637 Anti-Glomerular Basement Membrane Disease Diseases 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 210000000628 Antibody-Producing Cells Anatomy 0.000 description 1
- 108010011692 Anticardiolipin Antibodies Proteins 0.000 description 1
- 108090000298 Antinuclear Antibodies Proteins 0.000 description 1
- 108090000866 Antiphospholipid Antibodies Proteins 0.000 description 1
- 241001523209 Antissa Species 0.000 description 1
- 208000001839 Antisynthetase syndrome Diseases 0.000 description 1
- 229950003145 Apolizumab Drugs 0.000 description 1
- 102000006410 Apoproteins Human genes 0.000 description 1
- 108010083590 Apoproteins Proteins 0.000 description 1
- 206010059512 Apoptosis Diseases 0.000 description 1
- RYMCFYKJDVMSIR-RNFRBKRXSA-N Apricitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1S[C@H](CO)OC1 RYMCFYKJDVMSIR-RNFRBKRXSA-N 0.000 description 1
- 229950007936 Apricitabine Drugs 0.000 description 1
- KCFYEAOKVJSACF-UHFFFAOYSA-N Arbidol Chemical compound CN1C2=CC(Br)=C(O)C(CN(C)C)=C2C(C(=O)OCC)=C1CSC1=CC=CC=C1 KCFYEAOKVJSACF-UHFFFAOYSA-N 0.000 description 1
- 208000006400 Arbovirus Encephalitis Diseases 0.000 description 1
- 229940094361 Arcalyst Drugs 0.000 description 1
- 241000863009 Archangium gephyra Species 0.000 description 1
- 229950005725 Arcitumomab Drugs 0.000 description 1
- 241000712892 Arenaviridae Species 0.000 description 1
- 201000009695 Argentine hemorrhagic fever Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003246 Arthritis Diseases 0.000 description 1
- 229940110584 Arzerra Drugs 0.000 description 1
- 208000008715 Ascaridida Infections Diseases 0.000 description 1
- 241000244185 Ascaris lumbricoides Species 0.000 description 1
- 229950002882 Aselizumab Drugs 0.000 description 1
- 229960001230 Asparagine Drugs 0.000 description 1
- 229960005261 Aspartic Acid Drugs 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241001225321 Aspergillus fumigatus Species 0.000 description 1
- 229940091771 Aspergillus fumigatus Drugs 0.000 description 1
- 206010003486 Aspergillus infection Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 206010060971 Astrocytoma malignant Diseases 0.000 description 1
- BIDUPMYXGFNAEJ-APGVDKLISA-N Astromicin Chemical compound O[C@@H]1[C@H](N(C)C(=O)CN)[C@@H](OC)[C@@H](O)[C@H](N)[C@H]1O[C@@H]1[C@H](N)CC[C@@H]([C@H](C)N)O1 BIDUPMYXGFNAEJ-APGVDKLISA-N 0.000 description 1
- 241001533362 Astroviridae Species 0.000 description 1
- AXRYRYVKAWYZBR-GASGPIRDSA-N Atazanavir Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)[C@@H](O)CN(CC=1C=CC(=CC=1)C=1N=CC=CC=1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C1=CC=CC=C1 AXRYRYVKAWYZBR-GASGPIRDSA-N 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 229950000103 Atorolimumab Drugs 0.000 description 1
- 208000000659 Autoimmune Lymphoproliferative Syndrome Diseases 0.000 description 1
- 208000005783 Autoimmune Thyroiditis Diseases 0.000 description 1
- 206010071576 Autoimmune aplastic anaemia Diseases 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 206010065996 Autoimmune inner ear disease Diseases 0.000 description 1
- 206010069002 Autoimmune pancreatitis Diseases 0.000 description 1
- 206010071572 Autoimmune progesterone dermatitis Diseases 0.000 description 1
- 229940120638 Avastin Drugs 0.000 description 1
- 206010064097 Avian influenza Diseases 0.000 description 1
- SGRUZFCHLOFYHZ-MWLCHTKSSA-N Azidamfenicol Chemical compound [N-]=[N+]=NCC(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 SGRUZFCHLOFYHZ-MWLCHTKSSA-N 0.000 description 1
- ODFHGIPNGIAMDK-NJBDSQKTSA-N Azidocillin Chemical compound C1([C@@H](N=[N+]=[N-])C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 ODFHGIPNGIAMDK-NJBDSQKTSA-N 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N Azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- 229960003623 Azlocillin Drugs 0.000 description 1
- JTWOMNBEOCYFNV-NFFDBFGFSA-N Azlocillin Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC=CC=1)C(=O)N1CCNC1=O JTWOMNBEOCYFNV-NFFDBFGFSA-N 0.000 description 1
- WZPBZJONDBGPKJ-VEHQQRBSSA-N Aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 description 1
- 229960003644 Aztreonam Drugs 0.000 description 1
- 208000004736 B-Cell Leukemia Diseases 0.000 description 1
- 208000003950 B-Cell Lymphoma Diseases 0.000 description 1
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 description 1
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 description 1
- SPFYMRJSYKOXGV-UHFFFAOYSA-N BAY VP 2674 Chemical compound C1CN(CC)CCN1C(C(=C1)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1CC1 SPFYMRJSYKOXGV-UHFFFAOYSA-N 0.000 description 1
- 102100007326 BIRC5 Human genes 0.000 description 1
- 102100007327 BIRC7 Human genes 0.000 description 1
- 101700012308 BIRC8 Proteins 0.000 description 1
- 206010055181 BK virus infection Diseases 0.000 description 1
- 101700044940 BM86 Proteins 0.000 description 1
- 101700039562 BMPH Proteins 0.000 description 1
- 101710019228 BSG Proteins 0.000 description 1
- 241000223836 Babesia Species 0.000 description 1
- 229960002699 Bacampicillin Drugs 0.000 description 1
- 208000004429 Bacillary Dysentery Diseases 0.000 description 1
- 229940065181 Bacillus anthracis Drugs 0.000 description 1
- 229940075612 Bacillus cereus Drugs 0.000 description 1
- 241000193755 Bacillus cereus Species 0.000 description 1
- 206010060976 Bacillus infection Diseases 0.000 description 1
- 208000004926 Bacterial Vaginosis Diseases 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 206010058890 Bacteroides infection Diseases 0.000 description 1
- 241001235572 Balantioides coli Species 0.000 description 1
- 201000002827 Balo concentric sclerosis Diseases 0.000 description 1
- MGQLHRYJBWGORO-LLVKDONJSA-N Balofloxacin Chemical compound C1[C@H](NC)CCCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1OC MGQLHRYJBWGORO-LLVKDONJSA-N 0.000 description 1
- 229950000805 Balofloxacin Drugs 0.000 description 1
- 229950001863 Bapineuzumab Drugs 0.000 description 1
- 229940092524 Bartonella henselae Drugs 0.000 description 1
- 241001518086 Bartonella henselae Species 0.000 description 1
- 206010004161 Basedow's disease Diseases 0.000 description 1
- 229950007843 Bavituximab Drugs 0.000 description 1
- 241000244181 Baylisascaris Species 0.000 description 1
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone dipropionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 description 1
- 229950003269 Bectumomab Drugs 0.000 description 1
- 229960001192 Bekanamycin Drugs 0.000 description 1
- SKKLOUVUUNMCJE-FQSMHNGLSA-N Bekanamycin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SKKLOUVUUNMCJE-FQSMHNGLSA-N 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Belustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- 229940022836 Benlysta Drugs 0.000 description 1
- 229950000321 Benralizumab Drugs 0.000 description 1
- 229960002536 Benzathine benzylpenicillin Drugs 0.000 description 1
- BVGLIYRKPOITBQ-ANPZCEIESA-N Benzathine benzylpenicillin Chemical compound C=1C=CC=CC=1C[NH2+]CC[NH2+]CC1=CC=CC=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 BVGLIYRKPOITBQ-ANPZCEIESA-N 0.000 description 1
- 229950010015 Bertilimumab Drugs 0.000 description 1
- 229950010559 Besilesomab Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N Betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 229950002892 Bevirimat Drugs 0.000 description 1
- 229950001303 Biciromab Drugs 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 206010004661 Biliary cirrhosis primary Diseases 0.000 description 1
- 230000037177 Biodistribution Effects 0.000 description 1
- 229950002903 Bivatuzumab Drugs 0.000 description 1
- 206010004975 Black piedra Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 208000005740 Blastocystis Infections Diseases 0.000 description 1
- 229940011597 Blastocystis hominis Drugs 0.000 description 1
- 241000726107 Blastocystis hominis Species 0.000 description 1
- 241000335423 Blastomyces Species 0.000 description 1
- 208000009766 Blau syndrome Diseases 0.000 description 1
- OYVAGSVQBOHSSS-WXFSZRTFSA-O Bleomycin Chemical class N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](OC1C(C(O)C(O)C(CO)O1)OC1C(C(OC(N)=O)C(O)C(CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-WXFSZRTFSA-O 0.000 description 1
- 229960001561 Bleomycin Drugs 0.000 description 1
- 210000004369 Blood Anatomy 0.000 description 1
- 210000001772 Blood Platelets Anatomy 0.000 description 1
- 206010005913 Body tinea Diseases 0.000 description 1
- 201000009694 Bolivian hemorrhagic fever Diseases 0.000 description 1
- 102000013585 Bombesin Human genes 0.000 description 1
- 108010051479 Bombesin Proteins 0.000 description 1
- DNDCVAGJPBKION-DOPDSADYSA-N Bombesin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC2=CC=CC=C2C=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DNDCVAGJPBKION-DOPDSADYSA-N 0.000 description 1
- 210000000988 Bone and Bones Anatomy 0.000 description 1
- 229940052491 Bordetella pertussis Drugs 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 206010061591 Borrelia infection Diseases 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N Bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- UBPYILGKFZZVDX-UHFFFAOYSA-N Bosutinib Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCN4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl UBPYILGKFZZVDX-UHFFFAOYSA-N 0.000 description 1
- 208000003508 Botulism Diseases 0.000 description 1
- CBPBDGBVINMGGB-UHFFFAOYSA-N BrC=1C(N(C(C1Br)=O)CCOCCOCCOCCC(=O)ON1C(CCC1=O)=O)=O Chemical compound BrC=1C(N(C(C1Br)=O)CCOCCOCCOCCC(=O)ON1C(CCC1=O)=O)=O CBPBDGBVINMGGB-UHFFFAOYSA-N 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006143 Brain stem glioma Diseases 0.000 description 1
- 201000010424 Brazilian hemorrhagic fever Diseases 0.000 description 1
- 108010013795 Brentuximab Vedotin Proteins 0.000 description 1
- 229960000455 Brentuximab vedotin Drugs 0.000 description 1
- 229960001169 Brivudine Drugs 0.000 description 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N Bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 1
- 229960002802 Bromocriptine Drugs 0.000 description 1
- 210000000621 Bronchi Anatomy 0.000 description 1
- 241000589562 Brucella Species 0.000 description 1
- 229940056450 Brucella abortus Drugs 0.000 description 1
- 241000589567 Brucella abortus Species 0.000 description 1
- 229940038698 Brucella melitensis Drugs 0.000 description 1
- 241001148106 Brucella melitensis Species 0.000 description 1
- 241001148111 Brucella suis Species 0.000 description 1
- 206010006500 Brucellosis Diseases 0.000 description 1
- 241000244038 Brugia malayi Species 0.000 description 1
- 229960004436 Budesonide Drugs 0.000 description 1
- VOVIALXJUBGFJZ-VXKMTNQYSA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3O[C@@H](CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-VXKMTNQYSA-N 0.000 description 1
- 241001453380 Burkholderia Species 0.000 description 1
- 241000589513 Burkholderia cepacia Species 0.000 description 1
- 206010073031 Burkholderia infection Diseases 0.000 description 1
- 229940074375 Burkholderia mallei Drugs 0.000 description 1
- 241000722910 Burkholderia mallei Species 0.000 description 1
- 206010069747 Burkholderia mallei infection Diseases 0.000 description 1
- 241001136175 Burkholderia pseudomallei Species 0.000 description 1
- 206010069748 Burkholderia pseudomallei infection Diseases 0.000 description 1
- 208000006448 Buruli Ulcer Diseases 0.000 description 1
- 102100017562 C5AR1 Human genes 0.000 description 1
- 101700049499 C5AR1 Proteins 0.000 description 1
- 102100016446 CCDC54 Human genes 0.000 description 1
- 101710023968 CCDC54 Proteins 0.000 description 1
- 102100003215 CCNB1 Human genes 0.000 description 1
- 102100003731 CD109 Human genes 0.000 description 1
- 102100003268 CD14 Human genes 0.000 description 1
- 101700027514 CD14 Proteins 0.000 description 1
- 102100008207 CD209 Human genes 0.000 description 1
- 101700005213 CD209 Proteins 0.000 description 1
- 102100000197 CD24 Human genes 0.000 description 1
- 108060001249 CD24 Proteins 0.000 description 1
- 108060001251 CD34 Proteins 0.000 description 1
- 102100016492 CD34 Human genes 0.000 description 1
- 108010045374 CD36 Antigens Proteins 0.000 description 1
- 102100019144 CD46 Human genes 0.000 description 1
- 101710027020 CD46 Proteins 0.000 description 1
- 102100013078 CD47 Human genes 0.000 description 1
- 101700033237 CD47 Proteins 0.000 description 1
- 102100013076 CD48 Human genes 0.000 description 1
- 101700012453 CD48 Proteins 0.000 description 1
- 102100019284 CD53 Human genes 0.000 description 1
- 101700029492 CD53 Proteins 0.000 description 1
- 102100013391 CD55 Human genes 0.000 description 1
- 101710006195 CD55 Proteins 0.000 description 1
- 102100004444 CD58 Human genes 0.000 description 1
- 101710018147 CD58 Proteins 0.000 description 1
- 102100003281 CD59 Human genes 0.000 description 1
- 101700073334 CD59 Proteins 0.000 description 1
- 102100005827 CD63 Human genes 0.000 description 1
- 101700052224 CD63 Proteins 0.000 description 1
- 102100005833 CD68 Human genes 0.000 description 1
- 101700080416 CD69 Proteins 0.000 description 1
- 102100005832 CD69 Human genes 0.000 description 1
- 102100004099 CD74 Human genes 0.000 description 1
- 101710007476 CD74 Proteins 0.000 description 1
- 102100019451 CD80 Human genes 0.000 description 1
- 101700080477 CD80 Proteins 0.000 description 1
- 102100019450 CD81 Human genes 0.000 description 1
- 101700062651 CD81 Proteins 0.000 description 1
- 102100008204 CD82 Human genes 0.000 description 1
- 101700087069 CD82 Proteins 0.000 description 1
- 102100008186 CD83 Human genes 0.000 description 1
- 101700013105 CD83 Proteins 0.000 description 1
- 102100014435 CD96 Human genes 0.000 description 1
- 101710026045 CD96 Proteins 0.000 description 1
- 229950005258 CEFALONIUM Drugs 0.000 description 1
- 229960002129 CEFIXIME Drugs 0.000 description 1
- 229960000466 CEFPIROME Drugs 0.000 description 1
- GGQJXCQBBONZFX-IWVLMIASSA-N CHEMBL1237124 Chemical compound C=C([C@H]1[C@@H]2O)C3=C(Cl)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O GGQJXCQBBONZFX-IWVLMIASSA-N 0.000 description 1
- NPGNOVNWUSPMDP-UTEPHESZSA-N CHEMBL1650818 Chemical compound N(/[C@H]1[C@@H]2N(C1=O)[C@H](C(S2)(C)C)C(=O)OCOC(=O)C(C)(C)C)=C\N1CCCCCC1 NPGNOVNWUSPMDP-UTEPHESZSA-N 0.000 description 1
- BWWVAEOLVKTZFQ-ISVUSNJMSA-N CHEMBL530 Chemical compound N(/[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)=C\N1CCCCCC1 BWWVAEOLVKTZFQ-ISVUSNJMSA-N 0.000 description 1
- 102100004346 CLEC4C Human genes 0.000 description 1
- 101710026582 CLEC4C Proteins 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N CN(C)\N=N\c1[nH]cnc1C(N)=O Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- 102100018357 CNN1 Human genes 0.000 description 1
- 101700077824 CNN1 Proteins 0.000 description 1
- 101700083439 COL1 Proteins 0.000 description 1
- 101700042195 CR1 Proteins 0.000 description 1
- 201000002829 CREST syndrome Diseases 0.000 description 1
- 229950007258 CRISNATOL Drugs 0.000 description 1
- 102100005176 CSF1 Human genes 0.000 description 1
- 102100001891 CTAG1A Human genes 0.000 description 1
- 101710004449 CTAG1A Proteins 0.000 description 1
- 101700060333 CXCR6 Proteins 0.000 description 1
- 102100002068 CXCR6 Human genes 0.000 description 1
- 102100004047 CYP1B1 Human genes 0.000 description 1
- 101710036800 CYP1B1 Proteins 0.000 description 1
- ZVHNDZWQTBEVRY-UHFFFAOYSA-N CYT387 Chemical compound C1=CC(C(NCC#N)=O)=CC=C1C1=CC=NC(NC=2C=CC(=CC=2)N2CCOCC2)=N1 ZVHNDZWQTBEVRY-UHFFFAOYSA-N 0.000 description 1
- ONIQOQHATWINJY-UHFFFAOYSA-N Cabozantinib Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 ONIQOQHATWINJY-UHFFFAOYSA-N 0.000 description 1
- 241000714198 Caliciviridae Species 0.000 description 1
- 229940112129 Campath Drugs 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 229950007296 Cantuzumab mertansine Drugs 0.000 description 1
- YQXCVAGCMNFUMQ-UHFFFAOYSA-N Capravirine Chemical compound C=1C(Cl)=CC(Cl)=CC=1SC1=C(C(C)C)N=C(COC(N)=O)N1CC1=CC=NC=C1 YQXCVAGCMNFUMQ-UHFFFAOYSA-N 0.000 description 1
- 229950008230 Capravirine Drugs 0.000 description 1
- 229950001178 Capromab Drugs 0.000 description 1
- 229940041011 Carbapenems Drugs 0.000 description 1
- 229960003669 Carbenicillin Drugs 0.000 description 1
- FPPNZSSZRUTDAP-UWFZAAFLSA-N Carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 1
- 102000008646 Carbonic Anhydrase IX Human genes 0.000 description 1
- 108010088013 Carbonic Anhydrase IX Proteins 0.000 description 1
- OLESAACUTLOWQZ-UHFFFAOYSA-L Carboplatin Chemical compound O=C1O[Pt]([N]([H])([H])[H])([N]([H])([H])[H])OC(=O)C11CCC1 OLESAACUTLOWQZ-UHFFFAOYSA-L 0.000 description 1
- 229960004562 Carboplatin Drugs 0.000 description 1
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 1
- 208000002458 Carcinoid Tumor Diseases 0.000 description 1
- 206010007275 Carcinoid tumour Diseases 0.000 description 1
- BLMPQMFVWMYDKT-NZTKNTHTSA-N Carfilzomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)[C@]1(C)OC1)NC(=O)CN1CCOCC1)CC1=CC=CC=C1 BLMPQMFVWMYDKT-NZTKNTHTSA-N 0.000 description 1
- 208000003732 Cat-Scratch Disease Diseases 0.000 description 1
- DLNKOYKMWOXYQA-IONNQARKSA-N Cathine Chemical compound C[C@H](N)[C@@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-IONNQARKSA-N 0.000 description 1
- 229950006754 Cedelizumab Drugs 0.000 description 1
- RRYMAQUWDLIUPV-BXKDBHETSA-N Cefacetrile Chemical compound S1CC(COC(=O)C)=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CC#N)[C@@H]12 RRYMAQUWDLIUPV-BXKDBHETSA-N 0.000 description 1
- 229960003972 Cefacetrile Drugs 0.000 description 1
- 229960005361 Cefaclor Drugs 0.000 description 1
- 229960004841 Cefadroxil Drugs 0.000 description 1
- FUBBGQLTSCSAON-PBFPGSCMSA-N Cefaloglycin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)COC(=O)C)C(O)=O)=CC=CC=C1 FUBBGQLTSCSAON-PBFPGSCMSA-N 0.000 description 1
- 229950004030 Cefaloglycin Drugs 0.000 description 1
- FMZXNVLFJHCSAF-DNVCBOLYSA-N Cefalonium Chemical compound C1=CC(C(=O)N)=CC=[N+]1CC1=C(C([O-])=O)N2C(=O)[C@@H](NC(=O)CC=3SC=CC=3)[C@H]2SC1 FMZXNVLFJHCSAF-DNVCBOLYSA-N 0.000 description 1
- OLVCFLKTBJRLHI-AXAPSJFSSA-N Cefamandole Chemical compound CN1N=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)[C@H](O)C=3C=CC=CC=3)[C@H]2SC1 OLVCFLKTBJRLHI-AXAPSJFSSA-N 0.000 description 1
- 229960003012 Cefamandole Drugs 0.000 description 1
- UQLLWWBDSUHNEB-CZUORRHYSA-N Cefaprin Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C(O)=O)C(=O)CSC1=CC=NC=C1 UQLLWWBDSUHNEB-CZUORRHYSA-N 0.000 description 1
- 229960002420 Cefatrizine Drugs 0.000 description 1
- HGXLJRWXCXSEJO-GMSGAONNSA-N Cefazaflur Chemical compound CN1N=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CSC(F)(F)F)[C@H]2SC1 HGXLJRWXCXSEJO-GMSGAONNSA-N 0.000 description 1
- 229950004359 Cefazaflur Drugs 0.000 description 1
- VTLCNEGVSVJLDN-MLGOLLRUSA-N Cefazedone Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3C=C(Cl)C(=O)C(Cl)=C3)[C@H]2SC1 VTLCNEGVSVJLDN-MLGOLLRUSA-N 0.000 description 1
- MLYYVTUWGNIJIB-BXKDBHETSA-N Cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 description 1
- 229960001139 Cefazolin Drugs 0.000 description 1
- 229960001817 Cefbuperazone Drugs 0.000 description 1
- SMSRCGPDNDCXFR-CYWZMYCQSA-N Cefbuperazone Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H]([C@H](C)O)C(=O)N[C@]1(OC)C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 SMSRCGPDNDCXFR-CYWZMYCQSA-N 0.000 description 1
- HJJRIJDTIPFROI-NVKITGPLSA-N Cefcapene Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=C/CC)C1=CSC(N)=N1 HJJRIJDTIPFROI-NVKITGPLSA-N 0.000 description 1
- HOGISBSFFHDTRM-GHXIOONMSA-N Cefdaloxime Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC)C(O)=O)C(=O)C(=N/O)\C1=CSC(N)=N1 HOGISBSFFHDTRM-GHXIOONMSA-N 0.000 description 1
- 229950006550 Cefdaloxime Drugs 0.000 description 1
- KMIPKYQIOVAHOP-YLGJWRNMSA-N Cefditoren Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1\C=C/C=1SC=NC=1C KMIPKYQIOVAHOP-YLGJWRNMSA-N 0.000 description 1
- MQLRYUCJDNBWMV-GHXIOONMSA-N Cefetamet Chemical compound N([C@@H]1C(N2C(=C(C)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 MQLRYUCJDNBWMV-GHXIOONMSA-N 0.000 description 1
- OKBVVJOGVLARMR-QSWIMTSFSA-N Cefixime Chemical compound S1C(N)=NC(C(=N\OCC(O)=O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 OKBVVJOGVLARMR-QSWIMTSFSA-N 0.000 description 1
- 229960003585 Cefmetazole Drugs 0.000 description 1
- SNBUBQHDYVFSQF-HIFRSBDPSA-N Cefmetazole Chemical compound S([C@@H]1[C@@](C(N1C=1C(O)=O)=O)(NC(=O)CSCC#N)OC)CC=1CSC1=NN=NN1C SNBUBQHDYVFSQF-HIFRSBDPSA-N 0.000 description 1
- JSDXOWVAHXDYCU-VXSYNFHWSA-N Cefminox Chemical compound S([C@@H]1[C@@](C(N1C=1C(O)=O)=O)(NC(=O)CSC[C@@H](N)C(O)=O)OC)CC=1CSC1=NN=NN1C JSDXOWVAHXDYCU-VXSYNFHWSA-N 0.000 description 1
- DYAIAHUQIPBDIP-AXAPSJFSSA-N Cefonicid Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)[C@H](O)C=2C=CC=CC=2)CC=1CSC1=NN=NN1CS(O)(=O)=O DYAIAHUQIPBDIP-AXAPSJFSSA-N 0.000 description 1
- 229960004489 Cefonicid Drugs 0.000 description 1
- 229960004682 Cefoperazone Drugs 0.000 description 1
- GCFBRXLSHGKWDP-XCGNWRKASA-N Cefoperazone Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 GCFBRXLSHGKWDP-XCGNWRKASA-N 0.000 description 1
- SLAYUXIURFNXPG-CRAIPNDOSA-N Ceforanide Chemical compound NCC1=CC=CC=C1CC(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)CC(O)=O)CS[C@@H]21 SLAYUXIURFNXPG-CRAIPNDOSA-N 0.000 description 1
- GPRBEKHLDVQUJE-VINNURBNSA-N Cefotaxime Chemical compound N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C(O)=O)=O)C(=O)/C(=N/OC)C1=CSC(N)=N1 GPRBEKHLDVQUJE-VINNURBNSA-N 0.000 description 1
- 229960004261 Cefotaxime Drugs 0.000 description 1
- 229960005495 Cefotetan Drugs 0.000 description 1
- SRZNHPXWXCNNDU-RHBCBLIFSA-N Cefotetan Chemical compound N([C@]1(OC)C(N2C(=C(CSC=3N(N=NN=3)C)CS[C@@H]21)C(O)=O)=O)C(=O)C1SC(=C(C(N)=O)C(O)=O)S1 SRZNHPXWXCNNDU-RHBCBLIFSA-N 0.000 description 1
- 229960001242 Cefotiam Drugs 0.000 description 1
- QDUIJCOKQCCXQY-WHJQOFBOSA-N Cefozopran Chemical compound N([C@@H]1C(N2C(=C(CN3C4=CC=CN=[N+]4C=C3)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=NSC(N)=N1 QDUIJCOKQCCXQY-WHJQOFBOSA-N 0.000 description 1
- LNZMRLHZGOBKAN-KAWPREARSA-N Cefpimizole Chemical compound N1=CNC(C(=O)N[C@@H](C(=O)N[C@@H]2C(N3C(=C(C[N+]=4C=CC(CCS(O)(=O)=O)=CC=4)CS[C@@H]32)C([O-])=O)=O)C=2C=CC=CC=2)=C1C(=O)O LNZMRLHZGOBKAN-KAWPREARSA-N 0.000 description 1
- 229950004036 Cefpimizole Drugs 0.000 description 1
- PWAUCHMQEXVFJR-PMAPCBKXSA-N Cefpiramide Chemical compound C1=NC(C)=CC(O)=C1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 PWAUCHMQEXVFJR-PMAPCBKXSA-N 0.000 description 1
- WYUSVOMTXWRGEK-HBWVYFAYSA-N Cefpodoxime Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC)C(O)=O)C(=O)C(=N/OC)\C1=CSC(N)=N1 WYUSVOMTXWRGEK-HBWVYFAYSA-N 0.000 description 1
- 229950009592 Cefquinome Drugs 0.000 description 1
- RDLPVSKMFDYCOR-UEKVPHQBSA-N Cefradine Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CCC=CC1 RDLPVSKMFDYCOR-UEKVPHQBSA-N 0.000 description 1
- 229960002588 Cefradine Drugs 0.000 description 1
- RDMOROXKXONCAL-UEKVPHQBSA-N Cefroxadine Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)OC)C(O)=O)=CCC=CC1 RDMOROXKXONCAL-UEKVPHQBSA-N 0.000 description 1
- 229960003202 Cefsulodin Drugs 0.000 description 1
- 229960000484 Ceftazidime Drugs 0.000 description 1
- 229950000679 Cefteram Drugs 0.000 description 1
- DZMVCVMFETWNIU-LDYMZIIASA-N Ceftezole Chemical compound O=C([C@@H](NC(=O)CN1N=NN=C1)[C@H]1SC2)N1C(C(=O)O)=C2CSC1=NN=CS1 DZMVCVMFETWNIU-LDYMZIIASA-N 0.000 description 1
- UNJFKXSSGBWRBZ-BJCIPQKHSA-N Ceftibuten Chemical compound S1C(N)=NC(C(=C\CC(O)=O)\C(=O)N[C@@H]2C(N3C(=CCS[C@@H]32)C(O)=O)=O)=C1 UNJFKXSSGBWRBZ-BJCIPQKHSA-N 0.000 description 1
- 229950008880 Ceftiolene Drugs 0.000 description 1
- 229960001991 Ceftizoxime Drugs 0.000 description 1
- 229950004259 Ceftobiprole Drugs 0.000 description 1
- 229960004755 Ceftriaxone Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N Celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 206010007953 Central nervous system lymphoma Diseases 0.000 description 1
- 229940106164 Cephalexin Drugs 0.000 description 1
- CZTQZXZIADLWOZ-CRAIPNDOSA-N Cephaloridine Chemical compound O=C([C@@H](NC(=O)CC=1SC=CC=1)[C@H]1SC2)N1C(C(=O)[O-])=C2C[N+]1=CC=CC=C1 CZTQZXZIADLWOZ-CRAIPNDOSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108010070202 Certolizumab Pegol Proteins 0.000 description 1
- 210000003679 Cervix Uteri Anatomy 0.000 description 1
- 241000711969 Chandipura virus Species 0.000 description 1
- 102000004003 Chemokine CCL11 Human genes 0.000 description 1
- 108010082548 Chemokine CCL11 Proteins 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 241001647378 Chlamydia psittaci Species 0.000 description 1
- 229960005091 Chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N Chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N Chlormethine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 229960003677 Chloroquine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N Chloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- 229960004475 Chlortetracycline Drugs 0.000 description 1
- 239000004099 Chlortetracycline Substances 0.000 description 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 description 1
- 229940107111 Cholecalciferol Drugs 0.000 description 1
- 206010008803 Chromoblastomycosis Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 206010008909 Chronic hepatitis Diseases 0.000 description 1
- 206010008943 Chronic leukaemia Diseases 0.000 description 1
- 206010008958 Chronic lymphocytic leukaemia Diseases 0.000 description 1
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 description 1
- 229960000724 Cidofovir Drugs 0.000 description 1
- VWFCHDSQECPREK-LURJTMIESA-N Cidofovirum Chemical compound NC=1C=CN(C[C@@H](CO)OCP(O)(O)=O)C(=O)N=1 VWFCHDSQECPREK-LURJTMIESA-N 0.000 description 1
- DHSUYTOATWAVLW-WFVMDLQDSA-N Cilastatin Chemical compound CC1(C)C[C@@H]1C(=O)N\C(=C/CCCCSC[C@H](N)C(O)=O)C(O)=O DHSUYTOATWAVLW-WFVMDLQDSA-N 0.000 description 1
- 229960004912 Cilastatin Drugs 0.000 description 1
- 229940090100 Cimzia Drugs 0.000 description 1
- MYSWGUAQZAJSOK-UHFFFAOYSA-N Ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 1
- 229950010905 Citatuzumab bogatox Drugs 0.000 description 1
- 229950006647 Cixutumumab Drugs 0.000 description 1
- 229960003324 Clavulanic Acid Drugs 0.000 description 1
- HZZVJAQRINQKSD-PBFISZAISA-N Clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 description 1
- 229950002334 Clenoliximab Drugs 0.000 description 1
- GBBJCSTXCAQSSJ-XQXXSGGOSA-N Clevudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1[C@H](F)[C@@H](O)[C@H](CO)O1 GBBJCSTXCAQSSJ-XQXXSGGOSA-N 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N Clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- JKXQBIZCQJLVOS-GSNLGQFWSA-N Clometocillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C(OC)C1=CC=C(Cl)C(Cl)=C1 JKXQBIZCQJLVOS-GSNLGQFWSA-N 0.000 description 1
- BXVOHUQQUBSHLD-XCTBDMBQSA-N Clomocycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(=C(/O)NCO)/C(=O)[C@@]4(O)C(=O)C3=C(O)C2=C1O BXVOHUQQUBSHLD-XCTBDMBQSA-N 0.000 description 1
- 206010009344 Clonorchiasis Diseases 0.000 description 1
- 241001327965 Clonorchis sinensis Species 0.000 description 1
- 241001112695 Clostridiales Species 0.000 description 1
- 241000193163 Clostridioides difficile Species 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 241000193155 Clostridium botulinum Species 0.000 description 1
- 206010054236 Clostridium difficile infection Diseases 0.000 description 1
- 241000193449 Clostridium tetani Species 0.000 description 1
- LQOLIRLGBULYKD-JKIFEVAISA-N Cloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl LQOLIRLGBULYKD-JKIFEVAISA-N 0.000 description 1
- 241001522757 Coccidioides posadasii Species 0.000 description 1
- 206010009839 Coeliac disease Diseases 0.000 description 1
- 208000010007 Cogan Syndrome Diseases 0.000 description 1
- 206010009868 Cold type haemolytic anaemia Diseases 0.000 description 1
- 108010078777 Colistin Proteins 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 102000004266 Collagen Type IV Human genes 0.000 description 1
- 108010042086 Collagen Type IV Proteins 0.000 description 1
- 208000009802 Colorado Tick Fever Diseases 0.000 description 1
- 241000204955 Colorado tick fever virus Species 0.000 description 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
- LLLIKHLUUMWXPN-UHFFFAOYSA-N Conatumumab Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1.C1C(CC(C2)C3)CC3C12C1=NC(N(C(N(CCC)C2=O)=O)CCC)=C2N1 LLLIKHLUUMWXPN-UHFFFAOYSA-N 0.000 description 1
- 229950007276 Conatumumab Drugs 0.000 description 1
- 206010010252 Concentric sclerosis Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229940064701 Corticosteroid nasal preparations for topical use Drugs 0.000 description 1
- 229960001334 Corticosteroids Drugs 0.000 description 1
- JYGXADMDTFJGBT-VWUMJDOOSA-N Cortisol Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 1
- 241000186227 Corynebacterium diphtheriae Species 0.000 description 1
- 229940118765 Coxiella burnetii Drugs 0.000 description 1
- 241000606678 Coxiella burnetii Species 0.000 description 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 208000000307 Crimean Hemorrhagic Fever Diseases 0.000 description 1
- 201000003075 Crimean-Congo hemorrhagic fever Diseases 0.000 description 1
- 241000150230 Crimean-Congo hemorrhagic fever orthonairovirus Species 0.000 description 1
- SBRXTSOCZITGQG-UHFFFAOYSA-N Crisnatol Chemical compound C1=CC=C2C(CNC(CO)(CO)C)=CC3=C(C=CC=C4)C4=CC=C3C2=C1 SBRXTSOCZITGQG-UHFFFAOYSA-N 0.000 description 1
- 206010011401 Crohn's disease Diseases 0.000 description 1
- 229960001681 Croscarmellose Sodium Drugs 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 241000221204 Cryptococcus neoformans Species 0.000 description 1
- 208000008953 Cryptosporidiosis Diseases 0.000 description 1
- 206010011502 Cryptosporidiosis infection Diseases 0.000 description 1
- 241000223935 Cryptosporidium Species 0.000 description 1
- 206010011652 Cushing's syndrome Diseases 0.000 description 1
- 208000004921 Cutaneous Lupus Erythematosus Diseases 0.000 description 1
- 206010059547 Cutaneous larva migran Diseases 0.000 description 1
- 108010060385 Cyclin B1 Proteins 0.000 description 1
- 241000016605 Cyclospora cayetanensis Species 0.000 description 1
- 206010061802 Cyclosporidium infection Diseases 0.000 description 1
- 229940119017 Cyclosporine Drugs 0.000 description 1
- 241000205707 Cystoisospora belli Species 0.000 description 1
- 229960000684 Cytarabine Drugs 0.000 description 1
- 208000001763 Cytomegalovirus Retinitis Diseases 0.000 description 1
- 206010048843 Cytomegalovirus chorioretinitis Diseases 0.000 description 1
- 206010011831 Cytomegalovirus infection Diseases 0.000 description 1
- 206010049018 Cytomegalovirus oesophagitis Diseases 0.000 description 1
- OPTASPLRGRRNAP-UHFFFAOYSA-N Cytosine Chemical class NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- DYDCUQKUCUHJBH-UWTATZPHSA-N D-cycloserine Chemical compound N[C@@H]1CONC1=O DYDCUQKUCUHJBH-UWTATZPHSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 description 1
- DOAKLVKFURWEDJ-QCMAZARJSA-N DAPTOMYCIN Chemical compound C([C@H]1C(=O)O[C@H](C)[C@@H](C(NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@H](C(=O)N1)[C@H](C)CC(O)=O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CCCCCCCCC)C(=O)C1=CC=CC=C1N DOAKLVKFURWEDJ-QCMAZARJSA-N 0.000 description 1
- 101710004105 DCT Proteins 0.000 description 1
- 102100007097 DCT Human genes 0.000 description 1
- LRCZQSDQZJBHAF-PUBGEWHCSA-N DHA-paclitaxel Chemical compound N([C@H]([C@@H](OC(=O)CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC)C(=O)O[C@@H]1C(=C2[C@@H](OC(C)=O)C(=O)[C@]3(C)[C@@H](O)C[C@H]4OC[C@]4([C@H]3[C@H](OC(=O)C=3C=CC=CC=3)[C@](C2(C)C)(O)C1)OC(C)=O)C)C=1C=CC=CC=1)C(=O)C1=CC=CC=C1 LRCZQSDQZJBHAF-PUBGEWHCSA-N 0.000 description 1
- 101710007887 DHFR Proteins 0.000 description 1
- 102100005838 DHFR Human genes 0.000 description 1
- JJCQSGDBDPYCEO-XVZSLQNASA-N DIBEKACIN Chemical compound O1[C@H](CN)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N JJCQSGDBDPYCEO-XVZSLQNASA-N 0.000 description 1
- LHAPIGUPZIFFMA-XOGXUEEYSA-N Dacetuzumab Chemical compound O.Cl.O([C@@H]1[C@](C2=3)([C@]4(CC=5C6=CC=CC=C6NC=51)O)CC1)C=3C(O)=CC=C2CC4N1CC1CC1 LHAPIGUPZIFFMA-XOGXUEEYSA-N 0.000 description 1
- 229950007409 Dacetuzumab Drugs 0.000 description 1
- POZRVZJJTULAOH-LHZXLZLDSA-N Danazol Chemical compound C1[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=CC2=C1C=NO2 POZRVZJJTULAOH-LHZXLZLDSA-N 0.000 description 1
- 229960004385 Danofloxacin Drugs 0.000 description 1
- QMLVECGLEOSESV-RYUDHWBXSA-N Danofloxacin Chemical compound C([C@@H]1C[C@H]2CN1C)N2C(C(=CC=1C(=O)C(C(O)=O)=C2)F)=CC=1N2C1CC1 QMLVECGLEOSESV-RYUDHWBXSA-N 0.000 description 1
- 108010013198 Daptomycin Proteins 0.000 description 1
- 229960005484 Daptomycin Drugs 0.000 description 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 1
- 229960000958 Deferoxamine Drugs 0.000 description 1
- FMGSKLZLMKYGDP-USOAJAOKSA-N Dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 1
- 208000004275 Demyelinating Disease Diseases 0.000 description 1
- 206010061811 Demyelinating polyneuropathy Diseases 0.000 description 1
- 208000001490 Dengue Diseases 0.000 description 1
- 206010012310 Dengue fever Diseases 0.000 description 1
- 241000710829 Dengue virus group Species 0.000 description 1
- 108010043242 Denosumab Proteins 0.000 description 1
- 229940009976 Deoxycholate Drugs 0.000 description 1
- NIJJYAXOARWZEE-UHFFFAOYSA-N Depacane Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010012468 Dermatitis herpetiformis Diseases 0.000 description 1
- GRRNUXAQVGOGFE-UHFFFAOYSA-N Destomysin Chemical compound OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 1
- 229950008962 Detumomab Drugs 0.000 description 1
- 229960003957 Dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N Dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229950009751 Dexelvucitabine Drugs 0.000 description 1
- 206010012601 Diabetes mellitus Diseases 0.000 description 1
- 229960003807 Dibekacin Drugs 0.000 description 1
- YFAGHNZHGGCZAX-JKIFEVAISA-N Dicloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(Cl)C=CC=C1Cl YFAGHNZHGGCZAX-JKIFEVAISA-N 0.000 description 1
- 241000157306 Dientamoeba fragilis Species 0.000 description 1
- NOCJXYPHIIZEHN-UHFFFAOYSA-N Difloxacin Chemical compound C1CN(C)CCN1C(C(=C1)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1=CC=C(F)C=C1 NOCJXYPHIIZEHN-UHFFFAOYSA-N 0.000 description 1
- 229950001733 Difloxacin Drugs 0.000 description 1
- 206010013023 Diphtheria Diseases 0.000 description 1
- 206010013029 Diphyllobothriasis Diseases 0.000 description 1
- 241001137876 Diphyllobothrium Species 0.000 description 1
- AADVCYNFEREWOS-OBRABYBLSA-N Discodermolide Chemical compound C=C\C=C/[C@H](C)[C@H](OC(N)=O)[C@@H](C)[C@H](O)[C@@H](C)C\C(C)=C/[C@H](C)[C@@H](O)[C@@H](C)\C=C/[C@@H](O)C[C@@H]1OC(=O)[C@H](C)[C@@H](O)[C@H]1C AADVCYNFEREWOS-OBRABYBLSA-N 0.000 description 1
- 208000006926 Discoid Lupus Erythematosus Diseases 0.000 description 1
- AUZONCFQVSMFAP-UHFFFAOYSA-N Disulfiram Chemical compound CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 description 1
- 229960002563 Disulfiram Drugs 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N Docetaxel Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- NOPFSRXAKWQILS-UHFFFAOYSA-N Docosanol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 1
- AVAACINZEOAHHE-VFZPANTDSA-N Doripenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](CNS(N)(=O)=O)C1 AVAACINZEOAHHE-VFZPANTDSA-N 0.000 description 1
- 229960003722 Doxycycline Drugs 0.000 description 1
- 208000008576 Dracunculiasis Diseases 0.000 description 1
- 241001319090 Dracunculus medinensis Species 0.000 description 1
- 206010013637 Dressler's syndrome Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- VQNATVDKACXKTF-XELLLNAOSA-N Duocarmycin Chemical compound COC1=C(OC)C(OC)=C2NC(C(=O)N3C4=CC(=O)C5=C([C@@]64C[C@@H]6C3)C=C(N5)C(=O)OC)=CC2=C1 VQNATVDKACXKTF-XELLLNAOSA-N 0.000 description 1
- 102000003425 EC 1.14.18.1 Human genes 0.000 description 1
- 108060008724 EC 1.14.18.1 Proteins 0.000 description 1
- 101710038745 EEF1A2 Proteins 0.000 description 1
- 101700033006 EGF Proteins 0.000 description 1
- 102100010813 EGF Human genes 0.000 description 1
- 229960002549 ENOXACIN Drugs 0.000 description 1
- 102100016627 EPHA2 Human genes 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N EPIRUBICIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- 229960001904 EPIRUBICIN Drugs 0.000 description 1
- 102100003763 ERG Human genes 0.000 description 1
- 101700055371 ERG Proteins 0.000 description 1
- 102000033147 ERVK-25 Human genes 0.000 description 1
- 206010014071 Ebola disease Diseases 0.000 description 1
- 201000011001 Ebola hemorrhagic fever Diseases 0.000 description 1
- 241001115402 Ebolavirus Species 0.000 description 1
- 206010014096 Echinococciasis Diseases 0.000 description 1
- 208000009366 Echinococcosis Diseases 0.000 description 1
- 241000244160 Echinococcus Species 0.000 description 1
- 229950000006 Ecromeximab Drugs 0.000 description 1
- 208000005679 Eczema Diseases 0.000 description 1
- 229950011109 Edobacomab Drugs 0.000 description 1
- 108010070635 Edrecolomab Proteins 0.000 description 1
- 241000607471 Edwardsiella tarda Species 0.000 description 1
- XPOQHMRABVBWPR-ZDUSSCGKSA-N Efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 description 1
- 229950002209 Efungumab Drugs 0.000 description 1
- 241000605314 Ehrlichia Species 0.000 description 1
- 241000605310 Ehrlichia chaffeensis Species 0.000 description 1
- 241000605282 Ehrlichia ewingii Species 0.000 description 1
- 208000006036 Elephantiasis Diseases 0.000 description 1
- XOPYFXBZMVTEJF-PDACKIITSA-N Eleutherobin Chemical compound C(/[C@H]1[C@H](C(=CC[C@@H]1C(C)C)C)C[C@@H]([C@@]1(C)O[C@@]2(C=C1)OC)OC(=O)\C=C\C=1N=CN(C)C=1)=C2\CO[C@@H]1OC[C@@H](O)[C@@H](O)[C@@H]1OC(C)=O XOPYFXBZMVTEJF-PDACKIITSA-N 0.000 description 1
- 229960004137 Elotuzumab Drugs 0.000 description 1
- 229950002507 Elsilimomab Drugs 0.000 description 1
- JUZYLCPPVHEVSV-LJQANCHMSA-N Elvitegravir Chemical compound COC1=CC=2N([C@H](CO)C(C)C)C=C(C(O)=O)C(=O)C=2C=C1CC1=CC=CC(Cl)=C1F JUZYLCPPVHEVSV-LJQANCHMSA-N 0.000 description 1
- 229950006528 Elvucitabine Drugs 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- MLILORUFDVLTSP-UHFFFAOYSA-N Emivirine Chemical compound O=C1NC(=O)N(COCC)C(CC=2C=CC=CC=2)=C1C(C)C MLILORUFDVLTSP-UHFFFAOYSA-N 0.000 description 1
- 229950002002 Emivirine Drugs 0.000 description 1
- 229940073621 Enbrel Drugs 0.000 description 1
- 206010052369 Encephalitis lethargica Diseases 0.000 description 1
- 206010014611 Encephalitis venezuelan equine Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 210000001163 Endosomes Anatomy 0.000 description 1
- 108010032976 Enfuvirtide Proteins 0.000 description 1
- 229950000565 Enlimomab pegol Drugs 0.000 description 1
- IDYZIJYBMGIQMJ-UHFFFAOYSA-N Enoxacin Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 IDYZIJYBMGIQMJ-UHFFFAOYSA-N 0.000 description 1
- 229940007078 Entamoeba histolytica Drugs 0.000 description 1
- 241000224432 Entamoeba histolytica Species 0.000 description 1
- QDGZDCVAUDNJFG-FXQIFTODSA-N Entecavir Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@H]1C[C@H](O)[C@@H](CO)C1=C QDGZDCVAUDNJFG-FXQIFTODSA-N 0.000 description 1
- 241000498255 Enterobius vermicularis Species 0.000 description 1
- 241001529459 Enterovirus A71 Species 0.000 description 1
- 206010014909 Enterovirus infection Diseases 0.000 description 1
- 229950005837 Entinostat Drugs 0.000 description 1
- 241000235577 Entomophthorales Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010014954 Eosinophilic fasciitis Diseases 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 206010014979 Epidemic typhus Diseases 0.000 description 1
- 229940116977 Epidermal Growth Factor Drugs 0.000 description 1
- 241001480036 Epidermophyton floccosum Species 0.000 description 1
- 229950001757 Epitumomab Drugs 0.000 description 1
- 229950008932 Epolamine Drugs 0.000 description 1
- 229950009760 Epratuzumab Drugs 0.000 description 1
- 206010015108 Epstein-Barr virus infection Diseases 0.000 description 1
- 229940082789 Erbitux Drugs 0.000 description 1
- 229960002061 Ergocalciferol Drugs 0.000 description 1
- 229950004292 Erlizumab Drugs 0.000 description 1
- 229960001433 Erlotinib Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N Erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 229950008579 Ertumaxomab Drugs 0.000 description 1
- 208000007985 Erythema Infectiosum Diseases 0.000 description 1
- 206010015226 Erythema nodosum Diseases 0.000 description 1
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241001646719 Escherichia coli O157:H7 Species 0.000 description 1
- DMUAPQTXSSNEDD-QALJCMCCSA-N Espinomycin A1 Chemical compound C1[C@](O)(C)[C@@H](OC(=O)CC)[C@H](C)O[C@H]1O[C@H]1[C@H](N(C)C)[C@@H](O)[C@H](O[C@@H]2[C@H]([C@H](OC(=O)CC)CC(=O)O[C@H](C)C/C=C/C=C/[C@H](O)[C@H](C)C[C@@H]2CC=O)OC)O[C@@H]1C DMUAPQTXSSNEDD-QALJCMCCSA-N 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- 229950009569 Etaracizumab Drugs 0.000 description 1
- 229960000285 Ethambutol Drugs 0.000 description 1
- AEUTYOVWOVBAKS-UWVGGRQHSA-N Ethambutol Chemical compound CC[C@@H](CO)NCCN[C@@H](CC)CO AEUTYOVWOVBAKS-UWVGGRQHSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N Ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- PYGWGZALEOIKDF-UHFFFAOYSA-N Etravirine Chemical compound CC1=CC(C#N)=CC(C)=C1OC1=NC(NC=2C=CC(=CC=2)C#N)=NC(N)=C1Br PYGWGZALEOIKDF-UHFFFAOYSA-N 0.000 description 1
- 208000004332 Evans Syndrome Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 229950005562 Exbivirumab Drugs 0.000 description 1
- 102100014610 FCAR Human genes 0.000 description 1
- 101700041688 FCAR Proteins 0.000 description 1
- 102100015540 FCGR1A Human genes 0.000 description 1
- 101710003440 FCGR1A Proteins 0.000 description 1
- 101710044640 FCGR2A Proteins 0.000 description 1
- 102100015543 FCGR2B Human genes 0.000 description 1
- 101710044641 FCGR2B Proteins 0.000 description 1
- 101710044642 FCGR2C Proteins 0.000 description 1
- 102100015541 FCGR3A Human genes 0.000 description 1
- 101710044656 FCGR3A Proteins 0.000 description 1
- 101710044657 FCGR3B Proteins 0.000 description 1
- 229950003499 FIBRIN Drugs 0.000 description 1
- 102100011898 FOLR1 Human genes 0.000 description 1
- 101700050183 FOLR1 Proteins 0.000 description 1
- YMDXZJFXQJVXBF-STHAYSLISA-N FOSFOMYCIN Chemical compound C[C@@H]1O[C@@H]1P(O)(O)=O YMDXZJFXQJVXBF-STHAYSLISA-N 0.000 description 1
- 229960003704 FRAMYCETIN Drugs 0.000 description 1
- 229940118764 FRANCISELLA TULARENSIS Drugs 0.000 description 1
- 102100019327 FUT4 Human genes 0.000 description 1
- 101700004786 FUT4 Proteins 0.000 description 1
- 208000002980 Facial Hemiatrophy Diseases 0.000 description 1
- 241000272190 Falco peregrinus Species 0.000 description 1
- 229940093443 Fanolesomab Drugs 0.000 description 1
- 229950001488 Faralimomab Drugs 0.000 description 1
- 229950009929 Farletuzumab Drugs 0.000 description 1
- HGGAKXAHAYOLDJ-FHZUQPTBSA-N Faropenem Chemical compound S([C@@H]1[C@H](C(N1C=1C(O)=O)=O)[C@H](O)C)C=1[C@H]1CCCO1 HGGAKXAHAYOLDJ-FHZUQPTBSA-N 0.000 description 1
- 241000204939 Fasciola gigantica Species 0.000 description 1
- 241000242711 Fasciola hepatica Species 0.000 description 1
- 206010016235 Fasciolopsiasis Diseases 0.000 description 1
- 241001126302 Fasciolopsis buski Species 0.000 description 1
- 206010016256 Fatigue Diseases 0.000 description 1
- 229950001563 Felvizumab Drugs 0.000 description 1
- 210000003754 Fetus Anatomy 0.000 description 1
- 229950010512 Fezakinumab Drugs 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- 206010068715 Fibrodysplasia ossificans progressiva Diseases 0.000 description 1
- 229950008085 Figitumumab Drugs 0.000 description 1
- 208000005239 Filarial Elephantiasis Diseases 0.000 description 1
- 206010016675 Filariasis lymphatic Diseases 0.000 description 1
- 241000244009 Filarioidea Species 0.000 description 1
- 241000710831 Flavivirus Species 0.000 description 1
- 229960004273 Floxacillin Drugs 0.000 description 1
- UIOFUWFRIANQPC-JKIFEVAISA-N Floxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(F)C=CC=C1Cl UIOFUWFRIANQPC-JKIFEVAISA-N 0.000 description 1
- 229940072686 Floxin Drugs 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N Floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- 229960000961 Floxuridine Drugs 0.000 description 1
- XSFJVAJPIHIPKU-XWCQMRHXSA-N Flunisolide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O XSFJVAJPIHIPKU-XWCQMRHXSA-N 0.000 description 1
- 229960003973 Fluocortolone Drugs 0.000 description 1
- GAKMQHDJQHZUTJ-ULHLPKEOSA-N Fluocortolone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)CO)[C@@]2(C)C[C@@H]1O GAKMQHDJQHZUTJ-ULHLPKEOSA-N 0.000 description 1
- XOEUHCONYHZURQ-HNUBZJOYSA-N Flurithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@@](C)(F)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 XOEUHCONYHZURQ-HNUBZJOYSA-N 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N Flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- WMWTYOKRWGGJOA-CENSZEJFSA-N Fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 1
- 229940014144 Folate Drugs 0.000 description 1
- XCWFZHPEARLXJI-UHFFFAOYSA-N Fomivirsen Chemical compound C1C(N2C3=C(C(NC(N)=N3)=O)N=C2)OC(CO)C1OP(O)(=S)OCC1OC(N(C)C(=O)\N=C(\N)C=C)CC1OP(O)(=S)OCC1OC(N2C3=C(C(NC(N)=N3)=O)N=C2)CC1OP(O)(=S)OCC1OC(N2C(NC(=O)C(C)=C2)=O)CC1OP(O)(=S)OCC1OC(N2C(NC(=O)C(C)=C2)=O)CC1OP(O)(=S)OCC1OC(N2C(NC(=O)C(C)=C2)=O)CC1OP(O)(=S)OCC1OC(N2C3=C(C(NC(N)=N3)=O)N=C2)CC1OP(O)(=S)OCC1OC(N2C(N=C(N)C=C2)=O)CC1OP(O)(=S)OCC(C(C1)OP(S)(=O)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)O)OC1N1C=C(C)C(=O)NC1=O XCWFZHPEARLXJI-UHFFFAOYSA-N 0.000 description 1
- 241000122864 Fonsecaea pedrosoi Species 0.000 description 1
- 229950004923 Fontolizumab Drugs 0.000 description 1
- 206010016952 Food poisoning Diseases 0.000 description 1
- 229950011078 Foravirumab Drugs 0.000 description 1
- 108090000123 Fos-related antigen 1 Proteins 0.000 description 1
- 102000003817 Fos-related antigen 1 Human genes 0.000 description 1
- MLBVMOWEQCZNCC-OEMFJLHTSA-N Fosamprenavir Chemical compound C([C@@H]([C@H](OP(O)(O)=O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 MLBVMOWEQCZNCC-OEMFJLHTSA-N 0.000 description 1
- 241000589602 Francisella tularensis Species 0.000 description 1
- 229950004003 Fresolimumab Drugs 0.000 description 1
- PLHJDBGFXBMTGZ-WEVVVXLNSA-N Furazolidone Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)OCC1 PLHJDBGFXBMTGZ-WEVVVXLNSA-N 0.000 description 1
- 241000605909 Fusobacterium Species 0.000 description 1
- 206010017564 Fusobacterium infection Diseases 0.000 description 1
- 102100001448 GAST Human genes 0.000 description 1
- 101700005903 GAST Proteins 0.000 description 1
- 102100003780 GLRA1 Human genes 0.000 description 1
- 108060004408 GLRA1 Proteins 0.000 description 1
- 101710043857 GM1 Proteins 0.000 description 1
- 102100000899 GNRH1 Human genes 0.000 description 1
- 101700063410 GRFIN Proteins 0.000 description 1
- 102100018914 GYPA Human genes 0.000 description 1
- 101710042158 GYPA Proteins 0.000 description 1
- 229950001109 Galiximab Drugs 0.000 description 1
- 229960002963 Ganciclovir Drugs 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N Ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 229950002508 Gantenerumab Drugs 0.000 description 1
- NJDRXTDGYFKORP-LLVKDONJSA-N Garenoxacin Chemical compound N([C@@H](C1=CC=2)C)CC1=CC=2C(C=1OC(F)F)=CC=C(C(C(C(O)=O)=C2)=O)C=1N2C1CC1 NJDRXTDGYFKORP-LLVKDONJSA-N 0.000 description 1
- 102000004862 Gastrin releasing peptide Human genes 0.000 description 1
- 108090001053 Gastrin releasing peptide Proteins 0.000 description 1
- PUBCCFNQJQKCNC-XKNFJVFFSA-N Gastrin-ReleasingPeptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)C(C)C)[C@@H](C)O)C(C)C)[C@@H](C)O)C(C)C)C1=CNC=N1 PUBCCFNQJQKCNC-XKNFJVFFSA-N 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 206010017915 Gastroenteritis shigella Diseases 0.000 description 1
- 206010017916 Gastroenteritis staphylococcal Diseases 0.000 description 1
- XUBOMFCQGDBHNK-UHFFFAOYSA-N Gatifloxacin Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCNC(C)C1 XUBOMFCQGDBHNK-UHFFFAOYSA-N 0.000 description 1
- 229950004792 Gavilimomab Drugs 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N Gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N Gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- ZRCVYEYHRGVLOC-HYARGMPZSA-N Gemifloxacin Chemical compound C1C(CN)C(=N/OC)/CN1C(C(=C1)F)=NC2=C1C(=O)C(C(O)=O)=CN2C1CC1 ZRCVYEYHRGVLOC-HYARGMPZSA-N 0.000 description 1
- 108010091266 Gemtuzumab Proteins 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 244000168141 Geotrichum candidum Species 0.000 description 1
- 235000017388 Geotrichum candidum Nutrition 0.000 description 1
- 241000224467 Giardia intestinalis Species 0.000 description 1
- 229950002026 Girentuximab Drugs 0.000 description 1
- YALNUENQHAQXEA-UHFFFAOYSA-N Givinostat Chemical compound C1=CC2=CC(CN(CC)CC)=CC=C2C=C1COC(=O)NC1=CC=C(C(=O)NO)C=C1 YALNUENQHAQXEA-UHFFFAOYSA-N 0.000 description 1
- 229950010415 Givinostat Drugs 0.000 description 1
- 229950000918 Glembatumumab Drugs 0.000 description 1
- 229950009672 Glembatumumab vedotin Drugs 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- DHZIDIIBBCIIEG-XMMPIXPASA-N Globoidnan A Chemical compound C([C@H](C(=O)O)OC(=O)C=1C=C2C=C(O)C(O)=CC2=C(C=2C=C(O)C(O)=CC=2)C=1)C1=CC=C(O)C(O)=C1 DHZIDIIBBCIIEG-XMMPIXPASA-N 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 229960002989 Glutamic Acid Drugs 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N Glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 229960003180 Glutathione Drugs 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 241000497087 Gnathostoma hispidum Species 0.000 description 1
- 241001276383 Gnathostoma spinigerum Species 0.000 description 1
- 208000000807 Gnathostomiasis Diseases 0.000 description 1
- 108010084340 Gonadotropin-Releasing Hormone Proteins 0.000 description 1
- 208000001786 Gonorrhea Diseases 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 206010018620 Goodpasture's syndrome Diseases 0.000 description 1
- 206010056559 Graft infection Diseases 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
- 208000003807 Graves Disease Diseases 0.000 description 1
- 201000004779 Graves' disease Diseases 0.000 description 1
- 241000190708 Guanarito mammarenavirus Species 0.000 description 1
- 229940093912 Gynecological Sulfonamides Drugs 0.000 description 1
- 101700075868 HER1 Proteins 0.000 description 1
- 208000005721 HIV Infections Diseases 0.000 description 1
- 108010036449 HLA-DR10 antigen Proteins 0.000 description 1
- 102100003420 HMMR Human genes 0.000 description 1
- 101700034521 HMMR Proteins 0.000 description 1
- 101700071120 HSTN Proteins 0.000 description 1
- 101710015954 HVA1 Proteins 0.000 description 1
- 206010061190 Haemophilus infection Diseases 0.000 description 1
- 229940047650 Haemophilus influenzae Drugs 0.000 description 1
- 206010019143 Hantavirus pulmonary infection Diseases 0.000 description 1
- 208000003579 Hashimoto's encephalitis Diseases 0.000 description 1
- 210000003128 Head Anatomy 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 206010019375 Helicobacter infection Diseases 0.000 description 1
- 229940037467 Helicobacter pylori Drugs 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- ODZBBRURCPAEIQ-PIXDULNESA-N Helpin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(\C=C\Br)=C1 ODZBBRURCPAEIQ-PIXDULNESA-N 0.000 description 1
- 208000007475 Hemolytic Anemia Diseases 0.000 description 1
- 201000004331 Henoch-Schoenlein purpura Diseases 0.000 description 1
- 206010019617 Henoch-Schonlein purpura Diseases 0.000 description 1
- 208000005252 Hepatitis A Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 208000005331 Hepatitis D Diseases 0.000 description 1
- MCAHMSDENAOJFZ-BVXDHVRPSA-N Herbimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](OC)[C@@H](OC)C[C@H](C)[C@@H](OC)C2=CC(=O)C=C1C2=O MCAHMSDENAOJFZ-BVXDHVRPSA-N 0.000 description 1
- 229940022353 Herceptin Drugs 0.000 description 1
- 206010019939 Herpes gestationis Diseases 0.000 description 1
- 241000175212 Herpesvirales Species 0.000 description 1
- 241000700586 Herpesviridae Species 0.000 description 1
- 208000005100 Herpetic Keratitis Diseases 0.000 description 1
- 208000002557 Hidradenitis Diseases 0.000 description 1
- 201000006743 Hodgkin's lymphoma Diseases 0.000 description 1
- 206010020376 Hookworm infection Diseases 0.000 description 1
- 241000308514 Hortaea werneckii Species 0.000 description 1
- 229940084986 Human Chorionic Gonadotropin Drugs 0.000 description 1
- 108010084873 Human Immunodeficiency Virus nef Gene Products Proteins 0.000 description 1
- 102000005657 Human Immunodeficiency Virus nef Gene Products Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
- 241000701041 Human betaherpesvirus 7 Species 0.000 description 1
- 206010020429 Human ehrlichiosis Diseases 0.000 description 1
- 241001502974 Human gammaherpesvirus 8 Species 0.000 description 1
- 241000701027 Human herpesvirus 6 Species 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 241000702617 Human parvovirus B19 Species 0.000 description 1
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N Hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 1
- 229960004171 Hydroxychloroquine Drugs 0.000 description 1
- 229940097277 Hygromycin B Drugs 0.000 description 1
- 208000007188 Hymenolepiasis Diseases 0.000 description 1
- 241000244166 Hymenolepis diminuta Species 0.000 description 1
- 241001464384 Hymenolepis nana Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- QWPPOHNGKGFGJK-UHFFFAOYSA-N Hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 1
- 206010021042 Hypopharyngeal cancer Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 102100016020 IFNG Human genes 0.000 description 1
- 101700086956 IFNG Proteins 0.000 description 1
- 101700082799 IL2RA Proteins 0.000 description 1
- 102100008185 IL6R Human genes 0.000 description 1
- 108010026702 IMC1C11 Proteins 0.000 description 1
- 229960002182 IMIPENEM Drugs 0.000 description 1
- ZSKVGTPCRGIANV-ZXFLCMHBSA-N IMIPENEM Chemical compound C1C(SCC\N=C\N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 ZSKVGTPCRGIANV-ZXFLCMHBSA-N 0.000 description 1
- 229960000798 ISEPAMICIN Drugs 0.000 description 1
- 101700015336 ISG20 Proteins 0.000 description 1
- 102100002950 ISG20 Human genes 0.000 description 1
- 229960000310 ISOLEUCINE Drugs 0.000 description 1
- 101700025474 ISP2 Proteins 0.000 description 1
- 102100019336 ITGA2 Human genes 0.000 description 1
- 101710006710 ITGA2 Proteins 0.000 description 1
- 102100019335 ITGA3 Human genes 0.000 description 1
- 101710006708 ITGA3 Proteins 0.000 description 1
- 102100012151 ITGAE Human genes 0.000 description 1
- 101710006585 ITGAE Proteins 0.000 description 1
- 102100019441 ITGAM Human genes 0.000 description 1
- 101710006572 ITGAM Proteins 0.000 description 1
- 102100019438 ITGAV Human genes 0.000 description 1
- 101710006691 ITGAV Proteins 0.000 description 1
- 102100019437 ITGAX Human genes 0.000 description 1
- 101710006689 ITGAX Proteins 0.000 description 1
- 102100001478 ITGB1 Human genes 0.000 description 1
- 101710006661 ITGB1 Proteins 0.000 description 1
- 102100001477 ITGB3 Human genes 0.000 description 1
- 101710006664 ITGB3 Proteins 0.000 description 1
- 229960000908 Idarubicin Drugs 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin hydrochloride Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
- 229960004716 Idoxuridine Drugs 0.000 description 1
- 229960001101 Ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N Ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 229950002200 Igovomab Drugs 0.000 description 1
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Ilacox Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 1
- 229940071829 Ilaris Drugs 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N Imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 229950007354 Imciromab Drugs 0.000 description 1
- 108010027440 Immunoconjugates Proteins 0.000 description 1
- 102000018748 Immunoconjugates Human genes 0.000 description 1
- CBVCZFGXHXORBI-PXQQMZJSSA-N Indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 description 1
- 208000002979 Influenza in Birds Diseases 0.000 description 1
- 241001500351 Influenzavirus A Species 0.000 description 1
- 241001500350 Influenzavirus B Species 0.000 description 1
- 229950002133 Iniparib Drugs 0.000 description 1
- MDOJTZQKHMAPBK-UHFFFAOYSA-N Iniparib Chemical compound NC(=O)C1=CC=C(I)C([N+]([O-])=O)=C1 MDOJTZQKHMAPBK-UHFFFAOYSA-N 0.000 description 1
- 229950007937 Inolimomab Drugs 0.000 description 1
- 108010027059 Inotuzumab Ozogamicin Proteins 0.000 description 1
- 229950004101 Inotuzumab ozogamicin Drugs 0.000 description 1
- 102400000022 Insulin-Like Growth Factor II Human genes 0.000 description 1
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 1
- 102000004218 Insulin-like growth factor I Human genes 0.000 description 1
- 108090000723 Insulin-like growth factor I Proteins 0.000 description 1
- 229950000038 Interferon alfa Drugs 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 102000000646 Interleukin-3 Human genes 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010038501 Interleukin-6 Receptors Proteins 0.000 description 1
- 229940047122 Interleukins Drugs 0.000 description 1
- 208000005615 Interstitial Cystitis Diseases 0.000 description 1
- 229950001014 Intetumumab Drugs 0.000 description 1
- 206010061252 Intraocular melanoma Diseases 0.000 description 1
- JUZNIMUFDBIJCM-ANEDZVCMSA-N Invanz Chemical compound O=C([C@H]1NC[C@H](C1)SC=1[C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)NC1=CC=CC(C(O)=O)=C1 JUZNIMUFDBIJCM-ANEDZVCMSA-N 0.000 description 1
- 108010089187 Ipilimumab Proteins 0.000 description 1
- 229950010939 Iratumumab Drugs 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N Irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 102000004902 Iron regulatory protein 2 Human genes 0.000 description 1
- 108090001028 Iron regulatory protein 2 Proteins 0.000 description 1
- 208000002551 Irritable Bowel Syndrome Diseases 0.000 description 1
- UDIIBEDMEYAVNG-ZKFPOVNWSA-N Isepamicin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)O)[C@@H](N)C[C@H]1NC(=O)[C@@H](O)CN UDIIBEDMEYAVNG-ZKFPOVNWSA-N 0.000 description 1
- 229950007344 Ispinesib Drugs 0.000 description 1
- 241000701460 JC polyomavirus Species 0.000 description 1
- XJSFLOJWULLJQS-NGVXBBESSA-N JOSAMYCIN Chemical compound CO[C@H]1[C@H](OC(C)=O)CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](N(C)C)[C@H](O[C@@H]2O[C@@H](C)[C@H](OC(=O)CC(C)C)[C@](C)(O)C2)[C@@H](C)O1 XJSFLOJWULLJQS-NGVXBBESSA-N 0.000 description 1
- 241000712890 Junin mammarenavirus Species 0.000 description 1
- 101700085508 KCNH2 Proteins 0.000 description 1
- 101700011826 KCNH6 Proteins 0.000 description 1
- 102100016985 KIT Human genes 0.000 description 1
- 102100011339 KLK3 Human genes 0.000 description 1
- KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N Kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229950010828 Keliximab Drugs 0.000 description 1
- 206010023332 Keratitis Diseases 0.000 description 1
- 210000000244 Kidney Pelvis Anatomy 0.000 description 1
- 241001534216 Klebsiella granulomatis Species 0.000 description 1
- 229940045505 Klebsiella pneumoniae Drugs 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 1
- 239000005536 L01XE08 - Nilotinib Substances 0.000 description 1
- 239000003798 L01XE11 - Pazopanib Substances 0.000 description 1
- 239000002118 L01XE12 - Vandetanib Substances 0.000 description 1
- 239000002144 L01XE18 - Ruxolitinib Substances 0.000 description 1
- 239000002137 L01XE24 - Ponatinib Substances 0.000 description 1
- 239000002176 L01XE26 - Cabozantinib Substances 0.000 description 1
- 101710009221 LD Proteins 0.000 description 1
- 101700065814 LEA2 Proteins 0.000 description 1
- 101700021338 LEC Proteins 0.000 description 1
- 101700077545 LECC Proteins 0.000 description 1
- 101700028499 LECG Proteins 0.000 description 1
- 101700063913 LECT Proteins 0.000 description 1
- 101700006721 LMP2 Proteins 0.000 description 1
- 102100012758 LRP1 Human genes 0.000 description 1
- 101700005580 LRP1 Proteins 0.000 description 1
- 229950000518 Labetuzumab Drugs 0.000 description 1
- 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 description 1
- 229960001627 Lamivudine Drugs 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 229940039717 Lanolin Drugs 0.000 description 1
- BCFGMOOMADDAQU-UHFFFAOYSA-N Lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 1
- 208000004204 Larva Migrans Diseases 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 206010023927 Lassa fever Diseases 0.000 description 1
- 241000712902 Lassa mammarenavirus Species 0.000 description 1
- 229950002183 Lebrikizumab Drugs 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- 241000222722 Leishmania <genus> Species 0.000 description 1
- 241000222740 Leishmania braziliensis Species 0.000 description 1
- 241000222727 Leishmania donovani Species 0.000 description 1
- 241000222736 Leishmania tropica Species 0.000 description 1
- 208000004554 Leishmaniasis Diseases 0.000 description 1
- 229950001275 Lemalesomab Drugs 0.000 description 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N Lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 206010024238 Leptospirosis Diseases 0.000 description 1
- 108091007622 Lerdelimumab Proteins 0.000 description 1
- 229950010470 Lerdelimumab Drugs 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 206010024377 Leukocytoclastic vasculitis Diseases 0.000 description 1
- 229940089022 Leuprolide Acetate Drugs 0.000 description 1
- 229960004338 Leuprorelin Drugs 0.000 description 1
- 229950002884 Lexatumumab Drugs 0.000 description 1
- 229950005173 Libivirumab Drugs 0.000 description 1
- 208000007820 Lichen Sclerosus et Atrophicus Diseases 0.000 description 1
- 206010024434 Lichen sclerosus Diseases 0.000 description 1
- OJMMVQQUTAEWLP-KIDUDLJLSA-N Lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 1
- 229940041028 Lincosamides Drugs 0.000 description 1
- TYZROVQLWOKYKF-ZDUSSCGKSA-N Linezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCOCC1 TYZROVQLWOKYKF-ZDUSSCGKSA-N 0.000 description 1
- 229950002950 Lintuzumab Drugs 0.000 description 1
- 108010028921 Lipopeptides Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 229940115931 Listeria monocytogenes Drugs 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- 206010024641 Listeriosis Diseases 0.000 description 1
- 208000000185 Localized Scleroderma Diseases 0.000 description 1
- KBEMFSMODRNJHE-JFWOZONXSA-N Lodenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)C[C@@H]1F KBEMFSMODRNJHE-JFWOZONXSA-N 0.000 description 1
- 229950003557 Lodenosine Drugs 0.000 description 1
- ZEKZLJVOYLTDKK-UHFFFAOYSA-N Lomefloxacin Chemical compound FC1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNC(C)C1 ZEKZLJVOYLTDKK-UHFFFAOYSA-N 0.000 description 1
- 229950003526 Lorvotuzumab mertansine Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N Lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- 229950006243 Loviride Drugs 0.000 description 1
- CJPLEFFCVDQQFZ-UHFFFAOYSA-N Loviride Chemical compound CC(=O)C1=CC=C(C)C=C1NC(C(N)=O)C1=C(Cl)C=CC=C1Cl CJPLEFFCVDQQFZ-UHFFFAOYSA-N 0.000 description 1
- 229950004563 Lucatumumab Drugs 0.000 description 1
- 229940076783 Lucentis Drugs 0.000 description 1
- 229950000128 Lumiliximab Drugs 0.000 description 1
- 206010025135 Lupus erythematosus Diseases 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 208000003543 Lymphoma, T-Cell, Cutaneous Diseases 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102000016200 MART-1 Antigen Human genes 0.000 description 1
- 108010010995 MART-1 Antigen Proteins 0.000 description 1
- 108090000028 MMP12 Proteins 0.000 description 1
- MINDHVHHQZYEEK-HBBNESRFSA-N MUPIROCIN Chemical compound C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC(O)=O)OC1 MINDHVHHQZYEEK-HBBNESRFSA-N 0.000 description 1
- 102100018882 MYCN Human genes 0.000 description 1
- 241000712898 Machupo mammarenavirus Species 0.000 description 1
- 229940041033 Macrolides Drugs 0.000 description 1
- 229920002521 Macromolecule Polymers 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- TYMRLRRVMHJFTF-UHFFFAOYSA-N Mafenide Chemical compound NCC1=CC=C(S(N)(=O)=O)C=C1 TYMRLRRVMHJFTF-UHFFFAOYSA-N 0.000 description 1
- 229940057948 Magnesium stearate Drugs 0.000 description 1
- 208000009777 Majeed syndrome Diseases 0.000 description 1
- 241000555676 Malassezia Species 0.000 description 1
- 208000006178 Malignant Mesothelioma Diseases 0.000 description 1
- 206010025538 Malignant ascite Diseases 0.000 description 1
- 206010064281 Malignant atrophic papulosis Diseases 0.000 description 1
- 206010073059 Malignant neoplasm of unknown primary site Diseases 0.000 description 1
- 229950001869 Mapatumumab Drugs 0.000 description 1
- GSNHKUDZZFZSJB-QYOOZWMWSA-N Maraviroc Chemical compound CC(C)C1=NN=C(C)N1[C@@H]1C[C@H](N2CC[C@H](NC(=O)C3CCC(F)(F)CC3)C=3C=CC=CC=3)CC[C@H]2C1 GSNHKUDZZFZSJB-QYOOZWMWSA-N 0.000 description 1
- BPFYOAJNDMUVBL-UHFFFAOYSA-N Marbofloxacin Chemical compound C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3N(C)COC1=C32 BPFYOAJNDMUVBL-UHFFFAOYSA-N 0.000 description 1
- 208000000932 Marburg Virus Disease Diseases 0.000 description 1
- 201000011013 Marburg hemorrhagic fever Diseases 0.000 description 1
- 241001115401 Marburgvirus Species 0.000 description 1
- 229950008083 Maslimomab Drugs 0.000 description 1
- 229950008001 Matuzumab Drugs 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 229960004961 Mechlorethamine Drugs 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N Meglumine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 229960003194 Meglumine Drugs 0.000 description 1
- 102000011186 Membrane-spanning 4-domains subfamily A Human genes 0.000 description 1
- 108050001412 Membrane-spanning 4-domains subfamily A Proteins 0.000 description 1
- 240000006217 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- DMJNNHOOLUXYBV-PQTSNVLCSA-N Meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 description 1
- 229920001367 Merrifield resin Polymers 0.000 description 1
- 241001660197 Metagonimus Species 0.000 description 1
- 206010066226 Metapneumovirus infection Diseases 0.000 description 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
- 206010050513 Metastatic renal cell carcinoma Diseases 0.000 description 1
- 229950005555 Metelimumab Drugs 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- 229960003152 Metisazone Drugs 0.000 description 1
- 229960000282 Metronidazole Drugs 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010063344 Microscopic polyangiitis Diseases 0.000 description 1
- 241000243190 Microsporidia Species 0.000 description 1
- 229950003734 Milatuzumab Drugs 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- PQLXHQMOHUQAKB-UHFFFAOYSA-N Miltefosine Chemical compound CCCCCCCCCCCCCCCCOP([O-])(=O)OCC[N+](C)(C)C PQLXHQMOHUQAKB-UHFFFAOYSA-N 0.000 description 1
- 229960004023 Minocycline Drugs 0.000 description 1
- 229950002142 Minretumomab Drugs 0.000 description 1
- GQNZGCARKRHPOH-RQIKCTSVSA-N Miocamycin Chemical compound C1[C@](OC(C)=O)(C)[C@@H](OC(=O)CC)[C@H](C)O[C@H]1O[C@H]1[C@H](N(C)C)[C@@H](O)[C@H](O[C@@H]2[C@H]([C@H](OC(=O)CC)CC(=O)O[C@H](C)C/C=C/C=C/[C@H](OC(C)=O)[C@H](C)C[C@@H]2CC=O)OC)O[C@@H]1C GQNZGCARKRHPOH-RQIKCTSVSA-N 0.000 description 1
- 101710017500 MitHPPK/DHPS Proteins 0.000 description 1
- 229950003063 Mitumomab Drugs 0.000 description 1
- 208000003250 Mixed Connective Tissue Disease Diseases 0.000 description 1
- 229950007812 Mocetinostat Drugs 0.000 description 1
- 229950007856 Mofetil Drugs 0.000 description 1
- 208000008588 Molluscum Contagiosum Diseases 0.000 description 1
- 229940041009 Monobactams Drugs 0.000 description 1
- 229950008897 Morolimumab Drugs 0.000 description 1
- 206010027982 Morphoea Diseases 0.000 description 1
- 229960001521 Motavizumab Drugs 0.000 description 1
- FABPRXSRWADJSP-MEDUHNTESA-N Moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 description 1
- 239000005462 Mubritinib Substances 0.000 description 1
- 229950002212 Mubritinib Drugs 0.000 description 1
- ZTFBIUXIQYRUNT-MDWZMJQESA-N Mubritinib Chemical compound C1=CC(C(F)(F)F)=CC=C1\C=C\C1=NC(COC=2C=CC(CCCCN3N=NC=C3)=CC=2)=CO1 ZTFBIUXIQYRUNT-MDWZMJQESA-N 0.000 description 1
- 201000002795 Muckle-Wells syndrome Diseases 0.000 description 1
- 208000001725 Mucocutaneous Lymph Node Syndrome Diseases 0.000 description 1
- 241000235388 Mucorales Species 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- 229960003128 Mupirocin Drugs 0.000 description 1
- 206010028282 Murine typhus Diseases 0.000 description 1
- 108090000393 Muromonab-CD3 Proteins 0.000 description 1
- 229960003816 Muromonab-CD3 Drugs 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028320 Muscle necrosis Diseases 0.000 description 1
- 206010028417 Myasthenia gravis Diseases 0.000 description 1
- 206010028424 Myasthenic syndrome Diseases 0.000 description 1
- 208000008756 Mycetoma Diseases 0.000 description 1
- 241000041810 Mycetoma Species 0.000 description 1
- 241000186362 Mycobacterium leprae Species 0.000 description 1
- 241000178382 Mycobacterium lepromatosis Species 0.000 description 1
- 229940010383 Mycobacterium tuberculosis Drugs 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 241000187917 Mycobacterium ulcerans Species 0.000 description 1
- 206010066289 Mycobacterium ulcerans infection Diseases 0.000 description 1
- WKTLNJXZVDLRTJ-QRRXZRELSA-N Mycolactone Chemical compound C[C@@H](O)C[C@@H](O)[C@H](C)\C=C(/C)C[C@H](C)[C@H]1C\C=C(C)\C[C@H](C)[C@@H](OC(=O)\C=C\C(\C)=C\C(\C)=C\C=C\C(\C)=C\[C@H](O)[C@@H](O)C[C@H](C)O)CCCC(=O)O1 WKTLNJXZVDLRTJ-QRRXZRELSA-N 0.000 description 1
- 229960000951 Mycophenolic Acid Drugs 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 208000001572 Mycoplasma Pneumonia Diseases 0.000 description 1
- 229940013390 Mycoplasma pneumoniae Drugs 0.000 description 1
- 241000202934 Mycoplasma pneumoniae Species 0.000 description 1
- 201000008235 Mycoplasma pneumoniae pneumonia Diseases 0.000 description 1
- 206010028576 Myeloproliferative disease Diseases 0.000 description 1
- 208000006123 Myiasis Diseases 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 102000003505 Myosin family Human genes 0.000 description 1
- 108060008487 Myosin family Proteins 0.000 description 1
- 125000000534 N(2)-L-lysino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C([H])([H])C(C([H])([H])N([H])[H])([H])[H] 0.000 description 1
- QJZRFPJCWMNVAV-HHHXNRCGSA-N N-(3-aminopropyl)-N-[(1R)-1-(3-benzyl-7-chloro-4-oxoquinazolin-2-yl)-2-methylpropyl]-4-methylbenzamide Chemical compound NCCCN([C@H](C(C)C)C=1N(C(=O)C2=CC=C(Cl)C=C2N=1)CC=1C=CC=CC=1)C(=O)C1=CC=C(C)C=C1 QJZRFPJCWMNVAV-HHHXNRCGSA-N 0.000 description 1
- 108010010748 N-Myc Proto-Oncogene Protein Proteins 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinylpyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- XLXSAKCOAKORKW-KPKRHBJMSA-N N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[(2S)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl] Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-KPKRHBJMSA-N 0.000 description 1
- OWIUPIRUAQMTTK-UHFFFAOYSA-M N-aminocarbamate Chemical compound NNC([O-])=O OWIUPIRUAQMTTK-UHFFFAOYSA-M 0.000 description 1
- UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 description 1
- FDJKUWYYUZCUJX-AJKRCSPLSA-N N-glycoloyl-β-neuraminic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@@H]1O[C@](O)(C(O)=O)C[C@H](O)[C@H]1NC(=O)CO FDJKUWYYUZCUJX-AJKRCSPLSA-N 0.000 description 1
- FDJKUWYYUZCUJX-KVNVFURPSA-N N-glycolylneuraminic acid Chemical compound OC[C@H](O)[C@H](O)[C@@H]1O[C@](O)(C(O)=O)C[C@H](O)[C@H]1NC(=O)CO FDJKUWYYUZCUJX-KVNVFURPSA-N 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-hydroxy-Succinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 101710038602 NGFR Proteins 0.000 description 1
- 102100008795 NGFR Human genes 0.000 description 1
- 102100005498 NRP1 Human genes 0.000 description 1
- 101700048143 NRP1 Proteins 0.000 description 1
- JYJTVFIEFKZWCJ-UHFFFAOYSA-N Nadifloxacin Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)CCC3=C1N1CCC(O)CC1 JYJTVFIEFKZWCJ-UHFFFAOYSA-N 0.000 description 1
- 241000224438 Naegleria fowleri Species 0.000 description 1
- GPXLMGHLHQJAGZ-JTDSTZFVSA-N Nafcillin Chemical compound C1=CC=CC2=C(C(=O)N[C@@H]3C(N4[C@H](C(C)(C)S[C@@H]43)C(O)=O)=O)C(OCC)=CC=C21 GPXLMGHLHQJAGZ-JTDSTZFVSA-N 0.000 description 1
- 206010028729 Nasal cavity cancer Diseases 0.000 description 1
- 206010028767 Nasal sinus cancer Diseases 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- 108010035649 Natalizumab Proteins 0.000 description 1
- 241000498270 Necator americanus Species 0.000 description 1
- 210000003739 Neck Anatomy 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- QAGYKUNXZHXKMR-HKWSIXNMSA-N Nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 description 1
- PGBHMTALBVVCIT-VCIWKGPPSA-N Neomycin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 description 1
- 102000003729 Neprilysin Human genes 0.000 description 1
- 229950009675 Nerelimomab Drugs 0.000 description 1
- 241000750002 Nestor Species 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 206010072359 Neuromyotonia Diseases 0.000 description 1
- 206010029331 Neuropathy peripheral Diseases 0.000 description 1
- 231100000618 Neurotoxin Toxicity 0.000 description 1
- 229960000689 Nevirapine Drugs 0.000 description 1
- NQDJXKOVJZTUJA-UHFFFAOYSA-N Nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 description 1
- HHZIURLSWUIHRB-UHFFFAOYSA-N Nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 description 1
- 229950010203 Nimotuzumab Drugs 0.000 description 1
- 229960000564 Nitrofurantoin Drugs 0.000 description 1
- NXFQHRVNIOXGAQ-YCRREMRBSA-N Nitrofurantoin Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Nitrumon Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 241000187654 Nocardia Species 0.000 description 1
- 241000187678 Nocardia asteroides Species 0.000 description 1
- 206010029444 Nocardiosis Diseases 0.000 description 1
- 229960001180 Norfloxacin Drugs 0.000 description 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N Norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
- 229920001850 Nucleic acid sequence Polymers 0.000 description 1
- 229950005751 Ocrelizumab Drugs 0.000 description 1
- 208000003177 Ocular Onchocerciasis Diseases 0.000 description 1
- 229950010465 Odulimomab Drugs 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 229960002450 Ofatumumab Drugs 0.000 description 1
- LZMPYSIUWPEIRA-XFXZXTDPSA-N Ofatumumab Chemical compound N1=C2C=3COCCC=3N=CC2=N\C1=C1\NOC=C1 LZMPYSIUWPEIRA-XFXZXTDPSA-N 0.000 description 1
- 229960001699 Ofloxacin Drugs 0.000 description 1
- 229950008516 Olaratumab Drugs 0.000 description 1
- 239000004104 Oleandomycin Substances 0.000 description 1
- 206010073938 Ophthalmic herpes simplex Diseases 0.000 description 1
- 208000005225 Opsoclonus-Myoclonus Syndrome Diseases 0.000 description 1
- 208000007027 Oral Candidiasis Diseases 0.000 description 1
- QIPQASLPWJVQMH-DTORHVGOSA-N Orbifloxacin Chemical compound C1[C@@H](C)N[C@@H](C)CN1C1=C(F)C(F)=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1F QIPQASLPWJVQMH-DTORHVGOSA-N 0.000 description 1
- 229950007283 Oregovomab Drugs 0.000 description 1
- 229940035567 Orencia Drugs 0.000 description 1
- 229960003104 Ornithine Drugs 0.000 description 1
- 206010031096 Oropharyngeal cancer Diseases 0.000 description 1
- 229940029358 Orthoclone OKT3 Drugs 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101710034340 Os04g0173800 Proteins 0.000 description 1
- VSZGPKBBMSAYNT-RRFJBIMHSA-N Oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 description 1
- 229960003752 Oseltamivir Drugs 0.000 description 1
- 108010035042 Osteoprotegerin Proteins 0.000 description 1
- 229950002610 Otelixizumab Drugs 0.000 description 1
- UWYHMGVUTGAWSP-JKIFEVAISA-N Oxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 UWYHMGVUTGAWSP-JKIFEVAISA-N 0.000 description 1
- 229960000625 Oxytetracycline Drugs 0.000 description 1
- IWVCMVBTMGNXQD-PXOLEDIWSA-N Oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 1
- 239000004100 Oxytetracycline Substances 0.000 description 1
- 241001484645 Ozaena Species 0.000 description 1
- 101700011681 PAX3 Proteins 0.000 description 1
- 102100014642 PAX3 Human genes 0.000 description 1
- 101700057981 PAX5 Proteins 0.000 description 1
- 102100018849 PAX5 Human genes 0.000 description 1
- 102100004939 PDGFRB Human genes 0.000 description 1
- 102100018954 PECAM1 Human genes 0.000 description 1
- 101710027269 PECAM1 Proteins 0.000 description 1
- 229950003180 PEPLOMYCIN Drugs 0.000 description 1
- 102100002918 PEX19 Human genes 0.000 description 1
- 101700060762 PEX19 Proteins 0.000 description 1
- 101700037337 PIGA Proteins 0.000 description 1
- 102100012341 PIGA Human genes 0.000 description 1
- 102100001544 PLAC1 Human genes 0.000 description 1
- 108050005091 PLAC1 Proteins 0.000 description 1
- 101710008806 PLAUR Proteins 0.000 description 1
- 102100018916 PLAUR Human genes 0.000 description 1
- 206010053869 POEMS syndrome Diseases 0.000 description 1
- 101700067249 POP2 Proteins 0.000 description 1
- 102100018386 PRTN3 Human genes 0.000 description 1
- 101700029041 PRTN3 Proteins 0.000 description 1
- 102100018285 PSMB9 Human genes 0.000 description 1
- 101710033536 PSMB9 Proteins 0.000 description 1
- 102100005499 PTPRC Human genes 0.000 description 1
- 101700059076 PTPRC Proteins 0.000 description 1
- 229950010626 Pagibaximab Drugs 0.000 description 1
- 208000008443 Pancreatic Carcinoma Diseases 0.000 description 1
- TYMABNNERDVXID-DLYFRVTGSA-N Panipenem Chemical compound C([C@@H]1[C@H](C(N1C=1C(O)=O)=O)[C@H](O)C)C=1S[C@H]1CCN(C(C)=N)C1 TYMABNNERDVXID-DLYFRVTGSA-N 0.000 description 1
- 229950011346 Panipenem Drugs 0.000 description 1
- 229950003570 Panobacumab Drugs 0.000 description 1
- 208000009608 Papillomavirus Infections Diseases 0.000 description 1
- 241000526686 Paracoccidioides brasiliensis Species 0.000 description 1
- 206010033767 Paracoccidioides infection Diseases 0.000 description 1
- 206010033794 Paragonimiasis Diseases 0.000 description 1
- 241001480233 Paragonimus Species 0.000 description 1
- 241001480234 Paragonimus westermani Species 0.000 description 1
- 206010048705 Paraneoplastic cerebellar degeneration Diseases 0.000 description 1
- 208000004788 Pars Planitis Diseases 0.000 description 1
- 241000701945 Parvoviridae Species 0.000 description 1
- 229950011485 Pascolizumab Drugs 0.000 description 1
- 241000606860 Pasteurella Species 0.000 description 1
- 206010034107 Pasteurella infection Diseases 0.000 description 1
- 241000517324 Pediculidae Species 0.000 description 1
- 241000517307 Pediculus humanus Species 0.000 description 1
- 241000517308 Pediculus humanus capitis Species 0.000 description 1
- 201000000376 Pediculus humanus capitis infestation Diseases 0.000 description 1
- 241000517306 Pediculus humanus corporis Species 0.000 description 1
- 229960004236 Pefloxacin Drugs 0.000 description 1
- 208000008223 Pemphigoid Gestationis Diseases 0.000 description 1
- 241000721454 Pemphigus Species 0.000 description 1
- NLOOMWLTUVBWAW-HLLBOEOZSA-N Penamecillin Chemical compound N([C@H]1[C@@H]2N(C1=O)[C@H](C(S2)(C)C)C(=O)OCOC(=O)C)C(=O)CC1=CC=CC=C1 NLOOMWLTUVBWAW-HLLBOEOZSA-N 0.000 description 1
- 229940049954 Penicillin Drugs 0.000 description 1
- 206010034299 Penile cancer Diseases 0.000 description 1
- 108010057150 Peplomycin Proteins 0.000 description 1
- 108091005771 Peptidases Proteins 0.000 description 1
- 108010067902 Peptide Library Proteins 0.000 description 1
- XRQDFNLINLXZLB-CKIKVBCHSA-N Peramivir Chemical compound CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@@H](C(O)=O)C[C@H]1NC(N)=N XRQDFNLINLXZLB-CKIKVBCHSA-N 0.000 description 1
- 241000150350 Peribunyaviridae Species 0.000 description 1
- 208000008494 Pericarditis Diseases 0.000 description 1
- 206010034695 Pernicious anaemia Diseases 0.000 description 1
- 229950003203 Pexelizumab Drugs 0.000 description 1
- 206010034800 Phaeochromocytoma Diseases 0.000 description 1
- NONJJLVGHLVQQM-JHXYUMNGSA-N Pheneticillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C(C)OC1=CC=CC=C1 NONJJLVGHLVQQM-JHXYUMNGSA-N 0.000 description 1
- BPLBGHOLXOTWMN-MBNYWOFBSA-N Phenoxymethylpenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)COC1=CC=CC=C1 BPLBGHOLXOTWMN-MBNYWOFBSA-N 0.000 description 1
- IEQIEDJGQAUEQZ-UHFFFAOYSA-N Phthalocyanine Chemical compound N1C(N=C2C3=CC=CC=C3C(N=C3C4=CC=CC=C4C(=N4)N3)=N2)=C(C=CC=C2)C2=C1N=C1C2=CC=CC=C2C4=N1 IEQIEDJGQAUEQZ-UHFFFAOYSA-N 0.000 description 1
- 241001674048 Phthiraptera Species 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 208000007641 Pinealoma Diseases 0.000 description 1
- IVBHGBMCVLDMKU-GXNBUGAJSA-N Piperacillin Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 IVBHGBMCVLDMKU-GXNBUGAJSA-N 0.000 description 1
- 206010048895 Pityriasis lichenoides et varioliformis acuta Diseases 0.000 description 1
- ZEMIJUDPLILVNQ-ZXFNITATSA-N Pivampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)[C@H](C(S3)(C)C)C(=O)OCOC(=O)C(C)(C)C)=CC=CC=C1 ZEMIJUDPLILVNQ-ZXFNITATSA-N 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 241000223960 Plasmodium falciparum Species 0.000 description 1
- 241000223810 Plasmodium vivax Species 0.000 description 1
- 108010035030 Platelet Membrane Glycoprotein IIb Proteins 0.000 description 1
- 108010051742 Platelet-Derived Growth Factor beta Receptor Proteins 0.000 description 1
- CSOMAHTTWTVBFL-OFBLZTNGSA-N Platensimycin Chemical compound C([C@]1([C@@H]2[C@@H]3C[C@@H]4C[C@@]2(C=CC1=O)C[C@@]4(O3)C)C)CC(=O)NC1=C(O)C=CC(C(O)=O)=C1O CSOMAHTTWTVBFL-OFBLZTNGSA-N 0.000 description 1
- 206010061353 Pneumococcal infection Diseases 0.000 description 1
- 241000233872 Pneumocystis carinii Species 0.000 description 1
- 241000142787 Pneumocystis jirovecii Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- YJGVMLPVUAXIQN-XVVDYKMHSA-N Podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 description 1
- 206010065159 Polychondritis Diseases 0.000 description 1
- 208000007048 Polymyalgia Rheumatica Diseases 0.000 description 1
- 208000005987 Polymyositis Diseases 0.000 description 1
- 108010093965 Polymyxin B Proteins 0.000 description 1
- UVSMNLNDYGZFPF-UHFFFAOYSA-N Pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 description 1
- PHXJVRSECIGDHY-UHFFFAOYSA-N Ponatinib Chemical compound C1CN(C)CCN1CC(C(=C1)C(F)(F)F)=CC=C1NC(=O)C1=CC=C(C)C(C#CC=2N3N=CC=CC3=NC=2)=C1 PHXJVRSECIGDHY-UHFFFAOYSA-N 0.000 description 1
- 206010054161 Pontiac fever Diseases 0.000 description 1
- 208000004173 Post-Lyme Disease Syndrome Diseases 0.000 description 1
- 208000010366 Postpoliomyelitis Syndrome Diseases 0.000 description 1
- 229940069328 Povidone Drugs 0.000 description 1
- JHDKZFFAIZKUCU-ZRDIBKRKSA-N Pracinostat Chemical compound ONC(=O)/C=C/C1=CC=C2N(CCN(CC)CC)C(CCCC)=NC2=C1 JHDKZFFAIZKUCU-ZRDIBKRKSA-N 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N Prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229950003700 Priliximab Drugs 0.000 description 1
- 208000003991 Primitive Neuroectodermal Tumors Diseases 0.000 description 1
- MVTQIFVKRXBCHS-GPEZGQFLSA-N Pristinamycin Chemical compound C1C(=O)C[C@H](O)\C=C(/C)\C=C\CNC(=O)\C=C\[C@@H](C)[C@@H](C(C)C)OC(=O)C2=CCCN2C(=O)C2=COC1=N2.CC1OC(=O)C(C=2C=CC=CC=2)NC(=O)C2CC(=O)CCN2C(=O)C(CC=2C=CC=CC=2)N(C)C(=O)C2CCCN2C(=O)C(CC)NC(=O)C1NC(=O)C1=NC=CC=C1O MVTQIFVKRXBCHS-GPEZGQFLSA-N 0.000 description 1
- 229960003961 Pristinamycin Drugs 0.000 description 1
- 108010079780 Pristinamycin Proteins 0.000 description 1
- 229950009904 Pritumumab Drugs 0.000 description 1
- 229940092597 Prolia Drugs 0.000 description 1
- ABBQGOCHXSPKHJ-WUKNDPDISA-N Prontosil Chemical compound NC1=CC(N)=CC=C1\N=N\C1=CC=C(S(N)(=O)=O)C=C1 ABBQGOCHXSPKHJ-WUKNDPDISA-N 0.000 description 1
- HOCWPKXKMNXINF-XQERAMJGSA-N Propicillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C(CC)OC1=CC=CC=C1 HOCWPKXKMNXINF-XQERAMJGSA-N 0.000 description 1
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229940034080 Provenge Drugs 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000186336 Pseudopropionibacterium propionicum Species 0.000 description 1
- 206010037151 Psittacosis Diseases 0.000 description 1
- 206010037162 Psoriatic arthropathy Diseases 0.000 description 1
- 241000517305 Pthiridae Species 0.000 description 1
- 241000517304 Pthirus pubis Species 0.000 description 1
- 201000004360 Pthirus pubis infestation Diseases 0.000 description 1
- 208000003670 Pure Red-Cell Aplasia Diseases 0.000 description 1
- 208000009954 Pyoderma Gangrenosum Diseases 0.000 description 1
- IPEHBUMCGVEMRF-UHFFFAOYSA-N Pyrazinamide Chemical compound NC(=O)C1=CN=CC=N1 IPEHBUMCGVEMRF-UHFFFAOYSA-N 0.000 description 1
- 229960005206 Pyrazinamide Drugs 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010037688 Q fever Diseases 0.000 description 1
- 102100005031 RGS5 Human genes 0.000 description 1
- 101700002896 RGS5 Proteins 0.000 description 1
- 101700044616 RHOC Proteins 0.000 description 1
- ATEBXHFBFRCZMA-VXTBVIBXSA-N RIFABUTIN Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC(=C2N3)C(=O)C=4C(O)=C5C)C)OC)C5=C1C=4C2=NC13CCN(CC(C)C)CC1 ATEBXHFBFRCZMA-VXTBVIBXSA-N 0.000 description 1
- 101700044827 RNMT Proteins 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 229950011613 Racotumomab Drugs 0.000 description 1
- 229950002786 Rafivirumab Drugs 0.000 description 1
- GZUITABIAKMVPG-UHFFFAOYSA-N Raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
- 229960004622 Raloxifene Drugs 0.000 description 1
- 229960004742 Raltegravir Drugs 0.000 description 1
- CZFFBEXEKNGXKS-UHFFFAOYSA-N Raltegravir Chemical compound O1C(C)=NN=C1C(=O)NC(C)(C)C1=NC(C(=O)NCC=2C=CC(F)=CC=2)=C(O)C(=O)N1C CZFFBEXEKNGXKS-UHFFFAOYSA-N 0.000 description 1
- KGZHFKDNSAEOJX-WIFQYKSHSA-N Ramoplanin Chemical compound C([C@H]1C(=O)N[C@H](CCCN)C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C)C(=O)N[C@H](C(=O)O[C@@H]([C@@H](C(N[C@@H](C(=O)N[C@H](CCCN)C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)[C@H](C)O)C=1C=CC(O)=CC=1)C=1C=CC(O)=CC=1)[C@@H](C)O)C=1C=CC(O)=CC=1)=O)NC(=O)[C@H](CC(N)=O)NC(=O)\C=C/C=C/CC(C)C)C(N)=O)C=1C=C(Cl)C(O)=CC=1)C=1C=CC(O)=CC=1)[C@@H](C)O)C=1C=CC(O[C@@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC=1)C1=CC=CC=C1 KGZHFKDNSAEOJX-WIFQYKSHSA-N 0.000 description 1
- 229950003551 Ramoplanin Drugs 0.000 description 1
- 206010037844 Rash Diseases 0.000 description 1
- 206010071141 Rasmussen encephalitis Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 229960004910 Raxibacumab Drugs 0.000 description 1
- 206010037912 Raynaud's phenomenon Diseases 0.000 description 1
- 229950005854 Regavirumab Drugs 0.000 description 1
- 206010038294 Reiter's syndrome Diseases 0.000 description 1
- 208000009169 Relapsing Polychondritis Diseases 0.000 description 1
- 229940116176 Remicade Drugs 0.000 description 1
- 230000036045 Renal clearance Effects 0.000 description 1
- 241000702247 Reoviridae Species 0.000 description 1
- WHBIGIKBNXZKFE-UHFFFAOYSA-N Rescriptor Chemical compound CC(C)NC1=CC=CN=C1N1CCN(C(=O)C=2NC3=CC=C(NS(C)(=O)=O)C=C3C=2)CC1 WHBIGIKBNXZKFE-UHFFFAOYSA-N 0.000 description 1
- 229950010550 Resiquimod Drugs 0.000 description 1
- FECGNJPYVFEKOD-VMPITWQZSA-N Resminostat Chemical compound C1=CC(CN(C)C)=CC=C1S(=O)(=O)N1C=C(\C=C\C(=O)NO)C=C1 FECGNJPYVFEKOD-VMPITWQZSA-N 0.000 description 1
- 229950002821 Resminostat Drugs 0.000 description 1
- 208000005793 Restless Legs Syndrome Diseases 0.000 description 1
- 206010038979 Retroperitoneal fibrosis Diseases 0.000 description 1
- 241000712907 Retroviridae Species 0.000 description 1
- 241000711931 Rhabdoviridae Species 0.000 description 1
- 108010075569 Rheumatoid Factor Proteins 0.000 description 1
- 206010039073 Rheumatoid arthritis Diseases 0.000 description 1
- 208000004364 Rhinosporidiosis Diseases 0.000 description 1
- 241000293824 Rhinosporidium seeberi Species 0.000 description 1
- 206010061494 Rhinovirus infection Diseases 0.000 description 1
- 102000000505 Ribonucleotide Reductases Human genes 0.000 description 1
- 108010041388 Ribonucleotide Reductases Proteins 0.000 description 1
- NSKGQURZWSPSBC-NLZFXWNVSA-N Ribostamycin Chemical compound N[C@H]1[C@H](O)[C@@H](O)[C@H](CN)O[C@@H]1O[C@@H]1[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@H](CO)O2)O)[C@H](O)[C@@H](N)C[C@H]1N NSKGQURZWSPSBC-NLZFXWNVSA-N 0.000 description 1
- 229940046939 Rickettsia prowazekii Drugs 0.000 description 1
- 241000606697 Rickettsia prowazekii Species 0.000 description 1
- 229940075118 Rickettsia rickettsii Drugs 0.000 description 1
- 241000606695 Rickettsia rickettsii Species 0.000 description 1
- 241000606726 Rickettsia typhi Species 0.000 description 1
- 241000606651 Rickettsiales Species 0.000 description 1
- 229940081192 Rifamycins Drugs 0.000 description 1
- WDZCUPBHRAEYDL-GZAUEHORSA-N Rifapentine Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C(O)=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N(CC1)CCN1C1CCCC1 WDZCUPBHRAEYDL-GZAUEHORSA-N 0.000 description 1
- 208000000705 Rift Valley Fever Diseases 0.000 description 1
- 241000713124 Rift Valley fever virus Species 0.000 description 1
- 229950003238 Rilotumumab Drugs 0.000 description 1
- UBCHPRBFMUDMNC-UHFFFAOYSA-N Rimantadine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 description 1
- NCDNCNXCDXHOMX-XGKFQTDJSA-N Ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 1
- 229950001808 Robatumumab Drugs 0.000 description 1
- 206010039207 Rocky mountain spotted fever Diseases 0.000 description 1
- VYWWNRMSAPEJLS-MDWYKHENSA-N Rokitamycin Chemical compound C1[C@](OC(=O)CC)(C)[C@@H](OC(=O)CCC)[C@H](C)O[C@H]1O[C@H]1[C@H](N(C)C)[C@@H](O)[C@H](O[C@@H]2[C@H]([C@H](O)CC(=O)O[C@H](C)C/C=C/C=C/[C@H](O)[C@H](C)C[C@@H]2CC=O)OC)O[C@@H]1C VYWWNRMSAPEJLS-MDWYKHENSA-N 0.000 description 1
- 229960005009 Rolitetracycline Drugs 0.000 description 1
- 229950010316 Rontalizumab Drugs 0.000 description 1
- 206010067470 Rotavirus infection Diseases 0.000 description 1
- 229950009092 Rovelizumab Drugs 0.000 description 1
- RXZBMPWDPOLZGW-XMRMVWPWSA-N Roxithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=N/OCOCCOC)/[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 RXZBMPWDPOLZGW-XMRMVWPWSA-N 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- 229950005374 Ruplizumab Drugs 0.000 description 1
- 125000000066 S-methyl group Chemical group [H]C([H])([H])S* 0.000 description 1
- MNGBJGFSOBSOSR-MEWBUHPBSA-N SAR3419 Chemical compound CNC(=O)CCCSSC(C)(C)CCC(=O)N(C)C(C)C(=O)OC([C@@]1(O[C@H]1C1C)C)CC(=O)N(C)C(C(=C(OC)C=2)Cl)=CC=2C\C(C)=C\C=C\C(OC)[C@]2(O)NC(=O)O[C@H]1C2 MNGBJGFSOBSOSR-MEWBUHPBSA-N 0.000 description 1
- 101700037991 SART3 Proteins 0.000 description 1
- 102100016729 SART3 Human genes 0.000 description 1
- 102000035266 SCARB3 Human genes 0.000 description 1
- 102100003520 SELE Human genes 0.000 description 1
- 101710038665 SELE Proteins 0.000 description 1
- 102100003519 SELP Human genes 0.000 description 1
- 101700009186 SELP Proteins 0.000 description 1
- 102100001289 SEMA4D Human genes 0.000 description 1
- 101710023772 SEMA4D Proteins 0.000 description 1
- URWAJWIAIPFPJE-YFMIWBNJSA-N SISOMICIN Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC=C(CN)O2)N)[C@@H](N)C[C@H]1N URWAJWIAIPFPJE-YFMIWBNJSA-N 0.000 description 1
- 102100013834 SLC3A2 Human genes 0.000 description 1
- 101710007458 SLC3A2 Proteins 0.000 description 1
- 101710015409 SLC7A5 Proteins 0.000 description 1
- 101710003940 SPA17 Proteins 0.000 description 1
- 102100017511 SPN Human genes 0.000 description 1
- 101710018229 SPN Proteins 0.000 description 1
- 102100004865 SSX2 Human genes 0.000 description 1
- 101700030927 SSX2 Proteins 0.000 description 1
- 241000736032 Sabia <angiosperm> Species 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N Saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 Saccharin Drugs 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 1
- NGWSFRIPKNWYAO-SHTIJGAHSA-N Salinosporamide A Chemical compound C([C@@H]1[C@H](O)[C@]23C(=O)O[C@]2([C@H](C(=O)N3)CCCl)C)CCC=C1 NGWSFRIPKNWYAO-SHTIJGAHSA-N 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 241000369757 Sapovirus Species 0.000 description 1
- 229960001852 Saquinavir Drugs 0.000 description 1
- QWAXKHKRTORLEM-UGJKXSETSA-N Saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 description 1
- 241000509427 Sarcoptes scabiei Species 0.000 description 1
- 229950007308 Satumomab Drugs 0.000 description 1
- 208000005687 Scabies Diseases 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 210000004761 Scalp Anatomy 0.000 description 1
- 241000242678 Schistosoma Species 0.000 description 1
- 241000242683 Schistosoma haematobium Species 0.000 description 1
- 241000242677 Schistosoma japonicum Species 0.000 description 1
- 241000242680 Schistosoma mansoni Species 0.000 description 1
- 201000010848 Schnitzler syndrome Diseases 0.000 description 1
- 208000005511 Schoenlein-Henoch Purpura Diseases 0.000 description 1
- 206010039705 Scleritis Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- BTIHMVBBUGXLCJ-OAHLLOKOSA-N Seliciclib Chemical compound C=12N=CN(C(C)C)C2=NC(N[C@@H](CO)CC)=NC=1NCC1=CC=CC=C1 BTIHMVBBUGXLCJ-OAHLLOKOSA-N 0.000 description 1
- 229950000055 Seliciclib Drugs 0.000 description 1
- 229950004951 Sevirumab Drugs 0.000 description 1
- 208000009359 Sezary Syndrome Diseases 0.000 description 1
- 201000006984 Sezary's disease Diseases 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 229940007046 Shigella dysenteriae Drugs 0.000 description 1
- 241000607764 Shigella dysenteriae Species 0.000 description 1
- 241000607762 Shigella flexneri Species 0.000 description 1
- 229940115939 Shigella sonnei Drugs 0.000 description 1
- 241000607760 Shigella sonnei Species 0.000 description 1
- 241001243925 Sia Species 0.000 description 1
- 229950008684 Sibrotuzumab Drugs 0.000 description 1
- 229950010077 Sifalimumab Drugs 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 229940068638 Simponi Drugs 0.000 description 1
- 229940115586 Simulect Drugs 0.000 description 1
- 241000150288 Sin Nombre orthohantavirus Species 0.000 description 1
- 108010070144 Single-Chain Antibodies Proteins 0.000 description 1
- 102000005632 Single-Chain Antibodies Human genes 0.000 description 1
- 229950003804 Siplizumab Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N Sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 229960005456 Sisomicin Drugs 0.000 description 1
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 1
- 210000003491 Skin Anatomy 0.000 description 1
- 229940083599 Sodium Iodide Drugs 0.000 description 1
- 229950007874 Solanezumab Drugs 0.000 description 1
- 229940055944 Soliris Drugs 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 108010026080 Somatomedins Proteins 0.000 description 1
- 229950006551 Sontuzumab Drugs 0.000 description 1
- DZZWHBIBMUVIIW-DTORHVGOSA-N Sparfloxacin Chemical compound C1[C@@H](C)N[C@@H](C)CN1C1=C(F)C(N)=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1F DZZWHBIBMUVIIW-DTORHVGOSA-N 0.000 description 1
- 239000004187 Spiramycin Substances 0.000 description 1
- 241000605008 Spirillum Species 0.000 description 1
- 210000000952 Spleen Anatomy 0.000 description 1
- 241001149963 Sporothrix schenckii Species 0.000 description 1
- 206010041736 Sporotrichosis Diseases 0.000 description 1
- 108010007140 Stamulumab Proteins 0.000 description 1
- 229950002549 Stamulumab Drugs 0.000 description 1
- 208000008582 Staphylococcal Food Poisoning Diseases 0.000 description 1
- 206010041925 Staphylococcal infection Diseases 0.000 description 1
- 229940076185 Staphylococcus aureus Drugs 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- HKSZLNNOFSGOKW-FYTWVXJKSA-N Staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 1
- 229960001203 Stavudine Drugs 0.000 description 1
- 229940071598 Stelara Drugs 0.000 description 1
- 229940041160 Steroid antibacterials Drugs 0.000 description 1
- 206010072148 Stiff person syndrome Diseases 0.000 description 1
- 210000002784 Stomach Anatomy 0.000 description 1
- 241001478880 Streptobacillus moniliformis Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 229940030998 Streptococcus agalactiae Drugs 0.000 description 1
- 241000193985 Streptococcus agalactiae Species 0.000 description 1
- 229940031000 Streptococcus pneumoniae Drugs 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241001505901 Streptococcus sp. 'group A' Species 0.000 description 1
- 229940041030 Streptogramins Drugs 0.000 description 1
- 108010034396 Streptogramins Proteins 0.000 description 1
- 229960005322 Streptomycin Drugs 0.000 description 1
- 241000244177 Strongyloides stercoralis Species 0.000 description 1
- 206010042254 Strongyloidiasis Diseases 0.000 description 1
- 208000008467 Subacute Bacterial Endocarditis Diseases 0.000 description 1
- 206010042276 Subacute endocarditis Diseases 0.000 description 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
- FKENQMMABCRJMK-RITPCOANSA-N Sulbactam Chemical compound O=S1(=O)C(C)(C)[C@H](C(O)=O)N2C(=O)C[C@H]21 FKENQMMABCRJMK-RITPCOANSA-N 0.000 description 1
- 229960005256 Sulbactam Drugs 0.000 description 1
- 108010008378 Sulesomab Proteins 0.000 description 1
- 229950010708 Sulesomab Drugs 0.000 description 1
- SKIVFJLNDNKQPD-UHFFFAOYSA-N Sulfacetamide Chemical compound CC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 SKIVFJLNDNKQPD-UHFFFAOYSA-N 0.000 description 1
- 229960002673 Sulfacetamide Drugs 0.000 description 1
- VACCAVUAMIDAGB-UHFFFAOYSA-N Sulfamethizole Chemical compound S1C(C)=NN=C1NS(=O)(=O)C1=CC=C(N)C=C1 VACCAVUAMIDAGB-UHFFFAOYSA-N 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N Sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- 229960001940 Sulfasalazine Drugs 0.000 description 1
- 229940032484 Sulfisoxazole Drugs 0.000 description 1
- NHUHCSRWZMLRLA-UHFFFAOYSA-N Sulfizole Chemical compound CC1=NOC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1C NHUHCSRWZMLRLA-UHFFFAOYSA-N 0.000 description 1
- WINHZLLDWRZWRT-ATVHPVEESA-N Sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
- 108010002687 Survivin Proteins 0.000 description 1
- 208000002286 Susac Syndrome Diseases 0.000 description 1
- 208000010265 Sweet Syndrome Diseases 0.000 description 1
- 206010042732 Sydenham's chorea Diseases 0.000 description 1
- 206010042742 Sympathetic ophthalmia Diseases 0.000 description 1
- 229940036185 Synagis Drugs 0.000 description 1
- 208000006379 Syphilis Diseases 0.000 description 1
- 208000000389 T-Cell Leukemia Diseases 0.000 description 1
- 101710025884 TAGLN Proteins 0.000 description 1
- 102100016327 TEK Human genes 0.000 description 1
- 102100008904 TFRC Human genes 0.000 description 1
- 101710036041 TFRC Proteins 0.000 description 1
- 108091008149 TGN-1412 Proteins 0.000 description 1
- 102100011827 TMPRSS2 Human genes 0.000 description 1
- 101710044694 TMPRSS2 Proteins 0.000 description 1
- 102100012977 TNFRSF10C Human genes 0.000 description 1
- 101710030969 TNFRSF10C Proteins 0.000 description 1
- 102100011904 TNFRSF10D Human genes 0.000 description 1
- 101710030968 TNFRSF10D Proteins 0.000 description 1
- 102100000153 TNFRSF11B Human genes 0.000 description 1
- 101710038524 TNFRSF1B Proteins 0.000 description 1
- 101710038569 TNFRSF25 Proteins 0.000 description 1
- 102100003107 TNFRSF25 Human genes 0.000 description 1
- 108060008443 TPPP Proteins 0.000 description 1
- 101710021280 TRIM26 Proteins 0.000 description 1
- 229950001072 Tadocizumab Drugs 0.000 description 1
- 241000244155 Taenia Species 0.000 description 1
- 241000244157 Taenia solium Species 0.000 description 1
- 208000001106 Takayasu Arteritis Diseases 0.000 description 1
- 229960002780 Talampicillin Drugs 0.000 description 1
- SOROUYSPFADXSN-SUWVAFIASA-N Talampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(=O)OC2C3=CC=CC=C3C(=O)O2)(C)C)=CC=CC=C1 SOROUYSPFADXSN-SUWVAFIASA-N 0.000 description 1
- FKHIFSZMMVMEQY-UHFFFAOYSA-N Talc Chemical compound [Mg+2].[O-][Si]([O-])=O FKHIFSZMMVMEQY-UHFFFAOYSA-N 0.000 description 1
- 229940033134 Talc Drugs 0.000 description 1
- 229950004218 Talizumab Drugs 0.000 description 1
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 1
- 229960001603 Tamoxifen Drugs 0.000 description 1
- 229950008160 Tanezumab Drugs 0.000 description 1
- 229950001788 Tefibazumab Drugs 0.000 description 1
- 229960001608 Teicoplanin Drugs 0.000 description 1
- 108010053950 Teicoplanin Proteins 0.000 description 1
- ONUMZHGUFYIKPM-MXNFEBESSA-N Telavancin Chemical compound O1[C@@H](C)[C@@H](O)[C@](NCCNCCCCCCCCCC)(C)C[C@@H]1O[C@H]1[C@H](OC=2C3=CC=4[C@H](C(N[C@H]5C(=O)N[C@H](C(N[C@@H](C6=CC(O)=C(CNCP(O)(O)=O)C(O)=C6C=6C(O)=CC=C5C=6)C(O)=O)=O)[C@H](O)C5=CC=C(C(=C5)Cl)O3)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](NC(=O)[C@@H](CC(C)C)NC)[C@H](O)C3=CC=C(C(=C3)Cl)OC=2C=4)O[C@H](CO)[C@@H](O)[C@@H]1O ONUMZHGUFYIKPM-MXNFEBESSA-N 0.000 description 1
- 229960005240 Telavancin Drugs 0.000 description 1
- QKDHBVNJCZBTMR-UHFFFAOYSA-N Temafloxacin Chemical compound C1CNC(C)CN1C(C(=C1)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1=CC=C(F)C=C1F QKDHBVNJCZBTMR-UHFFFAOYSA-N 0.000 description 1
- BVCKFLJARNKCSS-DWPRYXJFSA-N Temocillin Chemical compound N([C@]1(OC)C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C(C(O)=O)C=1C=CSC=1 BVCKFLJARNKCSS-DWPRYXJFSA-N 0.000 description 1
- CBPNZQVSJQDFBE-HGVVHKDOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CCC2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-HGVVHKDOSA-N 0.000 description 1
- 102000007000 Tenascin Human genes 0.000 description 1
- 108010008125 Tenascin Proteins 0.000 description 1
- 229950001289 Tenatumomab Drugs 0.000 description 1
- 229950000301 Teneliximab Drugs 0.000 description 1
- 229960001278 Teniposide Drugs 0.000 description 1
- SGOIRFVFHAKUTI-ZCFIWIBFSA-N Tenofovir Chemical compound N1=CN=C2N(C[C@@H](C)OCP(O)(O)=O)C=NC2=C1N SGOIRFVFHAKUTI-ZCFIWIBFSA-N 0.000 description 1
- 229960004556 Tenofovir Drugs 0.000 description 1
- 229950010127 Teplizumab Drugs 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 229960002180 Tetracycline Drugs 0.000 description 1
- OFVLGDICTFRJMM-WESIUVDSSA-N Tetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O OFVLGDICTFRJMM-WESIUVDSSA-N 0.000 description 1
- 229940040944 Tetracyclines Drugs 0.000 description 1
- 229960003433 Thalidomide Drugs 0.000 description 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N Thalidomide Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- 229960003053 Thiamphenicol Drugs 0.000 description 1
- OTVAEFIXJLOWRX-NXEZZACHSA-N Thiamphenicol Chemical compound CS(=O)(=O)C1=CC=C([C@@H](O)[C@@H](CO)NC(=O)C(Cl)Cl)C=C1 OTVAEFIXJLOWRX-NXEZZACHSA-N 0.000 description 1
- SRVJKTDHMYAMHA-WUXMJOGZSA-N Thioacetazone Chemical compound CC(=O)NC1=CC=C(\C=N\NC(N)=S)C=C1 SRVJKTDHMYAMHA-WUXMJOGZSA-N 0.000 description 1
- 229960005454 Thioguanine Drugs 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 208000008732 Thymoma Diseases 0.000 description 1
- 229960002175 Thyroglobulin Drugs 0.000 description 1
- 102000009843 Thyroglobulin Human genes 0.000 description 1
- 108010034949 Thyroglobulin Proteins 0.000 description 1
- 210000001685 Thyroid Gland Anatomy 0.000 description 1
- 206010043778 Thyroiditis Diseases 0.000 description 1
- 102000011923 Thyrotropin Human genes 0.000 description 1
- 108010061174 Thyrotropin Proteins 0.000 description 1
- 229940035626 Thyrotropin Class in ATC Drugs 0.000 description 1
- FVRDYQYEVDDKCR-DBRKOABJSA-N Tiazofurin Chemical compound NC(=O)C1=CSC([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=N1 FVRDYQYEVDDKCR-DBRKOABJSA-N 0.000 description 1
- 229960004659 Ticarcillin Drugs 0.000 description 1
- OHKOGUYZJXTSFX-KZFFXBSXSA-N Ticarcillin Chemical compound C=1([C@@H](C(O)=O)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)C=CSC=1 OHKOGUYZJXTSFX-KZFFXBSXSA-N 0.000 description 1
- 229950004742 Tigatuzumab Drugs 0.000 description 1
- HPGGPRDJHPYFRM-UHFFFAOYSA-J Tin(IV) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 description 1
- 206010043865 Tinea blanca Diseases 0.000 description 1
- 206010043866 Tinea capitis Diseases 0.000 description 1
- 206010067197 Tinea manuum Diseases 0.000 description 1
- 206010043871 Tinea nigra Diseases 0.000 description 1
- 229960005053 Tinidazole Drugs 0.000 description 1
- HJLSLZFTEKNLFI-UHFFFAOYSA-N Tinidazolum Chemical compound CCS(=O)(=O)CCN1C(C)=NC=C1[N+]([O-])=O HJLSLZFTEKNLFI-UHFFFAOYSA-N 0.000 description 1
- SUJUHGSWHZTSEU-FYBSXPHGSA-N Tipranavir Chemical compound C([C@@]1(CCC)OC(=O)C([C@H](CC)C=2C=C(NS(=O)(=O)C=3N=CC(=CC=3)C(F)(F)F)C=CC=2)=C(O)C1)CC1=CC=CC=C1 SUJUHGSWHZTSEU-FYBSXPHGSA-N 0.000 description 1
- SPMVMDHWKHCIDT-UHFFFAOYSA-N Tivozanib Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)NC=1C=C(C)ON=1 SPMVMDHWKHCIDT-UHFFFAOYSA-N 0.000 description 1
- 206010051526 Tolosa-Hunt syndrome Diseases 0.000 description 1
- IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N Topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 229950001802 Toralizumab Drugs 0.000 description 1
- 229950005801 Tosedostat Drugs 0.000 description 1
- WUWFMDMBOJLQIV-UHFFFAOYSA-N Tosufloxacin Chemical compound C1C(N)CCN1C(C(=C1)F)=NC2=C1C(=O)C(C(O)=O)=CN2C1=CC=C(F)C=C1F WUWFMDMBOJLQIV-UHFFFAOYSA-N 0.000 description 1
- 206010044248 Toxic shock syndrome Diseases 0.000 description 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 description 1
- 231100000765 Toxin Toxicity 0.000 description 1
- 241000244030 Toxocara canis Species 0.000 description 1
- 241000244020 Toxocara cati Species 0.000 description 1
- 229940118701 Toxoplasma gondii Drugs 0.000 description 1
- 241000223997 Toxoplasma gondii Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 108010086427 Transforming growth factor alpha Proteins 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 208000009174 Transverse Myelitis Diseases 0.000 description 1
- 241000589886 Treponema Species 0.000 description 1
- 241000589884 Treponema pallidum Species 0.000 description 1
- 241000589904 Treponema pallidum subsp. pertenue Species 0.000 description 1
- 229960002117 Triamcinolone Acetonide Drugs 0.000 description 1
- YNDXUCZADRHECN-JNQJZLCISA-N Triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
- 229940096911 Trichinella spiralis Drugs 0.000 description 1
- 241000243777 Trichinella spiralis Species 0.000 description 1
- 208000003982 Trichinellosis Diseases 0.000 description 1
- 208000005448 Trichomonas Infections Diseases 0.000 description 1
- 241000224527 Trichomonas vaginalis Species 0.000 description 1
- 206010044620 Trichomoniasis Diseases 0.000 description 1
- 241001045770 Trichophyton mentagrophytes Species 0.000 description 1
- 241001480048 Trichophyton tonsurans Species 0.000 description 1
- 241000223231 Trichosporon beigelii Species 0.000 description 1
- RTKIYFITIVXBLE-QEQCGCAPSA-N Trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 description 1
- 241001489145 Trichuris trichiura Species 0.000 description 1
- VSQQQLOSPVPRAZ-RRKCRQDMSA-N Trifluridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C(F)(F)F)=C1 VSQQQLOSPVPRAZ-RRKCRQDMSA-N 0.000 description 1
- 229960003962 Trifluridine Drugs 0.000 description 1
- 229960001082 Trimethoprim Drugs 0.000 description 1
- 229960001099 Trimetrexate Drugs 0.000 description 1
- NOYPYLRCIDNJJB-UHFFFAOYSA-N Trimetrexate Chemical compound COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 NOYPYLRCIDNJJB-UHFFFAOYSA-N 0.000 description 1
- 206010044684 Trismus Diseases 0.000 description 1
- UMKFEPPTGMDVMI-UHFFFAOYSA-N Trofosfamide Chemical compound ClCCN(CCCl)P1(=O)OCCCN1CCCl UMKFEPPTGMDVMI-UHFFFAOYSA-N 0.000 description 1
- UXQDWARBDDDTKG-UHFFFAOYSA-N Tromantadine Chemical compound C1C(C2)CC3CC2CC1(NC(=O)COCCN(C)C)C3 UXQDWARBDDDTKG-UHFFFAOYSA-N 0.000 description 1
- 229940035504 Tromethamine Drugs 0.000 description 1
- 208000006786 Trophoblastic Neoplasm Diseases 0.000 description 1
- 208000006961 Tropical Spastic Paraparesis Diseases 0.000 description 1
- 206010044696 Tropical spastic paresis Diseases 0.000 description 1
- 241001442397 Trypanosoma brucei rhodesiense Species 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 229950003364 Tucotuzumab celmoleukin Drugs 0.000 description 1
- 206010045146 Tularaemia Diseases 0.000 description 1
- 102000003298 Tumor Necrosis Factor Receptors Human genes 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptors Proteins 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 241000287411 Turdidae Species 0.000 description 1
- 229950005082 Tuvirumab Drugs 0.000 description 1
- 206010061393 Typhus Diseases 0.000 description 1
- 229940079023 Tysabri Drugs 0.000 description 1
- 101710009757 UROD Proteins 0.000 description 1
- 229960004626 Umifenovir Drugs 0.000 description 1
- 206010071575 Undifferentiated connective tissue disease Diseases 0.000 description 1
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical class O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 1
- 210000000626 Ureter Anatomy 0.000 description 1
- 206010046431 Urethral cancer Diseases 0.000 description 1
- 210000003932 Urinary Bladder Anatomy 0.000 description 1
- 229950004362 Urtoxazumab Drugs 0.000 description 1
- 108010077389 Ustekinumab Proteins 0.000 description 1
- 206010046766 Uterine cancer Diseases 0.000 description 1
- JQOYPOSGHDJFLI-AVNCTIOFSA-N Uvaricin Chemical compound O1[C@@H]([C@@H](OC(C)=O)CCCCCCCCCC)CC[C@@H]1[C@@H]1O[C@@H]([C@H](O)CCCCCCCCCCCCC=2C(O[C@@H](C)C=2)=O)CC1 JQOYPOSGHDJFLI-AVNCTIOFSA-N 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N VANCOMYCIN Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- 108010027235 VB4-845 Proteins 0.000 description 1
- 229940029983 VITAMINS Drugs 0.000 description 1
- 208000007089 Vaccinia Diseases 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 206010046885 Vaginal cancer Diseases 0.000 description 1
- 206010062167 Vaginitis bacterial Diseases 0.000 description 1
- HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclover Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 description 1
- WPVFJKSGQUFQAP-GKAPJAKFSA-N Valcyte Chemical compound N1C(N)=NC(=O)C2=C1N(COC(CO)COC(=O)[C@@H](N)C(C)C)C=N2 WPVFJKSGQUFQAP-GKAPJAKFSA-N 0.000 description 1
- 229960003165 Vancomycin Drugs 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- UHTHHESEBZOYNR-UHFFFAOYSA-N Vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 description 1
- 229950000386 Vapaliximab Drugs 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 241000870995 Variola Species 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 1
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 208000004762 Vasculitis, Leukocytoclastic, Cutaneous Diseases 0.000 description 1
- 229940058865 Vectibix Drugs 0.000 description 1
- 229950000815 Veltuzumab Drugs 0.000 description 1
- 208000002687 Venezuelan Equine Encephalomyelitis Diseases 0.000 description 1
- 201000009145 Venezuelan equine encephalitis Diseases 0.000 description 1
- 241000710959 Venezuelan equine encephalitis virus Species 0.000 description 1
- 201000009693 Venezuelan hemorrhagic fever Diseases 0.000 description 1
- 229950005208 Vepalimomab Drugs 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N Verapamil Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- YTZALCGQUPRCGW-ZSFNYQMMSA-N Verteporfin Chemical compound N1C(C=C2C(=C(CCC(O)=O)C(C=C3C(CCC(=O)OC)=C(C)C(N3)=C3)=N2)C)=C(C=C)C(C)=C1C=C1C2=CC=C(C(=O)OC)[C@@H](C(=O)OC)[C@@]2(C)C3=N1 YTZALCGQUPRCGW-ZSFNYQMMSA-N 0.000 description 1
- 229960003895 Verteporfin Drugs 0.000 description 1
- 229940118696 Vibrio cholerae Drugs 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- CNPVJJQCETWNEU-CYFREDJKSA-N Vicriviroc Chemical compound N([C@@H](COC)C=1C=CC(=CC=1)C(F)(F)F)([C@H](C1)C)CCN1C(CC1)(C)CCN1C(=O)C1=C(C)N=CN=C1C CNPVJJQCETWNEU-CYFREDJKSA-N 0.000 description 1
- 229950009860 Vicriviroc Drugs 0.000 description 1
- 241000863480 Vinca Species 0.000 description 1
- 229960004355 Vindesine Drugs 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 102000016350 Viral Proteins Human genes 0.000 description 1
- 206010047504 Visceral larva migran Diseases 0.000 description 1
- 229950004393 Visilizumab Drugs 0.000 description 1
- BPQMGSKTAYIVFO-UHFFFAOYSA-N Vismodegib Chemical compound ClC1=CC(S(=O)(=O)C)=CC=C1C(=O)NC1=CC=C(Cl)C(C=2N=CC=CC=2)=C1 BPQMGSKTAYIVFO-UHFFFAOYSA-N 0.000 description 1
- 210000000239 Visual Pathways Anatomy 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229940021016 Vitamin IV solution additives Drugs 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- 229950001212 Volociximab Drugs 0.000 description 1
- 229960000237 Vorinostat Drugs 0.000 description 1
- WAEXFXRVDQXREF-UHFFFAOYSA-N Vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 1
- 229950003511 Votumumab Drugs 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 102100008060 WT1 Human genes 0.000 description 1
- 101700062995 WT1 Proteins 0.000 description 1
- 239000003875 Wang resin Substances 0.000 description 1
- 208000007510 West Nile Fever Diseases 0.000 description 1
- 241000710886 West Nile virus Species 0.000 description 1
- 208000008383 Wilms Tumor Diseases 0.000 description 1
- 208000006110 Wiskott-Aldrich Syndrome Diseases 0.000 description 1
- 102000001392 Wiskott-Aldrich Syndrome Protein Human genes 0.000 description 1
- 108010093528 Wiskott-Aldrich Syndrome Protein Proteins 0.000 description 1
- 101710019504 XAB2 Proteins 0.000 description 1
- 229940099073 Xolair Drugs 0.000 description 1
- 208000003152 Yellow Fever Diseases 0.000 description 1
- 241000710772 Yellow fever virus Species 0.000 description 1
- 229940098232 Yersinia enterocolitica Drugs 0.000 description 1
- 241000607447 Yersinia enterocolitica Species 0.000 description 1
- 229940055760 Yervoy Drugs 0.000 description 1
- 229950008250 Zalutumumab Drugs 0.000 description 1
- 229960001028 Zanamivir Drugs 0.000 description 1
- 229950009002 Zanolimumab Drugs 0.000 description 1
- 229950009083 Ziralimumab Drugs 0.000 description 1
- 206010061417 Zoonotic bacterial infection Diseases 0.000 description 1
- FBTUMDXHSRTGRV-ALTNURHMSA-N Zorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC=CC=1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 FBTUMDXHSRTGRV-ALTNURHMSA-N 0.000 description 1
- UOZODPSAJZTQNH-LSWIJEOBSA-N Zygomycin A1 Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO UOZODPSAJZTQNH-LSWIJEOBSA-N 0.000 description 1
- YCPOZVAOBBQLRI-PHDIDXHHSA-N [(2R,3R)-2,3-dihydroxy-4-methylsulfonyloxybutyl] methanesulfonate Chemical compound CS(=O)(=O)OC[C@@H](O)[C@H](O)COS(C)(=O)=O YCPOZVAOBBQLRI-PHDIDXHHSA-N 0.000 description 1
- QIMGFXOHTOXMQP-GFAGFCTOSA-N [(2R,3S,4S,5R,6R)-2-[(2R,3S,4S,5S,6S)-2-[(1R,2S)-2-[[6-amino-2-[(1S)-3-amino-1-[[(2S)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[[(2R,3S,4S)-3-hydroxy-5-[[(2S,3R)-3-hydroxy-1-oxo-1-[2-[4-[4-[3-[[(1S)-1-phenylethyl] Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCCN[C@@H](C)C=1C=CC=CC=1)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C QIMGFXOHTOXMQP-GFAGFCTOSA-N 0.000 description 1
- NBLHOLNNKJBEDC-XOGQCRKLSA-N [(2R,3S,4S,5R,6R)-2-[(2R,3S,4S,5S,6S)-2-[(1R,2S)-2-[[6-amino-2-[(1S)-3-amino-1-[[(2S)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[[(2R,3S,4S)-5-[[(2S,3R)-1-[2-[4-[4-[4-(diaminomethylideneamino)butylcarbamoyl]-1,3-th Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCCCN=C(N)N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C NBLHOLNNKJBEDC-XOGQCRKLSA-N 0.000 description 1
- RLAHNGKRJJEIJL-RFZPGFLSSA-N [(2R,4R)-4-(2,6-diaminopurin-9-yl)-1,3-dioxolan-2-yl]methanol Chemical compound C12=NC(N)=NC(N)=C2N=CN1[C@H]1CO[C@@H](CO)O1 RLAHNGKRJJEIJL-RFZPGFLSSA-N 0.000 description 1
- QTQAWLPCGQOSGP-DVKIRIBLSA-N [(3R,5R,6S,7R,8E,10R,11R,12E,14E)-6-hydroxy-5,11,21-trimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate Chemical compound N1C(=O)\C(C)=C\C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C\[C@@H](C)[C@H](O)[C@H](OC)C[C@H](C)CC2=C(OC)C(=O)C=C1C2=O QTQAWLPCGQOSGP-DVKIRIBLSA-N 0.000 description 1
- DLGSOJOOYHWROO-WQLSENKSSA-N [(Z)-(1-methyl-2-oxoindol-3-ylidene)amino]thiourea Chemical compound C1=CC=C2N(C)C(=O)\C(=N/NC(N)=S)C2=C1 DLGSOJOOYHWROO-WQLSENKSSA-N 0.000 description 1
- LIQODXNTTZAGID-OCBXBXKTSA-N [4-[(5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-methyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-8-oxo-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[5,6-f][1,3]benzodioxol-9-yl]-2,6-dimethoxyphenyl] dihydrogen phosphate Chemical compound COC1=C(OP(O)(O)=O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 LIQODXNTTZAGID-OCBXBXKTSA-N 0.000 description 1
- 241000606834 [Haemophilus] ducreyi Species 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 229960004748 abacavir Drugs 0.000 description 1
- 108010058250 abagovomab Proteins 0.000 description 1
- 229960003697 abatacept Drugs 0.000 description 1
- 229960000446 abciximab Drugs 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- 230000002378 acidificating Effects 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N acyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 108091003858 adecatumumab Proteins 0.000 description 1
- 229960001997 adefovir Drugs 0.000 description 1
- 239000000362 adenosine triphosphatase inhibitor Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000240 adjuvant Effects 0.000 description 1
- 230000001058 adult Effects 0.000 description 1
- 201000006966 adult T-cell leukemia Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 description 1
- 108010084841 afelimomab Proteins 0.000 description 1
- 229960003227 afelimomab Drugs 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 101710004777 afgp8 Proteins 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229960000919 alatrofloxacin Drugs 0.000 description 1
- 229960002459 alefacept Drugs 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 125000006193 alkinyl group Chemical group 0.000 description 1
- 125000005262 alkoxyamine group Chemical group 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 230000000172 allergic Effects 0.000 description 1
- 201000005794 allergic hypersensitivity disease Diseases 0.000 description 1
- 230000000735 allogeneic Effects 0.000 description 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 229960001830 amprenavir Drugs 0.000 description 1
- 108010080146 androgen receptors Proteins 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 108091021984 anrukinzumab Proteins 0.000 description 1
- 230000002280 anti-androgenic Effects 0.000 description 1
- 230000003476 anti-centromere Effects 0.000 description 1
- 230000001833 anti-estrogenic Effects 0.000 description 1
- 230000002583 anti-histone Effects 0.000 description 1
- 230000000569 anti-influenza Effects 0.000 description 1
- 230000001064 anti-interferon Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000000931 anti-neutrophil Effects 0.000 description 1
- 230000000244 anti-pseudomonad Effects 0.000 description 1
- 230000002241 anti-transferrin Effects 0.000 description 1
- 230000000259 anti-tumor Effects 0.000 description 1
- 230000002137 anti-vascular Effects 0.000 description 1
- 230000002155 anti-virotic Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 239000000611 antibody drug conjugate Substances 0.000 description 1
- 108091008116 antibody drug conjugates Proteins 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 108010042982 antiglomerular basement membrane antibody Proteins 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 229940045719 antineoplastic alkylating agents Nitrosoureas Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229950006356 aplaviroc Drugs 0.000 description 1
- 108010062611 apolizumab Proteins 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 229960005397 arbekacin Drugs 0.000 description 1
- 108091004612 arcitumomab Proteins 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- VLAXZGHHBIJLAD-UHFFFAOYSA-N arsphenamine Chemical compound [Cl-].[Cl-].C1=C(O)C([NH3+])=CC([As]=[As]C=2C=C([NH3+])C(O)=CC=2)=C1 VLAXZGHHBIJLAD-UHFFFAOYSA-N 0.000 description 1
- 229940003446 arsphenamine Drugs 0.000 description 1
- 201000009361 ascariasis Diseases 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 102000031064 asparaginylendopeptidase Human genes 0.000 description 1
- 108010055066 asparaginylendopeptidase Proteins 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 201000002909 aspergillosis Diseases 0.000 description 1
- 229950004074 astromicin Drugs 0.000 description 1
- 229960003277 atazanavir Drugs 0.000 description 1
- 230000002238 attenuated Effects 0.000 description 1
- 108010044540 auristatin Proteins 0.000 description 1
- 201000004984 autoimmune cardiomyopathy Diseases 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 201000005011 autoimmune peripheral neuropathy Diseases 0.000 description 1
- 201000011385 autoimmune polyendocrine syndrome Diseases 0.000 description 1
- 201000009780 autoimmune polyendocrine syndrome type 2 Diseases 0.000 description 1
- 201000004982 autoimmune uveitis Diseases 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- 229960002278 azidamfenicol Drugs 0.000 description 1
- 229960004328 azidocillin Drugs 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- PFOLLRNADZZWEX-FFGRCDKISA-N bacampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)[C@H](C(S3)(C)C)C(=O)OC(C)OC(=O)OCC)=CC=CC=C1 PFOLLRNADZZWEX-FFGRCDKISA-N 0.000 description 1
- 201000001178 bacterial pneumonia Diseases 0.000 description 1
- 108010047242 bapineuzumab Proteins 0.000 description 1
- 108010001114 bavituximab Proteins 0.000 description 1
- 229950000210 beclometasone dipropionate Drugs 0.000 description 1
- 108010004485 bectumomab Proteins 0.000 description 1
- 108010051561 belimumab Proteins 0.000 description 1
- 229960003270 belimumab Drugs 0.000 description 1
- 229960003094 belinostat Drugs 0.000 description 1
- NCNRHFGMJRPRSK-MDZDMXLPSA-N belinostat Chemical compound ONC(=O)\C=C\C1=CC=CC(S(=O)(=O)NC=2C=CC=CC=2)=C1 NCNRHFGMJRPRSK-MDZDMXLPSA-N 0.000 description 1
- 108010055391 benralizumab Proteins 0.000 description 1
- 229940095744 benzathine phenoxymethylpenicillin Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- VQXLZJJBXSYFDE-RUZDIDTESA-N benzyl (2R)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-(4-phenylmethoxyphenyl)propanoate Chemical compound C([C@@H](NC(=O)OC(C)(C)C)C(=O)OCC=1C=CC=CC=1)C(C=C1)=CC=C1OCC1=CC=CC=C1 VQXLZJJBXSYFDE-RUZDIDTESA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- WHRVRSCEWKLAHX-LQDWTQKMSA-N benzylpenicillin procaine Chemical compound [H+].CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 WHRVRSCEWKLAHX-LQDWTQKMSA-N 0.000 description 1
- 108010013918 besilesomab Proteins 0.000 description 1
- 239000003781 beta lactamase inhibitor Substances 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- YJEJKUQEXFSVCJ-WRFMNRASSA-N bevirimat Chemical compound C1C[C@H](OC(=O)CC(C)(C)C(O)=O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C YJEJKUQEXFSVCJ-WRFMNRASSA-N 0.000 description 1
- MRMBZHPJVKCOMA-YJFSRANCSA-N biapenem Chemical compound C1N2C=NC=[N+]2CC1SC([C@@H]1C)=C(C([O-])=O)N2[C@H]1[C@@H]([C@H](O)C)C2=O MRMBZHPJVKCOMA-YJFSRANCSA-N 0.000 description 1
- 229960003169 biapenem Drugs 0.000 description 1
- LKJPYSCBVHEWIU-KRWDZBQOSA-N bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
- 229960000997 bicalutamide Drugs 0.000 description 1
- 102000024070 binding proteins Human genes 0.000 description 1
- 108091007650 binding proteins Proteins 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 229960003008 blinatumomab Drugs 0.000 description 1
- 108090000514 blinatumomab Proteins 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 229960000517 boceprevir Drugs 0.000 description 1
- LHHCSNFAOIFYRV-DOVBMPENSA-N boceprevir Chemical compound O=C([C@@H]1[C@@H]2[C@@H](C2(C)C)CN1C(=O)[C@@H](NC(=O)NC(C)(C)C)C(C)(C)C)NC(C(=O)C(N)=O)CC1CCC1 LHHCSNFAOIFYRV-DOVBMPENSA-N 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- 108010034406 briakinumab Proteins 0.000 description 1
- 229960002874 briakinumab Drugs 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960001292 cabozantinib Drugs 0.000 description 1
- 201000004927 campylobacteriosis Diseases 0.000 description 1
- 108010036787 canakinumab Proteins 0.000 description 1
- 229960001838 canakinumab Drugs 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 108010016799 cantuzumab mertansine Proteins 0.000 description 1
- JSVCEVCSANKFDY-SFYZADRCSA-N carbacephem Chemical compound C1CC(C)=C(C(O)=O)N2C(=O)[C@@H](NC(=O)C)[C@H]21 JSVCEVCSANKFDY-SFYZADRCSA-N 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 230000000271 cardiovascular Effects 0.000 description 1
- 229960002438 carfilzomib Drugs 0.000 description 1
- 108010021331 carfilzomib Proteins 0.000 description 1
- 229960000717 carindacillin Drugs 0.000 description 1
- JIRBAUWICKGBFE-MNRDOXJOSA-N carindacillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(=O)OC=1C=C2CCCC2=CC=1)C1=CC=CC=C1 JIRBAUWICKGBFE-MNRDOXJOSA-N 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 229960000419 catumaxomab Drugs 0.000 description 1
- 108090000758 catumaxomab Proteins 0.000 description 1
- QYIYFLOTGYLRGG-GPCCPHFNSA-N cefaclor Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CS[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 QYIYFLOTGYLRGG-GPCCPHFNSA-N 0.000 description 1
- BOEGTKLJZSQCCD-UEKVPHQBSA-N cefadroxil Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=C(O)C=C1 BOEGTKLJZSQCCD-UEKVPHQBSA-N 0.000 description 1
- 229960003866 cefaloridine Drugs 0.000 description 1
- 229960000603 cefalotin Drugs 0.000 description 1
- 229960004350 cefapirin Drugs 0.000 description 1
- 229960005312 cefazedone Drugs 0.000 description 1
- 229960002966 cefcapene Drugs 0.000 description 1
- 229960003719 cefdinir Drugs 0.000 description 1
- 229960004069 cefditoren Drugs 0.000 description 1
- 229960004041 cefetamet Drugs 0.000 description 1
- 229960003791 cefmenoxime Drugs 0.000 description 1
- 229960002025 cefminox Drugs 0.000 description 1
- 229960001958 cefodizime Drugs 0.000 description 1
- 229960004292 ceforanide Drugs 0.000 description 1
- 229960002642 cefozopran Drugs 0.000 description 1
- 229960005446 cefpiramide Drugs 0.000 description 1
- 229960005090 cefpodoxime Drugs 0.000 description 1
- 229960003844 cefroxadine Drugs 0.000 description 1
- SYLKGLMBLAAGSC-QLVMHMETSA-N cefsulodin Chemical compound C1=CC(C(=O)N)=CC=[N+]1CC1=C(C([O-])=O)N2C(=O)[C@@H](NC(=O)[C@@H](C=3C=CC=CC=3)S(O)(=O)=O)[C@H]2SC1 SYLKGLMBLAAGSC-QLVMHMETSA-N 0.000 description 1
- 229960004366 ceftezole Drugs 0.000 description 1
- 229960004086 ceftibuten Drugs 0.000 description 1
- CXHKZHZLDMQGFF-ZSDSSEDPSA-N cefuzonam Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=CN=NS1 CXHKZHZLDMQGFF-ZSDSSEDPSA-N 0.000 description 1
- 229950000807 cefuzonam Drugs 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- UCKZMPLVLCKKMO-LHLIQPBNSA-N cephamycin Chemical compound S1CC(C)=C(C(O)=O)N2C(=O)[C@@H](C)[C@]21OC UCKZMPLVLCKKMO-LHLIQPBNSA-N 0.000 description 1
- 150000001782 cephems Chemical class 0.000 description 1
- 201000007335 cerebellar astrocytoma Diseases 0.000 description 1
- 229960003115 certolizumab pegol Drugs 0.000 description 1
- 201000004308 chancroid Diseases 0.000 description 1
- 150000001793 charged compounds Chemical class 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 102000009410 chemokine receptors Human genes 0.000 description 1
- 108050000299 chemokine receptors Proteins 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 201000006082 chickenpox Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 235000019365 chlortetracycline Nutrition 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 108091005269 cixutumumab Proteins 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 108010004508 clenoliximab Proteins 0.000 description 1
- 229960005338 clevudine Drugs 0.000 description 1
- QGPKADBNRMWEQR-UHFFFAOYSA-N clinafloxacin Chemical compound C1C(N)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1Cl QGPKADBNRMWEQR-UHFFFAOYSA-N 0.000 description 1
- 229950001320 clinafloxacin Drugs 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- 108010050895 clivatuzumab Proteins 0.000 description 1
- 229960001351 clometocillin Drugs 0.000 description 1
- 229960004094 clomocycline Drugs 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 229960003326 cloxacillin Drugs 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2R,3S,4R,5S)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2R)-1-[3-[(1R,2R,3R,4Z,7S,9Z,12S,13S,14Z,17S,18S,19R)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 201000003486 coccidioidomycosis Diseases 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229960004729 colecalciferol Drugs 0.000 description 1
- 229960003346 colistin Drugs 0.000 description 1
- XDJYMJULXQKGMM-RVYUQJQSSA-N colistin A Chemical compound CC[C@@H](C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O XDJYMJULXQKGMM-RVYUQJQSSA-N 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 201000003056 complement component 2 deficiency Diseases 0.000 description 1
- 108010070304 conatumumab Proteins 0.000 description 1
- 230000001268 conjugating Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 201000003278 cryoglobulinemia Diseases 0.000 description 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
- 108040003506 cyclic ADP-ribose hydrolase Proteins 0.000 description 1
- 150000004292 cyclic ethers Chemical class 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 150000001924 cycloalkanes Chemical class 0.000 description 1
- 125000002993 cycloalkylene group Chemical group 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- FWFGIHPGRQZWIW-SQNIBIBYSA-N cyclopentyl (2S)-2-[[(2R)-2-[(1S)-1-hydroxy-2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoyl]amino]-2-phenylacetate Chemical compound O=C([C@@H](NC(=O)[C@@H]([C@H](O)C(=O)NO)CC(C)C)C=1C=CC=CC=1)OC1CCCC1 FWFGIHPGRQZWIW-SQNIBIBYSA-N 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 229960003077 cycloserine Drugs 0.000 description 1
- 201000002641 cyclosporiasis Diseases 0.000 description 1
- PMATZTZNYRCHOR-UHFFFAOYSA-N cyclosporine A Chemical compound CCC1NC(=O)C(C(O)C(C)CC=CC)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(C(C)C)NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 201000000077 cysticercosis Diseases 0.000 description 1
- 201000008167 cystoisosporiasis Diseases 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 108010049391 dacetuzumab Proteins 0.000 description 1
- 230000002354 daily Effects 0.000 description 1
- KGPGQDLTDHGEGT-SZUNQUCBSA-N dalbavancin Chemical compound C=1C([C@@H]2C(=O)N[C@H](C(N[C@@H](C3=CC(O)=C4)C(=O)NCCCN(C)C)=O)[C@H](O)C5=CC=C(C(=C5)Cl)OC=5C=C6C=C(C=5O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@H](O5)C(O)=O)NC(=O)CCCCCCCCC(C)C)OC5=CC=C(C=C5)C[C@@H]5C(=O)N[C@H](C(N[C@H]6C(=O)N2)=O)C=2C(Cl)=C(O)C=C(C=2)OC=2C(O)=CC=C(C=2)[C@H](C(N5)=O)NC)=CC=C(O)C=1C3=C4O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O KGPGQDLTDHGEGT-SZUNQUCBSA-N 0.000 description 1
- 229960002488 dalbavancin Drugs 0.000 description 1
- 229960000766 danazol Drugs 0.000 description 1
- 229960002204 daratumumab Drugs 0.000 description 1
- 108010031324 daratumumab Proteins 0.000 description 1
- 229960005107 darunavir Drugs 0.000 description 1
- CJBJHOAVZSMMDJ-HEXNFIEUSA-N darunavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1[C@@H]2CCO[C@@H]2OC1)C1=CC=CC=C1 CJBJHOAVZSMMDJ-HEXNFIEUSA-N 0.000 description 1
- 229960002448 dasatinib Drugs 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960005319 delavirdine Drugs 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 229960002398 demeclocycline Drugs 0.000 description 1
- 230000003210 demyelinating Effects 0.000 description 1
- 201000002949 dengue disease Diseases 0.000 description 1
- 229960001251 denosumab Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-M deoxycholate Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-M 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- YXHKONLOYHBTNS-UHFFFAOYSA-N diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 1
- 229960001585 dicloxacillin Drugs 0.000 description 1
- 229960002656 didanosine Drugs 0.000 description 1
- 201000004587 dientamoebiasis Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000003066 diffuse scleroderma Diseases 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- 125000005072 dihydrothiopyranyl group Chemical group S1C(CCC=C1)* 0.000 description 1
- MUXOBHXGJLMRAB-UHFFFAOYSA-N dimethyl butanedioate Chemical compound COC(=O)CCC(=O)OC MUXOBHXGJLMRAB-UHFFFAOYSA-N 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 229940042397 direct acting antivirals Cyclic amines Drugs 0.000 description 1
- 229940042406 direct acting antivirals Neuraminidase inhibitors Drugs 0.000 description 1
- 229940042399 direct acting antivirals Protease inhibitors Drugs 0.000 description 1
- WLOHNSSYAXHWNR-DWIOZXRMSA-N dirithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@@H]2O[C@H](COCCOC)N[C@H]([C@@H]2C)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 WLOHNSSYAXHWNR-DWIOZXRMSA-N 0.000 description 1
- 229960004100 dirithromycin Drugs 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- VXNQMUVMEIGUJW-XNOMRPDFSA-L disodium;[2-methoxy-5-[(Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl] phosphate Chemical compound [Na+].[Na+].C1=C(OP([O-])([O-])=O)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 VXNQMUVMEIGUJW-XNOMRPDFSA-L 0.000 description 1
- 239000002612 dispersion media Substances 0.000 description 1
- 125000005883 dithianyl group Chemical group 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- 230000003291 dopaminomimetic Effects 0.000 description 1
- 229960000895 doripenem Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- ZWAOHEXOSAUJHY-ZIYNGMLESA-N doxifluridine Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ZWAOHEXOSAUJHY-ZIYNGMLESA-N 0.000 description 1
- 229950005454 doxifluridine Drugs 0.000 description 1
- JBIWCJUYHHGXTC-AKNGSSGZSA-N doxycycline Chemical compound O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O JBIWCJUYHHGXTC-AKNGSSGZSA-N 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 108010069578 ecromeximab Proteins 0.000 description 1
- 108010063231 eculizumab Proteins 0.000 description 1
- 229960002224 eculizumab Drugs 0.000 description 1
- 231100001003 eczema Toxicity 0.000 description 1
- 108010054916 edobacomab Proteins 0.000 description 1
- 229960001776 edrecolomab Drugs 0.000 description 1
- 108010010371 efalizumab Proteins 0.000 description 1
- 229960000284 efalizumab Drugs 0.000 description 1
- 229960003804 efavirenz Drugs 0.000 description 1
- 108010074770 efungumab Proteins 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 108010061937 elotuzumab Proteins 0.000 description 1
- 229960003586 elvitegravir Drugs 0.000 description 1
- 229960000366 emtricitabine Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 201000005901 endemic typhus Diseases 0.000 description 1
- 201000009273 endometriosis Diseases 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 229960002062 enfuvirtide Drugs 0.000 description 1
- PEASPLKKXBYDKL-FXEVSJAOSA-N enfuvirtide Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(C)=O)[C@@H](C)O)[C@@H](C)CC)C1=CN=CN1 PEASPLKKXBYDKL-FXEVSJAOSA-N 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960000740 enrofloxacin Drugs 0.000 description 1
- 229960000980 entecavir Drugs 0.000 description 1
- 230000002255 enzymatic Effects 0.000 description 1
- 229960002457 epicillin Drugs 0.000 description 1
- RPBAFSBGYDKNRG-NJBDSQKTSA-N epicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CCC=CC1 RPBAFSBGYDKNRG-NJBDSQKTSA-N 0.000 description 1
- 201000011114 epidermolysis bullosa acquisita Diseases 0.000 description 1
- 210000002919 epithelial cells Anatomy 0.000 description 1
- 108091003687 epitumomab Proteins 0.000 description 1
- XBRDBODLCHKXHI-UHFFFAOYSA-N epolamine Chemical compound OCCN1CCCC1 XBRDBODLCHKXHI-UHFFFAOYSA-N 0.000 description 1
- 108010007604 epratuzumab Proteins 0.000 description 1
- 229960002770 ertapenem Drugs 0.000 description 1
- 108090000148 ertumaxomab Proteins 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- 108010059577 etaracizumab Proteins 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 229960000752 etoposide phosphate Drugs 0.000 description 1
- 229960002049 etravirine Drugs 0.000 description 1
- 201000005889 eumycotic mycetoma Diseases 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 201000008819 extrahepatic bile duct carcinoma Diseases 0.000 description 1
- 229960004396 famciclovir Drugs 0.000 description 1
- GGXKWVWZWMLJEH-UHFFFAOYSA-N famcyclovir Chemical compound N1=C(N)N=C2N(CCC(COC(=O)C)COC(C)=O)C=NC2=C1 GGXKWVWZWMLJEH-UHFFFAOYSA-N 0.000 description 1
- 108010087285 farletuzumab Proteins 0.000 description 1
- 229960000379 faropenem Drugs 0.000 description 1
- 201000006061 fatal familial insomnia Diseases 0.000 description 1
- 101710004779 fba1 Proteins 0.000 description 1
- 230000001605 fetal Effects 0.000 description 1
- 108010062604 fezakinumab Proteins 0.000 description 1
- 108010025050 figitumumab Proteins 0.000 description 1
- MSBQEQDLFWWWMV-XZZGLLCESA-N fijianolide B Chemical compound C(/[C@H](O)[C@H]1OC(=O)\C=C/C[C@@H]2C=CC[C@H](O2)C[C@H](CC(=C)C[C@H](O)[C@@H]2O[C@H]2C1)C)=C\[C@@H]1CC(C)=CCO1 MSBQEQDLFWWWMV-XZZGLLCESA-N 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 229960002878 flomoxef Drugs 0.000 description 1
- 229960003760 florfenicol Drugs 0.000 description 1
- 229960005394 flucloxacillin Drugs 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960000676 flunisolide Drugs 0.000 description 1
- 229960001398 flurithromycin Drugs 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- 229960000289 fluticasone propionate Drugs 0.000 description 1
- 101700068417 fol1 Proteins 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 150000002224 folic acids Chemical class 0.000 description 1
- 229960001447 fomivirsen Drugs 0.000 description 1
- 108010017915 fontolizumab Proteins 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229960003142 fosamprenavir Drugs 0.000 description 1
- 229960000308 fosfomycin Drugs 0.000 description 1
- 108010073818 fresolimumab Proteins 0.000 description 1
- 125000002446 fucosyl group Chemical group C1([C@@H](O)[C@H](O)[C@H](O)[C@@H](O1)C)* 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N furane Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 229960001625 furazolidone Drugs 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 108010012206 galiximab Proteins 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 108010045722 gantenerumab Proteins 0.000 description 1
- 229960001430 garenoxacin Drugs 0.000 description 1
- 229960003923 gatifloxacin Drugs 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 229960003170 gemifloxacin Drugs 0.000 description 1
- 229960000578 gemtuzumab Drugs 0.000 description 1
- 201000011349 geniculate herpes zoster Diseases 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 201000003950 geotrichosis Diseases 0.000 description 1
- 201000006592 giardiasis Diseases 0.000 description 1
- 201000003641 glanders Diseases 0.000 description 1
- 108010085319 glembatumumab vedotin Proteins 0.000 description 1
- 201000010915 glioblastoma multiforme Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 201000000128 gnathomiasis Diseases 0.000 description 1
- 108010086781 golimumab Proteins 0.000 description 1
- 229960001743 golimumab Drugs 0.000 description 1
- 239000001963 growth media Substances 0.000 description 1
- 201000005648 hantavirus pulmonary syndrome Diseases 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 201000001066 hemolytic-uremic syndrome Diseases 0.000 description 1
- 201000000907 hemorrhagic fever with renal syndrome Diseases 0.000 description 1
- 201000010284 hepatitis E Diseases 0.000 description 1
- 229960003884 hetacillin Drugs 0.000 description 1
- DXVUYOAEDJXBPY-NFFDBFGFSA-N hetacillin Chemical compound C1([C@@H]2C(=O)N(C(N2)(C)C)[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 DXVUYOAEDJXBPY-NFFDBFGFSA-N 0.000 description 1
- 201000007162 hidradenitis suppurativa Diseases 0.000 description 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 1
- 229940121372 histone deacetylase inhibitors Drugs 0.000 description 1
- 201000002563 histoplasmosis Diseases 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 201000009163 human granulocytic anaplasmosis Diseases 0.000 description 1
- 201000001820 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 201000009162 human monocytic ehrlichiosis Diseases 0.000 description 1
- 150000002429 hydrazines Chemical class 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000002209 hydrophobic Effects 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 201000006866 hypopharynx cancer Diseases 0.000 description 1
- 230000002267 hypothalamic Effects 0.000 description 1
- 101700024633 ibp Proteins 0.000 description 1
- 201000009794 idiopathic pulmonary fibrosis Diseases 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 201000008319 inclusion body myositis Diseases 0.000 description 1
- 229960001936 indinavir Drugs 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 201000011422 infant botulism Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000977 initiatory Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 108010063254 inolimomab Proteins 0.000 description 1
- 239000002348 inosinate dehydrogenase inhibitor Substances 0.000 description 1
- 239000002850 integrase inhibitor Substances 0.000 description 1
- 108040006858 interleukin-6 receptor activity proteins Proteins 0.000 description 1
- 229940079867 intestinal antiinfectives Sulfonamides Drugs 0.000 description 1
- 108010009550 intetumumab Proteins 0.000 description 1
- 230000003834 intracellular Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 101700057991 invA4 Proteins 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N iodine atom Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229960005386 ipilimumab Drugs 0.000 description 1
- 108010093819 iratumumab Proteins 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- 229960003350 isoniazid Drugs 0.000 description 1
- AMIMRNSIRUDHCM-UHFFFAOYSA-N isopropylaldehyde Chemical compound CC(C)C=O AMIMRNSIRUDHCM-UHFFFAOYSA-N 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 229960004144 josamycin Drugs 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 108010056936 keliximab Proteins 0.000 description 1
- 239000003835 ketolide antibiotic agent Substances 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 230000002147 killing Effects 0.000 description 1
- 108010067624 labetuzumab Proteins 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229960004891 lapatinib Drugs 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 229960000433 latamoxef Drugs 0.000 description 1
- 108010010776 lebrikizumab Proteins 0.000 description 1
- 101700036391 lecA Proteins 0.000 description 1
- 229960004942 lenalidomide Drugs 0.000 description 1
- RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 1
- 229960003376 levofloxacin Drugs 0.000 description 1
- 108010046731 lexatumumab Proteins 0.000 description 1
- 201000011486 lichen planus Diseases 0.000 description 1
- 230000004301 light adaptation Effects 0.000 description 1
- 229960005287 lincomycin Drugs 0.000 description 1
- 229960003907 linezolid Drugs 0.000 description 1
- 108010018575 lintuzumab Proteins 0.000 description 1
- 201000006721 lip cancer Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 238000011068 load Methods 0.000 description 1
- 229960002422 lomefloxacin Drugs 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 229960004525 lopinavir Drugs 0.000 description 1
- 229960001977 loracarbef Drugs 0.000 description 1
- 108010057244 lorvotuzumab mertansine Proteins 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 108010020744 lucatumumab Proteins 0.000 description 1
- 108010011366 lumiliximab Proteins 0.000 description 1
- 201000005244 lung non-small cell carcinoma Diseases 0.000 description 1
- AHEVKYYGXVEWNO-UEPZRUIBSA-N lymecycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(=O)NCNCCCC[C@H](N)C(O)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O AHEVKYYGXVEWNO-UEPZRUIBSA-N 0.000 description 1
- 229960004196 lymecycline Drugs 0.000 description 1
- 230000000527 lymphocytic Effects 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 229960003640 mafenide Drugs 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 229960002366 magnesium silicate Drugs 0.000 description 1
- VASIZKWUTCETSD-UHFFFAOYSA-N manganese(II) oxide Inorganic materials [Mn]=O VASIZKWUTCETSD-UHFFFAOYSA-N 0.000 description 1
- 108010021856 mapatumumab Proteins 0.000 description 1
- 229960004710 maraviroc Drugs 0.000 description 1
- 229960002531 marbofloxacin Drugs 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 108010029633 matuzumab Proteins 0.000 description 1
- 101700001016 mbhA Proteins 0.000 description 1
- 229960001890 mecillinam Drugs 0.000 description 1
- 229960000826 meclocycline Drugs 0.000 description 1
- 230000001404 mediated Effects 0.000 description 1
- JBVNBBXAMBZTMQ-CEGNMAFCSA-N megestrol Chemical compound C1=CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 JBVNBBXAMBZTMQ-CEGNMAFCSA-N 0.000 description 1
- 229960001786 megestrol Drugs 0.000 description 1
- 229960001929 meloxicam Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 201000011475 meningoencephalitis Diseases 0.000 description 1
- 108010062313 mepolizumab Proteins 0.000 description 1
- 229960005108 mepolizumab Drugs 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 229960002260 meropenem Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229960003494 metacycline Drugs 0.000 description 1
- 201000001198 metagonimiasis Diseases 0.000 description 1
- 229960003806 metampicillin Drugs 0.000 description 1
- FZECHKJQHUVANE-MCYUEQNJSA-N metampicillin Chemical compound C1([C@@H](N=C)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 FZECHKJQHUVANE-MCYUEQNJSA-N 0.000 description 1
- AWIJRPNMLHPLNC-UHFFFAOYSA-N methanethioic S-acid Chemical compound SC=O AWIJRPNMLHPLNC-UHFFFAOYSA-N 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- VPABMVYNSQRPBD-AOJMVMDXSA-N methyl (2R)-2-[[(4-bromophenoxy)-[[(2S,5R)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)-2,5-dihydrofuran-2-yl]methoxy]phosphoryl]amino]propanoate Chemical compound N1([C@@H]2O[C@@H](C=C2)COP(=O)(N[C@H](C)C(=O)OC)OC=2C=CC(Br)=CC=2)C=C(C)C(=O)NC1=O VPABMVYNSQRPBD-AOJMVMDXSA-N 0.000 description 1
- QGWMIQPMNNKJMA-IBGZPJMESA-N methyl (2S)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-(4-phenylmethoxyphenyl)propanoate Chemical compound C1=CC(C[C@@H](C(=O)OC)NC(=O)OC(C)(C)C)=CC=C1OCC1=CC=CC=C1 QGWMIQPMNNKJMA-IBGZPJMESA-N 0.000 description 1
- KUWWRNNYEYGSBQ-UHFFFAOYSA-N methyl 1,3-thiazole-4-carboxylate Chemical compound COC(=O)C1=CSC=N1 KUWWRNNYEYGSBQ-UHFFFAOYSA-N 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 229960000198 mezlocillin Drugs 0.000 description 1
- YPBATNHYBCGSSN-VWPFQQQWSA-N mezlocillin Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC=CC=1)C(=O)N1CCN(S(C)(=O)=O)C1=O YPBATNHYBCGSSN-VWPFQQQWSA-N 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 230000003228 microsomal Effects 0.000 description 1
- 201000000090 microsporidiosis Diseases 0.000 description 1
- 229960002757 midecamycin Drugs 0.000 description 1
- 108010017913 milatuzumab Proteins 0.000 description 1
- 229960003775 miltefosine Drugs 0.000 description 1
- 229960000931 miocamycin Drugs 0.000 description 1
- 108010031818 monoclonal antibody BIWA 4 Proteins 0.000 description 1
- 235000013919 monopotassium glutamate Nutrition 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 108010008564 motavizumab Proteins 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 229960003702 moxifloxacin Drugs 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- 229950001738 mydecamycin Drugs 0.000 description 1
- 201000003793 myelodysplastic syndrome Diseases 0.000 description 1
- 201000002481 myositis Diseases 0.000 description 1
- 125000004370 n-butenyl group Chemical group [H]\C([H])=C(/[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960003808 nadifloxacin Drugs 0.000 description 1
- 229960000515 nafcillin Drugs 0.000 description 1
- 201000003631 narcolepsy Diseases 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 229960005027 natalizumab Drugs 0.000 description 1
- 108010017306 nebacumab Proteins 0.000 description 1
- 229960002915 nebacumab Drugs 0.000 description 1
- 108010033813 necitumumab Proteins 0.000 description 1
- 229960000513 necitumumab Drugs 0.000 description 1
- 229960000884 nelfinavir Drugs 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 239000002581 neurotoxin Substances 0.000 description 1
- 229960001346 nilotinib Drugs 0.000 description 1
- 108010043585 nimotuzumab Proteins 0.000 description 1
- LJDZFAPLPVPTBD-UHFFFAOYSA-M nitroformate Chemical compound [O-]C(=O)[N+]([O-])=O LJDZFAPLPVPTBD-UHFFFAOYSA-M 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 201000002674 obstructive nephropathy Diseases 0.000 description 1
- 108010030900 ocrelizumab Proteins 0.000 description 1
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005069 octynyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C#C* 0.000 description 1
- 201000002575 ocular melanoma Diseases 0.000 description 1
- 108010052070 ofatumumab Proteins 0.000 description 1
- 108010049284 olaratumab Proteins 0.000 description 1
- 229960002351 oleandomycin Drugs 0.000 description 1
- 235000019367 oleandomycin Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic Effects 0.000 description 1
- 108091008124 oncoproteins Proteins 0.000 description 1
- 102000025475 oncoproteins Human genes 0.000 description 1
- 229940005938 ophthalmologic antiinfectives Sulfonamides Drugs 0.000 description 1
- 201000005443 oral cavity cancer Diseases 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 229960004780 orbifloxacin Drugs 0.000 description 1
- 108010060422 oregovomab Proteins 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- VHFGEBVPHAGQPI-LXKZPTCJSA-N oritavancin Chemical compound O([C@@H]1C2=CC=C(C(=C2)Cl)OC=2C=C3C=C(C=2O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@@H]2O[C@@H](C)[C@H](O)[C@@](C)(NCC=4C=CC(=CC=4)C=4C=CC(Cl)=CC=4)C2)OC2=CC=C(C=C2Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]2C(=O)N[C@@H]1C(N[C@@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@@H](O)[C@H](C)O1 VHFGEBVPHAGQPI-LXKZPTCJSA-N 0.000 description 1
- 229960001607 oritavancin Drugs 0.000 description 1
- 108010006945 oritavancin Proteins 0.000 description 1
- 201000000901 ornithosis Diseases 0.000 description 1
- 201000006958 oropharynx cancer Diseases 0.000 description 1
- 230000003204 osmotic Effects 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 108010009925 otelixizumab Proteins 0.000 description 1
- 229960001019 oxacillin Drugs 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 235000019366 oxytetracycline Nutrition 0.000 description 1
- 101710027502 pagA Proteins 0.000 description 1
- 108010054892 pagibaximab Proteins 0.000 description 1
- 201000005580 palindromic rheumatism Diseases 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 229960005184 panobinostat Drugs 0.000 description 1
- FPOHNWQLNRZRFC-ZHACJKMWSA-N panobinostat Chemical compound CC=1NC2=CC=CC=C2C=1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FPOHNWQLNRZRFC-ZHACJKMWSA-N 0.000 description 1
- 201000000301 paracoccidioidomycosis Diseases 0.000 description 1
- 201000007052 paranasal sinus cancer Diseases 0.000 description 1
- 230000003071 parasitic Effects 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 229960001914 paromomycin Drugs 0.000 description 1
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 201000005115 pasteurellosis Diseases 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 229960000639 pazopanib Drugs 0.000 description 1
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 description 1
- 229960003407 pegaptanib Drugs 0.000 description 1
- 201000006518 pelvic inflammatory disease Diseases 0.000 description 1
- 201000011152 pemphigus Diseases 0.000 description 1
- 201000001976 pemphigus vulgaris Diseases 0.000 description 1
- 229960000596 penamecillin Drugs 0.000 description 1
- 229960001179 penciclovir Drugs 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- MEGKRPMNPGTIIG-VNYBMUHKSA-N penimepicycline Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)COC1=CC=CC=C1.O=C([C@@]1(O)C(O)=C2[C@@H]([C@](C3=CC=CC(O)=C3C2=O)(C)O)C[C@H]1[C@@H](C=1O)N(C)C)C=1C(=O)NCN1CCN(CCO)CC1 MEGKRPMNPGTIIG-VNYBMUHKSA-N 0.000 description 1
- 229960003187 penimepicycline Drugs 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 235000006678 peppermint Nutrition 0.000 description 1
- 235000015132 peppermint Nutrition 0.000 description 1
- 235000007735 peppermint Nutrition 0.000 description 1
- 238000005897 peptide coupling reaction Methods 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 229960001084 peramivir Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 108010018063 pexelizumab Proteins 0.000 description 1
- 230000000275 pharmacokinetic Effects 0.000 description 1
- 229960004894 pheneticillin Drugs 0.000 description 1
- 229960004331 phenoxymethylpenicillin Drugs 0.000 description 1
- BBTOYUUSUQNIIY-ANPZCEIESA-N phenoxymethylpenicillin benzathine Chemical compound C=1C=CC=CC=1C[NH2+]CC[NH2+]CC1=CC=CC=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)COC1=CC=CC=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)COC1=CC=CC=C1 BBTOYUUSUQNIIY-ANPZCEIESA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 230000002186 photoactivation Effects 0.000 description 1
- 239000003504 photosensitizing agent Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229960002292 piperacillin Drugs 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 229960001221 pirarubicin Drugs 0.000 description 1
- 201000002511 pituitary cancer Diseases 0.000 description 1
- 201000000508 pityriasis versicolor Diseases 0.000 description 1
- 229960003342 pivampicillin Drugs 0.000 description 1
- 229960004212 pivmecillinam Drugs 0.000 description 1
- 108010031345 placental alkaline phosphatase Proteins 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229960001237 podophyllotoxin Drugs 0.000 description 1
- 229930001140 podophyllotoxin Natural products 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000889 poly(m-phenylene isophthalamide) Polymers 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 201000006292 polyarteritis nodosa Diseases 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229960005266 polymyxin B Drugs 0.000 description 1
- 229920000024 polymyxin B Polymers 0.000 description 1
- 229920000259 polyoxyethylene lauryl ether Polymers 0.000 description 1
- 108040000983 polyphosphate:AMP phosphotransferase activity proteins Proteins 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229960000688 pomalidomide Drugs 0.000 description 1
- 229960001131 ponatinib Drugs 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 108010060090 pretubulysin Proteins 0.000 description 1
- 108010084129 priliximab Proteins 0.000 description 1
- 150000003141 primary amines Chemical group 0.000 description 1
- 201000002728 primary biliary cirrhosis Diseases 0.000 description 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
- 201000000742 primary sclerosing cholangitis Diseases 0.000 description 1
- 229940095783 procaine benzylpenicillin Drugs 0.000 description 1
- 230000000750 progressive Effects 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 229960003672 propicillin Drugs 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 108010043671 prostatic acid phosphatase Proteins 0.000 description 1
- 230000002633 protecting Effects 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 230000001681 protective Effects 0.000 description 1
- 201000004681 psoriasis Diseases 0.000 description 1
- 201000001263 psoriatic arthritis Diseases 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- INVTYAOGFAGBOE-UHFFFAOYSA-N pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC(=O)OCC1=CC=CN=C1 INVTYAOGFAGBOE-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 150000007660 quinolones Chemical class 0.000 description 1
- 108010020302 racotumomab Proteins 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 229960004432 raltitrexed Drugs 0.000 description 1
- 108010076689 ramoplanin Proteins 0.000 description 1
- 108010026911 ramucirumab Proteins 0.000 description 1
- 229960002633 ramucirumab Drugs 0.000 description 1
- 108010087730 raxibacumab Proteins 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000000306 recurrent Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- 238000001226 reprecipitation Methods 0.000 description 1
- 229960003254 reslizumab Drugs 0.000 description 1
- 108010069061 reslizumab Proteins 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 229960003485 ribostamycin Drugs 0.000 description 1
- 201000004282 rickettsialpox Diseases 0.000 description 1
- 229960000885 rifabutin Drugs 0.000 description 1
- 229960002599 rifapentine Drugs 0.000 description 1
- 229960001886 rilonacept Drugs 0.000 description 1
- 108010046141 rilonacept Proteins 0.000 description 1
- 108010011457 rilotumumab Proteins 0.000 description 1
- YIBOMRUWOWDFLG-ONEGZZNKSA-N rilpivirine Chemical compound CC1=CC(\C=C\C#N)=CC(C)=C1NC1=CC=NC(NC=2C=CC(=CC=2)C#N)=N1 YIBOMRUWOWDFLG-ONEGZZNKSA-N 0.000 description 1
- 229960002814 rilpivirine Drugs 0.000 description 1
- 229960000888 rimantadine Drugs 0.000 description 1
- 229960000311 ritonavir Drugs 0.000 description 1
- 108091002741 robatumumab Proteins 0.000 description 1
- 229960001170 rokitamycin Drugs 0.000 description 1
- HMEYVGGHISAPJR-IAHYZSEUSA-N rolitetracycline Chemical compound O=C([C@@]1(O)C(O)=C2[C@@H]([C@](C3=CC=CC(O)=C3C2=O)(C)O)C[C@H]1[C@@H](C=1O)N(C)C)C=1C(=O)NCN1CCCC1 HMEYVGGHISAPJR-IAHYZSEUSA-N 0.000 description 1
- 229960003452 romidepsin Drugs 0.000 description 1
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 description 1
- 108010091666 romidepsin Proteins 0.000 description 1
- 108010024190 rontalizumab Proteins 0.000 description 1
- 108091011590 rovelizumab Proteins 0.000 description 1
- 229960005224 roxithromycin Drugs 0.000 description 1
- 229960000215 ruxolitinib Drugs 0.000 description 1
- HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical compound C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 201000004409 schistosomiasis Diseases 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
- 150000003349 semicarbazides Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 108010014634 sevirumab Proteins 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 239000002911 sialidase inhibitor Substances 0.000 description 1
- 108010043794 sibrotuzumab Proteins 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- 108010037957 sifalimumab Proteins 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 108010056973 siltuximab Proteins 0.000 description 1
- 229960003323 siltuximab Drugs 0.000 description 1
- 108010073705 siplizumab Proteins 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- 229960003177 sitafloxacin Drugs 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 201000002314 small intestine cancer Diseases 0.000 description 1
- 239000001187 sodium carbonate Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- HHSGWIABCIVPJT-UHFFFAOYSA-M sodium;1-[4-[(2-iodoacetyl)amino]benzoyl]oxy-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)C1=CC=C(NC(=O)CI)C=C1 HHSGWIABCIVPJT-UHFFFAOYSA-M 0.000 description 1
- RPENMORRBUTCPR-UHFFFAOYSA-M sodium;1-hydroxy-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].ON1C(=O)CC(S([O-])(=O)=O)C1=O RPENMORRBUTCPR-UHFFFAOYSA-M 0.000 description 1
- ZAPNXDUFCQIHFS-UHFFFAOYSA-M sodium;2,5-dioxo-1-[6-[3-(pyridin-2-yldisulfanyl)propanoylamino]hexanoyloxy]pyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)CCCCCNC(=O)CCSSC1=CC=CC=N1 ZAPNXDUFCQIHFS-UHFFFAOYSA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 108010079667 solanezumab Proteins 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 108010072687 sonepcizumab Proteins 0.000 description 1
- 229960004954 sparfloxacin Drugs 0.000 description 1
- 229960001294 spiramycin Drugs 0.000 description 1
- 235000019372 spiramycin Nutrition 0.000 description 1
- 201000002190 staphyloenterotoxemia Diseases 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 description 1
- 101700054498 such-1 Proteins 0.000 description 1
- 229960004932 sulbenicillin Drugs 0.000 description 1
- 229960000654 sulfafurazole Drugs 0.000 description 1
- 229960005158 sulfamethizole Drugs 0.000 description 1
- IHBMMJGTJFPEQY-UHFFFAOYSA-N sulfanylidene(sulfanylidenestibanylsulfanyl)stibane Chemical compound S=[Sb]S[Sb]=S IHBMMJGTJFPEQY-UHFFFAOYSA-N 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 235000015487 sulforaphane Nutrition 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229960001796 sunitinib Drugs 0.000 description 1
- 230000000576 supplementary Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 201000008205 supratentorial primitive neuroectodermal tumor Diseases 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained Effects 0.000 description 1
- 229940040975 systemic penicillins Beta-lactamase inhibitors Drugs 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 108010088600 talizumab Proteins 0.000 description 1
- 108010038329 tanezumab Proteins 0.000 description 1
- 101700042113 tap Proteins 0.000 description 1
- 108010017101 telaprevir Proteins 0.000 description 1
- 108010089019 telavancin Proteins 0.000 description 1
- 229960004576 temafloxacin Drugs 0.000 description 1
- 229960001114 temocillin Drugs 0.000 description 1
- 108010018121 teplizumab Proteins 0.000 description 1
- DKACXUFSLUYRFU-UHFFFAOYSA-N tert-butyl N-aminocarbamate Chemical compound CC(C)(C)OC(=O)NN DKACXUFSLUYRFU-UHFFFAOYSA-N 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000005942 tetrahydropyridyl group Chemical group 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 150000003548 thiazolidines Chemical class 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- CNHYKKNIIGEXAY-UHFFFAOYSA-N thiolan-2-imine Chemical compound N=C1CCCS1 CNHYKKNIIGEXAY-UHFFFAOYSA-N 0.000 description 1
- ATGUDZODTABURZ-UHFFFAOYSA-N thiolan-2-ylideneazanium;chloride Chemical compound Cl.N=C1CCCS1 ATGUDZODTABURZ-UHFFFAOYSA-N 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 229960000874 thyrotropin Drugs 0.000 description 1
- 230000001748 thyrotropin Effects 0.000 description 1
- 229960003723 tiazofurine Drugs 0.000 description 1
- 108010092179 tigatuzumab Proteins 0.000 description 1
- 229950010206 tigemonam Drugs 0.000 description 1
- 201000009642 tinea barbae Diseases 0.000 description 1
- 201000003875 tinea corporis Diseases 0.000 description 1
- 201000005882 tinea unguium Diseases 0.000 description 1
- 229960000838 tipranavir Drugs 0.000 description 1
- 229960000940 tivozanib Drugs 0.000 description 1
- 230000000699 topical Effects 0.000 description 1
- 229940026752 topical Sulfonamides Drugs 0.000 description 1
- 229940083878 topical for treatment of hemorrhoids and anal fissures Corticosteroids Drugs 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- 108091004323 toralizumab Proteins 0.000 description 1
- 229960005267 tositumomab Drugs 0.000 description 1
- 229950008187 tosufloxacin Drugs 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 201000005485 toxoplasmosis Diseases 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 108010015605 transforming growth factor(alpha)-Pseudomonas aeruginosa exotoxin (38) Proteins 0.000 description 1
- 102000035402 transmembrane proteins Human genes 0.000 description 1
- 108091005683 transmembrane proteins Proteins 0.000 description 1
- LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 description 1
- 229960003181 treosulfan Drugs 0.000 description 1
- 150000004654 triazenes Chemical class 0.000 description 1
- UABRYPURASNHRO-UHFFFAOYSA-N trimethyltin;hydrate Chemical compound O.C[Sn](C)C UABRYPURASNHRO-UHFFFAOYSA-N 0.000 description 1
- 229960000875 trofosfamide Drugs 0.000 description 1
- 229960005041 troleandomycin Drugs 0.000 description 1
- LQCLVBQBTUVCEQ-QTFUVMRISA-N troleandomycin Chemical compound O1[C@@H](C)[C@H](OC(C)=O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](C)C(=O)O[C@H](C)[C@H](C)[C@H](OC(C)=O)[C@@H](C)C(=O)[C@@]2(OC2)C[C@H](C)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)OC(C)=O)[C@H]1C LQCLVBQBTUVCEQ-QTFUVMRISA-N 0.000 description 1
- 229960000832 tromantadine Drugs 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 201000006704 ulcerative colitis Diseases 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 150000003673 urethanes Chemical class 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 108091002641 urtoxazumab Proteins 0.000 description 1
- 229960003824 ustekinumab Drugs 0.000 description 1
- 229960001234 valaciclovir Drugs 0.000 description 1
- 229960002149 valganciclovir Drugs 0.000 description 1
- 229960000604 valproic acid Drugs 0.000 description 1
- 229960000241 vandetanib Drugs 0.000 description 1
- 201000001042 variant Creutzfeldt-Jakob disease Diseases 0.000 description 1
- 201000006266 variola major Diseases 0.000 description 1
- 201000000627 variola minor Diseases 0.000 description 1
- 108010035693 vedolizumab Proteins 0.000 description 1
- 229960004914 vedolizumab Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 108010063727 veltuzumab Proteins 0.000 description 1
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 description 1
- 229960003862 vemurafenib Drugs 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- HHJUWIANJFBDHT-KOTLKJBCSA-N vindesine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(N)=O)N4C)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 HHJUWIANJFBDHT-KOTLKJBCSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- GBABOYUKABKIAF-IELIFDKJSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IELIFDKJSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 108010010249 visilizumab Proteins 0.000 description 1
- 229960004449 vismodegib Drugs 0.000 description 1
- 230000004400 visual pathway Effects 0.000 description 1
- 235000001892 vitamin D2 Nutrition 0.000 description 1
- 239000011653 vitamin D2 Substances 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- 108010031272 volociximab Proteins 0.000 description 1
- 201000002173 von Economo's disease Diseases 0.000 description 1
- 230000003442 weekly Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- 229940051021 yellow-fever virus Drugs 0.000 description 1
- 229960000523 zalcitabine Drugs 0.000 description 1
- 108010023055 zalutumumab Proteins 0.000 description 1
- 108010052251 zanolimumab Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229960000641 zorubicin Drugs 0.000 description 1
Abstract
conjugate of a cytotoxic agent with a cell-surface receptor binding molecule having a structure of Formula (I) as defined in claim 1. The conjugate is used for targeted treatment of cancer, autoimmune disease, and infectious disease.
Description
CONJUGATES OF CELL BINDING MOLECULES WITH CYTOTOXIC AGENTS
1. FIELD OF THE INVENTION
This invention relates to conjugates of potent antimitotic agents with a cell-surface receptor
binding molecules for targeted therapy. The invention also relates to use of the compositions
comprising binding molecule-antimitotic agent conjugates for treating cancer, autoimmune
disease, and infectious disease.
2. BACKGROUND OF THE INVENTION
There are many articles appeared on the attempted specific targeting of pathogenic cells, in
particular, cancer cells utilizing cytotoxic drug conjugated to cell-surface receptor binding agents,
such as antibodies (Sela et al, in Immunoconjugates 189-216 (C. Vogel, ed. 1987); Ghose et al, in
Targeted Drugs 1-22 (E. Goldberg, ed. 1983); Diener et al, in Antibody mediated delivery
systems 1-23 (J. Rodwell, ed. 1988); Silverstein, Nat. Immunol. 2004, 5, 1211–7; Fanning et al,
Clin. Immunol. Immunopathol. 1996, 79, 1–14; Ricart A.D., et al., Nature Clinical Practice
Oncology 2007, 4, 245-255 ; Singh R. et al Rickson H.K., Therapeutic Antibodies: Methods and
Protocols, 2009, 525, 445-467), folic acids (Sudimack, J. et al, Adv. Drug Delivery Rev. 2000,
41, 147-162; Reddy, et al, Mol. Pharm. 2009, 6, 1518-25); PMSA (prostate specific membrane
antigen) binding ligands (Low, et al, A1); albumin with peptides (Temming, et
al, Bioconjugate Chem. 2006, 17, 1385-1394); Cobalamin and proteins (Gupta, et al, Crit. Rev.
Therap. Drug Carrier Syst. 2008, 25, 347-79; Petrus, et al, Angew. Chem. Int. Ed. 2009, 48,
1022-8); carbohydrate (Darbre, et al, Curr. Top. Med. Chem.. 2008, 8, 1286-93); bioactive
polymers (Dhar, et al, Proc. Natl. Acad. Sci. 2008, 105, 17356-61); dendrimers (Lee, et al, Nat.
Biotechnol. 2005, 23, 1517-26; Almutairi, et al; Proc. Natl. Acad. Sci. 2009, 106, 685-90);
nanoparticles (Liong, et al, ACS Nano, 2008, 19, 1309-12; Medarova, et al, Nat. Med. 2007, 13,
372-7; Javier, et al, Bioconjugate Chem. 2008, 19, 1309-12); liposomes (Medinai, et al, Curr.
Phar. Des. 2004, 10, 2981-9); viral capsides (Flenniken, et al, Viruses Nanotechnol. 2009, 327,
71-93), etc.
Different families of cytotoxic agents like calicheamicin derivative (Giles, et al Cancer
2003, 98, 2095-104; Hamann, et al, Bioconjug Chem 2002, 13, 47-58), maytansin derivative
(Widdison, et al, J Med Chem 2006, 49, 4392-408; Ikeda, et al, Clin Cancer Res 2009, 15, 4028 -
37; Xie, et al, Expert Opin Biol Ther 2006, 6, 281-91), auristatins (Sutherland, et al, J Biol Chem
2006, 281, 10540-7; Doronina, et al, Bioconjug Chem 2006, 17, 114-24), taxane derivatives
(Miller, et al, J Med Chem 2004, 47, 4802-5; WO 06061258), leptomycine derivatives (WO
07144709), CC-1065 and analogues (Suzawa, et al, J Control Release 2002, 79, 229-42; Suzawa,
et al, Bioorg Med Chem 2000, 8, 2175-84; WO 2007102069), doxorubicin (Trail, et al, Science
1993, 261, 212-5; Saleh et al, J Clin Oncol 2000, 18, 2282-92), or like methotrexate,
daunorubicin, vincristine, vinblastine, melphalan, mitomycin C, chlorambucil have been used for
the conjugation with a cell-surface receptor binding agent, in particular with antibodies (Wu, et al,
Nat. Biotechnol. 2005, 23, 1137–1146. Ricart, et al, Nat. Clin. Pract. Oncol. 2007, 4, 245–255).
The use of a cell-surface receptor binding agent, particularly a targeting antibody having an
affinity for the pathogenic cells makes it possible to deliver the cytotoxic agent directly in the
vicinity or directly in the pathogenic cell, thus increasing the efficiency of the cytotoxic agent
while minimizing the side-effects commonly associated with the cytotoxic agents.
Several short peptidic compounds that found to have biological activity have been isolated
from natural sources. One of them, Tubulysins (structures shown below), which were the first
time isolated by Hofle and Reichenbach et al. (GBF Braunschweig) from a culture browth
Tup, R = H
Mep Ile Tuv iii
Tut, R = OH
H R O
R COOH
i ii iii
Tubulysin R R R
A CH OCOCH CH(CH ) OCOCH OH
2 2 3 2 3
B CH OCOCH CH CH OCOCH OH
2 2 2 3 3
C CH OCOCH CH OCOCH OH
2 2 3 3
D CH OCOCH CH(CH ) OCOCH H
2 2 3 2 3
E CH OCOCH CH CH OCOCH H
2 2 2 3 3
F CH OCOCH CH OCOCH H
2 2 3 3
G CH OCOCH=CH OCOCH OH
2 2 3
H CH OCOCH OCOCH H
2 3 3
I CH OCOCH OCOCH OH
2 3 3
U H OCOCH H
V H OH H
Z H OH OH
Pretubulysin CH H H
(The structures of existing tubulysin compounds)
of the myxobacterial strains of Archangium gephyra (F. Sasse et al. J. Antibiot. 2000, 53, 879-885;
WO9813375), are members of group of antimitotic peptides that inhibit tubulin polymerization in
dividing cells, and thus inducing apoptosis. With the exceptional potency exceeding that of
vinblastine, taxol and epothilones (Wipf, et al, Org. Lett. 2004, 6, 4057–60; Peltier, et al, J. Am.
Chem. Soc. 2006, 128, 16018-9; Wipf, et al, Org. Lett., 2007, 9, 1605–1607; Wang, et al, Chem.
Biol. Drug Des. 2007, 70, 75-86; Pando, et al, Org. Lett. 2009, 11, 5567-9), these antimitotic
peptides are exciting leads for targeted therapies. Structurally, the tetrapeptide tubulysins are
comprising of N-methylpipecolinic acid (Mep) at the N-terminus, isoleucine (Ile) as the second
residue, the unique thiazole-containing tubuvaline (Tuv) as the third residue, and two possible γ-
amino acids at the C-terminus (tubutyrosine (Tut) or tubuphenylalanine (Tup)). Despite several
tubulysins have recently been synthesized, significant general toxicities (>20% animal body
weight loss) of the existing tubulysins at doses required for achieving a therapeutic effect
compromise their efficacy (US Patent appl. 2010/0048490). We have been interested in the art of
a conjugate of a cell surface binding ligand, particularly using an antibody to conjugate with
tubulysin derivaties for having significantly lower general toxicity, yet useful therapeutic
efficiency. However, the tubulysins are hardly soluble in a buffer solution, resulting in significant
amount of antibody aggregation when conjugated with the tubulysins. A simpler analog, such as
using phenyl analine (Phe) and tyrosine (Tyr) to replace Tup and Tut components respectively for
the antibody conjugation leads to the hydrolysis of Phe and Tyr in the animal blood circulation
and generates the much less potent (over 300 fold less) Mep-Ile-Tuv moiety. Here this patent
discloses conjugates of a cell surface binding ligand with soluble and stable tubulysin derivaties
and using these conjugates for treating cancer and immune disorders.
3. SUMMARY OF THE INVENTION
In one illustrative embodiment of the invention provides a conjugate of formula (I):
R R O
and pharmaceutical acceptable salts and solvates thereof
Wherein T is a targeting or binding ligand; L is a releasable linker; is a linkage bond
that L connects to an atom inside the bracket independently; n is 1-20 and m is 1-10;
1 2 3 4
Inside the bracket is a potent antimitotic agent wherein R , R R and R are independently
C -C of alkyl; C -C of heteroalkyl, , alkylcycloalkyl, heterocycloalkyl; C -C of aryl, Ar-alkyl,
1 8 2 8 3 8
heterocyclic, carbocyclic, cycloalkyl, heteroalkylcycloalkyl, alkylcarbonyl; or two R's, such as
1 2 1 3 2 3 3 4 5 6 12 13
R R R R R R R R , R R , and R R can be 3-7 members of a carbocyclic, cycloalkyl, or
, , ,
1 3 4
heterocyclic, heterocycloalkyl ring system; Y is N or CH; In addition, R , R , and R can be H,
and R can be absent;
6 8 10
Wherein R R , R and R are independently selected from H and C -C of alkyl or C -C
, 1 4 2 4
of heteroalkyl.
7 14 14 1 15 14 1 15 1
Wherein R is selected from H, R or -R C(=O)X R ; -R X R X is selected from O, S,
S-S, NH, or NR
9 14 14 14 14 15
Wherein R is H, -O-, -OR , -OC(=O)R -, -OC(=O)NHR -, -OC(=O) R SSR -,
14 14 15
OP(=O)(OR )-, or OR OP(=O)(OR );
11 14 14 16 14 2 16 14 2 2
Wherein R is H, R , -R C(=O)R , -R X R , -R C(=O)X , wherein X is -O-, -S-, -
14 14 14 14 14
NH-, -N(R )-, -O-R -, -S-R -, -S(=O)-R -, or -NHR -;
12 14 14
Wherein R is R , -O-, -S-, -N-, =N-, =NNH-, -OH, -SH, -NH , =NH, =NNH , -NH(R ),
14 16 16 14 14 14
-OR , -C(O)O-, -C(O)OR -,-COR , -COOR -, C(O)NH-, C(O)NH , C(O)NHR , -SR , -
14 16 16 16 16
S(=O)R , -P(=O)(OR ) , -OP(=O)(OR ) , -CH OP(=O)(OR ) , -SO R ;
2 2 2
Wherein R is C -C of alkyl, alkyl acid, alkyl amide, alkyl amine; or C -C of
1 10 2 10
heteroalkyl; or C -C of Ar; Ar refers to an aromatic or hetero aromatic group, composed of
3 10
one or several rings, comprising four to ten carbon atoms, preferentially four to six carbon
atoms. The term of hetero aromatic group refers to an aromatic group that has one or several
carbon atoms replaced by hetero atoms, preferentially one, two or three carbon atoms replaced
by O, N, Si, Se, P or S, more preferentially O, S, N. The term aryl or Ar also refers to an
aromatic group, wherein one or several H atoms can be replaced independently by R , F, Cl, Br,
16 16 16 17 16 16 16 17 16 17 16 16 16
I, OR , SR , NR R , N=NR , N= R , NR R , NO SOR R , SO R , SO R OSO R ,
2, ,
2 3 3
16 17 16 17 16 17 17 17 17
PR R , POR R , PO R R , OP(O)(OR ) , OCH OP(O)(OR ) , OC(O)OP(O)(OR ) ,
2 2 2 2 2
16 17 17 17 17 17
PO(OR )(OR ), OP(O)(OR )OP(O)(OR ) , OC(O)R or OC(O)NHR ;
14 15
Wherein R and R are independently H; C -C of alkyl; C -C of alkenyl, alkynyl,
1 8 2 8
heteroalkyl, heterocyclic, carbocyclic; C -C of aryl, cycloalkyl, alkylcycloalkyl,
heterocycloalkyl, heteroaralkyl, heteroalkylcycloalkyl, alkylcarbonyl;
14 14
Wherein when R is bivalent, it is a R that is further connected to an additional functional
group of one to four amino acid units, or (CH CH O) r is an integer ranging from 0 to 12, or
2 2 r,
C -C glycosides, or C -C of carboxylic acid.
4 12 1 8
16 14
Wherein R is H, OH, R or one to four amino acid units;
Wherein R is H, C -C of alkyl; C -C of alkenyl, alkynyl, heteroalkyl, heterocyclic; C -
1 8 2 8 3
C of aryl, carbocyclic, cycloalkyl, alkylcycloalkyl, heterocycloalkyl, heteroalkylcycloalkyl,
heteroaralkyl, alkylcarbonyl or C -C glycosides, or pharmaceutical salts;
4 12
12 13
In addition, R can be H when R is:
k=0~4
, , wherein Z
18 18 18 18 18 18
is H, CH OP(O)(OR ) , C(O)OP(O)(OR ) , PO(OR ) , P(O)(OR )OP(O)(OR ) , C(O)R ,
2 2 2 2 2
18 18
C(O)NHR , SO (OR ), C -C glycosides, C -C of alkyl, carboxyalkyl, or C -C of
2 4 12 1 8 3 8
heterocyclic; Wherein R is H, C -C of alkyl; C -C of carboxyalkyl, heteroalkyl, alkenyl,
1 8 2 8
19 18
alkynyl; C -C of aryl, alkylcarbonyl, heterocyclic; Wherein R is H, OH, NH , OSO (OR ),
3 8 2 2
18 18 18 18 18
XCH OP(O)(OR ) , XPO(OR ) XC(O)OP(O)(OR ) , XC(O) R , XC(O)NHR C -C of
2 2 2 2 1 8
alkyl, carboxylic acid derivative; C -C of alkenyl, alkynyl, carboxyalkyl C -C of aryl,
2 8 3 8
heterocyclic, alkylcarbonyl; or pharmaceutical salts; X is O, S, NH; Y and Y are N or CH,
independently;
12 11
Or R can be H when R is:
2 8 8
, , wherein X is O, S, N-R ; R is H, C -C of alkyl or C -C
of heteroalkyl;
In another embodiment, the linker L of the potent antimitotic agent- binding molecule
conjugates has the formula: --Ww—(Aa)r--Vv—; wherein: --W-- is a Stretcher unit; w is 0 or 1;
each --Aa-- is independently an Amino Acid unit; r is independently an integer ranging from 0 to
12; --V-- is a Spacer unit; and v is 0, 1 or 2. The Stretcher unit W may indepen-dently contain a
self-immolative spacer, peptidyl units, a hydrazone bond, disulfide or thiolether bonds.
In another embodiment, the cell-surface binding molecule T may be of any kind presently
known, or which become known cell binding ligands, such as peptides and non-peptides.
Generally the binding molecule T is an antibody; a single chain antibody; an antibody fragment
that binds to the target cell; a monoclonal antibody; a single chain monoclonal antibody; or a
monoclonal antibody fragment that binds the target cell; a chimeric antibody; a chimeric antibody
fragment that binds to the target cell; a domain antibody; a domain antibody fragment that binds
to the target cell; adnectins that mimic antibodies; DARPins; a lymphokine; a hormone; a vitamin;
a growth factor; a colony stimulating factor; or a nutrient-transport molecule (a transferrin); a
binding peptide, or protein, or antibody, or small molecule attached on albumin, polymers,
dendrimers, liposomes, nanoparticles, vesicles, (viral) capsids. Preferably the binding molecule T
is a monoclonal antibody.
In yet another aspect, a compound of formula I~VII or a pharmaceutically acceptable salt or
solvate thereof is used for treating cancer, an autoimmune disease or an infectious disease in a
human or an animal.
4. BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 shows the synthesis of branched linkers for conjugation of drugs to cell binding
agents.
Figure 2 shows the synthesis of maleimido linkers and their use for the drug-binding
molecule conjugation.
Figure 3 shows the synthesis of bromomaleimido and dibromomaleimido linkers and their
uses for the drug-binding molecule conjugation.
Figure 4 shows the synthesis of amino acid (Val-Cit) linkers for the conjugation antimitotic
agents with a cell surface binding ligand.
Figure 8 shows the synthesis of Tuv, Ile-Tuv and Mep-Ile-Tuv moieties of the antimitotic
agents.
Figure 9 shows the synthesis of Ile-Tuv, Mep-Leu-Tuv, Val-Ile-Tuv and Val-Ile-Tuv (O-
alkyl) moieties of the antimitotic agents.
Figure 10 shows the synthesis of a conjugatable antimotic agent and its conjugation to an
antibody.
Figure 11 shows the synthesis of amino acid (Phe-(D)Lys) linkers for conjugation of the
antimitotic agents.
Figure 12 shows the synthesis of an antibody-antimitotic agent conjugate.
Figure 13 shows the synthesis of antibody-antimitotic agent conjugates.
Figure 14 shows the synthesis of the binding molecule-antimitotic agent conjugates.
Figure 15 shows the synthesis of a binding molecule-antimitotic agent conjugate.
Figure 16 shows the synthesis of an antibody-antimitotic agent conjugate.
Figure 17 shows the synthesis of an antibody-antimitotic agent conjugate.
Figure 18 shows the synthesis of Tut analogs for the synthesis of the the hydrophilic
(phosphate prodrug of) antimitotic agents.
Figure 19 shows the synthesis of the conjugates of the antimitotic agents with an antibody.
Figure 20 shows the Boc solid-phase synthesis of the conjugatable antimitotic agents
Figure 21 shows the Fmoc solid-phase synthesis of the conjugatable antimitotic agents.
Figure 22 shows the synthesis of the hydrophilic antimitotic drugs and their conjugates with
an antibody.
Figure 23 shows the synthesis of Tuv derivatives and the solid phase synthesis of
components of Mep-Ile-Tuv and NMe -Val-Ile-Tuv.
Figure 24 shows the synthesis of the antimitotic agents and their conjugation with an
antibody.
Figure 25 shows the solid phase synthesis of an antimitotic agent and its conjugate with an
antibody.
Figure 26 shows the solid-phase synthesis of antimitotic drugs and their conjugates with an
antibody.
Figure 27 shows the synthesis of transarylcyclopropylamines, transarylcyclopropyl-
carboxyl acids and transarylethylepoxidyl carboxyl acids.
Figure 28 shows the synthesis of alkene amino acids and alkyl epoxidyl amino acids
Figure 29 shows the synthesis of hydrophilic Tut analogs for the synthesis of the
hydrophilic prodrugs of antimitotic agents
Figure 30 shows the synthesis of the hydrophilic prodrugs of antimitotic agents for the
conjugation with a cell binding agent.
Figure 31 shows the synthesis of the hydrophilic prodrugs of antimitotic agents for the
conjugation with an antibody.
Figure 32 shows the synthesis of the hydrophilic prodrugs of antimitotic agents for the
conjugation with an antibody.
Figure 33 shows the in vitro cytotoxic effects of antiCD22 antibody-antimitotic agent
(TZ01~TZ09) conjugates with drug /antibody ratio (D/A) 3.0 ~ 4.3 on Ramos (Burkitt lymphoma
cell line). The cells were incubated with the conjugates for 5 days and the IC50 values are: TZ07,
D/A = 3.8, IC =24.0 pM; TZ02, D/A = 4.3, IC =30.8 pM; TZ03, D/A = 4.2, IC =36.7 pM;
50 50 50
TZ04, D/A = 4.0, IC =71.9 pM; TZ09, D/A = 3.5, IC =531 pM; TZ01, D/A = 3.3, IC =660
50 50 50
pM; TZ05, D/A = 3.2, IC =3.41 nM; TZ08, D/A = 3.0, IC =2.79 nM;
50 50
Figure 34 shows the cytotoxic effects of Trastuzumab-antimitotic agent (TZ03, TZ04, and
TZ07) conjugates with drug /antibody ratio (DAR) 3.5 ~ 4.0 on KPL-4 (breast cancer cell line).
huHerTZ03, DAR=4.0, IC = 0.09 nM; huHerTZ04, DAR=3.5, IC = 0.11 nM; huHer
50 50
TZ07, DAR=3.5, IC = 0.12 nM; huHerTZ03 plus huHer2 (1uM), IC > 20 nM; It shows that
50 50
Trastuzumab-TZ03 conjugate induces a specifically potent antipro-liferative effect with IC = 90
pM in the absence of unconjugated Trastuzumab and IC > 20 nM in the presence of 1
micromole concentration of Trastuzumab (to saturate the antigen binding) respectively. The
specificity window is > 222 (IC = 20 nM/ IC =0.09 nM)
50 50
Figure 35 shows the cytotoxic effects of antiCD22 antibody-antimitotic agent (TZ03, TZ04,
and TZ07) conjugates with drug /antibody ratio (D/A) 3.8 - 4.2 and of unconjugated CD22
antibody as well as of CD20 antibody (Rituximab) on BJAB (Burkitt lymphoma cell line).
huCD22-TZ03, D/A =4.2, IC =0.005 nM; huCD22-TZ04, D/A =4.0, IC =0.017 nM; huCD22-
50 50
TZ07, D/A =3.8, IC =0.019 nM; huCD22-TZ03 plus huCD22 (1 uM), IC =3.3 nM; huCD22-
50 50
TZ07 plus huCD22 (1 uM), IC =15 nM; It shows that the conjugate induces much more potent
antiproliferative effect –with IC =5 - 19 pM than the unconjugated antibodies with IC > 20 nM.
50 50
The specificity windows when used 1 micromole concentration of unconjugated CD22 antibody
to saturate the antigen binding are > 660 (IC = 3.3 nM/ IC =0.005 nM) for huCD22-TZ03
50 50
conjugate and > 790 (IC = 15 nM/ IC =0.019 nM) for huCD-TZ07 conjugate.
50 50
Table 1 displays the structure of the antimitotic drugs made through solid phase synthesis
and their molecular ion of mass spectra and in vitro cytotoxicity of these drugs against Ramos cell
(ATCC, a human Burkitt’s lymphoma cell).
Table 2 displays the structures of some experimental antibody-antimitotic agent conjugates.
. DETAILED DESCRIPTION OF THE INVENTION
.1 DEFINITIONS
"Alkyl" means an aliphatic hydrocarbon group which may be straight or branched having 1
to 8 carbon atoms in the chain or branched. "Branched" means that one or more lower alkyl
groups such as methyl, ethyl or propyl are attached to a linear alkyl chain. Exemplary alkyl
groups include methyl, ethyl, n-propyl, i-propyl, n-butyl, t-butyl, n-pentyl, 3-pentyl, octyl, nonyl,
decyl, cyclopentyl, cyclohexyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, 2,2-dimethylpentyl, 2,3-
dimethylpentyl, 3,3-dimethylpentyl, 2,3,4-trimethylpentyl, 3-methylhexyl, 2,2-dimethylhexyl,
2,4-dimethylhexyl, 2,5-dimethylhexyl, 3,5-dimethylhexyl, 2,4-dimethylpentyl, 2-methylheptyl, 3-
methylheptyl, n-heptyl, isoheptyl, n-octyl, and isooctyl. A C -C alkyl group can be unsubstituted
or substituted with one or more groups including, but not limited to, -C ~C alkyl, -O-(C ~C
1 8 1 8
alkyl), -aryl, -C(O)R', -OC(O)R', -C(O)OR', -C(O)NH , -C(O)NHR', -C(O)N(R') -NHC(O)R', -
S(O) R', -S(O)R', -OH, -halogen (F, Cl, Br or I), -N , -NH , -NH(R'), -N(R') and -CN; where
2 3 2 2
each R' is independently selected from -C ~C alkyl and aryl.
A "C ~C carbocycle" means a 3-, 4-, 5-, 6-, 7- or 8-membered saturated or unsaturated
non-aromatic carbocyclic ring. Representative C ~C carbocycles include, but are not limited to, -
cyclopropyl, -cyclobutyl, -cyclopentyl, -cyclopentadienyl, -cyclohexyl, -cyclohexenyl, -1,3-
cyclohexadienyl, -1,4-cyclohexadienyl, -cycloheptyl, -1,3-cycloheptadienyl, -1,3,5-
cycloheptatrienyl, -cyclooctyl, and -cyclooctadienyl. A C ~C carbocycle group can be
unsubstituted or substituted with one or more groups including, but not limited to, --C ~C alkyl, -
O-( C ~C alkyl), -aryl, -C(O)R', -OC(O)R', -C(O)OR', -C(O)NH , -C(O)NHR', -C(O)N(R') -
1 8 2 2
NHC(O)R', -S(O) R', -S(O)R', -OH, -halogen, -N , -NH , -NH(R'), -N(R') and -CN; where each
2 3 2 2
R' is independently selected from -C ~C alkyl and aryl.
A "C ~C carbocyclo" refers to a C ~C carbocycle group defined above wherein one of
3 8 3 8
hydrogen atoms on the carbocycle is replaced with a bond.
"Alkenyl” means an aliphatic hydrocarbon group containing a carbon-carbon double bond
and which may be straight or branched having 2 to 8 carbon atoms in the chain. Exemplary
alkenyl groups include ethenyl, propenyl, n-butenyl, i-butenyl, 3-methylbutenyl, n-
pentenyl, hexylenyl, heptenyl, octenyl.
"Alkynyl" means an aliphatic hydrocarbon group containing a carbon-carbon triple bond
and which may be straight or branched having 2 to 8 carbon atoms in the chain. Exemplary
alkynyl groups include ethynyl, propynyl, n-butynyl, 2-butynyl, 3-methylbutynyl, pentynyl, n-
pentynyl, hexylynyl, heptynyl, and octynyl.
“Heteroalkyl” is C ~C alkyl in which one to four carbon atoms are independently replaced
with a heteroatom from the group consisting of O, S and N.
"Aryl" or Ar refers to an aromatic or hetero aromatic group, composed of one or several
rings, comprising three to fourteen carbon atoms, preferentially six to ten carbon atoms. The term
of hetero aromatic group refers one or several carbon on aromatic group, preferentially one, two,
three or four carbon atoms are replaced by O, N, Si, Se, P or S, preferentially by O, S, N. The
term aryl or Ar also refers to a aromatic group, wherein one or several H atoms are replaced
13 13 13 13 14 13 13 13 14
independently by R , F, Cl, Br, I, OR , or SR , NR R , N=NR , N=R NR R NO
, , 2,
13 14 13 13 13 13 14 13 14 13 14 13 14 13 14
SOR R , SO R , SO R OSO R , PR R , POR R , PO R R , OPO R R , or PO R R
2 3 , 3 2 3 3
13 14
wherein R R are independently H, alkyl, alkenyl, alkinyl, heteroalkyl, aryl, arylalkyl, carbonyl,
or pharmaceutical salts.
“Halogen atom” refers to fluorine, chlorine, bromine or iodine atom; preferably fluorine and
chlorine atom.
“Heterocycle" refers to an aromatic or non-aromatic C ~C carbocycle in which one to four
3 14
of the ring carbon atoms are independently replaced with a heteroatom from the group of O, N, S
Se, and P. Preferable heteroatoms are oxygen, nitrogen and sulfur. Suitable heterocycles are also
disclosed in The Handbook of Chemistry and Physics, 76 Edition, CRC Press, Inc., 1995-1996, p. 2-
to 2-26, the disclosure of which is hereby incorporated by reference. Preferred non aromatic
heterocyclic include, but are not limited to pyrrolidinyl, pyrazolidinyl, imidazolidinyl, oxiranyl,
tetrahydrofuranyl, dioxolanyl, tetrahydro-pyranyl, dioxanyl, dioxolanyl, piperidyl, piperazinyl,
morpholinyl, pyranyl, imidazolinyl, pyrrolinyl, pyrazolinyl, thiazolidinyl, tetrahydrothiopyranyl,
dithianyl, thiomorpholinyl, dihydro-pyranyl, tetrahydropyranyl, dihydropyranyl, tetrahydro-pyridyl,
dihydropyridyl, tetrahydropyrinidinyl, dihydrothiopyranyl, azepanyl, as well as the fused systems
resulting from the condensation with a phenyl group.
The term “heteroaryl” or aromatic heterocycles refers to a 5 to 14, preferably 5 to 10 membered
aromatic hetero, mono-, bi- or multicyclic ring. Examples include pyrrolyl, pyridyl, pyrazolyl, thienyl,
pyrimidinyl, pyrazinyl, tetrazolyl, indolyl, quinolinyl, purinyl, imidazolyl, thienyl, thiazolyl,
benzothiazolyl, furanyl, benzofuranyl, 1,2,4-thiadiazolyl, isothiazolyl, triazoyl, tetrazolyl, isoquinolyl,
benzothienyl, isobenzofuryl, pyrazolyl, carbazolyl, benzimidazolyl, isoxazolyl, pyridyl-N-oxide, as
well as the fused systems resulting from the condensation with a phenyl group.
"Alkyl", "cycloalkyl", “alkenyl”, "alkynyl", "aryl", "heteroaryl", "heterocycle" and the like refer
also to the corresponding "alkylene", "cycloalkylene", "alkenylene", "alkynylene", "arylene",
"heteroarylene", "heterocyclene" and the likes which are formed by the removal of two hydrogen
atoms.
“Pharmaceutically” or “pharmaceutically acceptable” refer to molecular entities and
compositions that do not produce an adverse, allergic or other untoward reaction when
administered to an animal, or a human, as appropriate.
“Pharmaceutically acceptable excipient” includes any carriers, diluents, adjuvants, or
vehicles, such as preserving or antioxidant agents, fillers, disintegrating agents, wetting agents,
emulsifying agents, suspending agents, solvents, dispersion media, coatings, antibacterial and
antifungal agents, isotonic and absorption delaying agents and the like. The use of such media and
agents for pharmaceutical active substances is well known in the art. Except insofar as any
conventional media or agent is incompatible with the active ingredient, its use in the therapeutic
compositions is contemplated. Supplementary active ingredients can also be incorporated into the
compositions as suitable therapeutic combinations.
As used herein, "pharmaceutical salts" refer to derivatives of the disclosed compounds wherein
the parent compound is modified by making acid or base salts thereof. The pharmaceutically
acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the
parent compound formed, for example, from non-toxic inorganic or organic acids. For example, such
conventional non-toxic salts include those derived from inorganic acids such as hydrochloric,
hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic
acids such as acetic, propionic, succinic, tartaric, citric, methanesulfonic, benzenesulfonic, glucoronic,
glutamic, benzoic, salicylic, toluenesulfonic, oxalic, fumaric, maleic, lactic and the like. Further
addition salts include ammonium salts such as tromethamine, meglumine, epolamine, etc., metal
salts such as sodium, potassium, calcium, zinc or magnesium.
The pharmaceutical salts of the present invention can be synthesized from the parent compound
which contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can
be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount
of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two. Generally,
non-aqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. Lists of
suitable salts are found in Remington's Pharmaceutical Sciences, 17 ed., Mack Publishing Company,
Easton, PA, 1985, p. 1418, the disclosure of which is hereby incorporated by reference.
.2 DRUG-LINKER- BINDING LIGAND CONJUGATES
As stated above, this invention provides a cell surface binding molecule - antimitotic agent
conjugate of formula (I):
4 9 12 13
N 11
10
and pharmaceutical acceptable salts and solvates thereof,
Wherein T is a targeting or binding ligand; L is a releasable linker; is a linkage bond
that L connects to an atom inside the bracket independently; n is 1~20 and m is 1~10.
1 2 3 4
Inside the bracket is a potent antimitotic agent wherein R , R R and R are independently
C ~C of alkyl, heteroalkyl; C ~C of heterocyclic, carbocyclic, cycloalkyl, alkylcycloalkyl,
1 8 2 8
heterocycloalkyl; C ~C of aryl, Ar-alkyl, heteroalkylcycloalkyl, alkylcarbonyl; or two R's, such
1 2 1 3 2 3 3 4 5 6 12 13
as R R R R R R R R , R R , and R R can be 3~7 members of a carbocyclic, cycloalkyl, or
, , ,
1 3 4
heterocyclic, heterocycloalkyl ring system; Y is N or CH; In addition, R , R , and R can be H,
and R can be absent.
6 8 10
Wherein R R , R and R are independently selected from H and C ~C of alkyl or
, 1 4
heteroalkyl.
7 14 14 1 15 14 1 15
Wherein R is independently selected from H, R or -R C(=O)X R ; -R X R wherein
14 15
R and R are independently selected from C ~C of alkyl, heteroalkyl; C ~C of alkenyl,
1 8 2 8
alkynyl, heterocyclic, carbocyclic, cycloalkyl,; C ~C of aryl, heterocycloalkyl,
1 14
heteroalkylcycloalkyl, heteroaralkyl, alkylcarbonyl; X is selected from O, S, S-S, NH, or NR
9 14 14 14
Wherein R is independently H, -O-, -OR , -OC(=O)R -, -OC(=O)NHR -, -OC(=O)
14 15 14 14 15 14 15
R SSR -, OP(=O)(OR )-, or OR OP(=O)(OR ), wherein R R are independently
C ~C of alkyl, heteroalkyl; C ~C of alkenyl, alkynyl, heterocyclic, carbocyclic; C ~C of aryl,
1 8 2 8 3 8
cycloalkyl, alkylcycloalkyl, heterocycloalkyl, heteroalkylcycloalkyl, heteroaralkyl,
alkylcarbonyl.
11 14 14 16 14 2 16 14 2 2
Wherein R is independently H, R , -R C(=O)R , -R X R , -R C(=O)X , wherein X
14 14 14 14 14 14
is -O-, -S-, -NH-, -N(R )-, -O-R -, -S-R -, -S(=O)-R -, or -NHR -; R is C ~C of alkyl,
heteroalkyl; C ~C of alkenyl, alkynyl, heterocyclic, carbocyclic; C ~C of aryl, cycloalkyl,
2 8 3 8
alkylcycloalkyl, heterocycloalkyl, heteroalkylcycloalkyl, heteroaralkyl, alkylcarbonyl; R is H,
OH, R , or one to four amino acid units;
12 14
Wherein R is independently R , -O-, -OH, -S-, -SH, -NH , -NH-, =NH, =N-, =NNH ,
14 14 16 14 14 14 14
=NNH-, -NH(R ), -OR , -COR , -COOR -, -C(O)NH , -C(O)NHR , -SR , -S(=O)R , -
16 16 16 16 14
P(=O)(OR ) , -OP(=O)(OR ) , -CH OP(=O)(OR ) , -SO R . R is independently C ~C of
2 2 2
2 2 1 8
alkyl, heteroalkyl; C ~C of alkenyl, alkynyl, hetero-cyclic, carbocyclic; C ~C of aryl,
2 8 3 8
cycloalkyl, alkylcycloalkyl, heterocycloalkyl, heteroaralkyl, heteroalkylcycloalkyl, alkylcarbonyl.
16 14
R is H, OH, R or one to four amino acid units;
Wherein R is C ~C of alkyl, heteroalkyl, alkyl acid, alkyl amide, alkyl amine, or Ar;
1 10
Ar refers to an aromatic or hetero aromatic group, composed of one or several rings, comprising
four to ten carbon atoms, preferentially four to six carbon atoms. The term of hetero aromatic
group refers to an aromatic group that has one or several carbon atoms replaced by hetero atoms,
preferentially one, two or three carbon atoms replaced by O, N, Si, Se, P or S, more
preferentially O, S, N. The term aryl or Ar also refers to an aromatic group, wherein one or
17 16 16 16 17
several H atoms can be replaced independently by R , F, Cl, Br, I, OR , SR , NR R ,
16 16 16 17 16 17 16 16 16 16 17 16 17
N=NR , N= R , NR R , NO SOR R , SO R , SO R OSO R , PR R , POR R ,
2, ,
2 3 3
16 17 17 17 17 16 17
PO R R , OP(O)(OR ) , OCH OP(O)(OR ) , OC(O)OP(O)(OR ) , PO(OR )(OR ),
2 2 2 2 2
17 17 17 17 16 17
OP(O)(OR )OP(O)(OR ) , OC(O)R or OC(O)NHR , wherein R R are independently H,
C ~C of alkyl, heteroalkyl; C ~C of alkenyl, alkynyl, heterocyclic, carbocyclic; C ~C of aryl,
1 8 2 8 3 8
cycloalkyl, alkylcycloalkyl, heterocycloalkyl, heteroalkylcycloalkyl, heteroaralkyl, alkylcarbonyl
or C ~C glycosides, or pharmaceutical salts.
4 12
12 10 13
In addition, R can be H when R is not H, or when R is:
k=0~4
, ,
1 18 18 18
wherein Z is H, CH OP(O)(OR ) , C(O)OP(O)(OR ) , PO(OR ) ,
2 2 2 2
18 18 18 18 18
P(O)(OR )OP(O)(OR ) , C(O)R , C(O)NHR , SO (OR ), C ~C glycosides, or C ~C of
2 2 4 12 1 8
alkyl, carboxyalkyl, heterocyclic; R is H, C ~C of alkyl, carboxyalkyl, heteroalkyl; C ~C of
1 8 2 8
19 18
alkenyl, alkynyl, heterocyclic; C ~C of aryl, alkylcarbonyl; R is H, OH, NH , OSO (OR ),
3 8 2 2
18 18 18 18 18
XCH OP(O)(OR ) , XPO(OR ) XC(O)OP(O)(OR , XC(O) R , XC(O)NHR C ~C of
, ) ,
2 2 2 2 1 8
alkyl, carboxyalkyl, carboxylic acid derivative; C ~C of alkenyl, alkynyl, heterocyclic; C ~C
2 8 3 8
of aryl, alkylcarbonyl; or pharmaceutical salts; X is O, S, NH; Y and Y are N or CH
respectively.
12 11
Or R can be H when R is:
2 8 6 8
, , wherein X is O, S, N-R ; R and R are H,
C ~C of alkyl or heteroalkyl respectively.
Wherein the said conjugate of the invention specifically excludes the following structures:
24 25 26
Wherein R is H or CH ; R is alkyl or C(O)alkyl or C(O)aryl; R is H, C ~C alkyl,
3 1 5
28 27
C ~C alkenyl, C(=O)C ~C alkyl, or C(=O)C ~C alkenyl; R is H or C ~C alkyl; R is H, 1 to
2 5 1 5 2 5 1 5
3 substituents selected from halo, nitro, carboxylate or a derivative thereof, cyano, hydroxyl, alkyl,
29 29
haloalkyl, alkoxy, haloalkoxy, phenol protecting groups, prodrug moieties, or OR , where R is
30 30 30
substituted aryl, C(O)R , P(O)(OR )2, or SO R , where R is selected from H, alkyl, alkenyl,
cycloalkyl, heterocyclyl, aryl, and arylalkyl or a metal cation; T is a targeting or binding ligand;
L is a releasable linker.
In another embodiment, conjugates of antimitotic agents have the formula (II)
R 13
T 11
Y N R
R 10
(II)
and pharmaceutical acceptable salts and solvates thereof;
1 2 3 4 5 6 7 8 10 11 13
Wherein T L, n, m, Y, R , R , R , R , R , R , R , R , R , R and R are defined the same
as in the claim 1;
9 14 14 14
Wherein R is independently H, -OH, -OR , -OC(=O)R -, -OC(=O)NHR -, -OC(=O)
14 15 14 14 15
R SSR , OP(=O)(OR ) , or OR OP(=O)(OR )
2 2;
12 14 14 14
Wherein R is independently R , -OH, -SH, -NH , =NH, =NNH , -NH(R ), -OR , -
16 14 14 14 14 16 16
COR , -COOR -, C(O)NH , C(O)NHR , -SR , -S(=O)R , -P(=O)(OR ) , -OP(=O)(OR ) , -
2 2 2
16 16
CH OP(=O)(OR ) , -SO R ;
14 15 16 17
Wherein R , R , R and R are defined the same as in the claim 1;
12 10 13
In addition, R can be H when R is not H, or when R is:
k=0~4 k=0~4
, ,
1 18 18 18
wherein Z is H, CH OP(O)(OR ) , C(O)OP(O)(OR ) , PO(OR ) ,
2 2 2 2
18 18 18 18 18
P(O)(OR )OP(O)(OR ) , C(O)R , C(O)NHR , SO (OR ), C -C glycosides, C -C of alkyl,
2 2 4 12 1 8
carboxyalkyl, or C -C of heterocyclic; R is H, C -C of alkyl, carboxyalkyl; C -C of
3 8 1 8 2 8
heteroalkyl; C -C of alkenyl, alkynyl; C -C of aryl, heterocyclic, alkylcarbonyl; R is H, OH,
2 8 3 8
18 18 18 18 18
NH , OSO (OR ), XCH OP(O)(OR ) , XPO(OR ) XC(O)OP(O)(OR , XC(O) R ,
2 2 2 2 2 2
XC(O)NHR C -C of alkyl, carboxyalkyl, carboxylic acid derivative; C -C of alkenyl,
1 8 2 8
alkynyl; C -C of aryl, heterocyclic, alkylcarbonyl; or pharmaceutical salts; X is O, S, NH; Y
and Y are N or CH;
12 11
Or R can be H when R is:
2 8 8
wherein X is O, S, N-R ; R is H, C -C of alkyl or C -C of heteroalkyl;
In addition, R can be absent.
Illustrative classes of compounds of formula II have the structures:
IIa
H NH
O Aa
T S Y'
OPO(OH)
H X' O
HN H O
N O Y' S
IIh
H OAc
HN N O
X' O
NH O N
S Z'
23 N
T NH N O
S H CO H
22 H
23 H
T NH
R' O S H
IIo
wherein Aa is a natural or an unnatural amino acid; n is 1 ~ 20; q = 1~5; X , Y and
’ 22 22 23
Z are independently CH, O, S, NH, or NR ; R and R are independently C ~C of alkyl;
C ~C of alkenyl, alkynyl, heteroalkyl; C ~C of aryl, heterocyclic, carbocyclic, cycloalkyl,
2 8 3 8
alkylcycloalkyl, heterocycloalkyl, Ar-alkyl, heteroalkylcycloalkyl, heteroaralkyl, or -
(OCH CH ) -; R’ and R’’ are independently H or CH . . Inside the round brackets are the
2 2 n 3
antimitotic drugs and the inside square brackets are the antimitotic drug conjugated to a cell
binding agent T via a linker.
In another embodiment, a conjugate of a cell binding molecule-antimitotic agent has the
formula (III):
8 13
R 10
O 5 6 10
R R R R
(III)
1 2 3 4 5 6 8 9 10 11 12 13
wherein T, L, m, Y, R , R R R , R R R R R R R R and n are defined the
, , , , , , , , ,
same as in formular (I) and (II).
7 14 14 1 15 14 1 15
Wherein R is independently selected from H, -R - or -R C(=O)X R - or -R X R -
14 15
wherein R and R are independently C ~C of alkyl, heteroalkyl; C ~C of alkenyl, alkynyl;
1 8 2 8
C ~C of aryl, heterocyclic, carbocyclic, cycloalkyl, heterocycloalkyl, heteroaralkyl
1 14
heteroalkylcycloalkyl, alkylcarbonyl; X is selected from O, S, S-S, NH, or NR
Illustrative examples of compounds of formula (III) have the structures:
IIIa
IIIb
IIIc
IIId
IIIe
IIIf
IIIg
IIIh
IIIi
IIIj
’ ’ ’ 22 23
Wherein Ar, n, q, X , Y , Z , R , R , R’ and R’’ are defined the same as for formula IIa ~
IIr.
In another embodiment, a binding molecule-antimitotic agent conjugate has the formula (IV)
8 13
3 4 R
Y N 11
O 5 6
(IV)
1 2 3 4 5 6 7 8 10 11 12 13
wherein T, L, m, R , R R R , R R R R R R R R and n are defined the same
, , , , , , , , ,
as in formular (II).
9 14 14 14
Wherein R is independently H, -O-, -OR -, -OC(=O)R -, -OC(=O)NHR -, -
14 15 14 14 15
OC(=O)R SSR -, -OP(=O)(OR )O-, wherein R R are independently C ~C of alkyl,
, 1 8
heteroalkyl; C ~C of aryl, heteroaryl, heterocyclic, carbocyclic, cycloalkyl, alkylcycloalkyl,
heterocycloalkyl, heteroalkylcycloalkyl, heteroaralkyl, alkylcarbonyl or pharmaceutical salts.
Illustrative examples of compounds of formula (IV) have the structures:
O 22
S NH
R'' O
R' q N
COOH
IV-1
HN q H
22 O
NH O
2 IV-2
HN HO
R'' R' O
23 N
IV-2
IVc
IV-2
q H O
R'' R'
T R'
IV-3
q H O
T NH
O N O O
O O H
NH IV-4
’ 22 23
wherein Ar, Aa, n, q, X , Y’, R , R , R’ and R’’ are defined the same as for formula IIa ~
IIr.
In another embodiment, a binding molecule -antimitotic agent conjugate has the formula (V)
8 13
3 4 R R R
6 10
R R R
1 2 3 4 5 6 7 8 9 10 12 13
wherein T, L, m, Y, R , R R R R R R R R R R R and n are defined the same
, , , , , , , , , ,
as in formular (II).
11 14 14 17 14 2 17 14 2
Wherein R is independently H, -R -, -R C(=O)R -, - R X R -, - R C(=O)X -, wherein
R is independently H, OH, C ~C of alkyl; C ~C of alkenyl, alkynyl, heteroalkyl; C ~C of aryl,
1 8 2 8 3 8
arylene, heterocyclic, carbocyclic, heterocycloalkyl; or an amino acid, or two amino acid units;
2 14 14 14 14 14 14
X is -O-, -S-, -NH-, -N(R )-, -O-R -, -S-R -, -S(=O)-R -, or -NHR -; R is C ~C of alkyl,
heteroalkyl; C ~C of alkenyl, alkynyl; C ~C of aryl, heterocyclic, carbocyclic, cycloalkyl,
2 8 3 8
alkylcycloalkyl, heterocycloalkyl, heteroalkylcycloalkyl, heteroaralkyl, alkylcarbonyl.
Illustrative examples of compounds of formula (V) have the structures:
N 22
S 23
H R'
(HO) OP
N R'
N N S R
R' R'' H
V-2 H
OAc O
OPO(OH)
OPO(OH)
OPO(OH)
N Aa
22 S
H OAc
O H 22
V-6 O
O N N
V-7 O
Vg
O N N
H H n
R' R''
’ 22 23
Wherein Ar, Aa, n, q, X , R , R , R’ and R’’ are defined the same as for formula IIa ~ IIr.
In another embodiment, a conjugates of a cell binding-antimitotic agent have the formula
(VI)
3 13
R O R
R 10
(VI)
1 2 3 4 5 6 7 8 9 11 13
wherein T, L, m, Y, R , R R R R R R R R R R and n are defined the same as
, , , , , , , , ,
in formular (II).
12 14 14 14
Wherein R is independently R , -O-, -S-, -NH-, =N-, =NNH-, -N(R )-, -OR -,C(O)O-,
14 14 14 14 15 15
C(O)NH-, C(O)NR -, -SR -, -S(=O)R - -NHR -, -CH OP(=O)(OR )- , -P(=O)(OR )-,. -
14 14 15
OP(=O)(OR )O-, -SO R , R R are independently C ~C of alkyl, heteroalkyl; C ~C of
2 , 1 8 2 8
alkenyl, alkynyl; C ~C of aryl, heterocyclic, carbocyclic, cycloalkyl, alkylcycloalkyl,
heterocycloalkyl, heteroaralkyl, heteroalkylcycloalkyl, alkylcarbonyl.
Illustrative examples of compounds of formula VI have the following structures:
22 S
R' R''
VI-1
R' R''
VI-2
NH T
VI-3
N NH
N R''
N R' T
O HN
22 N
VI-3
H O O
COOH
VI-3'
O N R' R''
N NH
O R' R''
VI-4
Ar R''
OAc N
Ar 23
N R N
Ar R'
H O O
N 22
H Ar
VI-5
R' R''
N S N R
N 22 T
VI-6
VI-7
’ 22 23
Wherein Ar, Aa, n, q, X , R , R , R’ and R’’ are defined the same as for formula IIa ~ IIr.
In another embodiment, the conjugates of the cell-surface binding molecule-antimitotic
agents have the formula (VII)
R 13
O S 10
(VII)
wherein T, L, m, Y, R , R R R R R R R R R R and n are defined the same as
1 2, 3, 4, 5, 6, 7, 8, 9, 11, 12
in formular (II).
Wherein R is C ~C of alkyl, heteroalkyl, alkyl acid, alkyl amide, alkyl amine, or Ar; Ar
1 10
refers to a aromatic or hetero aromatic group, composed of one or several rings, comprising four
to ten carbon, preferentially four to six carbon atoms. The term of hetero aromatic group refers
one or several carbon on aromatic group, preferentially one, two or three carbon atoms are
replaced by O, N, Si, Se, P or S, preferentially O, S, N. The term aryl or Ar also refers to a
aromatic group, wherein one or several H atoms are replaced independently by R , F, Cl, Br, I,
16 16 16 18 16 16 16 18 16 18 16 16 16
OR , SR , NR R , N=NR , N=R NR R NO SOR R , SO R , SO R OSO R ,
, , 2, 2 3 , 3
16 18 16 18 16 18 16 18 16 18 16 18
PR R , POR R , PO R R , OPO R R , or PO R R wherein R R are independently H,
2 3 3 ,
C ~C of alkyl; C ~C of alkenyl, alkynyl, heteroalkyl; C ~C of aryl, heterocyclic, carbocyclic,
1 8 2 8 3 8
cycloalkyl, alkylcycloalkyl, heterocycloalkyl, heteroaralkyl, heteroalkylcycloalkyl, alkylcarbonyl;
or C ~ C glycosides; or pharmaceutical salts.
4 12
12 13
In addition, R can be H when R is:
Y OZ
Y 18
k = 0 ~4
k=0~4
k = 0~4
, , .
1 18 18 18
wherein Z is H, CH OP(O)(OR )2, C(O)OP(O)(OR ) , PO(OR ) ,
2 2 2
18 18 18 18 18
PO(OR )OPO(OR ) , C(O)R , C(O)NHR , SO (OR ), C ~C glycosides, or C ~C of alkyl,
2 2 4 12 1 8
carboxyalkyl, heterocyclic; R is H, C ~C of alkyl, carboxyalkyl, heteroalkyl; C ~C of
1 8 2 8
19 18
alkenyl, alkynyl, heterocyclic; C ~C of aryl, alkylcarbonyl; R is H, OH, NH , OSO (OR ),
3 8 2 2
18 18 18 18 18
XCH OP(O)(OR ) , XC(O)OP(O)(OR ) , XPO(OR ) , XC(O)R , XC(O)NHR , C ~C of
2 2 2 2 1 8
alkyl, carboxyalkyl, carboxylic acid derivative; C ~C of alkenyl, alkynyl, heterocyclic; C ~C
2 8 3 8
of aryl, alkylcarbonyl; or pharmaceutical salts; X is O, S, NH; Y and Y are N or CH
respectively.
12 11
Or R can be H when R is:
2 8 8
wherein X is O, S, N-R ; R is H, C -C of alkyl or C -C of heteroalkyl;
Illustrative examples of compounds of formula VII have the following structures:
(HO) OPO
H NH
q H N
O OAc
N 22
O NH
2 H n
VII-1
VIIa
R' R''
R' R''
VII-2
VIIb
OPO(OH)
OAc 2
N S H
S Aa
O R'
24 O R''
VII-3
VIIc
OPO(OH)
OAc R' R''
R'' O n
VII-4 OH
VIId
OPO(OH)
S H O
VII-4
VIIe
OPO(OH)
N O T
24 H N
VII-4 OH 2 H
VIIf
OPO(OH)
O OAc
N O T
OH n
VII-4 O
VIIg
OSO H
N O T
VII-5 OH n
VIIh
O OH
H O OAc
X' 22
N O T
VII-6 OH n
VIIi
OSO H
R' T
O H H
R' R'' n
24 O
VII-5 OH
VIIj
O OH
H OAc OH O
N 23
R' T
O H R' H
VII-6
VIIk
O OH
H OAc
q OH
24 O
VII-6
R OH
VIIl
OSO H
H OAc
VII-5 OH
VIIm
OPO(OH)
H OAc
HN 22
VII-7
VIIn
NH H
O OAc
N O T
O HN
O NH
VII-8 O
VIIo
VIIP
H OAc
X' O
O S O
O S n
VII-9
VIIq
H OAc
O O N
H H N
VII-9 R
VIIr
H OAc
HN R
24 OH
VII-10
VIIs
H OAc
q O N
24 O
VII-11 R H N
VIIt
’ 22 23
Wherein Ar, Aa, n, q, X , R , R , R’ and R’’ are defined the same as for formula IIa ~ IIf;
R is H or CH .
In another embodiment, the synthetic routes to produce the antimitotic agents and their
conjugation to a cell-surface receptor binding molecules of the present invention are exampled,
but not limited to, shown in figures 1-32.
In another embodiment, the releasable linker (L) is a chain of atoms selected from C, N, O,
S, Si, and P that covalently connects the cell-surface binding ligand (T) to the potent antimitotic
agents. The linker may have a wide variety of lengths, such as in the range from about 2 to about
100 atoms. The atoms used in forming the linker may be combined in all chemically relevant
ways, such as forming alkylene, alkenylene, and alkynylene, ethers, polyoxyalkylene, esters,
amines, imines, polyamines, hydrazines, hydrazones, amides, ureas, semicarbazides, carbazides,
alkoxyamines, alkoxylamines, urethanes, amino acids, acyloxylamines, hydroxamic acids, and
many others. In addition, it is to be understood that the atoms forming the releasable linker (L)
may be either saturated or unsaturated, or may be radicals, or may be cyclized upon each other to
form divalent cyclic structures, including cyclo alkanes, cyclic ethers, cyclic amines, arylenes,
heteroarylenes, and the like in the linker.
The term releasable linker refers to a linker that includes at least one bond that can be
broken under physiological conditions, such as a pH-labile, acid-labile, base-labile, oxidatively
labile, metabolically labile, biochemically labile, or enzyme-labile bond. It is appreciated that
such physiological conditions resulting in bond breaking do not necessarily include a biological
or metabolic process, and instead may include a standard chemical reaction, such as a hydrolysis
or substitution reaction, for example, an endosome having a lower pH than cytosolic pH, and/or
disulfide bond exchange reaction with a intracellular thiol, such as the amillimolar range of
abundant of glutathione inside the malignant cells.
The releasable linker L of conjugates may have the formula: --Ww—(Aa)r--Vv-- wherein: -
-W-- is a Stretcher unit; w is 0 or 1; each --Aa-- is independently an Amino Acid unit; r is
independently an integer ranging from 0 to 12; --V-- is a Spacer unit; and v is 0, 1 or 2.
The Stretcher unit (--W--), when present, links a targeted binding molecular unit (T) to an
amino acid unit (--Aa--), or links V when an Aa is not present. The Stretcher unit W may
independently contain a self-immolative spacer, peptidyl units, a hydrazone bond, disulfide or
thiolether bonds. In this regard a binding molecular (T) has a functional group that can form a
bond with a functional group of a Stretcher. Useful functional groups that can be present on a
binding molecular, either naturally or via chemical manipulation include, but are not limited to,
sulfhydryl (--SH), amino, hydroxyl, carbonyl, the anomeric hydroxyl group of a carbohydrate,
and carboxyl. Preferred functional groups are sulfhydryl, carboxy and amino. Sulfhydryl groups
can be generated by reduction of an intramolecular disulfide bond of a Ligand. Alternatively,
sulfhydryl groups can be generated by reaction of an amino group of a lysine moiety of a binding
molecular using 2-iminothiolane (Traut's reagent) or thiolactone or another sulfhydryl generating
reagent, such as modifies T with a disulfide bond linker, or a thiol ester following by reduction or
hydrolysis respectively.
Illustrative examples of W linked to T have the structures:
T N T 20
S R N T
NHNH
O R' R'' H
; ; ;
R N T
NHNH HN O R N T
; ; ;
S O NH+ O
20
R N T R N T
H ; H ; H ;
R'' R' 20
S R N N
N O N C T
S S T H H H
; ; ;
O O 21
N T R N T S
H H O
; ; ;
20
R S R S
O H H
20
N R N R
N T N T
H O O
Ar O O
; ;
NH+ O
NHNH R N
T
H ; ; ;
20
NHNH
, , ,
, , ,
, ,
21
, wherein R and R are selected
from –C ~C alkylene-, -C ~C carbocyclo-, -O-( C ~C alkyl)-, -arylene-, -C ~C alkylene-
1 9 1 7 1 8 1 9
arylene-, -arylene, -C ~C alkylene-, -C ~C alkylene-(C ~C carbocyclo)-, -(C ~C carbocyclo)-
1 9 1 9 1 8 3 7
C ~C alkylene-, -C ~C heterocyclo-, -C ~C alkylene-(C ~C heterocyclo)-, -(C ~C
1 9 3 8 1 10 3 8 3 8
heterocyclo)- C ~C alkylene-, -(CH CH O) -, -(CH(CH )CH O) -, and -(CH CH O) -CH -; k is
1 9 2 2 k 3 2 k 2 2 k 2
an integer ranging from 1-20.; R’ and R’’ are independently H or CH .
In another embodiment, conjugation of W to T covalently as illustrated above can be via
various chemical reactions.
Examples of the formation of amide linkages:
+ H N T N T
R' R''
O O O O
H N T
+ N T
2 NNH R
Wherein the Stretcher unit contains a reactive site of E, which can form an amide bond with
a primary or secondary amino group of a Ligand. Example of the reactive E, includes, but is not
limited to, such as hydroxysuccinimidyl esters (NHS, Sulfo-NHS, etc), 4-nitrophenyl esters,
pentafluorophenyl esters, tetrafluorophenyl (includes sulfo-tetrafluorophenyl) esters, anhydrides,
acid chlorides, sulfonyl chlorides, isocyanates and isothiocyanates.
Examples of thiol ether or disulfide bond linkages:
HS T
2 20
S HS
H N T
N T O
R'' R'
R'' R' S
R'' R'
R'' R'
+ HS T
S S T
Wherein the Stretcher unit contains a sulfhydryl reactive site, which can form a thiol ether
or disulfide bond with a thiol group which is generated by reduction of an intramolecular
disulfide bond of the binding ligand T, or generated by a chemical modification on the binding
ligand T.
In yet another aspect of the invention, the reactive group of the Stretcher contains a reactive
site that is reactive to an aldehyde (--CHO) or a ketone (-C(=O)R) group that can be chemically
modified on a binding molecular T. For example, a carbohydrate on a binding molecular T can be
mildly oxidized using a reagent such as sodium periodate to generate an aldehyde or a ketone (-
C(=O)R) group; or an amine on an amino acid at the N-termini of antibodies (or proteins or
peptides ) can react with pyridoxal 5’-phosphate (PLP) in a buffer solution to introduce ketone
groups (Scheck & Francis, ACS Chem. Biol. 2007, 2, 247-251). The resulting (--C=O) unit can
be condensed with a Stretcher that contains a functionality such as a hydrazide, an oxime, a
primary or secondary amine, a hydrazine, a thiosemicarbazone, a hydrazine carboxylate, and an
arylhydrazide.
Examples of the conjugation of the hydrazone, or the oxime or imine linkages:
T + PLP (or NaIO )
21 20 21
S R N R NH S R N R N
25
T + PLP (or NaIO )
S O C N N
N NH S 20
R 25 R 25
R H R
21 25
wherein R and R are described above, R is an organic substituent of an amino acid.
In another aspect of the invention, the Stretchers (which may contain a spacer V and/or an
amino acid) can be linked to the binding molecules (T), followed by conjugation of a potent
antimitotic agent to the binding molecule-stretcher moiety in an aqueous buffered solution.
Examples of these kinds of two-step conjugations (a drug linked to R is omitted here):
26 26 O
O 20
H N T 16 S S R
2 20 T
S SH
E N 16
R' R'' H
R' R'' R''
H N T R
E N R
N N T
O O O Ar
NHNH
H N T
20
Ar E Ar N T 16 20 N
20 H
H N T R 16
N N T
N N T
O Br
O O 16
S
20 H
H N T R
N R R
N N T
N N T
Br 16
H N T T
2 J R T
wherein E includes, but is not limited to, such as hydroxysuccinimidyl esters (NHS, Sulfo-
NHS, etc), 4-nitrophenyl esters, pentafluorophenyl esters, tetrafluorophenyl (includes sulfo-
tetrafluorophenyl) esters, anhydrides, acid chlorides, sulfonyl chlorides, isocyanates and
16
isothiocyanates. R’ and R’’ are independently H or CH ; R , R and Ar are defined in various
embodiment through out this inventions; R is H, or F, or NO independently; J is F, Cl, Br, I,
tosylate (TsO) or mesylate (MsO) independently and wherein bears at least one
antimitotic agent/drug .
In another aspect of the invention, the Stretchers can be linked to a potent antimitotic agent
first, followed by conjugation of the binding molecules (T) in an aqueous pH 3 ~ 10 (preferably
pH 5 ~ 8.5) buffered solution containing up to 50% of organic cosolvents. Examples of these
kinds of two-step conjugations:
20 H N T
S SH 16
R 2 16 20
R R S R
S R S R
R' R'' R'
R' R''
R
16 20
R R E
N N H N T
16 N
Ar O O
O Ar
H N T
16 NHNH
R 20
16 N
NHN 16 20
Ar E E
R NHN R
R
R 20
SH R 16
16 E
H N T H
N E R 2
O 16
O R O
S S
16 R H N T H
R E 2 R
O 16
S O 16 S T
O O O O
R SH 16
H N T
J R S
wherein E includes, but is not limited to, such as hydroxysuccinimidyl esters (NHS, Sulfo-
NHS, etc), 4-nitrophenyl esters, pentafluorophenyl esters, tetrafluorophenyl (includes sulfo-
tetrafluorophenyl) esters, anhydrides, acid chlorides, sulfonyl chlorides, isocyanates and
16 20
isothiocyanates. R’ and R’’ are independently H or CH ; R , R and Ar are defined in various
embodiment through out this inventions; R is H, or F, or NO independently; J is F, Cl, Br, I,
tosylate (TsO) or mesylate (MsO) independently and wherein 16 bears at least one
antimitotic agent/drug.
The Amino Acid unit (--Aa--), when present, links the Stretcher unit to the Spacer unit if the
Spacer unit is present, links the Stretcher unit to the antimitotic agent unit if the Spacer unit is
absent, and links the binding molecule (T) unit to the antimitotic agent unit if the Stretcher unit
and Spacer unit are absent. --(Aa)r-- is a natural or unnatural amino acid, dipeptide, tripeptide,
tetrapeptide, pentapeptide, hexapeptide, heptapeptide, octapeptide, nonapeptide, decapeptide,
undecapeptide or dodecapeptide unit, and r is an integer ranging from 0 to 12. The term amino
acid as used herein refers generally to aminoalkylcarboxylate, where the alkyl radical is
optionally substituted, such as with alkyl, acyl, hydroxy alkyl, sulfhydrylalkyl, aminoalkyl,
carboxyalkyl, and the like, The structures of the natural and unnatural amino acids and peptides
are described in the book: G. C. Barrett and D. T. Elmore, “Amino Acid and Peptide”, Cambridge
University Press, 2004. In addition, amino acid refers to beta, gamma, and longer amino acids
with intra chain containing methyl, benzyl, hydroxymethyl, thiomethyl, carboxyl, carboxylmethyl,
guanidinopropyl, and the like. More preferably the amino acid is selected from asparagine,
aspartic acid, cysteine, glycine, glutamic acid, lysine, glutamine, arginine, serine, ornithine,
threonine, and the like.
The Amino Acid unit of the Invention can be enzymatically cleaved by one or more
enzymes, including a tumor-associated protease, to liberate the antimitotic agent, which in one
embodiment is protonated in vivo upon release to provide an antimitotic agent.
The Spacer unit (--V--), when present, links an Amino Acid unit to the antimitotic agent
when an Amino Acid unit is present. Alternately, the Spacer unit links the Stretcher unit to
antimitotic agent when the Amino Acid unit is absent. The Spacer unit also links antimitotic agent
to the binding molecule (T) when both the Amino Acid unit and Stretcher unit are absent. The
spacer linkers may contain function groups that substantially increase the water solubility,
biological transport, preferential renal clearance, uptake, absorption, biodistribution, and/or
bioavailability of the conjugate are described herein. Spacer units are of two general types: self-
immolative and non self-immolative. A non self-immolative Spacer unit is one in which part or
all of the Spacer unit remains bound to antimitotic agent after cleavage, particularly enzymatic, of
an Amino Acid unit from the antimitotic agent-Linker- binding molecule conjugate or the
antimitotic agent-Linker Compound.
Examples of the self-immolative spacer linkers:
Z * Z *
Z * v
Y Z *
Y Z *
Y Z *
; ;.
; X Y*; wherein the (*) atom is the point of attachment of
additional spacer or releasable linker units, the antimitotic agent, and/or the binding molecule (T);
X, Y and Z are independently NH, O, or S; Z is H, NH, O or S independently. v is 0 or 1; Q is
17 17 17 18 17
independently H, OH, C ~C alkyl, (OCH CH ) F, Cl, Br, I, OR , or SR , NR R , N=NR ,
1 6 2 2 n
17 17 18 17 18 17 17 17 17 18 17 18 17 18
N=R NR R NO SOR R , SO R , SO R OSO R , PR R , POR R , PO R R ,
, , 2, 2 3 , 3 2
17 18) 17 18 17 18
OPO(OR )(OR , or OCH PO(OR (OR ) wherein R R are independently H, C ~C of alkyl;
2 , 1 8
C ~C of alkenyl, alkynyl, heteroalkyl; C ~C of aryl, heterocyclic, carbocyclic, cycloalkyl,
2 8 3 8
heterocycloalkyl, heteroaralkyl, alkylcarbonyl; or pharmaceutical cation salts
Examples of the non-self-immolative spacer linkers:
(CH ) CO(OCH CH ) OCH (CH ) CON(CH CH O) COCH
2 m 2 2 n 3 2 m 2 2 n 3
*(CH CH O) *
2 2 n *CH* *CH*
; ; ;
(CH ) (OCH CH ) OCOCH
(CH ) CO(OCH CH ) OCOCH
2 m 2 2 n 3 2 m 2 2 n 3
*CH* H O
; *CH* ; ; ;
H N HS
HO HO
H N HS 2
m m m
P * * *
*N *N
* * *
* * *
OH O O O O O
; ; ; ; ; ; ;
17 17
COOH
COOH COOH
COOH
* *N
m m m O
O ; ; ; ; ; ;
* N* *
*X Y*
* * *
N* N*
O m m
m m m *N
; ; ; ; ; ; ;
COOH
O Ar
COOH
*X Y
* *X Y
S* m
O m H
; ; ; ; ;
R' H
Q Q OH
R' R'' N
*X Y* *X Y S*
; ; ; ; ;
H O O O
HOOC
R' R'' COOH
COOH
; ; ; ;
COOH
COOH
O COOH O
N N OH
N OH
COOH COOH
COOH
*N * *N
O O O
; ; ; ; ;
COOH
(OCH CH ) OCH
N (CH CH O) CH
2 2 n 3
2 2 n 3
COOH
*N * *
; O ; ;
H OH
N(CH CH O) CH
2 2 n 3 N
H N *
*N *
*N * *N *
HO *
O O HO O
; ; ; ;
HN HN HN
O O S
HO m O
OH O
*N * *N * *N
O O O
; ; ; ;
SO H
HO OH
HO OH
O HN N
COOH
O NHAc
m m m
*N * *N * *N *
O O O
; ; ;
SO H
HN HN HN
m m P
O OH
*N * *
*N * *N
H OH
O O O
; ; ;
Where the (*) atom is the point of attachment of additional spacer or releaseable linkers, the
antimitotic agents, and/or the binding molecules; m is 1~10; n is 1~20.
The binding molecule (T) may be of any kind presently known, or that become known,
molecule that binds to, complexes with or reacts with a moiety of a cell population sought to be
therapeutically or otherwise biologically modified. The binding molecule unit acts to deliver the
antimitotic agents to the particular target cell population with which the binding molecule (T)
reacts.
The cell binding agents include, but are not limited to, large molecular weight proteins
such as, for example, full-length antibodies (polyconal and monoclonal antibodies); single chain
antibodies; fragments of antibodies such as Fab, Fab', F(ab') , F [Parham, J. Immunol. 131,
2 v,
2895-2902 (1983)], fragments produced by a Fab expression library, anti-idiotypic (anti-Id)
antibodies, CDR's, and epitope-binding fragments of any of the above which immuno-
specifically bind to cancer cell antigens, viral antigens or microbial antigens; interferons (such
as type I, II, III); peptides; lymphokines such as IL-2, IL-3, IL-4, IL-6, GM-CSF, interferon-
gamma (IFN-γ); hormones such as insulin, TRH (thyrotropin releasing hormones), MSH
(melanocyte-stimulating hormone), steroid hormones, such as androgens and estrogens,
melanocyte-stimulating hormone (MSH); growth factors and colony-stimulating factors such as
epidermal growth factors (EGF), granulocyte-macrophage colony-stimulating factor (GM-CSF),
transforming growth factors (TGF), such as TGFα, TGFβ, insulin and insulin like growth
factors (IGF-I, IGF-II) G-CSF, M-CSF and GM-CSF [Burgess, Immunology Today, 5, 155-158
(1984)]; vaccinia growth factors (VGF); fibroblast growth factors (FGFs); smaller molecular
weight proteins, poly-peptide, peptides and peptide hormones, such as bombesin, gastrin,
gastrin-releasing peptide; platelet-derived growth factors; interleukin and cytokines, such as
interleukin-2 (IL-2), interleukin-6 (IL-6), leukemia inhibitory factors, granulocyte-macrophage
colony-stimulating factor (GM-CSF); vitamins, such as folate; apoproteins and glycoproteins,
such as transferrin {O'Keefe et al, 260 J. Biol. Chem. 932-937 (1985)}; sugar-binding proteins
or lipoproteins, such as lectins; cell nutrient-transport molecules; and small molecular inhibitors,
such as prostate-specific membrane antigen (PSMA) inhibitors and small molecular tyrosine
kinase inhibitors (TKI), non-peptides or any other cell binding molecule or substance, such as
bioactive polymers (Dhar, et al, Proc. Natl. Acad. Sci. 2008, 105, 17356-61); dendrimers (Lee,
et al, Nat. Biotechnol. 2005, 23, 1517-26; Almutairi, et al; Proc. Natl. Acad. Sci. 2009, 106,
685-90); nanoparticles (Liong, et al, ACS Nano, 2008, 19, 1309-12; Medarova, et al, Nat. Med.
2007, 13, 372-7; Javier, et al, Bioconjugate Chem. 2008, 19, 1309-12); liposomes (Medinai, et
al, Curr. Phar. Des. 2004, 10, 2981-9); viral capsides (Flenniken, et al, Viruses Nanotechnol.
2009, 327, 71-93). In general monoclonal antibodies are preferred as a cell-surface binding
agent if an appropriate one is available.
Prior to conjugating with the antimitotic agents of this invention, the binding molecules
can be modified through attachment of a more specific peptide, a protein, or a drug, or the other
functional molecules with a heterobifunctional cross linker such as with linkers of Amine-to-
Nonselective (succinimidyl (NHS)-diazirine (SDA), NHS ester /Azide), Amine-to-Sulfhydryl
(NHS ester/maleimide, NHS ester/ pyridyldithiol, NHS esters/ haloacetyl), Sulfhydryl-to-
Carbohydrate (Maleimide/Hydrazide, Pyridyldithiol /Hydrazide), Hydroxyl-to-Sulfhydryl
(Isocyanate / Maleimide), Amine-to-DNA (NHS ester/ Psoralen), Amine-to-Carboxyl
(Carbodiimide).
In the SDA linkage modification, the NHS ester of a SDA linker reacts with primary an
amine group of a binding molecule backbone in pH 6~9 buffer to form a stable amide bond
upon release of NHS. Then photoactivation of the diarzirine with long-wave UV light (330-
370nm) creates a reactive carbene intermediate that can react with an amine group of a more
specific peptide or a protein or the other functional molecule. The order of these two steps can
be different as this: an amine group of a functional molecule reacts with a SDA linker first
following by photoactive reaction of a binding molecule with long-wave UV light (330-370nm).
The SDA crosslinkers can be cleavable (with a disulfide bond inside such as SDAD linker).
In the NHS ester /Azide linkage modification, the NHS ester of the linker reacts with
primary an amine group of a binding molecule backbone in pH 6~9 buffer to form a stable
amide. Then an alkynyl group on a more specific peptide or a protein or the other functional
molecule reacts to the azide on the other side of the linker via Azide-Alkyne Huisgen
Cycloaddition to form a 1,2,3-triazole linkage (click chemistry). Also, the NHS ester of the
linker reacts with primary an amine group of a functional molecule in pH 6~9 buffer to form a
stable amide. Then an alkynyl group being linked on a binding molecule reacts to the azide on
the other side of the linker via 5 Azide-Alkyne Huisgen Cycloaddition to form a 1,2,3-triazole
linkage.
In the Amine-to-Sulfhydryl linkage modification, the NHS ester of the linker reacts with a
primary amine group of a binding molecule backbone in pH 6~9 buffer to form a stable amide
bond. Then a sulfhydryl on a more specific peptide or a protein or the other functional molecule
reacts to the maleimide, or pyridyldithiol, or haloacetyl on the other side of the Amine-
tosulfhydryl linker at pH 4.5 ~ 8.5 to form a thioether or a disulfide bond. The conjugation with
the Amine-to-Sulfhydryl linker can be in different orders. For instance, an amine group of a
functional molecule can be reacted with the linker to form an amide bond first, following by
reaction with a sulfhydryl on a binding molecule. Also a sulfhydryl group of a functional
molecule can be reacted with the linker to form a thioether or a disulfide bond at pH 4.5 ~ 7 first,
following by reaction with an amine group on a binding molecule at pH 6 ~ 9 to form an amide
bond.
In the Sulfhydryl-to-Carbohydrate linkage modification, the sulfhydryl group of a binding
molecule can be reacted with the maleimide or the pyridyldithiol on the linker to form a
thioether or a disulfide bond at pH 4.5 ~ 8 first, Then a carbonyl (aldehyde/ketone) group on a
functional molecule reacts with the hydrazide to form an hydrazone bond. Also the sulfhydryl
group on a functional molecule can react with the linker to form a thioether or a disulfide bond
at pH 4.5 ~ 8 first, following by reaction with a carbohydrate, or an oxidized carbohydrate, or an
carbonyl (aldehyde/ketone) group on a binding molecule form an hydrazone bond.
In the Hydroxyl-to-Sulfhydryl linkage modification, the sulfhydryl group of a binding
molecule can be reacted with the maleimide or the pyridyldithiol on the linker to form a
thioether or a disulfide bond at pH 6 ~ 8 first, Then a hydroxy group on a functional molecule
reacts with the isocyanate on the linker to form a carbamate bond at pH 8 ~9. Also the
sulfhydryl group on a functional molecule can react with the linker to form a thioether or a
disulfide bond at pH 6~ 8 first, following by reaction with a hydroxy on a binding molecule
form a carbamate bond at pH 8~9.
In yet another aspect of the invention, the production of antibodies used in the present
invention involves in vivo or in vitro procedures or combinations thereof. Methods for
producing polyclonal anti-receptor peptide antibodies are well-known in the art, such as in U.S.
Pat. No. 4,493,795 (to Nestor et al). A monoclonal antibody is typically made by fusing
myeloma cells with the spleen cells from a mouse that has been immunized with the desired
antigen (Köhler, G.; Milstein, C. (1975). Nature 256: 495-497). The detailed procedures are
described in “Antibodies--A Laboratory Manual”, Harlow and Lane, eds., Cold Spring Harbor
Laboratory Press, New York (1988), which is incorporated herein by reference. Particularly
monoclonal antibodies are produced by immunizing mice, rats, hamsters or any other mammal
with the antigen of interest such as the intact target cell, antigens isolated from the target cell,
whole virus, attenuated whole virus, and viral proteins. Splenocytes are typically fused with
myeloma cells using polyethylene glycol (PEG) 6000. Fused hybrids are selected by their
sensitivity to HAT (hypoxanthine-aminopterin-thymine). Hybridomas producing a monoclonal
antibody useful in practicing this invention are identified by their ability to immunoreact
specified receptors or inhibit receptor activity on target cells.
A monoclonal antibody used in the present invention can be produced by initiating a
monoclonal hybridoma culture comprising a nutrient medium containing a hybridoma that
secretes antibody molecules of the appropriate antigen specificity. The culture is maintained
under conditions and for a time period sufficient for the hybridoma to secrete the antibody
molecules into the medium. The antibody-containing medium is then collected. The antibody
molecules can then be further isolated by well-known techniques, such as using protein-A affinity
chromatography; anion, cation, hydrophobic, or size exclusive chromatographies (particularly by
affinity for the specific antigen after Protein A, and sizing column chromatography);
centrifugation, differential solubility, or by any other standard technique for the purification of
proteins.
Media useful for the preparation of these compositions are both well-known in the art and
commercially available and include synthetic culture media. An exemplary synthetic medium is
Dulbecco's minimal essential medium (DMEM; Dulbecco et al., Virol. 8:396 (1959))
supplemented with 4.5 gm/l glucose, 20 mm glutamine, 20% fetal calf serum and with an anti-
foaming agent, such as polyoxyethylene-polyoxypropylene block copolymer.
In addition, antibody-producing cell lines can also be created by techniques other than
fusion, such as direct transformation of B lymphocytes with oncogenic DNA, or transfection with
an oncovirus, such as Epstein-Barr virus (EBV, also called human herpesvirus 4 (HHV-4)) or
Kaposi's sarcoma-associated herpesvirus (KSHV). See, U.S. Pat. Nos. 4,341,761; 4,399,121;
4,427,783; 4,444,887; 4,451,570; 4,466,917; 4,472,500; 4,491,632; 4,493,890. A monoclonal
antibody may also be produced via an anti-receptor peptide or peptides containing the carboxyl
terminal as described well-known in the art. See Niman et al., Proc. Natl. Acad. Sci. USA, 80:
4949-4953 (1983); Geysen et al., Proc. Natl. Acad. Sci. USA, 82: 178-182 (1985); Lei et al.
Biochemistry 34(20): 6675-6688, (1995). Typically, the anti-receptor peptide or a peptide analog
is used either alone or conjugated to an immunogenic carrier, as the immunogen for producing
anti-receptor peptide monoclonal antibodies.
There are also a number of other well-known techniques for making monoclonal antibodies
as binding molecules in this invention. Particularly useful are methods of making fully human
antibodies. One method is phage display technology which can be used to select a range of human
antibodies binding specifically to the antigen using methods of affinity enrichment. Phage display
has been thoroughly described in the literature and the construction and screening of phage
display libraries are well known in the art, see, e.g., Dente et al, Gene. 148(1):7-13 (1994); Little
et al, Biotechnol Adv. 12(3):539-55 (1994); Clackson et al., Nature 352:264-628 (1991); Huse et
al., Science 246:1275-1281 (1989).
Moncolonal antibodies derived by hybridoma technique from another species than human,
such as mouse, can be humanized to avoid human anti-mouse antibodies when infused into
humans. Among the more common methods of humanization of antibodies are complementarity-
determining region grafting and resurfacing. These methods have been extensively described, see
e.g. U.S. Pat. Nos. 5,859,205 and 6,797,492; Liu et al, Immunol Rev. 222:9-27 (2008); Almagro
et al, Front Biosci. 1;13:1619-33 (2008); Lazar et al, Mol Immunol. 44(8):1986-98 (2007); Li et
al, Proc. Natl. Acad. Sci. U S A. 103(10):3557-62 (2006) each incorporated herein by reference.
Fully human antibodies can also be prepared by immunizing transgenic mice, rabbits, monkeys,
or other mammals, carrying large portions of the human immunoglobulin heavy and light chains,
with an immunogen. Examples of such mice are: the Xenomouse. (Abgenix, Inc.), the HuMAb-
Mouse (Medarex/BMS), the VelociMouse (Regeneron), see also U.S. Pat. No. 6,596,541 ,
6,207,418, No. 6,150,584, No. 6,111,166, No. 6,075,181, No. 5,922,545, Nos. 5,661,016,
,545,806, 5,436,149 and 5,569,825. In human therapy, murine variable regions and human
constant regions can also be fused to construct called “chimeric antibodies” that are considerably
less immunogenic in man than murine mAbs (Kipriyanov et al, Mol Biotechnol. 26:39-60 (2004);
Houdebine, Curr Opin Biotechnol. 13:625-9 (2002) each incorporated herein by reference). In
addition, site-directed mutagenesis in the variable region of an antibody can result in an antibody
with higher affinity and specificity for its antigen (Brannigan et al, Nat Rev Mol Cell Biol. 3:964-
70, (2002)); Adams et al, J Immunol Methods. 231:249-60 (1999)) and exchanging constant
regions of a mAb can improve its ability to mediate effector functions of binding and
cytotoxicity.
Antibodies immunospecific for a malignant cell antigen can also be obtained commercially
or produced by any method known to one of skill in the art such as, e.g., chemical synthesis or
recombinant expression techniques. The nucleotide sequence encoding antibodies
immunospecific for a malignant cell antigen can be obtained commercially, e.g., from the
GenBank database or a database like it, the literature publications, or by routine cloning and
sequencing.
Apart from an antibody, a peptide or protein that bind/block/target or in some other way
interact with the epitopes or corresponding receptors on a targeted cell can be used as a binding
molecule. These peptides or proteins could be any random peptide or proteins that have an
affinity for the epitopes or corresponding receptors and they don't necessarily have to be of the
immunoglobulin family. These peptides can be isolated by similar techniques as for phage display
antibodies (Szardenings, J Recept Signal Transduct Res. 2003; 23(4):307-49). The use of peptides
from such random peptide libraries can be similar to antibodies and antibody fragments. The
binding molecules of peptides or proteins may be conjugated on or linked to a large molecules or
materials, such as, but is not limited, an albumin, a polymer, a liposome, a nano particle, as long
as such attachment permits the peptide or protein to retain its antigen binding specificity.
Examples of antibodies used for conjugation of antimitotic agents in this prevention for
treating cancer, autoimmune disease, and infectious disease include, but are not limited to, 3F8
(anti-GD2), Abagovomab (anti CA-125), Abciximab (anti CD41 (integrin alpha-IIb),
Adalimumab (anti-TNF-α), Adecatumumab (anti-EpCAM, CD326), Afelimomab (anti-TNF-α);
Afutuzumab (anti-CD20), Alacizumab pegol (anti-VEGFR2), ALD518 (anti-IL-6), Alemtuzumab
(Campath, MabCampath, anti- CD52), Altumomab (anti-CEA), Anatumomab ( anti-TAG-72),
Anrukinzumab (IMA-638, anti-IL-13), Apolizumab (anti-HLA-DR), Arcitumomab (anti-CEA),
Aselizumab (anti-L-selectin (CD62L), Atlizumab (tocilizumab, Actemra, RoActemra, anti-IL-6
receptor), Atorolimumab (anti-Rhesus factor), Bapineuzumab (anti-beta amyloid), Basiliximab
(Simulect, antiCD25 (α chain of IL-2 receptor), Bavituximab (anti-phosphatidylserine),
Bectumomab (LymphoScan, anti-CD22), Belimumab (Benlysta, LymphoStat-B, anti-BAFF),
Benralizumab (anti-CD125), Bertilimumab (anti-CCL11 (eotaxin-1)), Besilesomab (Scintimun,
anti-CEA-related antigen), Bevacizumab (Avastin, anti-VEGF-A), Biciromab (FibriScint, anti-
fibrin II beta chain), Bivatuzumab (anti-CD44 v6), Blinatumomab (BiTE, anti-CD19),
Brentuximab (cAC10, anti-CD30 TNFRSF8), Briakinumab (anti-IL-12, IL-23) Canakinumab
(Ilaris, anti-IL-1), Cantuzumab (C242, anti-CanAg), Capromab, Catumaxomab (Removab, anti-
EpCAM, anti-CD3), CC49 (anti-TAG-72), Cedelizumab (anti-CD4), Certolizumab pegol (Cimzia
anti-TNF-α), Cetuximab (Erbitux, IMC-C225, anti-EGFR), Citatuzumab bogatox (anti-EpCAM),
Cixutumumab (anti-IGF-1), Clenoliximab (anti-CD4), Clivatuzumab (anti-MUC1),
Conatumumab (anti-TRAIL-R2), CR6261 (anti-Influenza A hemagglutinin), Dacetuzumab (anti-
CD40), Daclizumab (Zenapax, anti-CD25 (α chain of IL-2 receptor)), Daratumumab (anti-CD38
(cyclic ADP ribose hydrolase), Denosumab (Prolia, anti-RANKL), Detumomab (anti-B-
lymphoma cell), Dorlimomab, Dorlixizumab, Ecromeximab (anti-GD3 ganglioside), Eculizumab
(Soliris, anti-C5), Edobacomab (anti-endotoxin), Edrecolomab (Panorex, MAb17-1A, anti-
EpCAM), Efalizumab (Raptiva, anti-LFA-1 (CD11a), Efungumab (Mycograb, anti-Hsp90),
Elotuzumab (anti-SLAMF7), Elsilimomab (anti-IL-6), Enlimomab pegol (anti-ICAM-1 (CD54)),
Epitumomab (anti-episialin), Epratuzumab (anti-CD22), Erlizumab (anti-ITGB2 (CD18)),
Ertumaxomab (Rexomun, anti-HER2/neu, CD3), Etaracizumab (Abegrin, anti-integrin α β ),
Exbivirumab ( anti-hepatitis B surface antigen), Fanolesomab (NeutroSpec, anti-CD15),
Faralimomab (anti-interferon receptor), Farletuzumab (anti-folate receptor 1), Felvizumab (anti-
respiratory syncytial virus), Fezakinumab (anti-IL-22), Figitumumab (anti-IGF-1 receptor),
Fontolizumab (anti-IFN-γ), Foravirumab (anti-rabies virus glycoprotein), Fresolimumab (anti-
TGF-β), Galiximab (anti-CD80), Gantenerumab (anti- beta amyloid), Gavilimomab (anti-CD147
(basigin)), Gemtuzumab (anti-CD33), Girentuximab (anti-carbonic anhydrase 9),
Glembatumumab (CR011, anti-GPNMB), Golimumab (Simponi, anti-TNF-α), Gomiliximab
(anti-CD23 (IgE receptor)), Ibalizumab (anti-CD4), Ibritumomab (anti-CD20), Igovomab
(Indimacis-125, anti-CA-125), Imciromab (Myoscint, anti-cardiac myosin), Infliximab (Remicade,
anti-TNF-α), Intetumumab (anti-CD51), Inolimomab (anti-CD25 (α chain of IL-2 receptor)),
Inotuzumab (anti-CD22), Ipilimumab (anti-CD152), Iratumumab (anti- CD30 (TNFRSF8)),
Keliximab (anti-CD4), Labetuzumab (CEA-Cide, anti-CEA), Lebrikizumab (anti- IL-13),
Lemalesomab (anti-NCA-90 (granulocyte antigen)), Lerdelimumab (anti-TGF beta 2),
Lexatumumab (anti-TRAIL-R2), Libivirumab (anti-hepatitis B surface antigen), Lintuzumab
(anti-CD33), Lucatumumab (anti-CD40), Lumiliximab (anti- CD23 (IgE receptor),
Mapatumumab (anti-TRAIL-R1), Maslimomab (anti- T-cell receptor), Matuzumab (anti-EGFR),
Mepolizumab (Bosatria, anti-IL-5), Metelimumab (anti-TGF beta 1), Milatuzumab (anti-CD74),
Minretumomab (anti-TAG-72), Mitumomab (BEC-2, anti-GD3 ganglioside), Morolimumab
(anti-Rhesus factor), Motavizumab (Numax, anti-respiratory syncytial virus), Muromonab-CD3
(Orthoclone OKT3, anti-CD3), Nacolomab (anti-C242), Naptumomab (anti-5T4), Natalizumab
(Tysabri, anti-integrin α ) Nebacumab (anti-endotoxin), Necitumumab (anti-EGFR),
Nerelimomab (anti-TNF-α), Nimotuzumab (Theracim, Theraloc, anti-EGFR), Nofetumomab,
Ocrelizumab (anti-CD20), Odulimomab (Afolimomab, anti-LFA-1 (CD11a)), Ofatumumab
(Arzerra, anti-CD20), Olaratumab (anti-PDGF-R α), Omalizumab (Xolair, anti-IgE Fc region),
Oportuzumab (anti-EpCAM), Oregovomab (OvaRex, anti-CA-125), Otelixizumab (anti-CD3),
Pagibaximab (anti-lipoteichoic acid), Palivizumab (Synagis, Abbosynagis, anti-respiratory
syncytial virus), Panitumumab (Vectibix, ABX-EGF, anti-EGFR), Panobacumab (anti-
Pseudomonas aeruginosa), Pascolizumab (anti-IL-4), Pemtumomab (Theragyn, anti-MUC1),
Pertuzumab (Omnitarg, 2C4, anti-HER2/neu), Pexelizumab (anti-C5), Pintumomab (anti-
adenocarcinoma antigen), Priliximab (anti-CD4), Pritumumab (anti-vimentin), PRO 140 (anti-
CCR5), Racotumomab (1E10, anti-(N-glycolylneuraminic acid (NeuGc, NGNA)-gangliosides
GM3)), Rafivirumab (anti-rabies virus glycoprotein), Ramucirumab (anti-VEGFR2),
Ranibizumab (Lucentis, anti-VEGF-A), Raxibacumab (anti-anthrax toxin, protective antigen),
Regavirumab (anti-cytomegalovirus glycoprotein B), Reslizumab (anti-IL-5), Rilotumumab
(anti-HGF), Rituximab (MabThera, Rituxanmab, anti-CD20), Robatumumab (anti-IGF-1
receptor), Rontalizumab (anti-IFN-α), Rovelizumab (LeukArrest, anti-CD11, CD18), Ruplizumab
(Antova, anti-CD154 (CD40L)), Satumomab (anti-TAG-72), Sevirumab (anti-cytomegalovirus),
Sibrotuzumab (anti-FAP), Sifalimumab (anti-IFN-α), Siltuximab (anti-IL-6), Siplizumab (anti-
CD2), (Smart) MI95 (anti-CD33), Solanezumab (anti-beta amyloid), Sonepcizumab (anti-
sphingosinephosphate), Sontuzumab (anti-episialin), Stamulumab (anti-myostatin), Sulesomab
(LeukoScan, (anti-NCA-90 (granulocyte antigen), Tacatuzumab (anti-alpha-fetoprotein),
Tadocizumab (anti-integrin α β ), Talizumab (anti-IgE), Tanezumab (anti-NGF), Taplitumomab
IIb 3
(anti-CD19), Tefibazumab (Aurexis, (anti-clumping factor A), Telimomab, Tenatumomab (anti-
tenascin C), Teneliximab (anti-CD40), Teplizumab (anti-CD3), TGN1412 (anti-CD28),
Ticilimumab (Tremelimumab, (anti-CTLA-4), Tigatuzumab (anti-TRAIL-R2), TNX-650 (anti-
IL-13), Tocilizumab (Atlizumab, Actemra, RoActemra, (anti-IL-6 receptor), Toralizumab (anti-
CD154 (CD40L)), Tositumomab (anti-CD20), Trastuzumab (Herceptin, (anti-HER2/neu),
Tremelimumab (anti-CTLA-4), Tucotuzumab celmoleukin (anti-EpCAM), Tuvirumab (anti-
hepatitis B virus), Urtoxazumab (anti- Escherichia coli), Ustekinumab (Stelara, anti-IL-12, IL-23),
Vapaliximab (anti-AOC3 (VAP-1)), Vedolizumab, (anti-integrin α β ), Veltuzumab (anti-CD20),
Vepalimomab (anti-AOC3 (VAP-1), Visilizumab (Nuvion, anti-CD3), Vitaxin (anti-vascular
integrin avb3), Volociximab (anti-integrin α β ), Votumumab (HumaSPECT, anti-tumor antigen
CTAA16.88), Zalutumumab (HuMax-EGFr, (anti-EGFR), Zanolimumab (HuMax-CD4, anti-
CD4), Ziralimumab (anti-CD147 (basigin)), Zolimomab (anti-CD5), Etanercept (Enbrel®),
Alefacept (Amevive®), Abatacept (Orencia®), Rilonacept (Arcalyst), 14F7 [anti-IRP-2 (Iron
Regulatory Protein 2)], 14G2a (anti-GD2 ganglioside, from Nat. Cancer Inst. for melanoma and
solid tumors), J591 (anti-PSMA, Weill Cornell Medical School for prostate cancers), 225.28S
[anti-HMW-MAA (High molecular weight-melanoma-associated antigen), Sorin Radiofarmaci
S.R.L. (Milan, Italy) for melanoma], COL-1 (anti-CEACAM3, CGM1, from Nat. Cancer Inst.
USA for colorectal and gastric cancers), CYT-356 (Oncoltad®, for prostate cancers), HNK20
(OraVax Inc. for respiratory syncytial virus), ImmuRAIT (from Immunomedics for NHL), Lym-1
(anti-HLA-DR10, Peregrine Pharm. for Cancers), MAK-195F [anti-TNF (tumor necrosis factor;
TNFA, TNF-alpha; TNFSF2), from Abbott / Knoll for Sepsis toxic shock], MEDI-500 [T10B9,
anti-CD3, TRαβ (T cell receptor alpha/beta), complex, from MedImmune Inc for Graft-versus-
host disease], RING SCAN [ anti-TAG 72 (tumour associated glycoprotein 72), from Neoprobe
Corp. for Breast, Colon and Rectal cancers], Avicidin (anti-EPCAM (epithelial cell adhesion
molecule), anti-TACSTD1 (Tumor-associated calcium signal transducer 1), anti-GA733-2
(gastrointestinal tumor-associated protein 2), anti-EGP-2 (epithelial glycoprotein 2); anti-KSA;
KS1/4 antigen; M4S; tumor antigen 17-1A; CD326, from NeoRx Corp. for Colon, Ovarian,
Prostate cancers and NHL]; LymphoCide (Immunomedics, NJ), Smart ID10 (Protein Design
Labs), Oncolym (Techniclone Inc, CA), Allomune (BioTransplant, CA), anti-VEGF (Genentech,
CA); CEAcide (Immunomedics, NJ), IMC-1C11 (ImClone Systems, NJ) and Cetuximab
(ImClone, NJ) .
Other antibodies as binding ligands include, but are not limited to, are antibodies against the
following antigens: Aminopeptidase N (CD13), Annexin A1, B7-H3 (CD276, various cancers),
CA125 (ovarian), CA15-3 (carcinomas), CA19-9 (carcinomas), L6 (carcinomas), Lewis Y
(carcinomas), Lewis X (carcinomas), alpha fetoprotein (carcinomas), CA242 (colorectal),
placental alkaline phosphatase (carcinomas), prostate specific antigen (prostate), prostatic acid
phosphatase (prostate), epidermal growth factor (carcinomas), CD2 (Hodgkin’s disease, NHL
lymphoma, multiple myeloma), CD3 epsilon (T cell lymphoma, lung, breast, gastric, ovarian
cancers, autoimmune diseases, malignant ascites), CD19 (B cell malignancies), CD20 (non-
Hodgkin's lymphoma), CD22 (leukemia, lymphoma, multiple myeloma, SLE), CD30 (Hodgkin’s
lymphoma), CD33 (leukemia, autoimmune diseases), CD38 (multiple myeloma), CD40
(lymphoma, multiple myeloma, leukemia (CLL)), CD51 (Metastatic melanoma, sarcoma), CD52
(leukemia), CD56 (small cell lung cancers, ovarian cancer, Merkel cell carcinoma, and the liquid
tumor, multiple myeloma), CD66e (cancers), CD70 (metastatic renal cell carcinoma and non-
Hodgkin lymphoma), CD74 (multiple myeloma), CD80 (lymphoma), CD98 (cancers), mucin
(carcinomas), CD221 (solid tumors), CD227 (breast, ovarian cancers), CD262 (NSCLC and other
cancers), CD309 (ovarian cancers), CD326 (solid tumors), CEACAM3 (colorectal, gastric
cancers), CEACAM5 (carcinoembryonic antigen; CEA, CD66e) (breast, colorectal and lung
cancers), DLL4 (Δ-like-4), EGFR (Epidermal Growth Factor Receptor, various cancers), CTLA4
(melanoma), CXCR4 (CD184, Heme-oncology, solid tumors), Endoglin (CD105, solid tumors),
EPCAM (epithelial cell adhesion molecule, bladder, head, neck, colon, NHL prostate, and ovarian
cancers), ERBB2 (Epidermal Growth Factor Receptor 2; lung, breast, prostate cancers), FCGR1
(autoimmune diseases), FOLR (folate receptor, ovarian cancers), GD2 ganglioside (cancers), G-
28 (a cell surface antigen glyvolipid, melanoma), GD3 idiotype (cancers), Heat shock proteins
(cancers), HER1 (lung, stomach cancers), HER2 (breast, lung and ovarian cancers), HLA-DR10
(NHL), HLA-DRB (NHL, B cell leukemia), human chorionic gonadotropin (carcinoma), IGF1R
(insulin-like growth factor 1 receptor, solid tumors, blood cancers), IL-2 receptor (interleukin 2
receptor,T-cell leukemia and lymphomas), IL-6R (interleukin 6 receptor, multiple myeloma, RA,
Castleman’s disease, IL6 dependent tumors), Integrins (αvβ3, α5β1, α6β4, αllβ3, α5β5, αvβ5, for
various cancers), MAGE-1 (carcinomas), MAGE-2 (carcinomas), MAGE-3 (carcinomas), MAGE
4 (carcinomas), anti-transferrin receptor (carcinomas), p97 (melanoma), MS4A1 (membrane-
spanning 4-domains subfamily A member 1, Non-Hodgkin's B cell lymphoma, leukemia), MUC1
or MUC1-KLH (breast, ovarian, cervix, bronchus and gastrointestinal cancer), MUC16 (CA125)
(Ovarian cancers), CEA (colorectal), gp100 (melanoma), MART1 (melanoma), MPG (melanoma),
MS4A1 (membrane-spanning 4-domains subfamily A, small cell lung cancers, NHL), Nucleolin,
Neu oncogene product (carcinomas), P21 (carcinomas), Paratope of anti-(N-glycolylneuraminic
acid, Breast, Melanoma cancers), PLAP-like testicular alkaline phosphatase (ovarian, testicular
cancers), PSMA (prostate tumors), PSA (prostate), ROBO4, TAG 72 (tumour associated
glycoprotein 72, AML, gastric, colorectal, ovarian cancers), T cell transmembrane protein
(cancers), Tie (CD202b), TNFRSF10B (tumor necrosis factor receptor superfamily member 10B,
cancers), TNFRSF13B (tumor necrosis factor receptor superfamily member 13B, multiple
myeloma, NHL, other cancers, RA and SLE), TPBG (trophoblast glycoprotein, Renal cell
carcinoma), TRAIL-R1 (Tumor necrosis apoprosis Inducing ligand Receptor 1,lymphoma, NHL,
colorectal, lung cancers), VCAM-1 (CD106, Melanoma), VEGF, VEGF-A, VEGF-2 (CD309)
(various cancers). Some other tumor associated antigens recognized by antibodies have been
reviewed (Gerber, et al, mAbs 1:3, 247-253 (2009); Novellino et al, Cancer Immunol Immunother.
54(3),187-207 (2005). Franke, et al, Cancer Biother Radiopharm. 2000, 15, 459-76). Examples of
these antigens that antibodies against are: Many other Cluster of Differentiations (CD4, CD5,
CD6, CD7, CD8, CD9, CD10, CD11a, CD11b, CD11c, CD12w, CD14, CD15, CD16, CDw17,
CD18, CD21, CD23, CD24, CD25, CD26, CD27, CD28, CD29, CD31, CD32, CD34, CD35,
CD36, CD37, CD41, CD42, CD43, CD44, CD45, CD46, CD47, CD48, CD49b, CD49c, CD53,
CD54, CD55, CD58, CD59, CD61, CD62E, CD62L, CD62P, CD63, CD68, CD69, CD71, CD72,
CD79, CD81, CD82, CD83, CD86, CD87, CD88, CD89, CD90, CD91, CD95, CD96, CD100,
CD103, CD105, CD106, CD109, CD117, CD120, CD127, CD133, CD134, CD135, CD138,
CD141, CD142, CD143, CD144, CD147, CD151, CD152, CD154, CD156, CD158, CD163,
CD166, .CD168, CD184, CDw186, CD195, CD202 (a, b), CD209, CD235a, CD271, CD303,
CD304), Annexin A1, Nucleolin, Endoglin (CD105), ROBO4, Amino-peptidase N, Δ-like-4
(DLL4), VEGFR-2 (CD309), CXCR4 9CD184), Tie2, B7-H3, WT1, MUC1, LMP2, HPV E6 E7,
EGFRvIII, HER-2/neu, Idiotype, MAGE A3, p53 nonmutant, NY-ESO-1, GD2, CEA,
MelanA/MART1, Ras mutant, gp100, p53 mutant, Proteinase3 (PR1), bcr-abl, Tyrosinase,
Survivin, hTERT, Sarcoma translocation breakpoints, EphA2, PAP, ML-IAP, AFP, EpCAM,
ERG (TMPRSS2 ETS fusion gene), NA17, PAX3, ALK, Androgen receptor, Cyclin B1,
Polysialic acid, MYCN, RhoC, TRP-2, GD3, Fucosyl GM1, Mesothelin, PSCA, MAGE A1,
sLe(a), CYP1B1, PLAC1, GM3, BORIS, Tn, GloboH, ETV6-AML, NY-BR-1, RGS5, SART3,
STn, Carbonic anhydrase IX, PAX5, OY-TES1, Sperm protein 17, LCK, HMWMAA, AKAP-4,
SSX2, XAGE 1, B7H3, Legumain, Tie 2, Page4, VEGFR2, MAD-CT-1, FAP, PDGFR-β, MAD-
CT-2, Fos-related antigen 1.
In another specific embodiment, the antimitotic agent- binding molecule conjugates of the
invention are used in accordance with the compositions and methods of the invention for the
treatment of cancers. The cancers include, but are not limited, Adrenocortical Carcinoma, Anal
Cancer, Bladder Cancer, Brain Tumor (Adult, Brain Stem Glioma, Childhood, Cerebellar
Astrocytoma, Cerebral Astrocytoma, Ependymoma, Medulloblastoma, Supratentorial Primitive
Neuroectodermal and Pineal Tumors, Visual Pathway and Hypothalamic Glioma), Breast Cancer,
Carcinoid Tumor, Gastrointestinal, Carcinoma of Unknown Primary, Cervical Cancer, Colon
Cancer, Endometrial Cancer, Esophageal Cancer, Extrahepatic Bile Duct Cancer, Ewings Family
of Tumors (PNET), Extracranial Germ Cell Tumor, Eye Cancer, Intraocular Melanoma,
Gallbladder Cancer, Gastric Cancer (Stomach), Germ Cell Tumor, Extragonadal, Gestational
Trophoblastic Tumor, Head and Neck Cancer, Hypopharyngeal Cancer, Islet Cell Carcinoma,
Kidney Cancer (renal cell cancer), Laryngeal Cancer, Leukemia (Acute Lymphoblastic, Acute
Myeloid, Chronic Lymphocytic, Chronic Myelogenous, Hairy Cell), Lip and Oral Cavity Cancer,
Liver Cancer, Lung Cancer (Non-Small Cell, Small Cell, Lymphoma (AIDS-Related, Central
Nervous System, Cutaneous T-Cell, Hodgkin's Disease, Non-Hodgkin's Disease, Malignant
Mesothelioma, Melanoma, Merkel Cell Carcinoma, Metasatic Squamous Neck Cancer with
Occult Primary, Multiple Myeloma, and Other Plasma Cell Neoplasms, Mycosis Fungoides,
Myelodysplastic Syndrome, Myeloproliferative Disorders, Nasopharyngeal Cancer,
Neuroblastoma, Oral Cancer, Oropharyngeal Cancer, Osteosarcoma, Ovarian Cancer (Epithelial,
Germ Cell Tumor, Low Malignant Potential Tumor), Pancreatic Cancer (Exocrine, Islet Cell
Carcinoma), Paranasal Sinus and Nasal Cavity Cancer, Parathyroid Cancer, Penile Cancer,
Pheochromocytoma Cancer, Pituitary Cancer, Plasma Cell Neoplasm, Prostate Cancer
Rhabdomyosarcoma, Rectal Cancer, Renal Cell Cancer (kidney cancer), Renal Pelvis and Ureter
(Transitional Cell), Salivary Gland Cancer, Sezary Syndrome, Skin Cancer, Skin Cancer
(Cutaneous T-Cell Lymphoma, Kaposi's Sarcoma, Melanoma), Small Intestine Cancer, Soft
Tissue Sarcoma, Stomach Cancer, Testicular Cancer, Thymoma (Malignant), Thyroid Cancer,
Urethral Cancer, Uterine Cancer (Sarcoma), Unusual Cancer of Childhood, Vaginal Cancer,
Vulvar Cancer, Wilms' Tumor
In another specific embodiment, the antimitotic agent- binding molecule conjugates of the
invention are used in accordance with the compositions and methods of the invention for the
treatment or prevention of an autoimmune disease. The autoimmune diseases include, but are not
limited, Achlorhydra Autoimmune Active Chronic Hepatitis, Acute Disseminated
Encephalomyelitis, Acute hemorrhagic leukoencephalitis, Addison's Disease,
Agammaglobulinemia, Alopecia areata, Amyotrophic Lateral Sclerosis, Ankylosing Spondylitis,
Anti-GBM/TBM Nephritis, Antiphospholipid syndrome, Antisynthetase syndrome, Arthritis,
Atopic allergy, Atopic Dermatitis, Autoimmune Aplastic Anemia, Autoimmune cardiomyopathy,
Autoimmune hemolytic anemia, Autoimmune hepatitis, Autoimmune inner ear disease,
Autoimmune lymphoproliferative syndrome, Autoimmune peripheral neuropathy, Autoimmune
pancreatitis, Autoimmune polyendocrine syndrome Types I, II, & III, Autoimmune progesterone
dermatitis, Autoimmune thrombocytopenic purpura, Autoimmune uveitis, Balo disease/Balo
concentric sclerosis, Bechets Syndrome, Berger's disease, Bickerstaff's encephalitis, Blau
syndrome, Bullous Pemphigoid, Castleman's disease, Chagas disease, Chronic Fatigue Immune
Dysfunction Syndrome, Chronic inflammatory demyelinating polyneuropathy, Chronic recurrent
multifocal ostomyelitis, Chronic lyme disease, Chronic obstructive pulmonary disease, Churg-
Strauss syndrome, Cicatricial Pemphigoid, Coeliac Disease, Cogan syndrome, Cold agglutinin
disease, Complement component 2 deficiency, Cranial arteritis, CREST syndrome, Crohns
Disease (a type of idiopathic inflammatory bowel diseases), Cushing's Syndrome, Cutaneous
leukocytoclastic angiitis, Dego's disease, Dercum's disease, Dermatitis herpetiformis,
Dermatomyositis, Diabetes mellitus type 1, Diffuse cutaneous systemic sclerosis, Dressler's
syndrome, Discoid lupus erythematosus, Eczema, Endometriosis, Enthesitis-related arthritis,
Eosinophilic fasciitis, Epidermolysis bullosa acquisita, Erythema nodosum, Essential mixed
cryoglobulinemia, Evan's syndrome, Fibrodysplasia ossificans progressiva, Fibromyalgia,
Fibromyositis, Fibrosing aveolitis, Gastritis, Gastrointestinal pemphigoid, Giant cell arteritis,
Glomerulonephritis, Goodpasture's syndrome, Graves' disease, Guillain-Barré syndrome,
Hashimoto's encephalitis, Hashimoto's thyroiditis, Haemolytic anaemia, Henoch-Schonlein
purpura, Herpes gestationis, Hidradenitis suppurativa, Hughes syndrome (See Antiphospholipid
syndrome), Hypogammaglobulinemia, Idiopathic Inflammatory Demyelinating Diseases,
Idiopathic pulmonary fibrosis, Idiopathic thrombocytopenic purpura (See Autoimmune
thrombocytopenic purpura), IgA nephropathy (Also Berger's disease), Inclusion body myositis,
Inflammatory demyelinating polyneuopathy, Interstitial cystitis, Irritable Bowel Syndrome ,
Juvenile idiopathic arthritis, Juvenile rheumatoid arthritis, Kawasaki's Disease, Lambert-Eaton
myasthenic syndrome, Leukocytoclastic vasculitis, Lichen planus, Lichen sclerosus, Linear IgA
disease (LAD), Lou Gehrig's Disease (Also Amyotrophic lateral sclerosis), Lupoid hepatitis,
Lupus erythematosus, Majeed syndrome, Ménière's disease, Microscopic polyangiitis, Miller-
Fisher syndrome, Mixed Connective Tissue Disease, Morphea, Mucha-Habermann disease,
Muckle–Wells syndrome, Multiple Myeloma, Multiple Sclerosis, Myasthenia gravis, Myositis,
Narcolepsy, Neuromyelitis optica (Devic's Disease), Neuromyotonia, Occular cicatricial
pemphigoid, Opsoclonus myoclonus syndrome, Ord thyroiditis, Palindromic rheumatism,
PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcus),
Paraneoplastic cerebellar degeneration, Paroxysmal nocturnal hemoglobinuria, Parry Romberg
syndrome, Parsonnage-Turner syndrome, Pars planitis, Pemphigus, Pemphigus vulgaris,
Pernicious anaemia, Perivenous encephalomyelitis, POEMS syndrome, Polyarteritis nodosa,
Polymyalgia rheumatica, Polymyositis, Primary biliary cirrhosis, Primary sclerosing cholangitis,
Progressive inflammatory neuropathy, Psoriasis, Psoriatic Arthritis, Pyoderma gangrenosum,
Pure red cell aplasia, Rasmussen's encephalitis, Raynaud phenomenon, Relapsing polychondritis,
Reiter's syndrome, Restless leg syndrome, Retroperitoneal fibrosis, Rheumatoid arthritis,
Rheumatoid fever, Sarcoidosis, Schizophrenia, Schmidt syndrome, Schnitzler syndrome, Scleritis,
Scleroderma, Sjögren's syndrome, Spondyloarthropathy, Sticky blood syndrome, Still's Disease,
Stiff person syndrome, Subacute bacterial endocarditis, Susac's syndrome, Sweet syndrome,
Sydenham Chorea, Sympathetic ophthalmia, Takayasu's arteritis, Temporal arteritis (giant cell
arteritis), Tolosa-Hunt syndrome, Transverse Myelitis, Ulcerative Colitis (a type of idiopathic
inflammatory bowel diseases), Undifferentiated connective tissue disease, Undifferentiated
spondyloarthropathy, Vasculitis, Vitiligo, Wegener's granulomatosis, Wilson's syndrome,
Wiskott-Aldrich syndrome
In another specific embodiment, a binding molecule used for the conjugate for the treatment
or prevention of an autoimmune disease includes, but are not limited to, anti-elastin antibody;
Abys against epithelial cells antibody; Anti-Basement Membrane Collagen Type IV Protein
antibody; Anti-Nuclear Antibody; Anti ds DNA; Anti ss DNA, Anti Cardiolipin Antibody IgM,
IgG; anti-celiac antibody; Anti Phospholipid Antibody IgK, IgG; Anti SM Antibody; Anti
Mitochondrial Antibody; Thyroid Antibody; Microsomal Antibody, T-cells antibody;
Thyroglobulin Antibody, Anti SCL-70; Anti-Jo; Anti-U.sub.1RNP; Anti-La/SSB; Anti SSA; Anti
SSB; Anti Perital Cells Antibody; Anti Histones; Anti RNP; C-ANCA; P-ANCA; Anti
centromere; Anti-Fibrillarin, and Anti GBM Antibody, Anti-ganglioside antibody; Anti-
Desmogein 3 antibody; Anti-p62 antibody; Anti-sp100 antibody; Anti-Mitochondrial(M2)
antibody; Rheumatoid factor antibody; Anti-MCV antibody; Anti-topoisomerase antibody; Anti-
neutrophil cytoplasmic(cANCA) antibody
In certain preferred embodiments, the binding molecule for the conjugate in the present
invention, can bind to both a receptor or a receptor complex expressed on an activated
lymphocyte which is associated with an autoimmune disease. The receptor or receptor complex
can comprise an immunoglobulin gene superfamily member (e.g. CD2, CD3, CD4, CD8, CD19,
CD22, CD28, CD79, CD90, CD152/CTLA-4, PD-1, or ICOS), a TNF receptor superfamily
member (e.g. CD27, CD40, CD95/Fas, CD134/OX40, CD137/4-1BB, INF-R1, TNFR-2, RANK,
TACI, BCMA, osteoprotegerin, Apo2/TRAIL-R1, TRAIL-R2, TRAIL-R3, TRAIL-R4, and APO-
3), an integrin, a cytokine receptor, a chemokine receptor, a major histocompatibility protein, a
lectin (C-type, S-type, or I-type), or a complement control protein.
In another specific embodiment, useful binding ligands that are immunospecific for a viral
or a microbial antigen are humanized or human monoclonal antibodies. As used herein, the term
"viral antigen" includes, but is not limited to, any viral peptide, polypeptide protein (e.g. HIV
gp120, HIV nef, RSV F glycoprotein, influenza virus neuramimidase, influenza virus
hemagglutinin, HTLV tax, herpes simplex virus glycoprotein (e.g. gB, gC, gD, and gE) and
hepatitis B surface antigen) that is capable of eliciting an immune response. As used herein, the
term "microbial antigen" includes, but is not limited to, any microbial peptide, polypeptide,
protein, saccharide, polysaccharide, or lipid molecule (e.g., a bacterial, fungi, pathogenic
protozoa, or yeast polypeptide including, e.g., LPS and capsular polysaccharide 5/8) that is
capable of eliciting an immune response. Examples of antibodies available l for the viral or
microbial infection include, but are not limited to, Palivizumab which is a humanized anti-
respiratory syncytial virus monoclonal antibody for the treatment of RSV infection; PRO542
which is a CD4 fusion antibody for the treatment of HIV infection; Ostavir which is a human
antibody for the treatment of hepatitis B virus; PROTVIR which is a humanized IgG.sub.1
antibody for the treatment of cytomegalovirus; and anti-LPS antibodies.
The binding molecules –antimitotic agent conjugates of this invention can be used in the
treatment of infectious diseases. These infectious diseases include, but are not limited to,
Acinetobacter infections, Actinomycosis, African sleeping sickness (African trypanosomiasis),
AIDS (Acquired immune deficiency syndrome), Amebiasis, Anaplasmosis, Anthrax,
Arcanobacterium haemolyticum infection, Argentine hemorrhagic fever, Ascariasis, Aspergillosis,
Astrovirus infection, Babesiosis, Bacillus cereus infection, Bacterial pneumonia, Bacterial
vaginosis, Bacteroides infection, Balantidiasis, Baylisascaris infection, BK virus infection, Black
piedra, Blastocystis hominis infection, Blastomycosis, Bolivian hemorrhagic fever, Borrelia
infection, Botulism (and Infant botulism), Brazilian hemorrhagic fever, Brucellosis, Burkholderia
infection, Buruli ulcer, Calicivirus infection (Norovirus and Sapovirus), Campylobacteriosis,
Candidiasis (Moniliasis; Thrush), Cat-scratch disease, Cellulitis, Chagas Disease (American
trypanosomiasis), Chancroid, Chickenpox, Chlamydia, Chlamydophila pneumoniae infection,
Cholera, Chromoblastomycosis, Clonorchiasis, Clostridium difficile infection,
Coccidioidomycosis, Colorado tick fever, Common cold (Acute viral rhinopharyngitis; Acute
coryza), Creutzfeldt-Jakob disease, Crimean-Congo hemorrhagic fever, Cryptococcosis,
Cryptosporidiosis, Cutaneous larva migrans, Cyclosporiasis, Cysticercosis, Cytomegalovirus
infection, Dengue fever, Dientamoebiasis, Diphtheria, Diphyllobothriasis, Dracunculiasis, Ebola
hemorrhagic fever, Echinococcosis, Ehrlichiosis, Enterobiasis (Pinworm infection), Enterococcus
infection, Enterovirus infection, Epidemic typhus, Erythema infectiosum (Fifth disease),
Exanthem subitum, Fasciolopsiasis, Fasciolosis, Fatal familial insomnia, Filariasis, Food
poisoning by Clostridium perfringens, Free-living amebic infection, Fusobacterium infection, Gas
gangrene (Clostridial myonecrosis), Geotrichosis, Gerstmann-Sträussler-Scheinker syndrome,
Giardiasis, Glanders, Gnathostomiasis, Gonorrhea, Granuloma inguinale (Donovanosis), Group A
streptococcal infection, Group B streptococcal infection, Haemophilus influenzae infection, Hand,
foot and mouth disease (HFMD), Hantavirus Pulmonary Syndrome, Helicobacter pylori infection,
Hemolytic-uremic syndrome, Hemorrhagic fever with renal syndrome, Hepatitis A, Hepatitis B,
Hepatitis C, Hepatitis D, Hepatitis E, Herpes simplex, Histoplasmosis, Hookworm infection,
Human bocavirus infection, Human ewingii ehrlichiosis, Human granulocytic anaplasmosis,
Human metapneumovirus infection, Human monocytic ehrlichiosis, Human papillomavirus
infection, Human parainfluenza virus infection, Hymenolepiasis, Epstein-Barr Virus Infectious
Mononucleosis (Mono), Influenza, Isosporiasis, Kawasaki disease, Keratitis, Kingella kingae
infection, Kuru, Lassa fever, Legionellosis (Legionnaires’ disease), Legionellosis (Pontiac fever),
Leishmaniasis, Leprosy, Leptospirosis, Listeriosis, Lyme disease (Lyme borreliosis), Lymphatic
filariasis (Elephantiasis), Lymphocytic choriomeningitis, Malaria, Marburg hemorrhagic fever,
Measles, Melioidosis (Whitmore’s disease), Meningitis, Meningococcal disease, Metagonimiasis,
Microsporidiosis, Molluscum contagiosum, Mumps, Murine typhus (Endemic typhus),
Mycoplasma pneumonia, Mycetoma, Myiasis, Neonatal conjunctivitis (Ophthalmia neonatorum),
(New) Variant Creutzfeldt-Jakob disease (vCJD, nvCJD), Nocardiosis, Onchocerciasis (River
blindness), Paracoccidioidomycosis (South American blastomycosis), Paragonimiasis,
Pasteurellosis, Pediculosis capitis (Head lice), Pediculosis corporis (Body lice), Pediculosis pubis
(Pubic lice, Crab lice), Pelvic inflammatory disease, Pertussis (Whooping cough), Plague,
Pneumococcal infection, Pneumocystis pneumonia, Pneumonia, Poliomyelitis, Prevotella
infection, Primary amoebic meningoencephalitis, Progressive multifocal leukoencephalopathy,
Psittacosis, Q fever, Rabies, Rat-bite fever, Respiratory syncytial virus infection,
Rhinosporidiosis, Rhinovirus infection, Rickettsial infection, Rickettsialpox, Rift Valley fever,
Rocky mountain spotted fever, Rotavirus infection, Rubella, Salmonellosis, SARS (Severe Acute
Respiratory Syndrome), Scabies, Schistosomiasis, Sepsis, Shigellosis (Bacillary dysentery),
Shingles (Herpes zoster), Smallpox (Variola), Sporotrichosis, Staphylococcal food poisoning,
Staphylococcal infection, Strongyloidiasis, Syphilis, Taeniasis, Tetanus (Lockjaw), Tinea barbae
(Barber’s itch), Tinea capitis (Ringworm of the Scalp), Tinea corporis (Ringworm of the Body),
Tinea cruris (Jock itch), Tinea manuum (Ringworm of the Hand), Tinea nigra, Tinea pedis
(Athlete’s foot), Tinea unguium (Onychomycosis), Tinea versicolor (Pityriasis versicolor),
Toxocariasis (Ocular Larva Migrans), Toxocariasis (Visceral Larva Migrans), Toxoplasmosis,
Trichinellosis, Trichomoniasis, Trichuriasis (Whipworm infection), Tuberculosis, Tularemia,
Ureaplasma urealyticum infection, Venezuelan equine encephalitis, Venezuelan hemorrhagic
fever, Viral pneumonia, West Nile Fever, White piedra (Tinea blanca), Yersinia
pseudotuberculosis infection, Yersiniosis, Yellow fever, Zygomycosis.
The binding molecules, proffered antibodies described in this patent that are against
pathogenic strains include, but are not limit, Acinetobacter baumannii, Actinomyces israelii,
Actinomyces gerencseriae and Propionibacterium propionicus, Trypanosoma brucei, HIV
(Human immunodeficiency virus), Entamoeba histolytica, Anaplasma genus, Bacillus anthracis,
Arcanobacterium haemolyticum, Junin virus, Ascaris lumbricoides, Aspergillus genus,
Astroviridae family, Babesia genus, Bacillus cereus, multiple bacteria, Bacteroides genus,
Balantidium coli, Baylisascaris genus, BK virus, Piedraia hortae, Blastocystis hominis,
Blastomyces dermatitides, Machupo virus, Borrelia genus, Clostridium botulinum, Sabia,
Brucella genus, usually Burkholderia cepacia and other Burkholderia species, Mycobacterium
ulcerans, Caliciviridae family, Campylobacter genus, usually Candida albicans and other Candida
species, Bartonella henselae, Group A Streptococcus and Staphylococcus, Trypanosoma cruzi,
Haemophilus ducreyi, Varicella zoster virus (VZV), Chlamydia trachomatis, Chlamydophila
pneumoniae, Vibrio cholerae, Fonsecaea pedrosoi, Clonorchis sinensis, Clostridium difficile,
Coccidioides immitis and Coccidioides posadasii, Colorado tick fever virus, rhinoviruses,
coronaviruses, CJD prion, Crimean-Congo hemorrhagic fever virus, Cryptococcus neoformans,
Cryptosporidium genus, Ancylostoma braziliense; multiple parasites, Cyclospora cayetanensis,
Taenia solium, Cytomegalovirus, Dengue viruses (DEN-1, DEN-2, DEN-3 and DEN-4) –
Flaviviruses, Dientamoeba fragilis, Corynebacterium diphtheriae, Diphyllobothrium, Dracunculus
medinensis, Ebolavirus, Echinococcus genus, Ehrlichia genus, Enterobius vermicularis,
Enterococcus genus, Enterovirus genus, Rickettsia prowazekii, Parvovirus B19, Human
herpesvirus 6 and Human herpesvirus 7, Fasciolopsis buski, Fasciola hepatica and Fasciola
gigantica, FFI prion, Filarioidea superfamily, Clostridium perfringens, Fusobacterium genus,
Clostridium perfringens; other Clostridium species, Geotrichum candidum, GSS prion, Giardia
intestinalis, Burkholderia mallei, Gnathostoma spinigerum and Gnathostoma hispidum, Neisseria
gonorrhoeae, Klebsiella granulomatis, Streptococcus pyogenes, Streptococcus agalactiae,
Haemophilus influenzae, Enteroviruses, mainly Coxsackie A virus and Enterovirus 71, Sin
Nombre virus, Helicobacter pylori, Escherichia coli O157:H7, Bunyaviridae family, Hepatitis A
Virus, Hepatitis B Virus, Hepatitis C Virus, Hepatitis D Virus, Hepatitis E Virus, Herpes simplex
virus 1, Herpes simplex virus 2, Histoplasma capsulatum, Ancylostoma duodenale and Necator
americanus, Hemophilus influenzae, Human bocavirus, Ehrlichia ewingii, Anaplasma
phagocytophilum, Human metapneumovirus, Ehrlichia chaffeensis, Human papillomavirus,
Human parainfluenza viruses, Hymenolepis nana and Hymenolepis diminuta, Epstein-Barr Virus,
Orthomyxoviridae family, Isospora belli, Kingella kingae, Klebsiella pneumoniae, Klebsiella
ozaenas, Klebsiella rhinoscleromotis, Kuru prion, Lassa virus, Legionella pneumophila,
Legionella pneumophila, Leishmania genus, Mycobacterium leprae and Mycobacterium
lepromatosis, Leptospira genus, Listeria monocytogenes, Borrelia burgdorferi and other Borrelia
species, Wuchereria bancrofti and Brugia malayi, Lymphocytic choriomeningitis virus (LCMV),
Plasmodium genus, Marburg virus, Measles virus, Burkholderia pseudomallei, Neisseria
meningitides, Metagonimus yokagawai, Microsporidia phylum, Molluscum contagiosum virus
(MCV), Mumps virus, Rickettsia typhi, Mycoplasma pneumoniae, numerous species of bacteria
(Actinomycetoma) and fungi (Eumycetoma), parasitic dipterous fly larvae, Chlamydia
trachomatis and Neisseria gonorrhoeae, vCJD prion, Nocardia asteroides and other Nocardia
species, Onchocerca volvulus, Paracoccidioides brasiliensis, Paragonimus westermani and other
Paragonimus species, Pasteurella genus, Pediculus humanus capitis, Pediculus humanus corporis,
Phthirus pubis, Bordetella pertussis, Yersinia pestis, Streptococcus pneumoniae, Pneumocystis
jirovecii, Poliovirus, Prevotella genus, Naegleria fowleri, JC virus, Chlamydophila psittaci,
Coxiella burnetii, Rabies virus, Streptobacillus moniliformis and Spirillum minus, Respiratory
syncytial virus, Rhinosporidium seeberi, Rhinovirus, Rickettsia genus, Rickettsia akari, Rift
Valley fever virus, Rickettsia rickettsii, Rotavirus, Rubella virus, Salmonella genus, SARS
coronavirus, Sarcoptes scabiei, Schistosoma genus, Shigella genus, Varicella zoster virus, Variola
major or Variola minor, Sporothrix schenckii, Staphylococcus genus, Staphylococcus genus,
Staphylococcus aureus, Streptococcus pyogenes, Strongyloides stercoralis, Treponema pallidum,
Taenia genus, Clostridium tetani, Trichophyton genus, Trichophyton tonsurans, Trichophyton
genus, Epidermophyton floccosum, Trichophyton rubrum, and Trichophyton mentagrophytes,
Trichophyton rubrum, Hortaea werneckii, Trichophyton genus, Malassezia genus, Toxocara canis
or Toxocara cati, Toxoplasma gondii, Trichinella spiralis, Trichomonas vaginalis, Trichuris
trichiura, Mycobacterium tuberculosis, Francisella tularensis, Ureaplasma urealyticum,
Venezuelan equine encephalitis virus, Vibrio colerae, Guanarito virus, West Nile virus,
Trichosporon beigelii, Yersinia pseudotuberculosis, Yersinia enterocolitica, Yellow fever virus,
Mucorales order (Mucormycosis) and Entomophthorales order (Entomophthoramycosis),
Pseudomonas aeruginosa, Campylobacter (Vibrio) fetus, Aeromonas hydrophila, Edwardsiella
tarda, Yersinia pestis, Shigella dysenteriae, Shigella flexneri, Shigella sonnei, Salmonella
typhimurium, Treponema pertenue, Treponema carateneum, Borrelia vincentii, Borrelia
burgdorferi, Leptospira icterohemorrhagiae, Pneumocystis carinii, Brucella abortus, Brucella suis,
Brucella melitensis, Mycoplasma spp., Rickettsia prowazeki, Rickettsia tsutsugumushi, Clamydia
spp.; pathogenic fungi (Aspergillus fumigatus, Candida albicans, Histoplasma capsulatum);
protozoa (Entomoeba histolytica, Trichomonas tenas, Trichomonas hominis, Tryoanosoma
gambiense, Trypanosoma rhodesiense, Leishmania donovani, Leishmania tropica, Leishmania
braziliensis, Pneumocystis pneumonia, Plasmodium vivax, Plasmodium falciparum, Plasmodium
malaria); or Helminiths (Schistosoma japonicum, Schistosoma mansoni, Schistosoma
haematobium, and hookworms).
Other antibodies as a binding ligand in this invention for treatment of viral disease include,
but are not limited to, antibodies against antigens of pathogenic viruses, including as examples
and not by limitation: Poxyiridae, Herpesviridae, Adenoviridae, Papovaviridae, Enteroviridae,
Picornaviridae, Parvoviridae, Reoviridae, Retroviridae, influenza viruses, parainfluenza viruses,
mumps, measles, respiratory syncytial virus, rubella, Arboviridae, Rhabdoviridae, Arenaviridae,
Non-A/Non-B Hepatitis virus, Rhinoviridae, Coronaviridae, Rotoviridae, Oncovirus [such as,
HBV (Hepatocellular carcinoma), HPV (Cervical cancer, Anal cancer), Kaposi's sarcoma-
associated herpesvirus (Kaposi's sarcoma), Epstein-Barr virus (Nasopharyngeal carcinoma,
Burkitt's lymphoma, Primary central nervous system lymphoma), MCPyV (Merkel cell cancer),
SV40 (Simian virus 40), HCV (Hepatocellular carcinoma), HTLV-I (Adult T-cell
leukemia/lymphoma)], Immune disorders caused virus: [such as Human Immunodeficiency Virus
(AIDS)]; Central nervous system virus: [such as, JCV (Progressive multifocal
leukoencephalopathy), MeV (Subacute sclerosing panencephalitis), LCV (Lymphocytic
choriomeningitis), Arbovirus encephalitis, Orthomyxoviridae (probable) (Encephalitis lethargica),
RV (Rabies), Chandipura virus, Herpesviral meningitis, Ramsay Hunt syndrome type II;
Poliovirus (Poliomyelitis, Post-polio syndrome), HTLV-I (Tropical spastic paraparesis)];
Cytomegalovirus (Cytomegalovirus retinitis, HSV (Herpetic keratitis)); Cardiovascular virus
[such as CBV (Pericarditis, Myocarditis)]; Respiratory system/acute viral nasopharyngitis/viral
pneumonia: [Epstein-Barr virus (EBV infection/Infectious mononucleosis), Cytomegalovirus;
SARS coronavirus (Severe acute respiratory syndrome) Orthomyxoviridae: Influenzavirus A/B/C
(Influenza/Avian influenza), Paramyxovirus: Human parainfluenza viruses (Parainfluenza), RSV
(Human respiratory syncytial virus), hMPV]; Digestive system virus [MuV (Mumps),
Cytomegalovirus (Cytomegalovirus esophagitis); Adenovirus (Adenovirus infection); Rotavirus,
Norovirus, Astrovirus, Coronavirus; HBV (Hepatitis B virus), CBV, HAV (Hepatitis A virus),
HCV (Hepatitis C virus), HDV (Hepatitis D virus), HEV (Hepatitis E virus), HGV (Hepatitis G
virus)]; Urogenital virus [such as, BK virus, MuV (Mumps)].
According to a further object, the present invention also concerns pharmaceutical
compositions comprising the conjugate of the invention together with a pharmaceutically
acceptable carrier for treatment of cancer and autoimmune disorders. The method for treatment of
cancer and autoimmune disorders can be practiced in vitro, in vivo, or ex vivo. Examples of in
vitro uses include treatments of cell cultures in order to kill all cells except for desired variants
that do not express the target antigen; or to kill variants that express undesired antigen. Examples
of ex vivo uses include treatments of hematopoietic stem cells (HSC) prior to the performance of
the transplantation (HSCT) into the same patient in order to kill diseased or malignant cells. For
instance, clinical ex vivo treatment to remove tumor cells or lymphoid cells from bone marrow
prior to autologous transplantation in cancer treatment or in treatment of autoimmune disease, or
to remove T cells and other lymphoid cells from allogeneic bone marrow or tissue prior to
transplant in order to prevent graft-versus-host disease, can be carried out as follows. Bone
marrow is harvested from the patient or other individual and then incubated in medium containing
serum to which is added the conjugate of the invention, concentrations range from about 1 pM to
0.1 mM, for about 30 minutes to about 48 hours at about 37 ºC. The exact conditions of
concentration and time of incubation (=dose) are readily determined by the skilled clinicians.
After incubation the bone marrow cells are washed with medium containing serum and returned
to the patient by i.v. infusion according to known methods. In circumstances where the patient
receives other treatment such as a course of ablative chemotherapy or total-body irradiation
between the time of harvest of the marrow and reinfusion of the treated cells, the treated marrow
cells are stored frozen in liquid nitrogen using standard medical equipment.
For clinical in vivo use, the conjugate of the invention will be supplied as solutions or as a
lyophilized solid that can be redisolved in sterile water for injection. Examples of suitable
protocols of conjugate administration are as follows. Conjugates are given weekly for 8 weeks as
an i.v. bolus. Bolus doses are given in 50 to 500 ml of normal saline to which human serum
albumin (e.g. 0.5 to 1 mL of a concentrated solution of human serum albumin, 100 mg/mL) can
be added. Dosages will be about 50 µg to 20 mg/kg of body weight per week, i.v. (range of 10 µg
to 200 mg/kg per injection). 8 weeks after treatment, the patient may receive a second course of
treatment. Specific clinical protocols with regard to route of administration, excipients, diluents,
dosages, times, etc., can be determined by the skilled clinicians.
Examples of medical conditions that can be treated according to the in vivo or ex vivo
methods of killing selected cell populations include malignancy of any types of cancer,
autoimmune diseases, graft rejections, and infections (viral, bacterial or parasite).
The amount of a conjugate which is required to achieve the desired biological effect, will vary
depending upon a number of factors, including the chemical characteristics, the potency, and the
bioavailability of the conjugates, the type of disease, the species to which the patient belongs, the
diseased state of the patient, the route of administration, all factors which dictate the required dose
amounts, delivery and regimen to be administered.
In general terms, the conjugates of this invention may be provided in an aqueous physiological
buffer solution containing 0.1 to 10% w/v conjugates for parenteral administration. Typical dose
ranges are from 1 µg/kg to 0.1 g/kg of body weight per day; a preferred dose range is from 0.01
mg/kg to 20 mg/kg of body weight per day or an equivalent dose in a human child. The preferred
dosage of drug to be administered is likely to depend on such variables as the type and extent of
progression of the disease or disorder, the overall health status of the particular patient, the relative
biological efficacy of the compound selected, the formulation of the compound, the route of
administration (intravenous, intramuscular, or other), the pharmacokinetic properties of the compound
by the chosen delivery route, and the speed (bolus or continuous infusion) and schedule of
administrations (number of repetitions in a given period of time).
The conjugates of the present invention are also capable of being administered in unit dose
forms, wherein the term “unit dose” means a single dose which is capable of being administered to a
patient, and which can be readily handled and packaged, remaining as a physically and chemically
stable unit dose comprising either the active conjugate itself, or as a pharmaceutically acceptable
composition, as described hereinafter. As such, typical total daily dose ranges are from 0.01 to 100
mg/kg of body weight. By way of general guidance, unit doses for humans range from 1 mg to 3000
mg per day. Preferably the unit dose range is from 1 to 500 mg administered one to four times a day,
and even more preferably from 10 mg to 500 mg, once a day. Conjugatess provided herein can be
formulated into pharmaceutical compositions by admixture with one or more pharmaceutically
acceptable excipients. Such unit dose compositions may be prepared for use by oral administration,
particularly in the form of tablets, simple capsules or soft gel capsules; or intranasally, particularly in
the form of powders, nasal drops, or aerosols; or dermally, for example, topically in ointments,
creams, lotions, gels or sprays, or via trans-dermal patches. The compositions may conveniently be
administered in unit dosage form and may be prepared by any of the methods well known in the
pharmaceutical art, for example, as described in Remington: The Science and Practice of Pharmacy,
21 ed.; Lippincott Williams & Wilkins: Philadelphia, PA, 2005.
Preferred formulations include pharmaceutical compositions in which a compound of the
present invention is formulated for oral or parenteral administration. For oral administration, tablets,
pills, powders, capsules, troches and the like can contain one or more of any of the following
ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, or gum
tragacanth; a diluent such as starch or lactose; a disintegrant such as starch and cellulose derivatives; a
lubricant such as magnesium stearate; a glidant such as colloidal silicon dioxide; a sweetening agent
such as sucrose or saccharin; or a flavoring agent such as peppermint, or methyl salicylate. Capsules
can be in the form of a hard capsule or soft capsule, which are generally made from gelatin blends
optionally blended with plasticizers, as well as a starch capsule. In addition, dosage unit forms can
contain various other materials that modify the physical form of the dosage unit, for example, coatings
of sugar, shellac, or enteric agents. Other oral dosage forms syrup or elixir may contain sweetening
agents, preservatives, dyes, colorings, and flavorings. In addition, the active compounds may be
incorporated into fast dissolve, modified-release or sustained-release preparations and formulations,
and wherein such sustained-release formulations are preferably bi-modal. Preferred tablets contain
lactose, cornstarch, magnesium silicate, croscarmellose sodium, povidone, magnesium stearate, or
talc in any combination.
Liquid preparations for parenteral administration include sterile aqueous or non-aqueous
solutions, suspensions, and emulsions. The liquid compositions may also include binders, buffers,
preservatives, chelating agents, sweetening, flavoring and coloring agents, and the like. Non-aqueous
solvents include alcohols, propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and
organic esters such as ethyl oleate. Aqueous carriers include mixtures of alcohols and water, buffered
media, and saline. In particular, biocompatible, biodegradable lactide polymer, lactide/glycolide
copolymer, or polyoxyethylene-polyoxypropylene copolymers may be useful excipients to control the
release of the active compounds. Intravenous vehicles can include fluid and nutrient replenishers,
electrolyte replenishers, such as those based on Ringer's dextrose, and the like. Other potentially
useful parenteral delivery systems for these active compounds include ethylene-vinyl acetate
copolymer particles, osmotic pumps, implantable infusion systems, and liposomes.
Alternative modes of administration include formulations for inhalation, which include such
means as dry powder, aerosol, or drops. They may be aqueous solutions containing, for example,
polyoxyethylenelauryl ether, glycocholate and deoxycholate, or oily solutions for administration in
the form of nasal drops, or as a gel to be applied intranasally. Formulations for buccal administration
include, for example, lozenges or pastilles and may also include a flavored base, such as sucrose or
acacia, and other excipients such as glycocholate. Formulations suitable for rectal administration are
preferably presented as unit-dose suppositories, with a solid based carrier, such as cocoa butter, and
may include a salicylate. Formulations for topical application to the skin preferably take the form of
an ointment, cream, lotion, paste, gel, spray, aerosol, or oil. Carriers which can be used include
petroleum jelly, lanolin, polyethylene glycols, alcohols, or their combinations. Formulations suitable
for transdermal administration can be presented as discrete patches and can be lipophilic emulsions or
buffered, aqueous solutions, dissolved and/or dispersed in a polymer or an adhesive.
In a specific embodiment, a conjugate of the invention is administered concurrently with the
other known or will be known therapeutic agents such as the chemotherapeutic agent, the
radiation therapy, immunotherapy agents, autoimmune disorder agents, anti-infectious agents or
the other antibody-drug conjugates, resulting in a synergistic effect. In another specific
embodiment, the synergistic drugs or radiation therapy are administered prior or subsequent to
administration of a conjugate, in one aspect at least an hour, 12 hours, a day, a week, a month, in
further aspects several months, prior or subsequent to administration of a conjugate of the
invention.
In other embodiments, the synergistic drugs include, but not limited to:
1). Chemotherapeutic agents: a). Alkylating agents: such as [Nitrogen mustards:
(chlorambucil, cyclophosphamide, ifosfamide, mechlorethamine, melphalan, trofosfamide);
Nitrosoureas: (carmustine, lomustine); Alkylsulphonates: (busulfan, treosulfan); Triazenes:
(dacarbazine); Platinum containing compounds: (carboplatin, cisplatin, oxaliplatin)]; b). Plant
Alkaloids: such as [Vinca alkaloids: (vincristine, vinblastine, vindesine, vinorelbine); Taxoids:
(paclitaxel, docetaxol)]; c). DNA Topoisomerase Inhibitors: such as [Epipodophyllins: (9-
aminocamptothecin, camptothecin, crisnatol, etoposide, etoposide phosphate, irinotecan,
teniposide, topotecan,); Mitomycins: (mitomycin C)]; d). Anti-metabolites: such as {[Anti-folate:
DHFR inhibitors: (methotrexate, trimetrexate); IMP dehydrogenase Inhibitors: (mycophenolic
acid, tiazofurin, ribavirin, EICAR); Ribonucleotide reductase Inhibitors: (hydroxyurea,
deferoxamine)]; [Pyrimidine analogs: Uracil analogs: (5-Fluorouracil, doxifluridine, floxuridine,
ratitrexed(Tomudex)); Cytosine analogs: (cytarabine, cytosine arabinoside, fludarabine); Purine
analogs: (azathioprine, mercaptopurine, thioguanine)]}; e). Hormonal therapies: such as
{Receptor antagonists: [Anti-estrogen: (megestrol, raloxifene, tamoxifen); LHRH agonists:
(goscrclin, leuprolide acetate); Anti-androgens: (bicalutamide, flutamide)]; Retinoids/Deltoids:
[Vitamin D3 analogs: (CB 1093, EB 1089 KH 1060, cholecalciferol, ergocalciferol);
Photodynamic therapies: (verteporfin, phthalocyanine, photosensitizer Pc4, demethoxy-
hypocrellin A); Cytokines: (Interferon-alpha, Interferon-gamma, tumor necrosis factor (TNFs),
human proteins containing a TNF domain)]}; f). Kinase inhibitors, such as BIBW 2992 (anti-
EGFR/Erb2), imatinib, gefitinib, pegaptanib, sorafenib, dasatinib, sunitinib, erlotinib, nilotinib,
lapatinib, axitinib, pazopanib. vandetanib, E7080 (anti-VEGFR2), mubritinib, ponatinib
(AP24534), bafetinib (INNO-406), bosutinib (SKI-606), cabozantinib, vismodegib, iniparib,
ruxolitinib, CYT387, axitinib, tivozanib, sorafenib, bevacizumab, cetuximab, Trastuzumab,
Ranibizumab, Panitumumab, ispinesib; g). Others: such as gemcitabine, epoxomicins (e. g.
carfilzomib), bortezomib, thalidomide, lenalidomide, pomalidomide, tosedostat, zybrestat,
PLX4032, STA-9090, Stimuvax, allovectin-7, Xegeva, Provenge, Yervoy, Isoprenylation
inhibitors (such as Lovastatin), Dopaminergic neurotoxins (such as 1-methylphenylpyridinium
ion), Cell cycle inhibitors (such as staurosporine), Actinomycins (such as Actinomycin D,
dactinomycin), Bleomycins (such as bleomycin A2, bleomycin B2, peplomycin), Anthracyclines
(such as daunorubicin, doxorubicin (adriamycin), idarubicin, epirubicin, pirarubicin, zorubicin,
mtoxantrone, MDR inhibitors (such as verapamil), Ca ATPase inhibitors (such as thapsigargin),
Histone deacetylase inhibitors (Vorinostat, Romidepsin, Panobinostat, Valproic acid,
Mocetinostat (MGCD0103), Belinostat, PCI-24781, Entinostat, SB939, Resminostat, Givinostat,
AR-42, CUDC-101, sulforaphane, Trichostatin A) ; Thapsigargin, Celecoxib, glitazones,
epigallocatechin gallate, Disulfiram, Salinosporamide A.
2). An anti-autoimmune disease agent includes, but is not limited to, cyclosporine,
cyclosporine A, aminocaproic acid, azathioprine, bromocriptine, chlorambucil, chloroquine,
cyclophosphamide, corticosteroids (e.g. amcinonide, betamethasone, budesonide, hydrocortisone,
flunisolide, fluticasone propionate, fluocortolone danazol, dexamethasone, Triamcinolone
acetonide, beclometasone dipropionate), DHEA, enanercept, hydroxychloroquine, infliximab,
meloxicam, methotrexate, mofetil, mycophenylate, prednisone, sirolimus, tacrolimus.
3). An anti-infectious disease agent includes, but is not limited to, a). Aminoglycosides:
amikacin, astromicin, gentamicin (netilmicin, sisomicin, isepamicin), hygromycin B, kanamycin
(amikacin, arbekacin, bekanamycin, dibekacin, tobramycin), neomycin (framycetin,
paromomycin, ribostamycin), netilmicin, spectinomycin, streptomycin, tobramycin, verdamicin;
b). Amphenicols: azidamfenicol, chloramphenicol, florfenicol, thiamphenicol; c). Ansamycins:
geldanamycin, herbimycin; d). Carbapenems: biapenem, doripenem, ertapenem,
imipenem/cilastatin, meropenem, panipenem; e). Cephems: carbacephem (loracarbef), cefacetrile,
cefaclor, cefradine, cefadroxil, cefalonium, cefaloridine, cefalotin or cefalothin, cefalexin,
cefaloglycin, cefamandole, cefapirin, cefatrizine, cefazaflur, cefazedone, cefazolin, cefbuperazone,
cefcapene, cefdaloxime, cefepime, cefminox, cefoxitin, cefprozil, cefroxadine, ceftezole,
cefuroxime, cefixime, cefdinir, cefditoren, cefepime, cefetamet, cefmenoxime, cefodizime,
cefonicid, cefoperazone, ceforanide, cefotaxime, cefotiam, cefozopran, cephalexin, cefpimizole,
cefpiramide, cefpirome, cefpodoxime, cefprozil, cefquinome, cefsulodin, ceftazidime, cefteram,
ceftibuten, ceftiolene, ceftizoxime, ceftobiprole, ceftriaxone, cefuroxime, cefuzonam, cephamycin
(cefoxitin, cefotetan, cefmetazole), oxacephem (flomoxef, latamoxef); f). Glycopeptides:
bleomycin, vancomycin (oritavancin, telavancin), teicoplanin (dalbavancin), ramoplanin; g).
Glycylcyclines: e. g. tigecycline; g). β-Lactamase inhibitors: penam (sulbactam, tazobactam),
clavam (clavulanic acid); i). Lincosamides: clindamycin, lincomycin; j). Lipopeptides:
daptomycin, A54145, calcium-dependent antibiotics (CDA); k). Macrolides: azithromycin,
cethromycin, clarithromycin, dirithromycin, erythromycin, flurithromycin, josamycin, ketolide
(telithromycin, cethromycin), midecamycin, miocamycin, oleandomycin, rifamycins (rifampicin,
rifampin, rifabutin, rifapentine), rokitamycin, roxithromycin, spectinomycin, spiramycin,
tacrolimus (FK506), troleandomycin, telithromycin; l). Monobactams: aztreonam, tigemonam; m).
Oxazolidinones: linezolid; n). Penicillins: amoxicillin, ampicillin (pivampicillin, hetacillin,
bacampicillin, metampicillin, talampicillin), azidocillin, azlocillin, benzylpenicillin, benzathine
benzylpenicillin, benzathine phenoxymethylpenicillin, clometocillin, procaine benzylpenicillin,
carbenicillin (carindacillin), cloxacillin, dicloxacillin, epicillin, flucloxacillin, mecillinam
(pivmecillinam), mezlocillin, meticillin, nafcillin, oxacillin, penamecillin, penicillin, pheneticillin,
phenoxymethylpenicillin, piperacillin, propicillin, sulbenicillin, temocillin, ticarcillin; o).
Polypeptides: bacitracin, colistin, polymyxin B; p). Quinolones: alatrofloxacin, balofloxacin,
ciprofloxacin, clinafloxacin, danofloxacin, difloxacin, enoxacin, enrofloxacin, floxin, garenoxacin,
gatifloxacin, gemifloxacin, grepafloxacin, kano trovafloxacin, levofloxacin, lomefloxacin,
marbofloxacin, moxifloxacin, nadifloxacin, norfloxacin, orbifloxacin, ofloxacin, pefloxacin,
trovafloxacin, grepafloxacin, sitafloxacin, sparfloxacin, temafloxacin, tosufloxacin, trovafloxacin;
q). Streptogramins: pristinamycin, quinupristin/dalfopristin); r). Sulfonamides: mafenide,
prontosil, sulfacetamide, sulfamethizole, sulfanilimide, sulfasalazine, sulfisoxazole, trimethoprim,
trimethoprim-sulfamethoxazole (co-trimoxazole); s). Steroid antibacterials: e.g. fusidic acid; t).
Tetracyclines: doxycycline, chlortetracycline, clomocycline, demeclocycline, lymecycline,
meclocycline, metacycline, minocycline, oxytetracycline, penimepicycline, rolitetracycline,
tetracycline, glycylcyclines (e.g. tigecycline); u). Other types of antibiotics: annonacin,
arsphenamine, bactoprenol inhibitors (Bacitracin), DADAL/AR inhibitors (cycloserine),
dictyostatin, discodermolide, eleutherobin, epothilone, ethambutol, etoposide, faropenem, fusidic
acid, furazolidone, isoniazid, laulimalide, metronidazole, mupirocin, mycolactone, NAM
synthesis inhibitors (e. g. fosfomycin), nitrofurantoin, paclitaxel, platensimycin, pyrazinamide,
quinupristin/dalfopristin, rifampicin (rifampin), tazobactam tinidazole, uvaricin;
4). Anti-viral drugs: a). Entry/fusion inhibitors: aplaviroc, maraviroc, vicriviroc, gp41
(enfuvirtide), PRO 140, CD4 (ibalizumab); b). Integrase inhibitors: raltegravir, elvitegravir,
globoidnan A; c). Maturation inhibitors: bevirimat, vivecon; d). Neuraminidase inhibitors:
oseltamivir, zanamivir, peramivir; e). Nucleosides & nucleotides: abacavir, aciclovir, adefovir,
amdoxovir, apricitabine, brivudine, cidofovir, clevudine, dexelvucitabine, didanosine (ddI),
elvucitabine, emtricitabine (FTC), entecavir, famciclovir, fluorouracil (5-FU), 3’-fluoro-
substituted 2’, 3’-dideoxynucleoside analogues (e.g. 3’-fluoro-2’,3’-dideoxythymidine (FLT) and
3’-fluoro-2’,3’-dideoxyguanosine (FLG), fomivirsen, ganciclovir, idoxuridine, lamivudine (3TC),
l-nucleosides (e.g. β-l-thymidine and β-l-2’-deoxycytidine), penciclovir, racivir, ribavirin,
stampidine, stavudine (d4T), taribavirin (viramidine), telbivudine, tenofovir, trifluridine
valaciclovir, valganciclovir, zalcitabine (ddC), zidovudine (AZT); f). Non-nucleosides:
amantadine, ateviridine, capravirine, diarylpyrimidines (etravirine, rilpivirine), delavirdine,
docosanol, emivirine, efavirenz, foscarnet (phosphonoformic acid), imiquimod, interferon alfa,
loviride, lodenosine, methisazone, nevirapine, NOV-205, peginterferon alfa, podophyllotoxin,
rifampicin, rimantadine, resiquimod (R-848), tromantadine; g). Protease inhibitors: amprenavir,
atazanavir, boceprevir, darunavir, fosamprenavir, indinavir, lopinavir, nelfinavir, pleconaril,
ritonavir, saquinavir, telaprevir (VX-950), tipranavir; h). Other types of anti-virus drugs: abzyme,
arbidol, calanolide a, ceragenin, cyanovirin-n, diarylpyrimidines, epigallocatechin gallate
(EGCG), foscarnet, griffithsin, taribavirin (viramidine), hydroxyurea, KP-1461, miltefosine,
pleconaril, portmanteau inhibitors, ribavirin, seliciclib.
). Other immunotheraphy drugs: e.g. imiquimod, interferons (e.g. α, β), granulocyte
colony-stimulating factors, cytokines, Interleukins (IL-1 ~ IL-35), antibodies (e. g. trastuzumab,
pertuzumab, bevacizumab, cetuximab, panitumumab, infliximab, adalimumab, basiliximab,
daclizumab, omalizumab), Protein-bound drugs (e.g., Abraxane), an antibody conjugated with
drugs selected from calicheamicin derivative, of maytansine derivatives (DM1 and DM4) , CC-
1065 and duocarmycin minor groove binders, potent taxol derivatives, doxorubicin, auristatin
antimitotic drugs (e. g. Trastuzumab-DM1, Inotuzumab ozogamicin, Brentuximab vedotin,
Glembatumumab vedotin, lorvotuzumab mertansine, AN-152 LMB2, TP-38, VB4-845,
Cantuzumab mertansine, AVE9633, SAR3419, CAT-8015 (anti-CD22), IMGN388,
milatuzumab-doxorubicin, SGN-75 (anti-CD70), Anti-CD22-MCC-DM1).
According to a still further object, the present invention is also concerned with the process
of preparation of the conjugate of the invention. The conjugate and process of the present invention
may be prepared in a number of ways well known to those skilled in the art. The antimitotic agents
used in the conjugate can be synthesized, for example, by application or adaptation of the methods
described below, or variations thereon as appreciated by the skilled artisan. The appropriate
modifications and substitutions will be readily apparent and well known or readily obtainable from
the scientific literature to those skilled in the art. In particular, such methods can be found in R.C.
Larock, Comprehensive Organic Transformations, 2 Edition, Wiley-VCH Publishers, 1999.
In the reactions described hereinafter, it may be necessary to protect reactive functional groups,
for example hydroxy, amino, imino, thio or carboxy groups, where these are desired in the final
product, to avoid their unwanted participation in the reactions. Conventional protecting groups may be
used in accordance with standard practice, for examples see P. G. Wuts and T.W. Greene, Greene's
Protective Groups in Organic Synthesis, Wiley-Interscience; 4th edition (2006). Some reactions
may be carried out in the presence of a base, or an acid or in a suitable solvent. There is no particular
restriction on the nature of the base, acid and solvent to be used in this reaction, and any base, acid or
solvent conventionally used in reactions of this type may equally be used here, provided that it has no
adverse effect on other parts of the molecule. The reactions can take place over a wide range of
temperatures. In general, we find it convenient to carry out the reaction at a temperature of from -
80°C to 150°C (more preferably from about room temperature to 100°C). The time required for the
reaction may also vary widely, depending on many factors, notably the reaction temperature and the
nature of the reagents. However, provided that the reaction is effected under the preferred conditions
outlined above, a period of from 3 hours to 20 hours will usually suffice.
The work-up of the reaction can be carried out by conventional means. For example, the
reaction products may be recovered by distilling off the solvent from the reaction mixture or, if
necessary after distilling off the solvent from the reaction mixture, pouring the residue into water
followed by extraction with a water-immiscible organic solvent and distilling off the solvent from the
extract. Additionally, the product can, if desired, be further purified by various well known techniques,
such as recrystallization, reprecipitation or the various chromatography techniques, notably column
chromatography or preparative thin layer chromatography. The synthesis of the antimitotic agents
and their conjugates of this invention are illustrated in the figures 1 ~28.
The comjugates of binding molecules with potent antimitotic agents are further illustrated
but not restricted by the description in the following examples.
6. EXPERIMENTAL MATERIALS:
Mass spectra were obtained using a Bruker Esquire 3000 system. NMR spectra were
recorded on a Bruker AVANCE300 spectrometer. Chemical shifts are reported in ppm relative
to TMS as an internal standard. Ultraviolet spectra were recorded on a Hitachi U1200
spectrophotometer. HPLC was performed using an Agilent 1100 HPLC system equipped with a
fraction collector and a variable wavelength detector. Thin layer chromatography was performed
on Analtech GF silica gel TLC plates. Aminal acids and their derivatives as well as preloaded
resins were either from Merck Chemicals International Co, or Synthetech Co., or Peptides
International Inc or Chembridge International Co. or Sigma –Aldrich Co. Some of the linkers,
Linkers of NHS ester /Maleimide (AMAS, BMPS, GMBS, MBS, SMCC, EMCS or Sulfo-
EMCS, SMPB, SMPH, LC-SMCC, Sulfo-KMUS, SM(PEG)4, SM(PEG)6, SM(PEG)8,
SM(PEG)12, SM(PEG)24); NHS ester /Pyridyldithiol (SPDP, LC-SPDP or Sulfo-LC-SPDP,
SMPT, Sulfo-LC-SMPT); NHS esters /Haloacetyl (SIA, SBAP, SIAB or Sulfo-SIAB); NHS
ester /Diazirine (SDA or Sulfo-SDA, LC-SDA or Sulfo-LC-SDA, SDAD or Sulfo-SDAD);
Maleimide /Hydrazide (BMPH, EMCH, MPBH, KMUH); Pyridyldithiol /Hydrazide (PDPH);
Isocyanate /Maleimide (PMPI) were purchased from Thermo Fisher Scientific Co. SPDB, SPP
linkers were made according to the references (Cumber, A. et al, Bioconjugate Chem., 1992, 3,
397–401). Human anti-CD22 antibody was from Santa Cruz Biotechnology, Inc. and
Trastuzumab was from Genentech. All other chemicals or anhydrous solvents were from Sigma-
Aldrich International.
Example 1. Methyl 4-(bis(2-hydroxyethyl)amino)oxobutanoate (3)
Dimethyl succinate (20.0 g, 136.9 mmol) and dihydroxyethylamine (7.20 g, 68.7 mmol) in
the mixture of anhydrous toluene (500 ml) and pyridine (50 ml) were refluxed at 150 °C for 28
h. The mixture was concentrated and purified on SiO column eluted with EtOAc/DCM (5%
~25% EtOAc) to afford the title compound (12.5 g, 83% yield). ESI MS m/z+ for
C H NaNO (M + Na) cald 242.2, found 242.4.
9 17 5
Example 2. Methyl 4-(bis(2-((methylsulfonyl)oxy)ethyl)amino)oxobutanoate (4)
Methyl 4-(bis(2-hydroxyethyl)amino)oxobutanoate (12.0 g, 49.56 mmol) in anhydrous
pyridine (350 ml) was added methanesulfonyl chloride (20.0 g, 175.4 mmol). After stirred
overnight the mixture was concentrated, diluted with EtOAc (350 ml), washed with cold 1 M
NaH PO (2 × 300ml), dried over MgSO , filtered and evaporated to afford crude product
2 4 4
(~18.8 g, >100% yield). The crude product was used for next step without further purification.
ESI MS m/z+ for C H NaNO S (M + Na) cald 398.2, found 398.4.
11 21 9 2
Example 3. Methyl 4-(bis(2-(acetylthio)ethyl)amino)oxobutanoate (5)
Methyl 4-(bis(2-((methylsulfonyl)oxy)ethyl)amino)oxobutanoate (fresh made, 90%
pure, 8.5 g, ~20 mmol) in DMA (350 ml) at 0 °C was added thioacetic acid (10 ml, 134 mmol),
followed by addtion of Et N (30 ml, 215 mmol). The mixture was then stirred at room
temperature overnight, concentrated, diluted with EtOAc (350 ml), washed with NaHCO
(sat’ed, 300 ml), NaCl sat’ed solution (300 ml) and 1 M NaH PO (300 ml). The organic layer
was dried over Na SO , filtered, evaporated and purified on SiO column eluted with
2 4 2
EtOAc/hexane (10% ~ 25% EtOAc) to afford the title compound (5.1 g, 76% yield). ESI MS
m/z+ for 25 C H NaNO S (M + Na) cald 358.1, found 358.2.
13 21 5 2
Example 4. 4-(Bis(2-(pyridinyldisulfanyl)ethyl)amino)oxobutanoic acid (6)
Methyl 4-(bis(2-(acetylthio)ethyl)amino)oxobutanoate (5.0 g, 14.9 mmol) in THF (150
ml) was added NaOH (5.0 g, 125 mmol) in water (100 ml). The mixture was stirred at RT for
min, neutralized with H PO to pH 7. Then 1,2-di(pyridinyl)disulfane (Aldrithiol-2, 26.0
g, 118 mmol) in THF (100 ml) was added and the mixture was stirred for 4 h, concentrated and
purified on SiO column eluted with MeOH/DCM/HOAc (1:20/0.2) to afford the title product
(5.8 g, 85.6% yield). ESI MS m/z+ for C H NaN O S (M + Na) cald 478.0, found 478.2.
18 21 3 3 4
Example 5. 2,5-dioxopyrrolidinyl 4-(bis(2-(pyridinyldisulfanyl)ethyl)amino)
oxobutanoate (7)
4-(Bis(2-(pyridinyldisulfanyl)ethyl)amino)oxobutanoic acid (5.2 g, 11.5 mmol) in
DMA (100 ml) was added NHS (1.6 g, 13.9 mmol) and EDC (5.0 g, 26.1 mmol). The mixture
was stirred overnight, evaporated and purified on SiO column eluted with EtOAc/DCM (5%
to 15% EtOAc) to afford the title product (5.8 g, 85.6% yield). ESI MS m/z+ for
C H NaN O S (M + Na) cald 575.1, found 575.2.
22 24 4 5 4
Example 6. 3,6-endoxo-Δ-tetrahydrophthalimide (12)
Maleimide (10.0 g, 103.0 mmol) in toluene (200 ml) was added furan (10.0 ml, 137.4
mmol). The mixture was heated inside a 1 L of autoClave bomb at 100 °C for 8 h. The bomb
was cooled to room temperature, and the inside solid was rinsed with methanol, concentrated
and crystallized in ethyl acetate/hexane to afford 16.7 g (99%) of the title compound. 1H NMR
(CDCl ): 11.12 (s, 1H) (NH), 6.68~6.64 (m, 2H), 5.18~5.13 (m, 2H), 2.97 ~2.92 (m, 2H). MS
m/z+ for C H NaNO (M + Na) cald 188.04, found 188.04.
8 7 3
Example 7. Methyl 4-((2-((3aR,4R,7S,7aS)-1,3-dioxo-3a,4,7,7a-tetrahydro-1H-4,7-
epoxyisoindol-2(3H)-yl)ethyl)(2-((4R,7S,7aS)-1,3-dioxo-3a,4,7,7a-tetrahydro-1H-4,7-
epoxyisoindol-2(3H)-yl)ethyl)amino)oxobutanoate (13)
Methyl 4-(bis(2-((methylsulfonyl)oxy)ethyl)amino)oxobutanoate (4, fresh made, 90%
pure, 8.5 g, ~20 mmol) in DMA (350 ml) was added 3,6-endoxo-Δ-tetrahydrophthalimide
(10.2 g, 61.8 mmol), sodium carbonate (8.0 g, 75.5 mmol) and sodium iodide (0.3 g, 2.0
mmol). The mixture was then stirred at room temperature overnight, concentrated, diluted with
EtOAc (350 ml), washed with NaHCO (sat’ed, 300 ml), NaCl sat’ed solution (300 ml) and 1
M NaH PO (300 ml). The organic layer was dried over Na SO , filtered, evaporated, loaded
2 4 2 4
on SiO column and eluted with EtOAc/hexane (10% ~ 30% EtOAc) to afford the title
compound (7.9 g, 77% yield). ESI MS m/z+ for C H NaN O (M + Na) cald 536.2, found
27 3 9
536.4.
Example 8. 4-(bis(2-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)ethyl)amino)oxobutanoic
acid (14)
Compound 13 (3.0 g, 5.8 mmol) and trimethylstannanol (4.8 g, 26.4 mmol) in 1,2-
dichloroethane (150 ml) was refluxed at 80 °C for 8 h. It was cooled to room temperature and
the residue was passed a short silica gel column and eluted with dichloromethane/methanol to
remove the extra trimethyltin hydroxide. Then the pooled fractions were combined,
concentrated and diluted with DMA and toluene, refluxed at 120 °C overnight, loaded on SiO
column and eluted with MeOH/DCM (5% ~ 10% MeOH) to afford the title compound (1.62 g,
76% yield). ESI MS m/z+ for C H NaN O (M + Na) cald 386.1, found 386.2.
16 17 3 9
Example 9. 2,5-Dioxopyrrolidinyl 4-(bis(2-(2,5-dioxo-2,5-dihydro-1H-pyrrol
yl)ethyl)amino)oxobutanoate
Compound 14 (1.60 g, 4.4 mmol) in DMA (100 ml) was added NHS (0.76 g, 6.61 mmol)
and EDC (1.70 g, 8.90 mmol). The mixture was stirred overnight, evaporated and purified on
SiO2 column, eluted with EtOAc/DCM (5% to 15% EtOAc) to afford the title product (1.72 g,
85.0% yield). ESI MS m/z+ for C H NaN O (M + Na) cald 483.1, found 483.2.
20 4 9
Example 10. t-Butyl 5-(3’,6’-endoxo-Δ-tetrahydrophthalimido) pentanoate
To a solution of t-Butyl -hydroxy pentanote (10.0 g, 57.4 mmol) in pyridine (60 ml) was
added mesyl chloride (8.0 ml, 103.3 mmol) and the mixture was stirred for 6 h, evaporated,
diluted with EtOAc, washed with cold 1M NaH PO , pH 6, dried over MgSO , filtered and
2 4 4
evaporated to dryness. To a mixture of compound 12 (9.90 g, 60.0 mmol) and Na CO (8.5 g,
80.1 mmol) in DMF (80 ml) was added dry mesylate compound. The mixture was stirred
overnight, evaporated, diluted with EtOAc, washed with saline water and 1M NaH PO (pH 6),
dried over MgSO , evaporated and purified on SiO column, eluted with
EtOAc/dichloromethane (1:12) to afford the title compound (14.01 g, 76%). MS m/z+ for
C H NaNO (M + Na) cald 344.16, found 344.16.
17 23 5
Example 11. 5-maleimido-pentanoic acid (21b)
Compound 17 (5.0 g, 15.57 mmol) in 1,4-dioxanne (40 ml) was added HCl (10 ml, 36%)
at 4 °C and the mixture was stirred for 30 min, evaporated to dryness to form 5-(3’,6’-endoxo-
Δ-tetrahydrophthalimido) pentanoic acid (4.08 g, 99%). The dried compound in mixture of
DMF/toluene (1:1, 40 ml) was refluxed for 6h, evaporated and crystallized from
EtOH/ether/hexane to afford the title compound (2.76 g, 90%). MS m/z+ for C H NO (M +
9 12 4
H) cald 198.07, found 198.07.
Example 12. N-succinimidyl 5-maleimido-pentanoate (23b) (DMPS linker)
To a solution of 5-maleimido-pentanoic acid 21b (2.0 g, 10.1 mmol) in dichloromethane
(20 ml) was added N-hydroxysuccimide (1.50 g, 13.0 mmol) and EDC (7.0 g, 36.4 mmol) and
the mixture was stirred overnight, evaporated and purified on SiO column
(EtOAc/dichloromethane, 1:10) to afford the title compound 23b (2.43 g, 82%). MS m/z+ for
C H NaN O (M + Na) cald 317.09, found 317.09.
13 14 2 6
Example 13. t-Butyl 5-(3’,6’-endoxo-Δ-tetrahydrophthalimido)pentanoyl hydrazine
carboxylate (25a-a)
-(3’,6’-endoxo-Δ-tetrahydrophthalimido) pentanoic acid (1.0 g, 3.77 mmol) in DMF (30
ml) was added tert-butyl carbazate (0.60 g, 4.53 mmol) and EDC (2.0 g, 10.4 mmol). The
mixture was stirred overnight, evaporated and purified on SiO column
(EtOAc/dichloromethane, 1:10) to afford the title compound (1.18 g, 83%). MS m/z+ for
C H NaN O (M + Na) cald 402.17, found 402.18.
18 25 3 6
Example 14. 5-maleimido-pentanoic acid hydrazide (25a-b)
Compound 25a-a (1.18 g, 3.11 mmol) was dissolved in the mixture of DMF/toluene (1:1,
ml), refluxed for 6 h and evaporated. The residue was dissolved in 1,4-dioxanne (20 ml) and
HCl (5 ml, 36%) was added at 4 °C and the mixture was stirred for 30 min, evaporated to
dryness and crystallized from EtOH/ether/hexane to afford the title compound (577 mg, 88%).
MS m/z+ for C H N O (M + H) cald 212.10, found 212.10.
9 14 3 3
Example 15. General procedure for 3’-bromo-maleimdo compounds 39 and 40, and 3’,4’-
dibromo-maleimdo compounds 43 and 44.
To amine 37 or 38 (~ 6 g) in DMF (60 ml) was added bromomaleic anhydride (1 eq) or
2,3-dibromomaleic anhydride (1 eq) and the mixture was stirred overnight, evaporated on an
oil pump to dryness to afford the crude enoic acids. To the crude enoic acids were added
HOAc (~50 ml) and Ac O (2 ~ 4 g) and the reaction mixture was fluxed at 120 °C for 6 ~ 12 h,
concentrated and purified on SiO column, eluted with EtOAc/dichloromethane (1:10 ~ 1:1) to
afford (61% ~ 87% yield) of the 3’-bromo-maleimdo compounds 39 and 40, and 3’,4’-
dibromomaleimdo compounds 43 and 44 respectively.
-(3-bromo-2,5-dioxo-2,5-dihydro-1H-pyrrolyl)pentanoic acid MS m/z+ for
C H BrNO (M + H) cald 275.98, found 275.98.
9 11 4
3-(2-(2-(2-(3-bromo-2,5-dioxo-2,5-dihydro-1H-pyrrolyl)ethoxy)ethoxy)ethoxy)-
propanoic acid MS m/z+ for C H BrNO (M + H) cald 380.03, found 380.03.
13 19 7
-(3,4-dibromo-2,5-dioxo-2,5-dihydro-1H-pyrrolyl)pentanoic acid MS m/z+ for
C H Br NO (M + H) cald 353.89, found 353.89.
9 10 2 4
3-(2-(2-(2-(3,4-dibromo-2,5-dioxo-2,5-dihydro-1H-pyrrolyl)ethoxy)ethoxy)ethoxy)-
propanoic acid MS m/z+ for C H Br NO (M + H) cald 457.94, found 457.94.
13 18 2 7
Example 16. General procedure for NHS ester of 3’-bromo-maleimdo compounds 41 and 42,
and NHS ester of 3’,4’-dibromo-maleimdo compounds 45 and 46.
To the solution of 3’-bromo-maleimdo compounds 39 and 40 (1 eq), or 3’,4’-
dibromomaleimdo compounds 43 and 44 in DMA (~0.15 M) were added N-
hydroxysuccinimide (1.1 eq) and EDC (2~4 eq) and the mixture was stirred overnight,
concentrated and purified on SiO column, eluted with EtOAc/dichloromethane (1:20 ~ 1:5) to
afford (70% ~ 93% yield) of the 3’-bromomaleimdo linkers 41 and 42, and 3’,4’-dibromo-
maleimdo linkers 45 and 46 respectively.
2,5-dioxopyrrolidinyl 5-(3-bromo-2,5-dioxo-2,5-dihydro-1H-pyrrol
yl)pentanoate MS m/z+ for C H BrN NaO (M + Na) cald 395.00, found 395.00.
13 13 2 7
2,5-dioxopyrrolidinyl 5-(3,4-dibromo-2,5-dioxo-2,5-dihydro-1H-pyrrol
yl)pentanoate MS m/z+ for C H Br N NaO (M + Na) cald 472.91, found 472.91.
13 12 2 2 6
2,5-dioxopyrrolidinyl 3-(2-(2-(2-(3-bromo-2,5-dioxo-2,5-dihydro-1H-pyrrol
yl)ethoxy)ethoxy)ethoxy)propanoate MS m/z+ for C H BrN NaO (M + Na) cald 499.04,
17 21 2 9
found 499.04.
2,5-dioxopyrrolidinyl 3-(2-(2-(2-(3,4-dibromo-2,5-dioxo-2,5-dihydro-1H-pyrrol
yl)ethoxy)ethoxy)ethoxy)propanoate MS m/z+ for C H Br N NaO (M + Na) cald 576.95,
17 20 2 2 9
found 576.95.
Example 17. 4-(2-Pyridyldithio)methylpentanoic acid
4-Mercaptomethylpentanoic Acid (Goff, D. et al, BioConjugate Chem. 1990, 1, 381-
386) (4.67 g, 31.5 mmol) in methanol (15 ml) was added the solution of 2,2’-Dithiodipyridine
(30.0 g, 10 136.2 mmol) in the mixture of methanol (80 ml) and 100 mM sodium phosphate
buffer solution (pH 7.5, 70 ml). After stirred for 6 h, the mixture was concentrated, extracted
with EtOAc/Hexane (1:1). The aqueous solution was adjusted to pH 3 and extracted with
EtOAc (3 × 100 ml). The organic layers were combined, dried over Na SO , filtered,
evaporated and purified on SiO column (MeOH/dichloromethane/HOAc, 1:15:0.01) to afford
the title compound (7.05 g, 87%). MS m/z+ for C H NO S (M + H) cald 258.05, found
11 16 2 2
258.05.
Example 18. N-Succinimidyl 4-(2-pyridyldithio) methylpentanoate (243) (SMDP linker)
4-(2-pyridyldithio) methylpentanoic acid (2.0 g, 7.78 mmol) in dichloromethane (20 ml)
was added N-hydroxysuccimide (1.10 g, 9.56 mmol) and EDC (4.0 g, 20.8 mmol) and the
mixture was stirred overnight, evaporated and purified on SiO column
(EtOAc/dichloromethane, 1:10) to afford the title compound (2.48 g, 90%). MS m/z+ for
C H NaN O S (M + Na) cald 377.07, found 377.08.
18 2 4 2
Example 19. (3aR,4R,6S,6aR)((R)-2,2-dimethyl-1,3-dioxolanyl)-2,2-
dimethyltetrahydro-furo[3,4-d][1,3]dioxolol (62)
To a stirred slurry of D-gulonic-lactone (20.01 g, 112.37 mmol) and anhydrous CuSO
(25.0 g, 157.22 mmol) in dry acetone (450 mL) was added conc. H SO (1.6 mL), the mixture
was then stirred at room temperature for 24 h. The pH of the solution was adjusted to 7 with
Ca(OH) , and the resulting slurry was filtered and evaporated in vacuo to afford a diacetonide
(2,3:5,6-O-diisopropylidene-D-gulono-1,4-lactone) as a light-yellow syrup which was used in
the next step without further purification. To a stirred solution of diacetonide in THF (300 mL)
at -78 °C was added slowly 1 M solution of DIBAL-H (180 ml, 180 mM) in toluene. After
being stirred for 1 h at -78 °C, the reaction mixture was quenched with water (50 mL) and
filtered through Celite. The organic layer was separated, dried (Na SO ), and concentrated in
vacuo. The residue was purified by silica gel chromatography with hexane/ethyl acetate (5:1)
to give the title compound (25.27 g, 83% two steps) as colorless syrup. ESI MS m/z+ for
C H NaO (M +Na) cald 283.12, found 283.12.
12 20 6
Example 20. (3aR,4R,6S,6aR,Z)((R)-2,2-dimethyl-1,3-dioxolanyl)-2,2-dimethyl-N-(2-
methylpropylidene)tetrahydrofuro[3,4-d][1,3]dioxolamine oxide (64)
A mixture of 2,3:5,6-O-diisopropylidene-D-gulofuranose (62) (10.0 g, 38.4 mmol) and
hydroxylamine hydrochloride (25.01 g, 360.87 mmol) in pyridine (150 mL) was stirred at
room temperature for 1 h. The reaction mixture was concentrated in vacuo, added water (250
mL) and extracted with dichloromethane. The combined organic extracts were washed with
brine, dried (MgSO ), concentrated in vacuo and filtered through short silica gel column eluted
with ethyl acetate to give 2,3:5,6-O-diisopropylidene-D-gulose oxime (63) (10.34 g, 98%) as a
colorless vitreous substance which was used directly without further purification. A mixture of
this crude oxime (10.30 g, 37.43 mmol), isobutyraldehyde (3.00 g, 41.66 mmol), and MgSO
(3 g, 20 mmol) was stirred at the room temperature overnight. The mixture was filtered
through a pad of Celite. The filtered was concentrated in vacuo and the residue was passed
through a short SiO column and eluted with ethyl acetate to afford the title compound (11.57 g,
94% yield) as white solid. ESI MS m/z+ for C H NO cald 329.18., found 329.18.
16 27 6
Example 21. (3R,5R)((3aR,4R,6S,6aR)((R)-2,2-dimethyl-1,3-dioxolanyl)-2,2-
dimethyltetrahydrofuro[3,4-d][1,3]dioxolyl)[(-)-10',2'-camphorsultam]-
Npropylisoxazolidinecarboxamide (65)
A mixture of (3aR,4R,6S,6aR,Z)((R)-2,2-dimethyl-1,3-dioxolanyl)-2,2-dimethyl-N-
(2-methylpropylidene)tetrahydrofuro[3,4-d][1,3]dioxolamine oxide (6.00 g 18.22 mmol)
and (2R)-N-(acryloyl) bornane-10,2-sultams (5.10 g, 18.95 mmol) in dichloromethane (50 mL)
was heated under reflux for 37 h. After concentration, the residue was recrystallized from
EtOH (30 mL) to give the title compound (8.72 g, 80% yield) as a colorless solid. Flash
chromatography (silica gel, hexane/AcOEt 7:3) of the mother liquor gave further (0.47 g, 4%)
of the title compound as a colorless solid. MS ESI: m/z: [M+Na] , calcd for C H N NaO S
29 46 2 9
621.28, found 621.28.
Example 22. (3R,5R)(5 tert-butoxycarbonyl)isopropylisoxazolidinecarboxylic acid
(67)
A solution of LiOH (5.0 g, 208.7 mmol) in water (60 mL) at 45 °C was added to a solution
of (3R,5R)((3aR,4R,6S,6aR)((R)-2,2-dimethyl-1,3-dioxolanyl)-2,2-
dimethyltetrahydrofuro[3,4-d][1,3]dioxolyl)[(-)-10',2'-camphorsultam]-
Npropylisoxazolidinecarboxamide (30.0 g, 48.2 mmol) in THF (100 mL) and MeOH (60
mL). After stirred for 1 h, the mixture was concentrated, poured into H O (150 mL) and the
mixture was adjusted to pH 9 with 4 M HCl. The mixture was extracted with EtOAc, then the
aqueous layer was adjusted to pH 3 with 4 M HCl, extracted with EtOAc, the organic extract
was washed with brine, dried over Na SO , filtered, and concentrated in vacuo. The residue
was triturated with hexane to give (3R,5R){(3aR,4R,6S,6aR)[(R)-2,2-dimethyl-1,3-
dioxolanyl]-2,2-dimethyltetrahydrofuro[3,4-d,1,3]dioxolyl}isopropylisoxazolidine
carboxylic acid (66a, 17.1 g 88%) as a colorless solid. This material was used for the next step
without further purification. MS ESI: m/z: [M+Na] , calcd for C H NNaO , 424.19, found
19 31 8
424.19.
To a solution of this material (8.0 g, 19.95 mmol) in MeCN (80 mL) was added 60%
HClO aq. (6.0 mL, 35.77 mmol) at 45 °C, and the mixture was stirred at RT for 1 h. After
concentration, the residue was dissolved in 1,4-dioxane (40 mL), and then a suspension of
NaHCO (25 g, 297 mmol) in H O (32 mL) and Boc O (4.80 g, 22.00 mmol) was added at
3 2 2
4 °C. The mixture was stirred at RT for 4 h, concentrated, diluted with H O and
EtOAc/Hexane (1:1) and separated. The aqueous layer was adjusted to pH 3 with 4 M HCl aq.
The mixture was extracted with EtOAc, the organic layers were washed with brine, dried over
Na SO , filtered, and evaporated in vacuo. The residue was triturated with hexane to give
(3R,5R)(tertbutoxycarbonyl)- 3-isopropylisoxazolidinecarboxylic acid (4.91 g, 95%) as a
colorless amorphous solid. MS ESI: m/z: [M+Na] , calcd for C H NNaO , 282.13, found
12 21 5
282.13.
Example 23. Methyl (R)[(3R,5R)[(t-butyl-yl)methoxycarbonyl]
isopropylisoxazolidinecarboxamido](triphenylmethylthio)propionate (68)
Pr NEt (0.75 mL, 4.31 mmol) and TBTU (2.50 g, 7.78 mmol) were added to a solution of
(3R,5R)(tert-butoxycarbonyl)isopropylisoxazolidinecarboxylic acid (1.01 g, 3.89
mmol) and l-(S)-Tr-cysteine methyl ester hydrochloride (1.76 g, 4.27 mmol) in
dichloromethane (15 mL) at 4 °C and the mixture was stirred at RT overnight. The mixture
was poured into NaHCO (sat.) solution, extracted with dichloromethane, dried over Na SO ,
3 2 4
filtered, concentrated and silica gel chromatography (hexane/AcOEt 1:2) to give the title
compound (2.10 g, 87%) as colorless amorphous solid. MS ESI: m/z: [M+Na] , calcd for
C H N NaO S, 641.27, found 641.26.
42 2 6
Example 24. (3R,5R)-tert-butyl 3-isopropyl(4-(methoxycarbonyl)thiazol
yl)isoxazolidinecarboxylate (69)
Tf O (2.0 mL, 12.0 mmol) was added to a solution of Ph P=O (4.10 g, 14.74 mmol) in
dichloromethane (40.0 mL) and the mixture was stirred at -10 °C for 1 h. A solution of methyl
(R)[(3R,5R)[(t-butyl-yl)methoxycarbonyl]isopropylisoxazolidinecarboxamido]
(triphenylmethylthio)propionate (68) (4.00 g, 6.47 mmol) in dichloromethane (20 mL) was
added to the reaction mixture at -10 °C and the mixture was stirred at RT for 6 h, added to
NaHCO saturated solution at 4 °C and extracted with dichloromethane. The organic extracts
were washed with brine, dried over Na SO , filtered, concentrated in vacuo and SiO
2 4 2
chromatography (hexane/AcOEt 3:2) to give the corresponding thiazolidine derivative as a
yellow amorphous solid. MnO (5.80 g, 66.7 mmol) was added to a solution of this material in
dichloromethane (60 mL) and the mixture was stirred at RT for 24 h. The mixture was filtrated
via Celite, concentrated in vacuo and SiO chromatography (hexane/AcOEt 3:2) to give the
title compound (1.75 g, 75%) as a colorless amorphous solid. ESI: m/z: [M+Na] , calcd for
C H N NaO S, 379.13, found 379.14.
16 24 2 5
Example 25. Methyl 2-((1R,3R)(tert-butoxycarbonylamino)hydroxy
methylpentyl)-thiazolecarboxylate (70)
Mo(CO) (1.10 g, 3.12 mmol) was added to a solution of (3R,5R)-tert-butyl 3-
isopropyl(4-(methoxycarbonyl)thiazolyl)isoxazolidinecarboxylate (69) (1.00 g,
2.81 mmol) in CH CN (20 ml) and H O (2 ml) and the mixture was stirred at 70 °C for
16 h. After concentration, the residue was diluted with EtOAc (50 mL) and a 10% aq.
solution of citric acid (50 ml). NaIO was added to the mixture until the aqueous layer
became clear, and extracted with EtOAc. The organic extracts were washed with a 10%
aq. Na S O and brine, dried over Na SO , filtered, concentrated and SiO
2 2 3 2 4 2
chromatography (hexane/EtOAc 3:2) to give the title compound (906 mg, 90%) as a
colorless solid. MS ESI: m/z: [M+Na] , calcd for C H N NaO S, 381.14, found 381.14.
16 26 2 5
Example 26. Methyl 2-((1R,3R)acetoxy(tert-butoxycarbonyl-amino)
methylpentyl)-5 thiazolecarboxylate (71)
Compound 70 (900 mg, 2.51 mmol) in pyridine (15 ml) was added Ac O (0.5 ml, 5.29
mmol) and the mixture was stirred overnight, concentrated, SiO chromatography
(hexane/EtOAc 4:1) to give the title compound (950 mg, 95%) as a colorless solid. MS ESI:
m/z: [M+Na] , calcd for C H N NaO S, 423.15, found 423.16.
18 28 2 6
Example 27. 2-((1R,3R)acetoxy(tert-butoxycarbonylamino)methylpentyl)thiazole-
4-carboxylic acid (72)
Compound 71 (940 mg, 2.35 mmol) in THF (15 ml) was added NaH (120 mg, 3.0 mmol,
60% in oil) at 4 °C and the mixture was stirred for 2 h, then CH I (0.155 ml, 2.49 mmol) was
added. After stirred overnight, concentrated, re-dissolved in EtOAc, filtered through short SiO
column and evaporated to dryness to give a crude 2-((1R,3R)acetoxy(tert-
butoxycarbonyl-(methyl)amino)methylpentyl)thiazolecarboxylic acid (73a). To the
dry compound (73a) in 1,2-dichloroethane (20 ml) was added trimethyltin hydroxide (620 mg,
3.43 mmol). The mixture was stirred at 80 °C overnight, concentrated, re-dissolved
MeOH/dichloromethane/HOAc (1:5:0.01, 20 ml), filtered through short SiO column,
concentrated and co-evaporated with toluene to dryness. To the dry compound in pyridine (15
ml) was added Ac O (0.4 ml, 4.23 mmol). After stirred overnight, the mixture was
concentrated, purified by SiO chromatography (MeOH/dichloromethane/HOAc (1:10:0.01) to
give the title compound (735 mg, 78%) as a colorless solid. ESI: m/z: [M+Na] , calcd for
C H N NaO S 423.15, found 423.16.
18 28 2 6
Example 28. Methyl 2-((1R,3R)(tert-butoxycarbonyl(methyl)amino)(3-(1,3-
dioxoisoindolinyl)propoxy)methylpentyl)thiazolecarboxylate (86)
Compound 70 (850 mg, 2.37 mmol) in THF (15 ml) at -20 °C was added NaH (100 mg,
2.5 mmol, 60% in oil). After stirred for 30 min at -20 °C, N-(3-Bromopropyl)phthalimide (655
mg, 2.4 mmol) was added and the mixture was stirred at -20 °C for 30 min and then warmed
up to room temperature in 4 h. The reaction mixture was quenched with methanol (0.5 ml),
diluted with dichloromethane (60 ml), filtered through a short silica gel column, evaporated to
dryness to provide crude methyl 2-((1R,3R)(tert-butoxycarbonyl-amino)(3-(1,3-
dioxoisoindolinyl)propoxy)methylpentyl)thiazolecarboxylate (85) which was used
directly without further purification. To the crude compound 85 in THF (25 ml) at room
temperature was added NaH (170 mg, 4.25 mmol, 60% in oil). After stirred for 45 min, CH I
(0.20 ml, 3.21 mmol) was added. The mixture was stirred at room temperature overnight,
quenched with NaH PO (2.0 M, 2 ml). The mixture was diluted with DMA (5ml), evaporated
in vacuo, purified by SiO chromatography with EtOAc/dichloromethane (1:10 ~ 1:4) to afford
the title compound (921 mg, 69%). ESI: m/z: [M+Na] , calcd for C H N NaO S 582.22,
28 37 3 7
found 582.22.
Example 29. 2-((1R,3R)(tert-butoxycarbonyl(methyl)amino)(3-(1,3-dioxoisoindolin-
2-yl)propoxy)methylpentyl)thiazolecarboxylic acid (87)
To the dry compound 86 (910 mg, 1.63 mmol) in 1,2-dichloroethane (20 ml) was added
trimethyltin hydroxide (400 mg, 2.21 mmol). The mixture was stirred at 80 °C overnight,
concentrated, purified on SiO column, eluted with CH OH/dichloromethane/HOAc (1:10:0.01)
to afford the title compound (756 mg, 85%). ESI: m/z: [M+Na] , calcd for C H N NaO S
27 36 3 7
546.22, found 546.22.
Example 30. Methyl 2-((1R,3R)acetoxy(tert-butoxycarbonyl(3-(1,3-dioxoisoindolin-
2-yl)propyl)amino)methylpentyl)thiazolecarboxylate (89)
To the compound 71 (800 mg, 2.00 mmol) in THF (30 ml) at room temperature was added
NaH (150 mg, 3.75 mmol, 60% in oil). After stirred for 45 min, N-(3-
Bromopropyl)phthalimide (655 mg, 2.4 mmol) was added. The mixture was stirred at room
temperature overnight, quenched with NaH PO (2.0 M, 2 ml). The mixture was added DMA
(5 ml), evaporated and purified on SiO column, eluted with EtOAc/dichloromethane (1:10 ~
1:4) to afford the title compound (971 mg, 82%). ESI: m/z: [M+Na] , calcd for
C H N NaO S 610.22, found 610.22.
29 37 3 8
Example 31. 2-((1R,3R)acetoxy(tert-butoxycarbonyl(3-(1,3-dioxoisoindolin
yl)propyl)amino)methylpentyl)thiazolecarboxylic acid (90)
To the dry compound 89 (900 mg, 1.53 mmol) in 1,2-dichloroethane (35 ml) was added
trimethyltin hydroxide (400 mg, 2.21 mmol). The mixture was stirred at 80 °C overnight,
concentrated. Then the mixture in pyridine (20 ml) was added Ac O (3 ml) and stirred
overnight, evaporated, purified on SiO column (MeOH/dichloromethane/HOAc, 5 1:10:0.01)
to afford the title compound (755 mg, 86%). ESI: m/z: [M+Na] , calcd for C H N NaO S
28 35 3 8
596.20, found 596.20.
Example 32. (S)-Ethyl 5-(4-(benzyloxy)phenyl)(tert-butoxy-carbonylamino)
methylpentenoate (185)
(S)-Methyl 3-(4-(benzyloxy)phenyl)(tert-butoxy-carbonylamino)propanoate (184, 8.00
g, 20.76 mmol) in dichloromethane (250 ml) at -78 °C was added dropwise DIBAL (40 ml, 40
mmol, 1.0 M) in dichloromethane. After stirred at -78 °C for 2 h, the reaction was quenched
with addition of MeOH (5 ml). The mixture was warmed to RT, acidified with 1 M HCl to pH
4 and separated. The aqueous layer was extracted with DCM (2 × 150 ml). The organic layers
were washed with water, dried over Na SO , filtered and evaporated to dryness to form cude
aldehyde intermediate. Then the crude intermediate aldehyde was dissolved in DCM, the ylide
solution prepared from 1-(1-ethoxycarbonyl ethyl)-triphenylphosphonium bromide (18.0 g,
40.64 mmol) and KO Bu (5.00g, 44.64 mmol) in dichloromethane (80 ml) was added at RT.
After stirred at RT over night, the mixture was extracted concentrated and purified by SiO
chromatography (EtOAc/Hexane, 1:8 ~ 1:4) to afford (6.90 g, 76%) of the title compound. ESI:
m/z: [M+Na] , calcd for C H NNaO 462.22, found 462.22.
26 33 5
Example 33. (4R)-ethyl 4-((tert-butoxycarbonyl)amino)(4-hydroxyphenyl)
methylpentanoate (186)
(S)-Ethyl 5-(4-(benzyloxy)phenyl)(tert-butoxy-carbonylamino)methylpentenoate
(185, 6.70 g, 15.26 mmol) in a hydrogenation bottle was charged methanol (150 ml), Pd/C (0.3
g, 10% Pd). The hydrogenation reaction was conducted at 30 psi for 6 h. The mixture was
filtered through Celite, evaporated and crystallized with EtOH/hexane to the title compound
(4.61 g, 86% yield). ESI: m/z: [M+Na] , calcd for C H NNaO 374.20, found 374.30.
19 29 5
Example 34. (4R)-ethyl 4-((tert-butoxycarbonyl)amino)(4-hydroxynitrophenyl)
methylpentanoate (187)
To a solution of compound 186 (4.50 g, 12.81 mmol) in anhydrous dichloromethane (200
ml) was added Ac O (2 ml, 21.16 mmol) and fuming HNO (0.65 ml, 14.07 mmol). The
mixture was stirred at RT for 4 h, diluted with water (150 ml), separated and the aqueous layer
was extracted with EtOAc. The organic layers were combined, dried over Na SO , evaporated
and purified on SiO column (EtOAc/DCM, 1:10) to afford (4.21 g, 83%) of the title
compound. ESI: m/z: [M+Na] , calcd for C H N NaO , 419.19, found 419.20.
19 28 2 7
Example 35. ethyl 4-((tert-butoxycarbonyl)amino)methyl(3-nitro
(phosphonooxy)phenyl)pentanoate (188)
Compound 187 (4.00 g, 10.09 mmol) in a mixture of CH CN (70 ml) and DMA (30 ml)
was added DIPEA (4.00 ml, 23.00 mmol) at 0 °C. After stirred for 2 min, POCl (2.00 ml,
21.45 mmol) was added dropwise at 0 °C. The mixture was stirred at RT for 8 h, and quenched
with slowly addition of NaHCO (3.5 g, 41.60 mmol) in water (20 ml) at 0 °C. After stirred at
0 °C overnight, the mixture was concentrated and purified on C-18 cartridge (20 x 4 cm) eluted
with gradient mixture, 25 ml/min, A: 0.5% HOAc, B: CH OH, from 100% A in 10 min, then to
75% A and 25% B in 45 min. The fractions containing the product was pooled and evaporated
to afford the title compound (3.89 g, 81% yield). ESI: m/z: [M-H] , calcd for C H N O P
19 28 2 10
475.16, found 475.20.
Example 36. (4R)((tert-butoxycarbonyl)amino)methyl(3-nitro
(phosphonooxy)phenyl)pentanoic acid (189)
To a solution of LiOH (5.0 g, 208.7 mmol) in water (60 mL) was added to a solution of
compound (188) (3.75 g, 7.87 mmol) in THF (100 mL). After stirred for 4 h at 0 °C, the
mixture was adjusted to pH ~6 with 4 M HCl, concentrated, and purified by C-18
chromatography, eluted with gradient mixture, 25 ml/min, A: 0.5% HOAc, B: CH OH, from
100% A in 10 min, then to 75% A and 25% B in 45 min. The fractions containing the product
was pooled and evaporated to afford the title compound (2.82 g, 80% yield). ESI: m/z: [M-H] ,
calcd for C H N O P 447.12, found 447.20.
17 24 2 10
Example 37. (4R)(3-amino(phosphonooxy)phenyl)((tert-butoxycarbonyl)amino)-
2-methylpentanoic acid (190)
Compound 189 (2.60 g, 5.80 mmol) in a hydrogenation bottle was charged methanol (80
ml), Pd/C (0.2 g, 10% Pd). The hydrogenation reaction was conducted at 35 psi of H for 6 h.
The mixture was filtered through Celite, evaporated to afford the crude title compound (190)
(2.18 g, 90% yield), which was used directly without further purification. ESI: m/z: [M+Na] ,
calcd for C H N O P 417.15, found 417.15.
17 26 2 8
Example 38. (S)-methyl 2-((tert-butoxycarbonyl)amino)(4-hydroxy
nitrophenyl)propanoate (196)
To a solution of (S)-methyl 2-((tert-butoxycarbonyl)amino)(4-hydroxyphenyl)
propanoate (195, 4.5 g, 15.24 mmol) in anhydrous dichloromethane (240 ml) was added Ac O
(4 ml, 42.32 mmol) and fuming HNO (0.85 ml, 18.40 mmol). The mixture was stirred at RT
for 4 h, diluted with water (150 ml), separated and the aqueous layer was extracted with EtOAc.
The organic layers were combined, dried over Na SO , evaporated and purified on SiO
2 4 2
column (EtOAc/DCM, 1:10) to afford (4.30 g, 83%) of the title compound. ESI: m/z: [M+Na] ,
calcd for C H N NaO , 363.13, found 363.20.
20 2 7
Example 39. (S)-methyl 2-((tert-butoxycarbonyl)amino)(3-nitro
(phosphonooxy)phenyl)propanoate (197)
To a solution of compound 196 (4.10 g, 12.05 mmol) in a mixture of CH CN (90 ml) was
added DIPEA (4.00 ml, 23.00 mmol) at 0 °C. After stirred for 2 min, POCl (2.00 ml, 21.45
mmol) was added dropwise at 0 °C. The mixture was stirred at RT for 8 h, and quenched with
slowly addition of NaHCO (3.5 g, 41.60 mmol) in water (20 ml) at 0 °C. After stirred at 0 °C
overnight, the mixture was concentrated and purified on C-18 cartridge (20 × 4 cm) eluted with
gradient mixture, 25 ml/min, A: 0.5% HOAc, B: CH OH, from 100% A in 10 min, then to
75% A and 25% B in 45 min. The fractions containing the product was pooled and evaporated
to afford (4.20 g, 83%) the title compound. ESI: m/z: [M-H] , calcd for C H N O P 419.08,
20 2 10
found 419.10.
Example 40. 3-[3-amino(phosphonooxy)phenyl]-(2R){[(tert-
butoxy)carbonyl]amino}-propanoic acid (198)
To the dry compound 197 (4.0 g, 9.52 mmol) in the mixture of 1,2-dichloroethane (50 ml)
and DMA (60 ml) was added trimethyltin hydroxide (4.00 g, 22.1 mmol). The mixture was
stirred at 80 °C for 6h, evaporated, filtered through short SiO column eluted with
water/MeCN (1:4). The fractions containing the product were pooled, concentrated to generate
(S)((tert-butoxycarbonyl)amino)(3-nitro(phosphonooxy)phenyl)propanoic acid. In a
hydrogenation bottle was charged DMA (70 ml), Pd/C (0.3 g, 10% Pd), followed by the
addition of the prepared propanoic acid. The hydrogenation reaction was conducted at 30 psi of
hydrogen for 6 h. The mixture was filtered through Celite, evaporated, and crystallized to
afford (2.86 g, 80% yield) of the title compound (198), which was used directly without further
purification. ESI: m/z: [M-H] , calcd for C H N O P 375.10, found 375.10.
14 20 2 8
Example 41. Benzyl 3-[4-(benzyloxy)phenyl]-(2R){[(tert-butoxy)carbonyl]-(methyl)-
amino}-propanoate (200)
A solution of benzyl 3-[4-(benzyloxy)phenyl]-(2R){[(tert-butoxy)carbonyl]-
amino}propanoate (4.0 g, 8.67 mmol) in THF (60 ml) was added NaH (430 mg, 10.75 mmol,
60% in oil). After stirred at RT for 1 h, CH I (1.82 g, 12.82 mmol) was added, and the mixture
was stirred overnight, quenched with CH OH (0.5 ml), evaporated and purified on SiO
column (EtOAc/dichloromethane, 1:10) to afford the title compound (3.83 g, 93%). MS ESI:
m/z: [M+Na] , calcd for C H NNaO 498.24, found 498.24.
29 33 5
Example 42. (2R){[(tert-butoxy)carbonyl](methyl)amino}(4-hydroxy
nitrophenyl)propanoic acid (201)
Compound 200 (3.80 g, 8.00 mmol) in a hydrogenation bottle was charged methanol (80
ml), Pd/C (0.3 g, 10% Pd). The hydrogenation reaction was conducted at 30 psi of hydrogen
for 6 h. The mixture was filtered through Celite, evaporated to afford crude (2R)
{[(tertbutoxy)carbonyl](methyl)amino}(4-hydroxyphenyl)propanoic acid (201a), which was
used directly without further purification. To the compound 201a in anhydrous
dichloromethane (240 ml) at -25 °C was added dropwise a mixture of SnCl4 (1.5 ml, 12.75
mmol) and fuming HNO (0.60 ml, 12.98 mmol) in dichloromethane (40 ml). The mixture was
stirred at -25 °C for 75 min, quenched with saturated NaHCO to pH 3~4, separated and the aq.
layer was extracted with EtOAc. The organic layers were combined, dried over Na SO ,
concentrated and purified on SiO2 column (MeOH/DCM/HOAc 1:8:0.01) to afford (1.98 g,
73%) of the title compound. ESI: m/z: [M+Na] , calcd for C H N NaO 363.13, found
20 2 7
363.13.
Example 43. (2R){[(tert-butoxy)carbonyl](methyl)amino}[3-nitro(phosphonooxy)-
phenyl]propanoic acid (202)
To a solution of compound 201 (1.98 g, 5.82 mmol) in a mixture of CH3CN (30 ml) and
DMA (30 ml) was added DIPEA (2.00 ml, 11.50 mmol) at 0 °C. After stirred for 2 min, POCl
(1.10 ml, 11.79 mmol) was added dropwise at 0 °C. The mixture was stirred at RT for 8 h, and
quenched with slowly addition of NaHCO (2.0 g, 23.80 mmol) in water (10 ml) at 0 °C. After
stirred at 0 °C overnight, the mixture was concentrated and purified on C-18 cartridge (20 × 4
cm) eluted with gradient mixture, 25 ml/min, A: 0.5% HOAc, B: CH OH, from 100% A in 10
min, then to 75% A and 25% B in 45 min. The fractions containing the product was pooled and
evaporated to afford (1.96, 80%) the title compound. ESI: m/z: [M-H] , calcd for
C H N O P 419.09, found 419.09.
20 2 10
Example 44. 3-[3-amino(phosphonooxy)phenyl]-(2R)[(tert-butoxycarbonyl)
(methyl)-amino]-propanoic acid (203)
Compound 202 (1.96 g, 4.67 mmol) in a hydrogenation bottle was charged DMA (60 ml),
Pd/C (0.2 g, 10% Pd). The hydrogenation reaction was conducted at 30 psi of hydrogen for 6 h.
The mixture was filtered through Celite, evaporated to dryness to afford (1.74 g, 95%) of the
title compound, which was used directly without further purification. ESI: m/z: [M-H] , calcd
for C H N O P 389.12, found 389.12.
22 2 8
Example 45. tert-butyl N-(1-oxophenylpropan(2R)-yl)carbamate (204)
(1S,2R)-(+)-Norephedrine (7.0 g, 46.29 mmol) in the mixture of THF (40 ml) and 1M
NaHCO (100 ml) at 4 °C was added dropwise Boc O (10.15 g, 46.53 mmol) in THF (60 ml)
in 45 min. The mixture then stirred at RT for 6 h, concentrated, extracted with EtOAc, dried
over Na SO , concentrated and filtered through short SiO column eluted with EtOAc/Hexane
2 4 2
(1:2), concentrated to afford the crude tert-butyl N-((1S)-hydroxyphenylpropan(2R)-
yl)carbamate (204b) ( 10.81, 93%). MS ESI: m/z+: [M+Na] , calcd for C H NaNO 274.15,
14 21 3
found 274.15.
The crude compound was used directly without further purification. Compound 204b in
dichloromethane (50 ml) was added Dess-Martin periodinane solution in dichloromethane (180
ml, 0.3 M). After stirred for 1h, the mixture was added ice cold NaOH (1 M, 100 ml),
separated and the organic layers were washed with 1M NaH PO , pH 6 (100 ml), dried over
Na SO , evaporated and purified on SiO column (EtOAc/hexane 1:5) to afford the title
2 4 2
compound (9.34 g, 81% in two steps). MS ESI: m/z+: [M+Na] , calcd for C H NaNO
14 19 3
272.14, found 272.14.
Example 46. (1R,3R)((2S,3S)-N-(methyl)methyl((R)methylpiperidine
carboxamido)-pentamido)methyl(4-( (1-oxophenylpropan
yl)carbamoyl)thiazolyl)-pentyl acetate (205)
Compound 204 (180 mg, 0.722 mmol) in 4 ml of dioxane was added HCl conc. (1.0 ml,
37%) at 4 °C and the mixture was stirred at RT for 30 min, evaporated and coevaporated with
toluene to dryness. Then to the dryness solid in DMA (7 ml) were added compound 106 (251
mg, 0.466 mmol), EDC (305 mg, 1.56 mmol) and DIPEA (0.13 ml, 0.747 mmol) and the
mixture was stirred for 8h, evaporated and purified on SiO column (EtOAc/dichloromethane,
1:4) to afford the title compound (255.3 mg, 82%). ESI: m/z+: [M+Na] , calcd for
C H NaN O S 692.36, found 692.36.
51 5 6
Example 47. (1R,3R)((2S,3S)-N,3-dimethyl((R)methylpiperidinecarboxamido)-
pentanamido)(4-((R)(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)oxophenyl-3,6,9-
trioxa-13,14-diazaheptadecenylcarbamoyl)thiazolyl)methylpentyl acetate
(206)
Compound 205 (75 mg, 0.112 mmol) in methanol (5 ml) was added compound 12 (50 mg
in HCl salt, 0.126 mmol) and HOAc (3 ul, 0.052 mmol). The mixture was stirred overnight,
neutralized with DIPEA (23 ul, 0.132 mmol), evaporated and purified on SiO cartridge (4 g,
EtOAc/dichloromethane, 1:5 ~1:3) to afford the title compound (79.3 mg, 70%). MS ESI:
m/z+: [M+Na] , calcd for C H NaN O S 1033.51, found 1033.50.
50 74 8 12
Example 48. (1S,2R)(2-((1R,3R)acetoxy((2S,3S)-N,3-dimethyl((R)
methylpiperidinecarboxamido)pentanamido)methylpentyl)thiazole
carboxamido)phenyl-propyl 3-(2-(2 5 -(2-(2,5-dioxo-2,5-dihydro-1H-pyrrol
yl)ethoxy)ethoxy)ethoxy)-propanoate (211)
Compound 208a (95 mg, 0.141 mmol) and 3-(2-(2-(2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-
1-yl)ethoxy)ethoxy)ethoxy)propanoic acid (55 mg, 0.182 mmol) in dichloromethane (5 ml)
were added DCC (122 mg, 0.591 mmol) and DMAP (25 mg, 0.204 mmol) and the mixture was
stirred overnight, evaporated and purified with SiO chromatography (EtOAc/dichloromethane,
1:3) to afford the title compound (95.1 mg, 71%). MS ESI: m/z+: [M+Na] , calcd for
C H NaN O S 977.47, found 977.47.
48 70 6 12
Example 49. 2,5-dioxopyrrolidinyl 2-((1R,3R)acetoxy((2S,3S)-N,3-dimethyl
((R)methylpiperidinecarboxamido)pentanamido)methylpentyl)thiazole
carboxylate (234)
Compound 106 (788.1 mg, 1.464 mmol) in DMF (10 ml) were added NHS (202.0 mg,
1.756 mmol) and EDC (980 mg, 5.104 mmol) and the mixture was stirred overnight,
evaporated and purified with SiO chromatography (EtOAc/dichloromethane, 1:3) to afford the
title compound (762.8 mg, 82%). MS ESI: m/z+: [M+Na] , calcd for C H NaN O S 658.30,
45 5 8
found 658.30.
Example 50. (4R)(tert-butoxycarbonylamino)(3-(5-(2,5-dioxo-2,5-dihydro-1H-
pyrrolyl)pentanamido)(phosphonooxy)phenyl)methylpentanoic acid (235)
Compound 190 (825.1 mg, 1.973 mmol) in DMF (7 ml) was added 2,5-dioxopyrrolidin
yl 5-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)pentanoate (23d) (711 mg, 2.417 mmol) and
DIPEA (0.250 ml, 1.438 mmol), and the mixture was stirred overnight, evaporated and
purified with C-18 chromatography (4×25 cm, v = 15 ml/min, 100% of 1% HOAc to 75% of
1% HOAc/25% MeOH in 45 min ) to afford the title compound (895.7 mg, 76%). MS ESI:
m/z-: [M-H] , calcd for C H N O P 596.21, found 596.21.
26 35 3 11
Example 51. (4R)(tert-butoxycarbonylamino)(3-(3-(2-(2-(2-(2,5-dioxo-2,5-dihydro-
1Hpyrrolyl)ethoxy)ethoxy)ethoxy)propanamido)(phosphonooxy)phenyl)
methylpentanoic acid (236)
Compound 190 (632.5 mg, 1.512 mmol) in DMF (7 ml) were added 2,5-dioxopyrrolidin-
1-yl 3-(2-(2-(2-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)ethoxy)ethoxy)ethoxy)propanoate (24c)
(727 mg, 1.826 mmol) and DIPEA (0.250 ml, 1.438 mmol), and the mixture was stirred
overnight, evaporated and purified with C-18 chromatography (4 × 25 cm, v = 15 ml/min,
100% of 1% HOAc to 75% of 1% HOAc/25% MeOH in 45 min ) to afford the title compound
236 (763.2 mg, 72%). MS ESI: m/z-: [M-H] , calcd for C H N O P 700.25, found 700.25.
44 3 14
Example 52. (4R)(2-((1R,3R)acetoxy((2S,3S)-N,3-dimethyl((R)
methylpiperidinecarboxamido)pentanamido)methylpentyl)thiazole
carboxamido)(3-(5-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)pentanamido)
(phosphonooxy)phenyl)methylpentanoic acid (239)
Compound 235 (102 mg, 0.171 mmol) in 1,4-dioxane (4 ml) was added conc. HCl (1 ml,
37%) and the mixture was stirred for 30 min, evaporated to dryness to afford crude compound
237. To the crude compound in DMA (5 ml) were added compound 234 (110 mg, 0.173 mmol)
and DIPEA (30 µl, 0.172 mmol), and the mixture was stirred for overnight, evaporated and
purified by SiO chromatography (1% HOAc in water/acetone, 1:9 ~ 1:4) to afford the title
compound (123.2 mg, 71%). MS ESI: m/z-: [M-H] , calcd for C H N O PS 1016.42, found
47 67 7 14
1016.42.
Example 53. (4R)(2-((1R,3R)acetoxy((2S,3S)-N,3-dimethyl((R)
methylpiperidinecarboxamido)pentanamido)methylpentyl)thiazole
carboxamido)(3-(3-(2-(2-(2-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)ethoxy)ethoxy)-
ethoxy)-propanamido)(phosphonooxy)phenyl)methylpentanoic acid (240)
Compound 236 (108 mg, 0.154 mmol) in 1,4-dioxane (4 ml) was added conc. HCl (1 ml,
37%) and the mixture was stirred for 30 min, evaporated to dryness to afford the crude
compound 238. To the crude compound in DMA (5 ml) were added compound 234 (110 mg,
0.173 mmol) and DIPEA (30 µl, 0.172 mmol), and the mixture was stirred for overnight,
evaporated and purified by SiO chromatography (1% HOAc in water/acetone, 1:9 ~ 1:4) to
afford the title compound (131.2 mg, 76%). MS ESI: m/z-: [M-H] , calcd for C H N O PS
51 75 7 17
1120.47, found 1120.48.
Example 54. (4R)(tert-butoxycarbonylamino)methyl(4-(phosphonooxy)(4-
(pyridinyldisulfanyl)butanamido)phenyl)pentanoic acid (244)
To a solution of compound 190 (548.3 mg, 1.311 mmol) in DMF (10 ml) were added
succinimidyl 4-(pyridinyl)disulfanyl)-butyrate (550.2mg, 1.687 mmol) and DIPEA (0.18 ml,
1.03 mmol). The mixture was stirred overnight, evaporated and purified by SiO
chromatography (1% HOAc in water/acetone, 1:9 ~ 1:4) to afford the title compound (660.2
mg, 80%). MS ESI: m/z-: [M-H] , calcd for C H N O PS 628.16, found 628.16.
26 36 3 9 2
Example 55. (4R)(2-((1R,3R)acetoxy((2S,3S)-N,3-dimethyl((R)
methylpiperidinecarboxamido)pentanamido)methylpentyl)thiazole
carboxamido)methyl(4-(phosphonooxy)(4-(pyridin
yldisulfanyl)butanamido)phenyl)pentanoic acid(248)
Compound 244 (110.5 mg, 0.175 mmol) in 1,4-dioxane (4 ml) was added conc. HCl (1 ml,
37%) and the mixture was stirred at 4 °C for 30 min, evaporated to dryness to afford the crude
compound 246. To the crude compound in DMA (5 ml) were added compound 234 (110 mg,
0.173 mmol) and DIPEA (30 ul, 0.172 mmol). The mixture was stirred overnight, evaporated
and purified by SiO chromatography (1% HOAc in water/acetone, 1:9 ~ 1:4) to afford the title
compound (129.1 mg, 71%). MS ESI: m/z-: [M-H] , calcd for C H N O PS 1048.38, found
47 68 7 12 3
1048.38.
Example 56. (4R)(2-((1R,3R)acetoxy((2S,3S)-N,3-dimethyl((R)
methylpiperidinecarboxamido)pentanamido)methylpentyl)thiazole
carboxamido)(3-(4-mercaptobutanamido)(phosphonooxy)phenyl)
methylpentanoic acid (248b)
Compound 248 (30 mg, 0.0285 mmol) in a mixture of DMA (2 ml) and NaH PO (0.1 M,
pH 7) was added dithiothreitol (20 mg, 0.129 mmol). The mixture was stirred for 2 h,
evaporated and purified by SiO chromatography (1% HOAc in water/CH CN, 1:9 ~ 1:4) to
afford the title compound (22 mg, 85%). MS ESI: m/z-: [M-H] , calcd for C H N O PS
42 64 6 12 2
939.38, found 939.38.
Example 57. 4-(4-bromobutyl)oxaazatricyclo[5.2.1.0{2,6}]decene-3,5-dione (271)
-oxaazatricyclo[5.2.1.0{2,6}]decene-3,5-dione (6.0 g, 36.35 mmol) and NaH
(1.50 g, 37.50 mmol, 60% in oil) were stirred in DMA (60 ml) for 1 h, then 1,4-dibromobutane
(35.0 g, 162.10 mmol) and NaI (0.50 g, 3.33 mmol) were added. The mixture was stirred
overnight, quenched with CH OH (0.5 ml), evaporated, purified on SiO column
(EtOAc/Hexane, 1:8) to afford the title compound (9.34 g, 86%). MS ESI: m/z+: [M+Na] ,
calcd for C H BrNaNO 322.02, found 322.02.
12 14 3
Example 58. Methyl 2-((1R,3R)(tert-butoxycarbonylamino)[4’-(3’’,6’’-endoxo-Δ-
tetrahydrophthalimido)butyloxy]methylpentyl)thiazolecarboxylate (272)
Methyl 2-((1R,3R)(tert-butoxycarbonylamino)hydroxymethylpentyl)thiazole
carboxylate (70) (1.0 g, 2.79 mmol) and NaH (120 mg, 3.00 mmol, 60% in oil) were stirred in
THF (30 ml) for 20 min and compound 271 (1.00 g, 3.34 mmol) and NaI (50 mg, 0.33 mmol)
were added. The mixture was stirred overnight, quenched with MeOH (0.5 ml), evaporated and
purified on SiO column (EtOAc/dichloromethane, 1:10) to afford the title compound (1.36 g,
84%). MS ESI: m/z+: [M+Na] , calcd for C H NaN O S 600.25, found 600.25.
28 39 3 8
Example 59. Methyl 2-((1R,3R)(N,N-tert-butoxycarbonylmethylamino)[4’-(3’’,6’’-
endoxo-Δ-tetrahydrophthalimido)butyloxy]methylpentyl)thiazolecarboxylate (273)
Compound 272 (1.30 g, 2.25 mmol) and NaH (108 mg, 2.70 mmol, 60% in oil) stirred in
DMF (80 ml) for 1 h was added CH I (460 mg, 3.24 mmol). The mixture was stirred overnight,
evaporated and purified on SiO column (EtOAc/dichloromethane, 1:12 ~ 1:8) to afford the
title compound (1.01 g, 76%). MS ESI: m/z+: [M+Na] , calcd for C H NaN O S 614.26,
29 41 3 8
found 614.26.
Example 60. 2-((1R,3R)(N,N-tert-butoxycarbonylmethyl-amino)(4’-
maleimidobutyloxy)methylpentyl)thiazolecarboxylic acid (274)
To compound 273 (900 mg, 1.52 mmol) in a mixture of 1,2-dichloroethane (30 ml) and
toluene was added trimethyltin hydroxide (400 mg, 2.21 mmol). The mixture was stirred at
100 °C overnight, concentrated, purified on SiO column eluted with
MeOH/dichloromethane/HOAc (1:10:0.01) to afford the title compound (730 mg, 94%). ESI:
m/z: [M+Na] , calcd for C H N NaO S 532.22, found 532.22.
24 35 3 7
Example 61. Methyl 2-((1R,3R)acetoxy(N,N-(tert-butoxycarbonyl)(4’-(3’’,6’’-
endoxo-Δ-tetrahydrophthalimido)butyl)amino)methylpentyl)-thiazolecarboxylate
(275)
Compound 71 (1.50 g, 3.74 mmol) and NaH (180 mg, 4.50 mmol, 60% in oil) stirred in
DMF (80 ml) for 1 h was added compound 271 (1.48 g, 4.94 mmol) and NaI (70 mg, 0.467
mmol). The mixture was stirred overnight, evaporated and purified on SiO column
(EtOAc/dichloromethane, 1:10 ~ 1:6) to afford the title compound (1.60 g, 69%). MS ESI:
m/z+: [M+Na] , calcd for C H NaN O S 642.26, found 642.26.
41 3 9
Example 62. 2-((1R,3R)acetoxy(N,N-(tert-butoxycarbonyl)(4’-
maleimidobutyl)amino)methylpentyl)-thiazolecarboxylic acid (276)
To compound 275 (800 mg, 1.29 mmol) in a mixture of 1,2-dichloroethane (40 ml) and
toluene was added trimethyltin hydroxide (400 mg, 2.21 mmol). The mixture was stirred at
100 °C overnight, filtered through a short SiO column, washed the column with
MeOH/dichloromethane/HOAc (1:5:0.01) and evaporated to dryness. To the crude dryness
mixture in pyridine (15 ml) was added Ac O (0.3 ml, 3.17 mmol) at 0 °C. The mixture was
stirred at RT overnight, evaporated and purified on SiO column eluted with
MeOH/dichloromethane/HOAc (1:10:0.01) to afford the title compound (578.4 mg, 74%). ESI:
m/z: [M+Na] , calcd for C H N NaO S 628.24, found 628.24.
29 39 3 9
Example 63. Phenylalanine-ketoepoxide
N-Boc phenylalanine-ketoepoxide (Sun, L. et al, J. Mol. Catalysis A: Chem., 2005, 234
(1-2), 29-34) (300 mg, 1.08 mmol) in 1,4-dioxane (8 mL) at 0 °C was added hydrochloric acid
(37%, 2 mL). The mixture was stirred for 1 hour at which time TLC showed complete
consumption of starting material. The resulting solution was diluted with toluene (10 ml),
evaporated and crystallized with EtOH/hexanes to yield HCl salt of the title compound (201
mg, 87%). ESI: m/z: [M+H] , calcd for C H NO 178.12, found 178.12.
11 16
Example 64. (S, E)-Ethyl 5-phenyl(tert-butoxy-carbonylamino)methylpentenoate
(327)
L-t-Boc-phenylalanine methyl ester 326 (5.60 g, 20.05 mmol) in dichloromethane (80 ml)
at -78 °C was added dropwise DIBAL (40 ml, 40 mmol, 1.0 M) in dichloromethane. After
stirred at -78 °C for 45 min, the ylide solution prepared from 1-(1-ethoxycarbonyl ethyl)-
triphenylphosphonium bromide (18.0 g, 40.64 mmol) and KO Bu (5.00g, 44.64 mmol) in
dichloromethane (80 ml) at RT was added at -78 °C. After stirred at -78 °C for 1 h and RT
over night, the mixture was poured into 1 L of NaH PO (sat’ed.) solution with vigorously
stirring. Separated and the aqueous phase was extracted with dichloromethane. The organic
layers were dried over Na SO , concentrated and purified by SiO chromatography
2 4 2
(EtOAc/Hexane, 1:7 ~ 1:5) to afford 5.50 g (83% yields) of the title compound. ESI: m/z:
[M+Na] , calcd for C H NNaO 356.19, found 356.20.
19 27 4
Example 65. Ethyl 3-((S)(tert-butoxycarbonylamino)phenylethyl)methyloxirane-
2-carboxylate (328)
The compound 327 (5.0 g, 15.0 mmol) in dichloromethane (80 ml) was added 3-
chloroperoxybenzoic acid (5.5 g, 22.3 mmol) and the mixture was stirred overnight, diluted
with NaHCO (25 ml, sat’ed), separated and extracted the aqueous solution with
dichloromethane. The organic layers were combined, dried over Na SO , filtered, evaporated
and purified on SiO column (1:4 EtOAc/Hexane) to afford 4.71 g (90% yield) of the title
compound. ESI: m/z: [M+Na] , calcd for C H NNaO 372.19, found 372.20.
19 27 5
Example 66. 3-((S)(tert-butoxycarbonylamino)phenylethyl)methyloxirane
carboxylic acid (329)
To a solution of LiOH (5.0 g, 208.7 mmol) in water (60 mL) was added to a solution of
compound (328) (4.70 g, 13.45 mmol) in THF (100 mL). After stirred for 1 h, the mixture was
concentrated, poured into water (150 mL) and the mixture was adjusted to pH ~ 4 with 4 M
HCl aq. The mixture was extracted with EtOAc, dried over Na SO , concentrated and purified
by SiO chromatography (MeOH/DCM/HOAc 1:10:0.01) to afford (3.97 g, 92%) of the title
compound. ESI: m/z: [M+Na] , calcd for C H NNaO 344.16, found 344.16.
17 23 5
Example 67. 3-((S)(((9H-fluorenyl)methoxy)carbonylamino)phenylethyl)
methyloxiranecarboxylic acid (331)
To a solution of compound (329) (3.90g, 12.14 mmol) in dichloromethane (40 ml) at 0 °C,
was added TFA (10 ml) and the mixture was stirred at 0 °C for 30 min, diluted with toluene,
evaporated to dryness to form the crude TFA salt of compound 330. In a solution of Na CO
(5.0 g, 47.16 mmol) in mixture of water (60 mL) and ethanol (30 ml) were added the crude
compound 330 and Fmoc-Cl (3.70 g, 14.30 mmol). After stirred for 6 h, the mixture was
concentrated, poured into water (150 mL) and the mixture was adjusted to pH ~ 4 with 4 M
HCl aq. The mixture was extracted with EtOAc, dried over Na SO , concentrated and purified
by SiO chromatography (MeOH/DCM/HOAc 1:10:0.01) to afford 3.87 g (72% yields over 2
steps) of the title compound. ESI: m/z: [M+Na] , calcd for C H NNaO 466.17, found 466.17.
27 25 5
Example 68. General Solution Peptide Coupling Procedure:
The HCl salt of an amine (1 eq) was dissolved in dichloromethane or DMF (0.2 M) and
cooled to 4 °C in an ice bath, followed by the addition of the appropriate Boc-protected amino
acid (1.3 eq), EDC (2 eq), or TBTU (2 eq), or PyBrOP (2 eq), HOBt (1.5 eq) and DIPEA (3.5
eq). The reaction was allowed to slowly warm to room temperature and stirred for 15 h, after
which it was diluted with EtOAc and washed successively with aqueous solutions of 1M HCl,
saturated sodium bicarbonate, water and saturated sodium chloride. The organic layer was
dried with Na SO , filtered and concentrated under reduced pressure. Purification by column
chromatography (0% to 20% MeOH:dichloromethane) yielded Boc protected peptide.
Example 69. General Boc Deprotection Procedure:
The Boc protected amino acid was dissolved in 20% TFA in dichloromethane or 4 M HCl
in dioxane and stirred 30 min, or until the reaction was deemed complete by TLC. The solution
was then concentrated under reduced pressure to give the TFA or HCl salt of the peptide. The
TFA salt of the peptide was co-evaporated with 2% HCl in dichloromethane/toluene for 3~ 4
times to generate the HCl salt.
Example 70. General Solid Phase Peptide Synthesis (SPPS) Procedure:
Boc SPPS was used Merrifield resin or modified 5 PAM resin or MBHA resin. Fmoc
SPPS was used Wang resin, or 2-chlorotrityl resin, or HMPB, MBHA resin. The pre-treatment
of the resin (pre-swell) and the first loading of an amino compound were followed the
manufacture’s labels or notes. Resin bound Boc protected amino acids were deprotected with
% TFA in dichloromethane or 3 M HCl in dioxane for 30 minutes and washed with DMF,
MeOH, 50% DIPEA ( Pr NEt) in dichloromethane and dichloromethane. For steps involving
the deprotection of multiple free amines, this step was repeated once before acylation to ensure
completeness of reaction. Resin bound Fmoc protected amino acids were deprotected with
% piperidine in DMF for 30 minutes and washed with DMF, MeOH and dichloromethane.
For steps involving the deprotection of multiple free amines, this step was repeated once before
acylation to ensure completeness of reaction. The free amine beads were then suspended in a
solution of the protected amino acid (3 eq per eq of free amine), TBTU or PyBrOP (3 eq per eq
of free amine) and DIPEA (5 eq per eq of free amine) and mixed for 4 h, and then washed with
DMF, MeOH and dichloromethane. For steps involving the acylation of multiple free amines,
the coupling pr°Cedure was repeated once before deprotection to ensure completeness of
reaction. These steps were repeated until the desired peptide was synthesized.
Example 71. General Cleavage of Peptides from Wang Resin or 2-Chlorotrityl resin:
The peptide bound with Wang resin was mixed with 50% TFA in dichloromethane and
triisopropylsilane (1~5%) or the peptide bound with 2-Chlorotrityl resin was mixed with 1%
TFA in dichloromethane. Mixed for 2 h and then filtered. The resin was washed with
dichloromethane (3×30 ml), methanol (3×30 ml), which were combined with the filtrate and
evaporated to almost dryness. Cold Et O was then added to precipitate the desired deprotected
peptide.
Example 72. General Cleavage of Peptides from Merrifield, MBHA or PAM resin:
The peptide bound with the resins was mixed with HF/Me S/anisole (10:1:1) or
CH SO H/Me S/ anisole (20:1:1), or HF/anisole/Me S/p-thioCresol (10:1:1:0.2) for peptide
3 3 2 2
containing Cys mixed for 2 h, concentrated under a stream of N , diluted with TFA and filtered.
The resin was washed with dichloromethane (3×30 ml), Methanol (3×30 ml), which were
combined with the filtrate and condensed under reduced pressure to almost dryness. Cold Et O
was then added to precipitate the desired deprotected peptide.
Example 73. Chromatographic purification:
The crude peptide mixture was then purified through SiO column chromatography (10%
to 25% MeOH in dichloromethane) or by a reverse phase HPLC eluted with gradient from
100% of water (optionally containing 1% HOAc) to 30% of water (containing 1% HOAc)/70%
methanol in 1h, pooled the fraction, evaporated to give the desired protected.
Example 74. Conjugate Preparation.
A binding molecule, preferably an antibody can be conjugated to an antimitotic agents of
this prevention through amide, or thiol ether or disulfide bond linkage. In a experiment of
generating free thiols on an antibody, the antibodies (mAbs) (>5 mg/mL) in PBS containing 50
mM sodium borate, pH 8.0, were treated with dithiothreitol (10 mM final) at 35 °C for 30 min.
After gel filtration (G-25, PBS containing 1mM EDTA), thiol determination using Ellman's
reagent [5,5’-dithiobis(2-nitrobenzoic acid)] indicated that there were approximately eight
thiols per mAb. The free thiols were also introduced through conjugation of Traut’s Reagent
(2-Iminothiolane) (Jue, R., et al. BioChem. 1978, 17 (25): 5399-5405), or through conjugation
of SATP (N-succinimidyl-S-acetylthiopropionate) or SAT(PEG) linkers at pH 7~8, followed
by releasing SH group with hydroxylamine treatment (Duncan, R, et al, Anal. BioChem. 1983,
132, 68-73; Fuji, N. et al, Chem. Pharm. Bull. 1985, 33, 362-367). On average, 5 ~ 8 of free
thiols were introduced on mAbs.
To the mAbs containing free thiols at 4 °C were added the drug bearing maleimide or
bromoacetamide (0.5 M sodium borate buffer pH 9 was required to promote mAb alkylation
with bromoacetamide) (1.2~ 1.5 equiv of drug derivatives /SH group ratio) in cold DMA
(2~20% v/v). After 1~2 h, the reactions were quenched with excess cysteine; the conjugates
were concentrated by centrifugal ultrafiltration, gel filtered (G-25, PBS), and sterile filtered.
Protein concentration and drug loading were determined by spectral analysis at 280 and 252
nm, respectively. Size-exclusion HPLC was used to determine percent monomer of each
conjugate prepared, and RP-HPLC established that there was less than 0.5% unconjugated
cysteine quenched drug. The resulting conjugate was monomeric and contained, on the average,
3.2−4.2 antimitotic agents linked per antibody molecule for these thiol ether linked conjugation.
For the conjugation through DMPS, SMDP, SMPT, SPP, SPDP, SPDB, SMCC, or
SM(PEG)n linkers. A solution of mAb (>5 mg/mL) in aqueous buffer (50 mM PBS, 50 mM
NaCl, 1 mM EDTA) at pH 6.5~7.5 was incubated for 2 h with a 6 to 10-fold molar excess of a
linker. The reaction mixture was purified via a Sephadex G25 gel filtration column to remove
low molecular weight material. (The concentration of the antibody was determined
spectrophotometrically if the linkers contained a pyridylthio. The coefficients for the antibody
-1 -1
ε =2067550 M cm . An aliquot of the modified antibody was treated with an excess (>20
280nm
equiv) of dithiothreitol and the release of pyridinethione determined using the known
-1 -1 -1 -1
extinction coefficients of ε = 8080 M cm and ε = 5100 M cm for pyridine
343nm 280nm
thione). The modified antibody was treated with 1.2 ~ 1.5 equiv of an antimitotic agent bearing
a thiol group.
The reaction mixture was incubated for 5~18 h at RT. The reaction mixture was purified
via a Sephadex G25 gel filtration column to remove the unconjugated drug and other low
molecular weight species. The concentration of the conjugate was determined
spectrophotometrically at 280 and 252 nm. The resulting conjugate was monomeric and
contained, on the average, 3.2−4.5 antimitotic agent molecules linked per antibody molecule.
Example 75. In Vitro Cytotoxicity Assays
BJAB (Burkitt’s lymphoma), BT-474 (breast carcinoma) cells, Namalwa (human Burkitt’s
lymphoma), Ramos (human Burkitt’s lymphoma), COLO 205 (human colon aden°Carcinoma),
and A375 (human malignant melanoma,) were from ATCC. The breast tumor line KPL-4 was
from Dr. J. Kurebayashi (Kurebayashi, J. et al. Br J Cancer 1999; 79: 707–17).The cultures
were maintained in RPMI 1640 supplemented with 10% heat-inactivated fetal bovine serum
(FBS). All cell lines were cultured in a humidified incubator at 37°C, 6% CO . The
cytotoxicity study was performed using a clonogenic assay similar to a reference described
(Franken, et al, Nature Protocols 1, 2315-2319 (2006)). The test cell lines were plated into 6-
well culture dishes at a constant number of 5000 cells per well. The cells were incubated with
varying concentrations (1 pM to 50 nM) of the test-agent (the antimitotic agents or their
conjugates) for 72 h. The medium was then aspirated from the plates and replaced with fresh
medium. The cultures were allowed to grow and form colonies for a total of 7 to 10 days after
plating. The cultures were then fixed and stained with 0.2% crystal violet in 10% formalin
/PBS, and the colonies were counted. Plating efficiency of non-treated cells (medium alone)
was determined by dividing the number of colonies counted by the number of cells plated. The
surviving fraction of cells exposed to a toxic agent was determined by dividing the number of
colonies in wells that were exposed to the agent by the number of colonies in the control wells.
References:
Zanda, M. ; et al, Can. Pat. Appl. CA 2710693 (2011).
Chai, Y.; et al. Eur. Pat. Appl. 2174947 (2010), PCT WO 2010034724.
Leamon, C.; et al, PCT WO 2010033733, WO 2009002993..
Ellman, J.; et al, PCT WO 2009134279; PCT WO 2009012958
Matschiner, G.; et al, PCT WO 2009095447.
Vlahov, I.; et al, PCT WO 2009055562, WO 2008112873.
Low, P.; et al, PCT WO 2009026177.
Richter, W., PCT WO 2008138561.
Kjems, J.; et al, PCT WO 2008125116.
Davis, M.; et al, PCT WO 2008076333.
Diener, J.; et al, U.S. Pat. Appl. 20070041901, WO 2006096754
Matschiner, G.; et al, PCT WO 2006056464.
Vaghefi, F.; et al, PCT WO 2006033913
Doemling, A., Ger. Offen. DE 102004030227; PCT WO 2004005327; WO
2004005326; WO 2004005269.
Stanton, M.; et al, U.S. Pat. Appl. Publ. 20040249130.
Hoefle, G.; et al, Ger. Offen. DE 10254439 ; DE 10241152; DE 10008089.
Leung, D.; et al, PCT WO 2002077036.
Reichenbach, H.; et al, Ger. Offen. DE 19638870
Shibue, T., et al., Bioorg Med Chem Lett, 2011. 21(1): p. 431-4.
Floyd, W.C., 3rd, et al., ChemMedChem, 2011. 6(1): p. 49-53.
Shibue, T., et al., Total Syntheses of Tubulysins. Chemistry, 2010.
Kubicek, K., et al., Angew Chem Int Ed Engl, 2010. 49(28): p. 4809-12.
Chai, Y., et al., Chem Biol, 2010. 17(3): p. 296-309.
Chandrasekhar, S.,et al, J Org Chem, 2009. 74(24): p. 9531-4.
Pando, O., et al., Org Lett, 2009. 11(24): p. 5567-9.
Reddy, J.A., Mol Pharm, 2009. 6(5): p. 1518-25.
Ullrich, A., et al., Angew Chem Int Ed Engl, 2009. 48(24): p. 4422-5.
Ullrich, A.; et al, European J. Org. Chem. 2009, 36, 6367-6378
Schluep, T., et al., Clin Cancer Res, 2009. 15(1): p. 181-9.
Balasubramanian, R., et al., J Med Chem, 2009. 52(2): p. 238-40.
Leamon, C.P., et al.,. Cancer Res, 2008. 68(23): p. 9839-44.
Vlahov, I.R., et al., Bioorg Med Chem Lett, 2008. 18(16): p. 4558-61.
Patterson, A.W., et al, J Org Chem, 2008. 73(12): p. 4362-9.
Balasubramanian, R., et al., Bioorg Med Chem Lett, 2008. 18(9): p. 2996-9.
Raghavan, B., et al., J Med Chem, 2008. 51(6): p. 1530-3.
Richter, C.D., et al., Nat Chem Biol, 2008. 4(1): p. 75-81.
Patterson, A.W., et al., Chemistry, 2007. 13(34): p. 9534-41.
Wang, Z., et al., Chem Biol Drug Des, 2007. 70(2): p. 75-86.
Sani, M., et al., Angew Chem Int Ed Engl, 2007. 46(19): p. 3526-9.
Wipf, P. et al, Org Lett, 2007. 9(8): p. 1605-7.
Sasse, F., et al, Nat Chem Biol, 2007. 3(2): p. 87-9.
Peltier, H.M., et al., J Am Chem S°C, 2006. 128(50): p. 16018-9.
Domling, A., et al., Angew Chem Int Ed Engl, 2006. 45(43): p. 7235-9.
Khalil, M.W., et al., Chembi°Chem, 2006. 7(4): p. 678-83.
Kaur, G., et al., Bi°Chem J, 2006. 396(2): p. 235-42.
Wipf, P., et al, Org Lett, 2004. 6(22): p. 4057-60.
Steinmetz, H., et al., Angew Chem 5 Int Ed Engl, 2004. 43(37): p. 4888-92.
Friestad, G.K., et al, Org Lett, 2004. 6(19): p. 3249-52.
Sandmann, A., et al, Chem Biol, 2004. 11(8): p. 1071-9.
Sasse, F., et al., J Antibiot (Tokyo), 2000. 53(9): p. 879-85.
Claims (16)
1. A conjugate having a structure of Formula (I): 9 12 4 13 R R R R N 11 5 R 10 and pharmaceutical acceptable salts and solvates thereof, 5 wherein T is a targeting or binding ligand; L is a releasable linker; is a linkage bond that L connects to an atom inside the bracket independently; n is 1-20 and m is 1-10, wherein the cell-binding ligand T is selected from an antibody; a single chain antibody; an antibody fragment that binds to the target cell; a monoclonal antibody; a single chain monoclonal antibody; or a monoclonal antibody fragment that binds to the target cell; a 10 chimeric antibody; a chimeric antibody fragment that binds to the target cell; a domain antibody; a domain antibody fragment that binds to the target cell; adnectins that mimic antibodies; DARPins; a lymphokine; a hormone; a vitamin; a growth factor; a colony stimulating factor; a nutrient-transport molecule (a transferrin); or a binding peptide, protein, small molecule attached on albumin, a polymer, a dendrimer, a liposome, a nanoparticle, a 15 vesicle, or a (viral) capside, wherein the releasable linker L has the formula of: , wherein: - W- is a stretcher unit, which links a targeted binding molecular unit (T) to an amino acid unit (Aa) when presents, or links V when an Aa is not present, and W may independently contain a self-immolative spacer, a peptidyl unit, a hydrazone, a disulfide, a thioether, an ester, or an 20 amide bond; w is 0 or 1; Wherein Aa is independently a natural or unnatural amino acid unit; r is independently an integer ranging from 0 to 12; (Aa) represents a natural or unnatural amino acid, dipeptide, tripeptide, tetrapeptide, pentapeptide, hexapeptide, heptapeptide, octapeptide, nonapeptide, decapeptide, undecapeptide or dodecapeptide unit; Wherein V is a spacer unit and is independently H, O, NH, S, C -C of alkyl; C -C of heteroalkyl, alkenyl, 1 8 2 8 25 alkynyl; C -C of aryl, heterocyclic, carbocyclic, cycloalkyl, alkylcycloalkyl, heterocycloalkyl, heteroaralkyl, heteroalkylcycloalkyl, alkylcarbonyl, or one to four amino acid units, or (CH CH O) r is an integer ranging from 0 to 12; and v is 0, 1 or 2, 2 2 r, 1 2 3 4 inside the bracket is a potent antimitotic agent wherein R , R R and R are independently C -C of alkyl; C -C of heteroalkyl; C -C of aryl, Ar-alkyl, heterocyclic, carbocyclic, 1 8 2 8 3 8 30 alkylcycloalkyl, heterocycloalkyl heteroalkylcycloalkyl, alkylcarbonyl; or two R's, such as R R 2 3 3 4 5 6 12 13 R R R R , R R , and R R can be 3-7 members of a carbocyclic, cycloalkyl, or heterocyclic, 1 3 4 2 heterocycloalkyl ring system; Y is N or CH. In addition, R , R , and R can be H, and R can be absent, 5 6 8 10 wherein R R , R and R are independently H and C -C of alkyl or C -C heteroalkyl, , 1 4 2 4 7 14 14 1 15 14 1 15 1 wherein R is independently selected from H, R or -R C(=O)X R ; -R X R ; X is 5 selected from O, S, S-S, NH, or NR 9 14 14 14 wherein R is independently H, -O-, -OR , -OC(=O)R -, -OC(=O)NHR -, -OC(=O) 14 15 14 14 15 R SSR -, OP(=O)(OR )-, or OR OP(=O)(OR ), 11 14 14 16 14 2 16 14 2 2 wherein R is independently H, R , -R C(=O)R , -R X R , -R C(=O)X , wherein X 14 14 14 14 14 is -O-, -S-, -NH-, -N(R )-, -O-R -, -S-R -, -S(=O)-R -, or -NHR ; 12 14 14 14 10 wherein R is independently R , -O-, -S-, -N-, =N-, =NNH-, -NH(R ), -OR , - 16 14 14 14 16 C(O)O-, -C(O)OR -,C(O)NH-, C(O)NHR , -SR , -S(=O)R , -P(=O)(OR ) , - 16 16 16 OP(=O)(OR ) , -CH OP(=O)(OR ) , -SO R ; wherein R is C -C of alkyl, heteroalkyl, alkyl acid, alkyl amide, alkyl amine; C -C 1 10 2 10 of heteroalkyl; or Ar; Ar refers to an aromatic or hetero aromatic group, composed of one or 15 several rings, comprising four to ten carbon atoms, preferentially four to six carbon atoms, the term of hetero aromatic group refers to an aromatic group that has one or several carbon atoms replaced by hetero atoms, preferentially one, two or three carbon atoms replaced by O, N, Si, Se, P or S, more preferentially O, S, N, the term aryl or Ar also refers to an aromatic group, 17 16 16 wherein one or several H atoms can be replaced independently by R , F, Cl, Br, I, OR , SR , 16 17 16 16 16 17 16 17 16 16 16 16 17 20 NR R , N=NR , N= R , NR R , NO SOR R , SO R , SO R OSO R , PR R , 2, , 2 3 3 16 17 16 17 17 17 17 POR R , PO R R , OP(O)(OR ) , OCH OP(O)(OR ) , OC(O)OP(O)(OR ) , 2 2 2 2 2 16 17 17 17 17 17 PO(OR )(OR ), OP(O)(OR )OP(O)(OR ) , OC(O)R or OC(O)NHR , 14 15 wherein R and R are independently selected from C -C of alkyl; C -C of heteroalkyl 1 8 2 8 alkenyl, alkynyl; C -C of aryl, cycloalkyl, heterocyclic, carbocyclic, balkylcycloalkyl, 25 heterocycloalkyl, heteroalkylcycloalkyl, heteroaralkyl, alkylcarbonyl, 16 17 wherein R , R are independently H, C -C of alkyl; C -C of heteroalkyl, alkenyl, 1 8 2 8 alkynyl; C -C of aryl, cycloalkyl, heterocyclic, carbocyclic, alkylcycloalkyl, heterocycloalkyl, heteroalkylcycloalkyl, heteroaralkyl, alkylcarbonyl or C -C glycosides, or pharmaceutical 4 12 salts, 12 10 13 30 in addition, R can be H when R is not H, or when R is: k=0~4 , , , wherein Z 18 18 18 18 18 18 is H, CH OP(O)(OR ) , C(O)OP(O)(OR ) , PO(OR ) , P(O)(OR )OP(O)(OR ) , C(O)R , 2 2 2 2 2 18 18 C(O)NHR , SO (OR ), C -C glycosides, or C -C of alkyl, or C -C of carboxyalkyl, 2 4 12 1 8 3 8 heterocyclic; wherein R is H, C -C of alkyl; C -C of heteroalkyl, alkenyl, alkynyl; C -C of 1 8 2 8 3 8 2 18 19 aryl, carboxyalkyl, heterocyclic or alkylcarbonyl; where Z is NHR wherein R is H, OH, 18 18 18 18 18 NH , OSO (OR ), XCH OP(O)(OR ) , XPO(OR ) XC(O)OP(O)(OR , XC(O) R , 2 2 2 2 2 2 XC(O)NHR C -C of alkyl, carboxylic acid; C -C of alkenyl, alkynyl, carboxyalkyl; C -C 1 8 2 8 3 8 5 of aryl, heterocyclic, alkylcarbonyl; or pharmaceutical salts; X is O, S, NH; Y and Y are N or CH, independently, 12 11 or R can be H when R is: 2 8 8 or wherein X is O, S, N-R ; R is H, C -C of alkyl or C -C of heteroalkyl, 10 wherein the said conjugate of the invention specifically excludes the following structures: 24 25 26 wherein R is H or CH ; R is alkyl or C(O)alkyl or C(O)aryl; R is H, C -C alkyl, C - 3 1 5 2 28 27 C alkenyl, C(=O)C -C alkyl, or C(=O)C -C alkenyl; R is H or C -C alkyl; R is H, 1 to 3 5 1 5 2 5 1 5 15 substituents selected from halo, nitro, or carboxylate, cyano, hydroxyl, alkyl, haloalkyl, alkoxy, 29 29 30 haloalkoxy, phenol protecting groups, or OR , wherein R is substituted aryl, C(O)R , 30 30 30 P(O)(OR )2, or SO R , wherein R is selected from H, alkyl, alkenyl, cycloalkyl, heterocyclyl, aryl, and arylalkyl or a metal cation; T is a targeting or binding ligand; L is a releasable linker.
2. A conjugate according to claim 1 having Formula (II): 4 R R 1 11 R R n (II) and pharmaceutical acceptable salts and solvates thereof, 9 14 14 14 wherein R is independently H, -OH, -OR , -OC(=O)R -, -OC(=O)NHR -, -OC(=O) 14 15 14 14 15 R SSR , OP(=O)(OR ) , or OR OP(=O)(OR ) , 12 14 14 14 wherein R is independently R , -OH, -SH, -NH , =NH, =NNH , -NH(R ), -OR , - 16 14 14 14 14 16 16 COR , -COOR -, C(O)NH , C(O)NHR , -SR , -S(=O)R , -P(=O)(OR ) , -OP(=O)(OR ) , 2 2 2 16 16 -CH OP(=O)(OR ) , -SO R , 12 10 13 5 in addition, R can be H when R is not H, or when R is: k=0~4 k=0~4 , , , wherein Z is H, 18 18 18 18 18 18 CH OP(O)(OR ) , C(O)OP(O)(OR ) , PO(OR ) , P(O)(OR )OP(O)(OR ) , C(O)R , 2 2 2 2 2 18 18 C(O)NHR , SO (OR ), C -C glycosides, or C -C of alkyl; C -C of carboxyalkyl, C -C of 2 4 12 1 8 2 8 3 8 2 18 18 heterocyclic; where Z is NHR or OPO(OR ) 12 11 10 or R can be H when R has: or group , wherein is attachment that is H, C -C of alkyl, C -C of alkyl carboxylic acid, C -C of alkyl carboxylic amide, C -C of alkyl carboxylic 1 6 2 6 2 6 2 8 8 ester, or C -C of heteroalkyl; wherein X is O, S, CH , N-R ; R is H, C -C of alkyl or C -C 2 6 2 1 6 2 6 of heteroalkyl. 15
3. The conjugate according to claim 1 having the structure of Formula (III): 12 13 O 5 6 R R R (III) and pharmaceutical acceptable salts and solvates thereof, 7 14 14 1 15 14 1 15 wherein R is independently selected from R or -R C(=O)X R -, or -R X R - in addition, R can be absent.
4. The conjugate according to claim 1, having the structure of Formula (IV): 9 12 O 5 6 R R R (IV) and pharmaceutical acceptable salts and solvates thereof, 9 14 14 14 wherein R is independently -O-, -OR -, -OC(=O)R -, -OC(=O)NHR -, -OC(=O) 14 15 14 9 R SSR -, OP(=O)(OR )O, in addition, R can be absent.
5. A conjugate according to claim 1 having a structure of Formula (V): 9 12 4 13 N 11 5 10 R R (V) and pharmaceutical acceptable salts and solvates thereof, 11 14 14 17 14 2 17 14 2 wherein R is independently -R -, -R C(=O)R -, -R X R -, -R C(=O)X -; 10 wherein R is independently H, OH, C -C of alkyl; C -C of alkenyl, alkynyl, 1 8 2 8 heteroalkyl; C -C of aryl, arylene, heterocyclic, carbocyclic, heterocycloalkyl, or an 2 14 14 14 14 amino acid, or two amino acid; X is -O-, -S-, -NH-, -N(R )-, -O-R -, -S-R -, -S(=O)-R -, 14 14 or -NHR -; R is C -C of alkyl; C -C of alkenyl, alkynyl, heteroalkyl C -C of aryl, 1 8 2 8 3 8 heterocyclic, carbocyclic, cycloalkyl, alkylcycloalkyl, heterocycloalkyl, 15 heteroalkylcycloalkyl, heteroaralkyl, alkylcarbonyl, wherein said conjugate of the Formula (V) specifically excludes the following structures: 25 26 wherein R is alkyl or C(O)alkyl or C(O)aryl; R is H, C -C alkyl, C -C alkenyl, C(=O)C - 1 5 2 5 1 C alkyl, or C(=O)C -C alkenyl; R is H, or 1 to 3 substituents selected from halo, nitro, 5 2 5 20 carboxylate or a derivative thereof, cyno, hydroxyl, alkyl, haloalkyl, alkoxy, haloalkoxy, 29 29 30 30 phenol protecting groups, and OR , wherein R is substituted aryl, C(O)R , P(O)(OR ) , 30 30 or SO R , wherein R is selected from H, alkyl, alkenyl, cycloalkyl, heterocyclyl, aryl, and arylalkyl or a metal cation; T is a targeting or binding ligand; L is a releasable linker. 25
6. A conjugate according to claim 1 having a structure of Formula (VI): (VI) and pharmaceutical acceptable salts and solvates thereof, 12 14 14 14 wherein R is independently R , -O-, -S-, -NH-, =N-, =NNH-, -N(R )-, -OR -, - 14 14 14 14 15 C(O)O-, -C(O)NH-, C(O)NR -, -SR -, -S(=O)R -, -NHR -, -CH OP(=O)(OR )-, - 15 15 15 14 14 15 5 P(=O)(OR ) -, -C(O)OP(=O)(OR )-, -OP(=O)(OR )O , -SO R , wherein R and R are independently C -C of alkyl; C ~C of alkenyl, alkynyl, heteroalkyl; C -C of aryl, 1 8 2 8 3 8 heterocyclic, carbocyclic, cycloalkyl, alkylcycloalkyl, heterocycloalkyl, heteroaralkyl, heteroalkylcycloalkyl, alkylcarbonyl.
7. A conjugate according to claim 2 having a structure of Formula (VII): 10 (VII) and pharmaceutical acceptable salts and solvates thereof, wherein R is C -C of alkyl, alkyl acid, alkyl amide, alkyl amine; C -C of 1 10 2 10 heteroalkyl; or Ar; Ar refers to an aromatic or hetero aromatic group, composed of one or several rings, comprising four to ten carbon atoms, preferentially four to six carbon atoms, 15 the term of hetero aromatic group refers to an aromatic group that has one or several carbon atoms replaced by hetero atoms, preferentially one, two or three carbon atoms replaced by O, N, Si, Se, P or S, preferentially O, S, N, the term aryl or Ar also refers to an aromatic 18 16 group, wherein one or several H atoms are replaced independently by R , F, Cl, Br, I, OR , 16 16 17 16 16 16 18 16 18 16 16 16 SR , NR R , N=NR , N= R , NR R , NO SOR R , SO R , SO R OSO R , 2, , 2 3 3 16 18 16 18 16 18 16 18 16 18 20 PR R , POR R , PO R R , OPO OR R , CH OPO R R , 16 18 16 18 16 18 16 18 OP(O)(OR )OP(O)(OR ) , C(O)OPO R R , or PO R R , wherein R R are 3 3 , independently H, C ~C of alkyl; C ~C of alkenyl, alkynyl, heteroalkyl; C ~C of aryl, 1 8 2 8 3 8 heterocyclic, carbocyclic, cycloalkyl, alkylcycloalkyl, heterocycloalkyl, heteroaralkyl, heteroalkylcycloalkyl, alkylcarbonyl; or C ~C glycosides; or pharmaceutical salts, 4 12 25 wherein said conjugate of the formula (VII) specifically excludes the following structures: 24 25 26 wherein R is H or CH ; R is alkyl or C(O)alkyl or C(O)aryl; R is H, C -C alkyl, C -C 3 1 5 2 5 alkenyl, C(=O)C -C alkyl, or C(=O)C -C alkenyl; R is H or C -C alkyl; T is a targeting 1 5 2 5 1 5 or binding ligand; L is a releasable linker.
8. The conjugate according to claim 1, having the structure of Formula (VIII): OAc O (VIII) and pharmaceutical acceptable salts and solvates thereof; wherein T is a targeting or binding ligand; L is a releasable linker that connects to a 10 molecule inside the bracket independently; n is 1-20 and m is 1-10; q = 1-5; 1 18 18 18 wherein Z is H, CH OP(O)(OR , PO(OR ) C(O)OP(O)(OR ) , 2 2 2 2 18 18 18 18 18 P(O)(OR )OP(O)(OR ) , C(O)R , C(O)NHR , SO (OR ), C -C glycosides, or C -C 2 2 4 12 1 8 of alkyl, C -C carboxyalkyl, C -C heterocyclic; R is H, C -C of alkyl, heteroalkyl; of of 2 8 3 8 1 8 C -C of alkenyl, alkynyl, carboxyalkyl; C -C of aryl, alkylcarbonyl, heterocyclic; R is H or 2 8 3 8 15 CH .
9. The conjugate according to any one of claim 1, 2, 3, 4, 5, 6, 7 or 8 having a structure according to the formula IIa, IIb, IIg, IIh, IIi, , IIk, IIo, IIp, IIq, IIIa, , IIIc, IIIh, IIIi, IIIj, IVa, IVb, IVc, IVd, Va, Vb, Vc, Ve, Vh,VIa, VIb, VIc, VId, VIf, VIg, VIh, VIi, VIIa, VIIb, VIId, VIIe, VIIf, VIIg, VIIh, VIIi, VIIj,VIIk, VIIl, VIIm, and VIIn: 20 IIa OPO(OH) H X' O HN H O R N N N O Y' S NH Z' 5 IIk IIIa IIIc IIIh IIIi 5 IIIj 5 Va VIIa 5 VIIb VIId VIIe VIIf VIIg VIIh VIIi 5 VIIj VIIk VIIl VIIm VIIn ’ ’ ’ wherein Aa is a natural or unnatural amino acid; Ar is aryl; n is 1-20; q = 1-5; X , Y and Z are 22 22 23 independently CH, O, S, NH, or NR ; R and R are independently C -C of alkyl; C -C of 1 8 2 8 5 alkenyl, alkynyl, heteroalkyl; C -C of aryl, heterocyclic, carbocyclic, cycloalkyl, alkylcycloalkyl, heterocycloalkyl, Ar-alkyl, heteroalkylcycloalkyl, heteroaralkyl, or - (OCH CH ) -; R , R’ and R’’ are independently H or CH . Inside the round brackets are the 2 2 n 3 antimitotic drugs and the inside square brackets are the antimitotic drug conjugated to a cell- binding agent T via a linker.
10 10. The conjugate of the cytotoxic agents according to any one of claims 1, 2, 3, 4, 5, 6, 7 or 8 comprises antimitotic agents and linkers having structures of 232a, 232b, 232c, 232d, 232e, 232f, 232g, 232h, 232i, 232j, 232k, 232l, 232m, 232n, 232o, 232p, 232q, 232r, 232s, 232t, 221a, 221b, 233a, 233b, 233c, 233d, 222a, 290, 299a, 299b, 241, 242, 247, 248, 206, 211, 346, 350, 354, 357, 361, 366, 371, and 376 which are illustrated below: 15 232a 232b 232c 232d 232e 232f 232g 5 232h 232i 232j 232k 232l 232m 232n 5 232o 232p 232q 232r 232s 232t 221a 5 221b 233a 233b 233c 233d 222a 5 299a 299b 5 350
11. The conjugate of the cytotoxic agents according to any one of claim 1, 2, 3, 4, 5, 6, 7 5 or 8 comprises Formula of: mAb-TZ01, mAb-TZ04, mAb-TZ05, mAb-TZ06, mAb-TZ07, mAb-TZ08, mAb-TZ10a, mAb-TZ10b, mAb-5 TZ11, mAb-TZ12, mAb-TZ13, mAb-TZ14, mAb-TZ17, mAb-TZ18, mAb-TZ19, mAb-TZ20, mAb-TZ21, mAb-TZ22, mAb-TZ23, mAb- TZ24, and mAb-TZ25 which are illustrated below: mAb- 10 TZ01 mAb-TZ04 mAb- TZ05 mAb-TZ06 mAb-TZ07 mAb- TZ08 mAb- 5 mAb-TZ10a mAb-TZ10b mAb-TZ11 mAb-TZ12 mAb- 10 TZ13 mAb- TZ14 mAb-TZ17 5 mAb-TZ18 mAb- TZ19 mAb- TZ20 mAb-TZ21 mAb-TZ22 mAb-TZ23 mAb- 5 TZ24 mAb- TZ25 wherein mAb is an antibody.
12. The conjugate of the cytotoxic agents according to any one of claims 1, 2, 3, 4, 5, 6, 10 7, 8, 9, 10, or 11, for use in the manufacture of a medicament to target cells selected from tumor cells, virus infected cells, microorganism infected cells, parasite infected cells, autoimmune cells, activated cells, myeloid cells, activated T-cells, B cells, or melanocytes, cells expressing one or more of Apo2, ASLG659, BAFF-R, BMPR1B (bone morphogenetic protein receptor), IGF-IR, CA125, CanAg, E16, EGFR, EphA2 receptor, ErbB2, 15 interleukin,MUC1, MUC16, Napi3b (NAPI-3B, NPTIIb, SLC34A2, solute carrier family 34, member 2, type II sodium –dependent phosphate transporter 3b), VEGF, TF, MY9, anti-B4, EpCAM, FcRH2, C242, CD2, CD3, CD4, CD5, CD6, CD11, CD 11a, CD18, CD19, CD20, CD21, CD22, CD26, CD30, CD33, CD37, CD38, CD40, CD44, CD56, CD70, CD72, CD79, CD79a, CD79b, CD90, CD105, CD138, CRIPTO (CR, CR1, CRGF, 20 CRIPTO, CXCR5, LY64, TDGF1, Tetratocarcinoma-derived growth factors), endothelin B receptor (ETBR), EphA receptors, EphB receptors, EGFr, EGFRvIII, ETBR (Endothelin), FCRH1, HER2, HER2/neu, HER3, HLA-DOB (MHC class II molecule Ia antigen), integrins, IRTA2, LIV-1, MPF (MPF, MSLN, SMR, megakaryocyte potentiating factor, mesothelin), GEDA, Mesothelin, NaPi2b, PDL1, Sema 5b (FLJ10372, KIAA1445, 5 Mm42015, SEMA5B, 5EMAG, semaphoring 5 bHlog, sdema domain, seven thrombospondin repeats, cytoplasmic domain), PSCA, PSMA, STEAP1 (six transmembrane epithelial antigen of prostate 1), and STEAP2 (HGNC 8639, IPCA-1, PCANP1, STAMP1, STEAP2, STMP, prostate) antigens; and cells expressing insulin growth factor receptor, epidermal growth factor receptor, or folate receptor.
13. A linker when used to conjugate two cytotoxic agents of Formula (I), (II), (III), (IV),(V), (VI), (VII) or (VIII) per linker according to any one of claims 1, 2, 3, 4, 5, 6, 7, or 8 having a 3- bromo-maleimido, or 3, 4-dibromo-maleimido terminus of the formula: Wherein R is C -C alkyl or C H (OC H ) , n is 1-20; X is H or Br. 1 8 2 4 2 4 n 15
14. A cytotoxic agent- binding molecule conjugate of any one of claims 1, 2, 3, 4, 5, 6, 7, or 8, wherein two cytotoxic agents of Formula (I), (II), (III), (IV), (V), (VI), (VII) or (VIII) incorporated per linker, having the formula: Wherein R is C -C alkyl or C H (OC H ) , n is 1-20; D is a cytotoxic agent/drug of 1 8 2 4 2 4 n 20 Formula (I), (II), (III), (IV), (V), (VI), (VII) or (VIII), T is a cell binding molecule.
15. A cytotoxic agent- binding molecule conjugate any one of claims 1, 2, 3, 4, 5, 6, 7, or 8, wherein when two cytotoxic agents of Formula (I), (II), (III), (IV), (V), (VI), (VII) or (VIII), incorporated per linker, having the formula: 25 or Wherein R is C -C alkyl or C H (OC H ) , n is 1-20; D is a cytotoxic agent/drug of Formula (I), 1 8 2 4 2 4 n (II), (III), (IV), (V), (VI), (VII) or (VIII), T is a cell binding molecule.
16. A pharmaceutical composition comprising a therapeutically effective amount of the antimitotic agents-cell binding molecule conjugates of any one of claims 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11, or its pharmaceutically acceptable salt, and carrier, diluent, or excipient therefore, or 5 a combination therefore, for the treatment or prevention of cancer, autoimmune disease, or infectious disease.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ719369A NZ719369B2 (en) | 2012-07-12 | Conjugates of Cell Binding Molecules with Cytotoxic Agents |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ70348712 | 2012-07-12 | ||
NZ719369A NZ719369B2 (en) | 2012-07-12 | Conjugates of Cell Binding Molecules with Cytotoxic Agents |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ719369A NZ719369A (en) | 2017-04-28 |
NZ719369B2 true NZ719369B2 (en) | 2017-08-01 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11767294B2 (en) | Conjugates of cell binding molecules with cytotoxic agents | |
US10293055B2 (en) | Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule | |
US10265291B2 (en) | Disulfur bridge linkers for conjugation of a cell-binding molecule | |
US10696700B2 (en) | Charged linkers and their uses for conjugation | |
US9988408B2 (en) | Cytotoxic agents for conjugation to a cell binding molecule | |
US10131682B2 (en) | Hydrophilic linkers and their uses for conjugation of drugs to a cell binding molecules | |
AU2015242213A1 (en) | Bridge linkers for conjugation of cell-binding molecules | |
NZ719369B2 (en) | Conjugates of Cell Binding Molecules with Cytotoxic Agents |